FINAL PROGRAMME Programme Final Fp1 2013__ 15.08.13 10:32 Seite 2

Title_Final_prog2013__ 15.08.1310:51Seite1

EASD 2013 BARCELONA FINAL PROGRAMME Programme Final fp1_2013__ 15.08.13 10:32 Seite 2

49th annual meeting oF the euroPean association For the study oF diabetes

scientific Programme Page European Foundation for the Study of Diabetes 10 General Information 14 Map of the Conference Centre 22 Programme at a Glance 24 Monday, 23 September 34 EASD App 35 Tuesday, 24 September 36 Opening Ceremony 37 Minkowski Lecture 37 Poster Event A and B 45 Camillo Golgi Lecture 55 Albert Renold Lecture 57 Rising Star Symposium 58 Wednesday, 25 September 60 Poster Event C and D 69 Thursday, 26 September 82 Poster Event E and F 91 EASD General Assembly 102 Friday, 27 September 104 Claude Bernard Lecture 119 Closing Ceremony 120 Posters 121 Index of Presenting Authors 276 Index of Invited Speakers 293 50th Annual Meeting 296

2 fp1_2013__ 15.08.13 10:32 Seite 3

dear members, dear guests,

From 23 to 27 september it will be my great honour and pleasure to welcome you to the 49th easd annual meeting. under the outstanding chairmanship of our honorary secretary, Prof. mark Walker, the scientific Programme committee has selected 1361 from a total of 2321 submitted abstracts for presentation this year. the scientific Programme comprises six parallel tracks which include inspiring symposia, keynote lectures and debates covering basic and clinical science. the scientific Programme reflects the ongoing efforts to understand, cure and prevent diabetes.

our main hall is named after claude bernard in order to celebrate his 200th birthday. 30 years ago saw the inception and planning of the dcct, and the final results of the uKPds were presented at the 34th easd annual meeting in barcelona. to acknowledge these major milestones in clinical diabetology, two symposia will discuss new data resulting from these trials. the easd annual meeting is the ideal place to communicate and interact with top-level researchers from all over the world. this communication is now even easier thanks to the easd Virtual meeting app and website. i encourage you to download the app and make use of its outstanding features. lectures and posters will also be available, for free, on the easd Virtual meeting website.

again, this is an excellent opportunity to communicate with peers, colleagues and other scientists both during and after the annual meeting. i would like to take this opportunity to wish you a very successful easd annual meeting in barcelona.

andrew J.m. boulton President easd/eFsd

3 fp1_2013__ 15.08.13 10:32 Seite 4

Welcome address

on behalf of the local organising committee, we welcome you to the 49th easd annual meeting at the Fira de barcelona’s gran Via exhibition centre, one of the biggest and most modern convention facilities in europe. during your stay, we hope that you enjoy the mild mediterranean climate and open personality that characterises the catalan capital. We also hope that you have the opportunity to participate in the festivities of ‘la mercè’, in honour of the patron saint our lady of mercy, as these activities give testimony to barcelona’s lively and dynamic spirit.

thanks to its privileged position on the coast, barcelona has been exposed to different civilizations and cultures throughout the ages, inspiring designers, architects, and artists, such as dalí, miró, Picasso, and gaudí, as well as leaders of new, world-renowned movements in culinary art. similarly, the city is an active member of the international scientific community, having made huge advancements in biomedical research in the last 20 years. barcelona’s architecture attests to its 2,000+ years of history: ruins of the defensive wall that surrounded the roman colony, barcino; the majestic gothic Quarter reflecting barcelona’s golden age, from the 13th to the 15th centuries; modernist gems built in the eixample district in the early 20th century; and, finally, cutting-edge, contemporary works that attest to barcelona’s current position as a major cosmopolitan metropolis.

the annual meeting will begin with the Welcome reception on monday, 23 september, and end with the Farewell reception on Friday, 27 september. may the meeting be a fruitful and rewarding experience for all participants.

ramon gomis chairman local organising committee

4 fp1_2013__ 15.08.13 10:32 Seite 5

MESSAGE OF GREETING

Barcelona is a city committed to healthcare. A city that aims at improving citizens’ wellbeing and quality of life through the promotion of healthy lifestyles and the prevention of diseases. A city that stands at the forefront of healthcare and biomedical research with its world-renowned centres.

We are particularly committed to fighting diabetes, a growing worldwide epidemic. A disease that in Catalonia alone affects over 800,000 people, many of whom have been properly diagnosed, while many others do not even know that they suffer from it.

Nowadays, diabetes can be considered a manageable health problem, with patients playing a leading role in their treatment. They have joined forces, assembled in associations, and become actively involved in pushing health practitioners, hospitals, and governments to place a greater emphasis on the human dimension of this disease.

The proof lies in recent editions of international gatherings, such as those organised by the European Association for the Study of the Diabetes (EASD), which have steadily promoted this focus. I am sure that this 49th Annual Meeting of the EASD will be no exception.

This is the model which we must adopt, not only when dealing with diabetes, but with all diseases: putting patients at the forefront, adopting a more human approach, investing in research and development, and actively involving all stakeholders.

Xavier Trias Mayor of Barcelona

5 fp1_2013__ 15.08.13 10:32 Seite 6

executiVe committee President: a.J.m. boulton, uK Vice-President: s. del Prato, it Vice-President: b. thorens, ch honorary secretary: m. Walker, uK honorary treasurer: m. roden, de chairman of the Pgec: c. tack, nl editor-in-chief, diabetologia: J. Zierath, se

easd council comprises the officers above and the following members:

term expiring 2013 term expiring 2014 term expiring 2015 F. beguinot, it K. birkeland, no h. beck-nielsen, dK J. dekker, nl J. bodansky, uK s. bolgarskaya, ua F. Karpe, uK c. levy-marchal, Fr a. novials, es V. urbanavicius, lt P. nawroth, de r. Weitgasser, at

the Past President, u. smith, se, and the secretary of the Postgraduate education committee, l. czupryniak, Pl, are members of the council ex officio.

honorary auditors P. diem, ch, l. m. gardete-correia, Pt

the easd executive committee is also the executive committee of the european Foundation for the study of diabetes (eFsd).

oFFice executive director: V. Jörgens Vice director: m. grüsser rheindorfer Weg 3 40591 düsseldorf, germany Phone: +49-211-7584690 www.easd.org

6 fp1_2013__ 15.08.13 10:32 Seite 7

honorary members g. alberti, uK; d. andreani, it; J.-P. assal, ch; P. bennett, usa; e. cerasi, il; o.-b. crofford, usa; t. deckert, dK; P. Freychet, Fr; e. Kohner, uK; P. lefèbvre, be; J. ludvigsson, se; c. c. e. mogensen, dK; J. nerup, dK; l. orci, ch; J. Pirart, be; g.m. reaven, usa; J. roth, usa; e. shafrir, il; d. steiner, usa; r. unger, usa; i. Valverde, es; e. von Wasielewski, de; W. Waldhäusl, at; c.b. Wollheim ch; P. Zimmet, au

local organising committee barcelona

chairman r. gomis, es

Vice chairman i. conget, es

members e. esmatjes, es r. gasa, es a. novials, es J. Vidal, es

administration K. Katte, es

easd thanks the following companies for their support of the annual meeting: sanofi merck & co. inc. eli lilly and company takeda Pharmaceuticals international gmbh novo nordisk a/s bristol-myers squibb emea sarl boehringer ingelheim international gmbh

7 fp1_2013__ 15.08.13 10:32 Seite 8

the mission oF easd is to Promote excellence in diabetes care through research and education

since its foundation in 1965, easd has been organising an annual meeting, which has become the largest international annual conference on diabetes research worldwide. although the meetings have grown so dramatically, they are still driven by the academic traditions of the founding members. the easd meeting is a meeting of members where guests are welcome. chairpersons of oral presentations and poster sessions are chosen exclusively from the easd membership. the abstracts are evaluated on a strictly anonymous basis and the selection is based exclusively on the quality of the science, regardless of the place of work. the easd honorary secretary is solely responsible for inviting speakers and chairpersons for symposia and lectures. comments, advice and proposals from the membership and the Programme committee are welcome. none of the speakers or chairpersons at the easd annual meeting receives an honorarium; reimbursement of their travel costs is exclusively provided by the association. easd and its Foundation eFsd are academic charities dedicated to diabetes research.

as an academic society, easd encourages cooperation with industry and other institutions conducting and funding diabetes research. easd is committed to transparency. in 2005, its annual meeting endorsed the following policy with respect to duality of interest: prior to the meeting speakers invited to symposia or lectures declare to easd the existence of any relationship or arrangement that could be reasonably considered to affect the content of the presentation. invited speakers who declare a duality of interest are asked by easd to disclose this on a slide of their presentation. any occasional, positive balance resulting from the annual meeting is used to encourage further diabetes research in europe. it is a tradition that other meetings organised by third parties, including pharmaceutical companies, are held on the occasion of the annual meeting. easd is involved neither in the organisation nor the programmes of these meetings, which are restricted to the days before and after the annual meeting. during the days of the meeting, no other activities should be organised by third parties, and all activities during this period are under the sole responsibility of easd. Increasingly, major end-point related trials are carried out to evaluate diabetes treatments. EASD encourages these trials and provides an outstanding forum to announce their results to the scientific community.

8 fp1_2013__ 15.08.13 10:32 Seite 9

The EASD regulations on the presentation of major clinical trials state that all data of the trial must be openly available, and clear information should be provided on the role of the funding source/sponsor on study design, data collection, analysis and interpretation of the data. Moreover, a commentator, nominated by the EASD Honorary Secretary, must have prior access to the data in order to prepare an unbiased review. EASD Meetings are organised in such a way as to ensure the academic independence of physicians and scientists as the patients' advocates.

Article 1, Section 2 Statutes of the European Association for the Study of Diabetes, Diabetologia 1, 256-260 (1965):

The aims of the Association are to encourage and support research in the field of diabetes, to rapidly spread acquired knowledge and to facilitate its application.

9 fp1_2013__ 15.08.13 10:32 Seite 10

in 1999 the european association for the study of diabetes (easd) created its own non-profit Foundation - the european Foundation for the study of diabetes (eFsd) - in order to support more actively diabetes research in europe and to serve the goals of easd. EFSD is a non-profit organisation, which supports highest quality research to find a cure for diabetes and associated complications and to prevent their onset. EFSD cooperates with non-governmental and governmental agencies in order to enhance excellence in diabetes research. Through its actions and programmes, EFSD also strives to enhance awareness of diabetes. the easd executive committee is also the executive committee of eFsd.

eFsd is greatly indebted to the following companies and organisations for their most generous support of european diabetes research:

astraZeneca/bristol-myers squibb: eFsd european diabetes research Programme in Patient education supported by an educational research grant from aZ-bms this programme supports research into the clinical and medical evaluation of patient-related outcomes in relation to the diabetes chronic condition.

boehringer ingelheim: eFsd/boehringer ingelheim european diabetes research Programmes these Programmes consist of two elements, each with a different focus: regulation of secretion and/or Function of non-insulin Peptides from the endocrine Pancreas for basic research projects; mechanisms relating renal dysfunction to cardiovascular disease in type 2 diabetes for clinical/translational research projects.

chinese diabetes society and lilly: eFsd/cds/lilly Programme for collaborative diabetes research between china and europe this Programme offers grants in support of collaborative research endeavours between european and chinese research centres and/or individual investigators in the area of diabetes and its complications.

10 fp1_2013__ 15.08.13 10:32 Seite 11

eFsd/cds/lilly research Fellowships the objective of these fellowships is to provide the opportunity for young researchers in china to visit a european institution.

Janssen: eFsd/Janssen Programme for the study of the role of the Kidney in diabetes basic and clinical research is supported in order to stimulate understanding of the role of the kidney in diabetes.

eFsd/Janssen rising star Fellowships the rising star Fellowships support promising and innovative young researchers in basic and clinical research.

Japan diabetes society: eFsd/Jds reciprocal travel research Fellowships the objective of these fellowships is to encourage collaborative research between europe and Japan in the field of diabetes.

Juvenile diabetes research Foundation and novo nordisk a/s: eFsd/JdrF/novo nordisk european Programme in type 1 diabetes research the aim of this Programme is to foster research targeted at finding a cure for type 1 diabetes and its complications.

eFsd/JdrF/novo nordisk Fellowships in type 1 diabetes research the objective of the eFsd/JdrF/nn research Fellowships is to support young investigators engaged in research focused on type 1 diabetes and its complications.

lilly: eFsd/lilly european diabetes research Programme these grants are offered within the frame of the eFsd/lilly Fund and cover any area of basic or clinical diabetes research.

11 fp1_2013__ 15.08.13 10:32 Seite 12

eFsd/lilly mental health and diabetes Programme the Programme focuses on european research aimed at clinical research into improved care of patients with diabetes and mental diseases including all forms of depression, schizophrenia and alzheimer’s disease.

eFsd/lilly research Fellowships the objective of these Fellowships is to encourage research in the field of metabolism and complications of diabetes, and to promote excellence in medical education.

merck sharp & dohme: eFsd/msd european research Programme on novel therapies for type 2 diabetes this programme is intended to stimulate and accelerate european research focusing on the identification and molecular understanding of new targets for the treatment of type 2 diabetes.

novartis: eFsd/novartis european research Programme in microvascular complications of diabetes the objective of this Programme is to encourage european basic and clinical research focusing on microvascular complications of diabetes.

novo nordisk a/s: eFsd/novo nordisk Programme for diabetes research in europe this Programme accepts applications from all fields of clinical and basic diabetes research.

sanofi: eFsd/sanofi european research Programme: innovative approaches for the treatment of type 1 and type 2 diabetes the Programme is intended to stimulate european research focusing on innovative approaches to treat type 1 and/or type 2 diabetes through increased understanding of the underlying pathophysiological processes.

12 fp1_2013__ 15.08.13 10:32 Seite 13

eFsd/sanofi Programme for collaborative clinical diabetes research between european and non-european countries the intention of the Programme is to initiate collaboration between european clinical research in rapidly developing countries where clinical research is approaching the standard of international excellence, and who would particularly benefit from the collaboration with research institutes in europe.

in addition to its partnership activities, eFsd runs the following programmes:

eFsd clinical research grants in diabetes this stand-alone eFsd Programme is intended to stimulate clinical research into all aspects of diabetes.

eFsd new horizons collaborative research initiative historically, funding for european diabetes research tends to be unevenly distributed. to redress in part this imbalance, this Programme has been created to foster inter-regional collaboration in diabetes research throughout europe. in 2013, fellowships were also offered within the framework of the eFsd new horizons initiative.

eFsd research Programme in diabetes and cancer this Programme aims at investigating why diabetes is associated with increased morbidity and mortality in certain forms of cancer.

eFsd albert renold travel Fellowships the fellowships enable young scientists to stay at other institutions to learn new techniques in basic or clinical diabetes research. an unrestricted educational grant from merck sharp & dohme contributes to the funding.

all programme announcements are published in diabetologia, the official journal of easd. eFsd awards are strictly competitive and decisions are based upon a rigorous and fully independent peer-review process. Further information on eFsd Programmes: www.europeandiabetesfoundation.org/

13 fp1_2013__ 15.08.13 10:32 Seite 14

GENERAL INFORMATION

Meeting venue: Fira de Barcelona - Gran Via Venue Av. Joan Carles I, 64 L'Hospitalet de Llobregat (Barcelona) http://www.firabcn.es/en/venues_granvia

Registration: Sunday 22 September 10:00 - 18:30 Monday 23 September 08:00 - 18:30 Tuesday 24 September 08:00 - 18:30 Wednesday 25 September 08:00 - 18:00 Thursday 26 September 08:00 - 18:00 Friday 27 September 08:00 - 12:00

Press registration: Press delegates can register online and will receive important press information beforehand.

Participants’ registration fee includes: Admission to the Scientific Programme Admission to the Industry Exhibition Scientific Programme and Abstract Volume Lunches from Tuesday to Thursday Coffee breaks from Tuesday to Friday Free public transportation

cme accreditation: The Meeting has been awarded CME credit by the Catalan Council for Continuing Education in the Health Professions. Certificates can be printed on Friday on workstations in the Registration Hall by scanning the name badge.

easd booth: the easd booth is located in the registration hall.

silence room: the silence room is located behind the ramón y cajal hall in building cc2.

14 fp1_2013__ 15.08.13 10:32 Seite 15

Food and beverages: Food and beverages are not allowed in the lecture halls.

insurance: the registration fees do not include the insurance of participants against accidents, sickness, cancellation, theft, property loss or damage. Participants are advised to take out adequate personal travel insurance.

disclaimer: all efforts will be made to adhere to the programme as printed. however, easd and its agents reserve the right to alter or cancel, without prior notice, any of the arrangements, timetables, plans or other items relating directly or indirectly to the meeting, for any case beyond their reasonable control. easd and the local conference organisers are not liable for any other loss or inconvenience caused as a result of such changes.

associations’ Village opening hours: tuesday 24 september 09:30 – 17:30 h Wednesday 25 september 09:30 – 17:30 h thursday 26 september 09:30 – 17:30 h Friday 27 september 09:30 – 12:00 h

Lunch: Lunch is served in the Associations’ Village and in the Exhibition Hall.

Exhibition opening hours: Tuesday 24 september 09:30 – 17:30 h Wednesday 25 september 09:30 – 17:30 h Thursday 26 september 09:30 – 17:30 h Friday 27 september 09:30 – 12:00 h

Children under the age of 16 years are not permitted to enter the Exhibition Hall.

Press: The Press Centre and Press Conference Hall are located on the lower floor in the Registration hall. The schedule of press conferences is available in the Press Centre.

First aid: the First aid centre is located in the exhibition hall. in case of emergency: contact the nearest staff member.

15 fp1_2013__ 15.08.13 10:32 Seite 16

speakers’ lounge: the speakers’ lounge is located on the lower floor in the registration hall. Please check your presentation at the speakers’ lounge at least two hours before your scheduled presentation time. if your presentation is scheduled in the morning, you are kindly asked to check your presentation at the speakers’ lounge the day before. the presentations will be transferred to the lecture halls by the staff.

speakers’ lounge opening hours: Sunday 22 September 08:00 – 18:30 h Monday 23 September 08:00 – 18:30 h Tuesday 24 September 08:00 – 18:30 h Wednesday 25 September 08:00 – 18:00 h Thursday 26 September 08:00 – 18:00 h Friday 27 September 08:00 – 14:00 h

Posters: Posters can be mounted on monday, 23 September between 13:00 and 17:30 h and tuesday, 24 September between 8:30 and 10:00 h. Posters must not be removed before 12:00 h on Friday, 27 september. Posters that have not been taken down by 14.30 h on Friday, 27 september by the author(s) will be removed by the organisation. the authors are required to be present to discuss their work with a Poster chairperson during the poster events. Poster chairpersons were nominated by the Programme committee. they will visit the posters at the indicated time. the Poster chairperson is a scientist with knowledge of the respective field of work. he/she will have studied the abstracts and will elaborate on the findings together with the author.

Poster event a: Tuesday 24 September 12:30 ‒ 13:30 h Poster event b: Tuesday 24 September 13:45 ‒ 14:45 h Poster event c: Wednesday 25 September 12:30 ‒ 13:30 h Poster event d: Wednesday 25 September 13:45 ‒ 14:45 h Poster event e: Thursday 26 September 12:30 ‒ 13:30 h Poster event F: Thursday 26 September 13:45 ‒ 14:45 h

16 fp1_2013__ 15.08.13 10:32 Seite 17

security: any suspicious or unidentified items are to be reported immediately to the nearest staff member. security staff are on duty to ensure that all persons entering the venue are wearing a badge. For your safety, it is strongly advised to leave all your valuables in a safe at your hotel.

luggage storage/cloakroom/lost and Found counter: the cloakroom is located on the ground floor in the registration hall. there are facilities to store the delegates` luggage and the lost and found counter is also located in the cloakroom.

internet access unrestricted internet access is available throughout the conference centre.

badges: the delegates’ name badges serve as an admission pass to all scientific sessions and the exhibition. delegates are asked to keep their name badges displayed at all times during the meeting. lost badges can be replaced in special situations and will be charged for.

badge-colours:

17 fp1_2013__ 15.08.13 10:32 Seite 18

transport and accesses to the venue

by Plane barcelona airport: el Prat has two terminals, t1 and t2, in which around 100 companies operate.

direct access from the airport: - by road:12 kilometres away (c-31) - tmb bus: line 46 ("Pl. espanya" stop)

by road the gran Via venue is located in a new business development area, connected to the main motorways and roads to barcelona: aP-7, aP-2, a-2, c-16, c-58, c-31, c-32, c-33

gPs 41.35448, 2.12698

bus tmb lines: 72 and 79, "europa/Fira" station

train Ferrocarrils generalitat de catalunya (Fgc) lines s8, s33, r6, r5, s4,"europa/Fira" station

renfe "barcelona-sants" station, 4 km from the venue, is connected to a complete regional, national and international rail network.

connection gran Via - montjuïc venues - bus: tmb line 79 - Ferrocarrils de la generalitat de catalunya (Fgc) all lines that pass through "europa/Fira" station end their journey at "espanya" station, next to the montjuïc venue.

18 fp1_2013__ 15.08.13 10:32 Seite 19

19 fp1_2013__ 15.08.13 10:32 Seite 20

abstract selection:

Of the 2321 abstracts received by the Association 1360 were accepted for inclusion. All abstracts were considered anonymously and were scored by 40 referees. The Programme Committee Members designed the programme and created Oral and Poster Sessions based upon the abstracts.

abstract review committee: amanda adler, uK, hadi al-hasani, germany, anne bouloumié, France, Karim bouzakri, switzerland, bernard charbonnel, France, mirelle cormont, France, eva corpeleijn, netherlands, leszek czupryniak, Poland, J. hans deVries, nehterlands, Jürgen eckel, germany, Jorge Ferrer, uK, Paul W. Franks, sweden, luigi gnudi, uK, ramon gomis, spain, Per-henrik groop, Finland, gabriella gruden, italy, martin haluzik, czech republic, richard i. g. holt, uK, Peter Kempler, hungary, aileen King, uK, bernd Kowall, germany, anna Krook, sweden, charlotte ling, sweden, Piero marchetti, italy, claudia miele, italy, michael a. nauck, germany, ewan r. Pearson, united Kingdom, shanta J. Persaud, uK, John Petrie, uK, Peter Plomgaard, denmark, giuseppe Pugliese, italy, romano regazzi, switzerland, robert a. ritzel, germany, Peter rossing, denmark, mikael ryden, sweden, naveed sattar, uK, Peter a. senior, canada, anna solini, italy, solomon tesfaye, uK, mark Walker, chair, uK.

Final Programme committee: the Final Programme was selected by the Programme committee: amanda adler, uK, hadi al-hasani, germany, anne bouloumié, France, Karim bouzakri, switzerland, eva corpeleijn, netherlands, Jorge Ferrer, uK, Paul W. Franks, sweden, ramon gomis, spain, Per-henrik groop, Finland, gabriella gruden, italy, michael a. nauck, germany, shanta J. Persaud, uK, guiseppe Pugliese, italy, Peter a. senior, canada, solomon tesfaye, uK, mark Walker, chair, united Kingdom.

20 fp1_2013__ 15.08.13 10:32 Seite 21

Publication of abstracts When submitting an abstract to the easd abstract submission site you accept its publication in the Volume of abstracts as well as online in the easd Virtual meeting, the easd abstract system and in the official easd app for ios and android.

abstracts accepted for presentation have been published in the volume of abstracts and will be sent to easd members one month prior to the easd annual meeting. Furthermore, all accepted abstracts have be published online and can be accessed via the associations’ website, www.easd.org.

embargo policies embargo policies are as follows for presentations for the easd annual meeting:

information contained in those abstracts published online and in the Volume of abstracts have been made available online before the annual meeting takes place. Poster Presentations are under embargo until 11:59 cet on 24 september 2013. oral Presentations are under embargo until one (1) minute following the commencement of the speakers’ presentation.

21 fp1_2013__ 15.08.13 10:32 Seite 22

22 fp1_2013__ 15.08.13 10:32 Seite 23

23 fp1_2013__ 15.08.13 10:32 Seite 24 Break Break rising star Ochoa Hall Servet Hall Carrasco Hall Pi i Sunyer Hall symposium Hall Lecture Albert Renold Ramón y Cajal 12:30 - 13:30 Poster Event A 13:45 - 14:45 Poster Event B A 12:30 - 13:30 Poster Event OP 7OP 8 OP 9 OP 10 OP 11 OP 12 OP lecture Lecture Opening Ceremony Minkowski camillo golgi Pres. Address Pres. tuesday, 24 september tuesday, Time Bernard Hall

9:00 - 9:15 9:15 - 10:30 10:45 - 12:15 1 OP 15:00 - 16:30 2 OP 16:45 - 18:25 3 OP 4 OP 5 OP 6 OP

24 fp1_2013__ 15.08.13 10:33 Seite 25 and lipid system in The endo- ChREBP, a ChREBP, metabolism metabolism and beyond cannabinoid master switch linking glucose coupled players in regulation receptors: T cell: key T in beta cell presentation diabetogenic novel players Activating the Islet G-protein of islet antigens diabetic Diabetes epigenetics nephropathy Novel urinary biomarkers of Break Break diabetes issues in Ochoa Hall Servet Hall Carrasco Hall Pi i Sunyer Hall Neuropathy Psychosocial Hall quality diabetes Diabetes and type 2 technology: Inflammation the search for Ramón y Cajal 12:30 - 13:30 Poster Event C 13:45 14:45 E vent D from OP 19OP 20 OP 21 OP 22 OP 23 OP 24 OP UKPDS: questions Barcelona 15 years on unanswered medications: research and Incretin-based areas of active Time Bernard Hall Wednesday, 25 september Wednesday, 9:00 - 10:30 16:45 - 18:15 10:45 - 12:15 13 OP 15:00 - 16:30 14 OP 15 OP 16 OP 17 OP 18 OP

25 fp1_2013__ 15.08.13 10:33 Seite 26 Pancreas lessons from lessons development: model systems model New pathways and resistance regeneration and regeneration in insulin action Gen. Assembly Gen. Gene– therapies not destiny en route to interactions: environment personalised metabolomics why heredity is Genetics meets current cell-based in diabetes: EASD/JDRF symposium: treatment of therapy in the Lipid-lowering controversies? type 1 diabetes Break type 2 Break Patho- diabetes Bariatric an update 2 diabetes: Ochoa Hall Servet Hall Carrasco Hall Pi i Sunyer Hall physiological phenotypes in surgery in type Hall OP 26OP 27 OP 28 OP 29 OP 30 OP OP 32OP 33 OP 34 OP 35 OP 36 OP a deadly 30 years after DCCT EASD/ESC EASD/ADA intersection heart failure Symposium: Symposium: and diabetes: Ramón y Cajal 12:30 - 13:30 Poster Event E 13:45 14:45 vent F drugs OP 25 OP OP 31 OP and CVD Risks and benefits of DPP-4 inhibitors thursday,26 september Time Bernard Hall 18:30 9:00 - 10:30 10:45 - 12:15 15:00 - 16:30 16:45 - 18:15

26 fp1_2013__ 15.08.13 10:33 Seite 27 Tissue Tissue cross-talk Nutritional epidemiology learnt? to function: what have we From gene loci Break Break Break imaging: the future Metabolic looking to Ochoa Hall Servet Hall Carrasco Hall Pi i Sunyer Hall Hall OP 44OP 45 OP 46 OP 47 OP 48 OP disease diabetes: cardiorenal a surrogate Dogmata in endpoint for albuminura is Ramón y Cajal OP 43 OP better? Lecture Closing Ceremony debate: new the longer Hon. Members basal insulins - Michael Berger EFSD activities Claude Bernard Friday, 27 Friday, september Time Bernard Hall 14:00 9:00 - 10:00 10:15 - 11:15 37 OP - 12:30 11:30 38 OP 39 OP 40 OP 41 OP 42 OP 12:45 - 14:00

27 fp1_2013__ 15.08.13 10:33 Seite 28

claude bernard (1813 - 1878)

this year, easd celebrates the 200th birthday of claude bernard. he was born in saint-Julien en beaujolais on 12 July 1813. in 1834, he moved to Paris to present the manuscript of a drama, but the critique of saint-marc girardin convinced him to study medicine rather than literature. he worked for the physiologist François magendie. the beginning of his career was difficult; he tried to set up a private laboratory for physiology, but the project failed. Finally, he was employed by François magendie and in 1855 he succeeded him as full professor. claude bernard can be considered as the founder of modern physiology; his findings were the basis for the understanding of metabolism. Following numerous experiments, he published in 1848 ‘de l’origine du sucre dans l'économie animale’, where for the first time he described the production of glucose by the liver.1 later, he identified glycogen. he was the first to define the milieu interieur. this mode of thinking opened the way for modern research. he crowned his work publishing ‘introduction à l’étude de la médecine experimentale’.2 the book can still be recommended nowadays to learn a proper scientific approach. giving numerous examples from his own scientific work, he explains how important it is to properly design experiments and to concentrate on an unbiased observation which may contradict a prevailing theory. at the end of his life, claude bernard received numerous honours: he was admitted as a member to the academy of France, where he was sitting near girardin, and he became the head of the museum of natural history. he was accorded a public funeral, which was bestowed on a man of science for the first time in France. the european association for the study of diabetes commemorates claude bernard by having awardied the claude bernard lecture since 1969; the first two recipients, de duve and sutherland, were later awarded the nobel Prize.

1 claude bernard, de l’origine du sucre dans l'économie animale, archives générales de médicine, 1848

2 claude bernard, introduction à l’étude de la médecine experimentale, Paris, librairie delgrave, 1865

28 fp1_2013__ 15.08.13 10:33 Seite 29

santiago ramón y caJal (1852 - 1934)

considered the founding father of modern neuroscience, histologist santiago ramón y cajal was born in Petilla de aragón. he was strongly influenced by his father, a rural surgeon, to study medicine at the university of Zaragoza. after finishing his degree in 1873, he performed doctoral studies at the university of madrid, where his contact with aureliano maestre de san Juan played a decisive role in turning his focus to histology. he held professorship positions in the 1880s and ‘90s at the universities of Valencia, barcelona, and madrid, teaching and investigating first in the area of descriptive anatomy, then in histology and pathological anatomy. in 1897, he published one of his most important works, el sistema nervioso en el hombre y los vertebrados (histology of the nervous system in man and vertebrates).

ramón y cajal learned golgi’s method of staining with silver nitrate and the two were awarded the nobel Prize for Physiology or medicine in 1906 for their contributions towards neuron doctrine as the base of nervous structure and function. he improved the technique and created a gold stain in 1913 for distinguishing neurons from other types of cells and for identifying and describing the structure of nervous tissue in the brains and spinal cords of animals and embryos. he was appointed director of the laboratory of biological research in madrid, which would later be renamed the ramón y cajal institute and where he founded the journal, trabajos del laboratorio de investigaciones biológicas, in which he would publish several of his nearly 300 articles.

ramón y cajal is undoubtedly responsible for stimulating a scientific renaissance in spain and for overturning the intellectual isolation that dominated the country in his era.

29 fp1_2013__ 15.08.13 10:33 Seite 30

seVero ochoa (1905 - 1993)

biochemist severo ochoa was born in luarca but developed an interest in biology while growing up in málaga, where his family resided after his father’s death. influenced by santiago ramón y cajal, he studied medicine at the university of madrid, living at the same student residence as dalí, garcía lorca and other intellectuals, and he developed a method for measuring muscle creatinine. his work appeared in the Journal of biological chemistry in 1929, the same year in which he finished his medical degree. Following graduation, he was invited to study muscle physiology with otto meyerhof at the Kaiser Wilhelm institute for medical research in berlin-dahlem. in the 1930s, ochoa worked as assistant Professor of Physiology and biochemistry in madrid, also pursuing research on the enzyme glyoxalase at the london national institute for medical research with sir henry dale.

When the spanish civil War erupted in 1936, ochoa returned to meyerhof’s laboratory, which had relocated to heidelberg, where he investigated the processes of glycolysis and fermentation. he also performed studies on thiamine at the university of oxford before emigrating to the united states in 1941, this time due to the outbreak of World War ii. he held a number of professorship positions in the u.s., first at Washington university in st. louis, then at new york university, where he went on to become Professor and chair of biochemistry in 1954.

in 1955, ochoa made the discovery of the enzyme polynucleotide phosphorylase, which he determined was necessary to synthesize rna. his findings, along with those made by his american colleague arthur Kornberg one year later, were awarded with the nobel Prize for Physiology or medicine in 1959 and enabled significant future discoveries involving the role of rna intermediaries in the translation of hereditary information into the enzymes that define cell functions and characteristics.

image source: enciclonet, the online encyclopedia in spanish.

30 fp1_2013__ 15.08.13 10:33 Seite 31

miguel serVet (1511 - 1553)

Physician, theologian, and renaissance humanist miguel servet was born in Villanueva de sigena in 1511. he accompanied his patron, the Franciscan Juan de Quintana, to Paris and, after studying law in toulouse, he again travelled with Quintana to bologna for the coronation of emperor charles V. disgusted by the Pope’s display of wealth and the emperor’s support of such pomp, servet abandoned his patron and visited basel and strasbourg, meeting with reformation leaders. in 1531, he published de trinitatis erroribus libri vii, which, with its unconventional Pantheist views on the trinity, was condemned by both catholics and Protestants.

after moving to lyon, servet focused on scientific works, including a translation of Ptolemy’s geographia, and became friends with dr. symphorien champier, who convinced servet to study medicine at the university of Paris. he then practiced as a physician in several French towns, even serving the archbishop of Vienne, while conducting his theological studies in private.

in 1546, servet sent a manuscript of christianismi restitutio to John calvin in geneva, which, by obscuring the redemptive nature of christ, infuriated him. While addressing the concept of regeneration and spirit in the work, servet became the first european to accurately describe the pulmonary circulation of blood. convicted for heresy shortly thereafter, he was burned alive, alongside his manuscript and works, in 1553.

31 fp1_2013__ 15.08.13 10:33 Seite 32

rossend carrasco i Formiguera (1892 - 1990)

rossend carrasco i Formiguera was a highly important figure in catalan and spanish diabetes research in the twentieth century. a native of barcelona, he studied medicine there with august Pi i sunyer, later studying at harvard university (usa). a member of the institute of Physiology and of the catalan biological society, he pioneered studies on diabetes in barcelona, and, together with Pere gonzález, in the 1920s he performed groundbreaking studies in continental europe on the preparation and use of insulin as a means of treating diabetes.

he published his work in international journals of prestige, including the british medical Journal and the american Journal of Physiology. in the 1930s, he worked as an associate professor at the autonomous university of barcelona. having been exiled in 1939 at the end of the war, he became a professor at the university of Puebla and at the national autonomous university of mexico. later in his academic career, he headed the physiology departments of universities in mérida and maracay (Venezuela), finally serving as chair of Physiology at the central university of Venezuela from 1963-1972.

image source: Fundació rossend carrasco i Formiguera

32 fp1_2013__ 15.08.13 10:33 Seite 33

august Pi i sunyer (1879 - 1965)

barcelona-born physiologist august Pi i sunyer played a fundamental role in bringing catalan research to european standards of excellence and in spreading the use of the catalan language as a means of scientific communication. he obtained his medical degree from the university of barcelona in 1899 and his doctorate a year later from the university of madrid, writing his dissertation on anaerobic life. he began his academic career first as a professor of physiology for seville’s medical school and then for barcelona’s, becoming distinguished Professor in 1916.

Pi i sunyer initially conducted his research at the barcelona municipal laboratory under the direction of ramon turró and later founded the institute of Physiology that would bear his name and gain international prestige with numerous research publications. however, when the spanish civil War broke out, the institute was dismantled and Pi i sunyer went into exile in 1939, first heading to Paris briefly, continuing on to Venezuela for many years and finally retiring to mexico. in caracas, he served as Professor of Physiology and biochemistry and founded and directed the institute of experimental medicine, where he also set up a school of physiology similar to the one he had created in barcelona, gaining a large following. With many diverse interests, Pi i sunyer studied and wrote scientific works on the sympathetic nervous system, glycaemic response, circulatory regulation and glucose metabolism, as well as literary works. in 1955, he received the Kalinga Prize for the Popularisation of science from unesco.

image source: the Pi-sunyer family

33 fp1_2013__ 15.08.13 10:33 Seite 34

49th easd annual meeting

17:30 Welcome ceremony Foyer of claude bernard hall followed by

Welcome recePtion monday, 23 monday, september

associations’ Village

the associations’ Village is a special exhibition area, organised by easd in collaboration with idF europe, which brings together international diabetes associations, societies and study groups. each represented association, society and study group has an exhibition stand displaying its current activities and highlighting its work and practices.

the associatons’ Village is located next to the Poster exhibition.

the associations’ Village is a multinational networking platform which aims to further increase and facilitate the exchange of knowledge and experiences among diabetes associations, and to provide information to physicians and researchers from all over the world on the existing professional and patient associations.

at the associations’ Village you will have the opportunity to learn about diabetes in a variety of different countries, speak with colleagues and get the latest information on diabetes research from all over europe, and beyond. representatives at each stand will be happy to answer any questions you may have – it is a wonderful opportunity to obtain information and exchange ideas.

34 fp2_2013__ 15.08.13 10:38 Seite 35

35 fp2_2013__ 15.08.13 10:38 Seite 36

MINKOWSKI PRIZE

The prize will be given in relation to research which has been carried out by a person normally residing in Europe. It is awarded for distinction, manifested by publications which contribute to Tuesday, 24 September Tuesday, 24 the advancement of knowledge concerning diabetes mellitus. The candidate must be less than 45 years of age.

The prize commemorates Oskar Minkowski (1858-1931) who successfully performed the extirpation of the pancreas in dogs in 1889 and noticed that they developed diabetes.

MINKOWSKI LECTURERS

1966 Aarhus P.J. RANDLE, UK 1990 Copenhagen P. A. HALBAN, CH 1967 Stockholm E.R. FROESCH, CH 1991 Dublin C. BOITARD, FR 1968 Louvain L.A. CARLSON, SE 1992 Prague E. VAN SCHAFTINGEN, BE 1969 Montpellier B. HELLMAN, SE 1993 Istanbul H. YKI-JÄRVINEN, FI 1970 Warsaw B. JEANRENAUD, CH 1994 Düsseldorf T. MANDRUP POULSEN, DK 1971 Southampton C.N. HALES, UK 1995 Stockholm J. TODD, UK 1972 Madrid W.J. MALAISSE, BE 1996 Vienna P. RORSMAN, DK 1973 Brussels L. ORCI, CH 1997 Helsinki P. FROGUEL, FR 1974 Jerusalem E. CERASI, SE 1998 Barcelona J.H. AUWERX, FR 1975 Munich P. FREYCHET, FR 1999 Brussels R. SCHARFMANN, FR 1976 Helsinki K.D. HEPP, DE 2000 Jerusalem H. EDLUND, SE 1977 Geneva J. WAHREN, SE 2001 Glasgow J.R. ZIERATH, SE 1978 Zagreb J. NERUP, DK 2002 Budapest B.O. ROEP, NL 1979 Vienna S.J.H. ASHCROFT, UK 2003 Paris M. STUMVOLL, DE 1980 Athens I.-B. TALJEDAL, SE 2004 Munich G.A. RUTTER, UK 1981 Amsterdam P. DE MEYTS, BE 2005 Athens P. ROSSING, DK 1982 Budapest G.F. BOTTAZZO, UK 2006 Copenhagen M. RODEN, AT 1983 Oslo S.L. HOWELL, UK 2007 Amsterdam M. STOFFEL, CH 1984 London A. LERNMARK, DK 2008 Rome J.C. BRÜNING, DE 1985 Madrid E. VAN OBBERGHEN, FR 2009 Vienna G. PERSEGHIN, IT 1986 Rome D. PIPELEERS, BE 2010 Stockholm F. GRIBBLE, UK 1987 Leipzig J.-L. CARPENTIER, CH 2011 Lisbon N. SATTAR, UK 1988 Paris J.C. HUTTON, UK 2012 Berlin T.M. FRAYLING, UK 1989 Lisbon H.U. HÄRING, DE

36 fp2_2013__ 15.08.13 10:38 Seite 37

9:00 - 9:15 OPENING CEREMONY Bernard Hall A.J.M. Boulton, President, EASD and EFSD R. Gomis, Chair, Local Organising Committee

9:15 - 9:45 PRESIDENTIAL ADDRESS A.J.M. Boulton, President, EASD and EFSD

9:45-10:30 48TH MINKOWSKI LECTURE A.J.M. Boulton, President, EASD and EFSD Speaker: M. Cnop, Belgium

Title: The heart of the matter: beta cells in diabetes

Miriam Cnop obtained her medical degree at the Vrije Universiteit Brussel. Training in Internal Medicine and Endocrinology, she obtained a PhD for her work on the effects of lipoproteins and free fatty acids on beta cells. Tuesday, 24 Tuesday, September She worked as a postdoctoral fellow in the laboratory of S. Kahn at the University of Washington, before joining the Endocrine Division of the Erasmus Hospital & Laboratory of Experimental Medicine, directed by D. Eizirik, at the Université Libre de Bruxelles. Her group focusses on the role of pancreatic beta cell and apoptosis in the pathogenesis of monogenic and type 2 diabetes, to develop strategies to improve beta cell function and mass. They identified ER stress as a cellular response contributing to free fatty acid-induced beta cell apoptosis. Using small molecules and RNA interference strategies to modulate ER stress response and mitochondrial pathways of cell death, her team is elucidating signal transduction by which free fatty acids induce beta cell apoptosis and searches therapeutic targets to protect beta cells. They also study mutations in genes with a role in ER and mitochondrial function and have demonstrated that beta cell dysfunction and death are central in the pathogenesis of diabetes in Friedreich's ataxia, where frataxin deficiency leads to mitochondrial dysfunction.

Her awards include: Endocrinology Prize by the Belgian Royal Academy of Science 2003, Belgian Novo Nordisk Prize for Diabetology 2004, EASD Rising Star 2005, Belgian Endocrine Society Award 2010, and GB Morgagni Young Investigator Award 2010. She served as Associate Editor and is member of the Advisory Board of Diabetologia.

37 fp2_2013__ 15.08.13 10:38 Seite 38

10:45 - 12:15 Bernard Hall

OP 01 Individualising the choice among GLP-1 receptor agonists

Chair: F.K. Knop, Denmark, M.A. Nauck, Germany

Tuesday, 24 September Tuesday, 24 1 Glycaemic control and hypoglycaemia in metformin-treated T2DM patients with exenatide BID vs insulin lispro TID added to titrated insulin glargine QD: the 4B trial B.H. Wolffenbuttel, M.A. Nauck, R. Shaginian, J. Malone, S. Cleall, D. De Vries, B. Hoogwerf, L. MacConell, M. Diamant, Netherlands, Germany, USA, UK

2 Sustaining HbA1c control over three years during treatment with exenatide once weekly compared with insulin glargine J. Malloy, B. Guerci, M. Trautmann, W. Huang, J. Han, M. Diamant, USA, France, Germany, Netherlands

3 Positive effects of liraglutide as adjunct to insulin in type 1 diabetes: glycaemic control and safety in a randomised, double blind, placebo controlled crossover trial S.R. Heller, S. Korsatko, J. Gurban, L. Jensen, E. Christiansen, F. Kiyomi, T.R. Pieber, UK, Austria, Denmark, Japan

4 Efficacy and safety of dulaglutide vs metformin in type 2 diabetes (AWARD-3) S. Tofé Povedano, G. Umpierrez, F. Perez Manghi, L. Shurzinske, V. Pechtner, Spain, USA, Argentina, France

5 HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin S. Johnson, B. Ahrén, M. Stewart, D. Cirkel, F. Yang, C. Perry, USA, Sweden, UK

6 Therapeutic efficacy of lixisenatide added to basal insulin is greater when FPG is well-controlled J. Vidal, R. Aronson, F. Giorgino, M. Fisher, P. Miossec, W. Stager, D. Raccah, L.E. Litwak, M. Riddle, Spain, Canada, Italy, UK, France, USA, Argentina

38 fp2_2013__ 15.08.13 10:38 Seite 39

10:45 - 12:15 Ramón y Cajal Hall

OP 02 Predictors of cardiovascular disease

Chair: E. Esmatjes, Spain, N. Sattar, UK

7 Risk factors for stroke and subtypes of stroke in patients with type 1 diabetes S. Hägg, L.M. Thorn, C.M. Forsblom, D. Gordin, M. Saraheimo, J. Wadén, R. Liebkind, J. Putaala, T. Tatlisumak, P.-H. Groop, FinnDiane Study Group, Finland

8 ProBNP strongly predicts future macrovascular events independently from the baseline coronary artery disease state in patients with and without type 2 diabetes C.H. Saely, P. Rein, A. Vonbank, H. Drexel, Austria, Liechtenstein, USA

9 Biomarkers for prediction of CVD in type 2 diabetes Tuesday, 24 Tuesday, September I. Brady, H.C. Looker, M. Colombo, T. Zeller, B. Thorand, L. Groop, C.N. Palmer, A. Hamsten, U. De Faire, E. Nogoceke, N. Barbarini, F.V. Agakov, P.M. McKeigue, H.M. Colhoun, on behalf of the SUMMIT Investigators, UK, Germany, Sweden, Switzerland, Italy

10 Metabolic profiles improve the prediction of cardiovascular events in elderly patients S. Rizza, M. Copetti, M. Cianfarani, A. Luzi, C. Pecchioli, A. Urbani, C. Rossi, G. Di Cola, F. Pellegrini, M. Federici, Italy

11 Low concentrations of testosterone predict acute myocardial infarction in men with type 2 diabetes mellitus B. Daka, U. Lindblad, C.A. Larsson, T. Rosen, P. Jansson, L. Råstam, R.D. Langer, Sweden, USA

12 Soluble C5b-9, a marker for terminal complement activation, is not associated with markers of atherosclerosis or prevalent cardiovascular disease: The CODAM study E. Hertle, M.M. Van Greevenbroek, I.C. Arts, C.J. Van der Kallen, I. Ferreira, E.J. Feskens, C.G. Schalkwijk, C.D. Stehouwer, Netherlands

39 fp2_2013__ 15.08.13 10:38 Seite 40

10:45 - 12:15 Ochoa Hall

OP 03 Biomarkers and risk scores, out with the old, in with the new?

Chair: S.J.L. Bakker, Netherlands, A. Novials, Spain

Tuesday, 24 September Tuesday, 24 13 Calcium concentration predicts future development of diabetes and impaired glucose tolerance: the Insulin Resistance Atherosclerosis study C. Lorenzo, A.J. Hanley, S.M. Haffner, USA, Canada

14 Visceral adiposity predicts incident diabetes more strongly in South Asians than in Europeans or African Caribbeans, independent of insulin resistance and other fat depots S.V. Eastwood, T. Tillin, A. Wright, J. Heasman, A. Hughes, N. Chaturvedi, UK

15 A simple self-assessment score for predicting the risk of non-alcoholic fatty liver disease Y.-H. Lee, H. Bang, Y. Park, E. Kang, B.-W. Lee, K.J. Kim, B. Cha, H. Lee, J. Bae, W. Lee, D. Kim, Korea, Republic of, USA

16 Investigating the validity of the UKPDS outcomes equations in current clinical practice T. Ward, P. McEwan, K. Bergenheim, UK, Sweden

17 Skin collagen advanced glycation endproducts (AGEs) as prospective markers of sub-clinical cardiovascular disease (CVD) outcomes in type 1 diabetes V.M. Monnier, W. Sun, D.R. Sell, P.A. Cleary, J.M. Lachin, S.M. Genuth, DCCT/EDIC Research Group, USA

18 Assessment of serum ghrelin as a biomarker of HNF1A-MODY N. Nowak, J. Skupien, M. Szopa, I. Solecka, M. Malecki, Poland, USA

40 fp2_2013__ 15.08.13 10:38 Seite 41

10:45 - 12:15 Servet Hall

OP 04 Beta cell genes and type 2 diabetes

Chair: F. Bosch, Spain, L. Groop, Sweden

19 The P300/CBP-associated factor (PCAF) is a histone acetyl transferase that controls beta cell function J.-S. Annicotte, N. Rabhi, C. De Bettignies, P.-D. Denechaud, A. Bonnefond, P. Froguel, France, Switzerland

20 Exploration of novel genes contributing to pathogenesis of type 2 diabetes in human pancreatic islets J. Taneera, M. Zhang, J. Fadista, U. Krus, E. Renström, L. Groop, Sweden

21 Paternal allelic mutation at the Kcnq1 locus reduces pancreatic beta cell mass via epigenetic modification of Cdkn1c

H. Inoue, S.-I. Asahara, H. Etoh, K. Teruyama, Y. Ihara, T. Matsuda, 24 Tuesday, September M. Koyanagi-Kimura, A. Kanno, K. Nagashima, W. Nishimura, K. Yasuda, N. Inagaki, S. Seino, M. Kasuga, Y. Kido, Japan

22 Hypoxia alters the expression of the type 2 diabetes-associated Zn2+ transporter Slc30a8/ZnT8 and cytosolic Zn2+ levels in human and rodent islets P.A. Gerber, E.A. Bellomo, G. Meur, D.J. Hodson, A. Solomou, M. Hollinshead, F. Chimienti, V.J. Lavallard, D. Bosco, S.J. Hughes, P.R. Johnson, G.A. Rutter, UK, France, Switzerland

23 IGF-2 expression in beta cells induces susceptibility to develop diabetes A. Casellas, C. Mallol, A. Salavert, V. Jimenez, M. Obach, M. Garcia, J. Agudo, M. Molas, R. Lage, L. Vilà, M. Morró, J. Ruberte, F. Bosch, Spain

24 Carriers of loss-of-function mutations in EXT display impaired pancreatic beta cell reserve due to smaller pancreas volume S.J. Bernelot Moens, H.L. Mooij, H.C. Hassing, J.K. Kruit, J.J. Witjes, M.A. Van de Sande, A.J. Nederveen, G.M. Dallinga-Thie, E.S. Stroes, M. Nieuwdorp, Netherlands

41 fp2_2013__ 15.08.13 10:38 Seite 42

10:45 - 12:15 Carrasco Hall

OP 05 New frontiers in autoantibody epidemiology

Chair: L.A. Castaño Gonzalez, Spain, M. Knip, Finland

Tuesday, 24 September Tuesday, 24 25 N-terminally truncated GAD discriminates progression in GAD antibody positive relatives of patients with type 1 diabetes A.J. Williams, V. Lampasona, M. Schlosser, P.W. Mueller, D. Pittman, W.E. Winter, R. Wyatt, B. Akolkar, P.J. Bingley, P. Achenbach, UK, Italy, Germany, USA

26 PTPN2 rs45450798 polymorphism is associated with accelerated progression of beta cell autoimmunity to clinical type 1 diabetes J. Lempainen, A.-P. Laine, A. Hammais, R. Veijola, O. Simell, M. Knip, J. Ilonen, Finland

27 Relation between beta cell autoimmunity and levels of allergen-specific IgEs in young Finnish and Estonian children H. Siljander, A. Peet, V. Tillmann, T. Härkönen, O. Niemelä, J. Ilonen, L. Von Hertzen, T. Haahtela, E. Von Mutius, M. Knip, Finland, Estonia, Germany

28 Incidence of type 1 diabetes in Sweden 2007-2011: reassessing the spring harvest theory A. Rawshani, M. Landin-Olsson, A.-M. Svensson, H.J. Arnqvist, L. Nyström, J. Bolinder, S. Gudbjörnsdottir, Sweden

29 Enterovirus RNA in longitudinal blood samples from children at the highest genetic risk of type 1 diabetes, and the development of islet autoimmunity: the MIDIA study O. Cinek, L.C. Stene, L. Kramná, G. Tapia, S. Oikarinen, E. Witsø, K. Holkova, T. Rasmussen, H. Hyöty, K.S. Rønningen, Czech Republic, Norway, Finland

30 NPY minor autoantibodies in newly diagnosed type 1 diabetes patients H. Skärstrand, F. Vaziri-Sani, C. Andersson, H. Elding-Larsson, S. Ivarsson, Å. Lernmark, Skåne Study Group, Sweden

42 fp2_2013__ 15.08.13 10:38 Seite 43

10:45 - 12:15 Pi i Sunyer Hall

OP 06 Molecular players in adipogenesis

Chair: H. Al-Hasani, Germany, A. Bouloumié, France

31 The novel adipokine WISP2 regulates adipogenesis and is a canonical Wnt ligand J.R. Grünberg, A. Hammarstedt, S. Hedjazifar, U. Smith, Sweden

32 BMPs regulate glucose uptake in 3T3L1 adipocytes in an insulin independent manner K. Ruschke, G. Doerpholz, P. Knaus, Germany

33 SHORT syndrome with partial lipodystrophy due to impaired PI 3-kinase signalling P.R. Njolstad, K.K. Chudasama, J. Winney, S. Johansson, T. Claudi, R. Koenig, I. Haldorsen, B. Johansson, J.R. Woo, D. Aarskog, J.V. Sagen, Tuesday, 24 Tuesday, September C. Kahn, A. Molven, USA, Norway, Germany

34 The role of microRNA 107 in the regulation of adipogenesis D. Löffler, D. Rockstroh, W. Kiess, A. Körner, Germany

35 Regulation of PPARγ activity by a novel serine phophorylation T. Oh, B.-H. Park, Y.-H. Lee, Korea, Republic of

36 The transcription factor Prep1 impairs adipose tissue differentiation A. Liotti, F. Oriente, S. Cabaro, I. Cimmino, F. Ariemma, S. Ricci, F. Blasi, P. Formisano, F. Beguinot, Italy

43 fp2_2013__ 15.08.13 10:38 Seite 44

Poster Events

Poster presentations rank equally with oral presentations at EASD Meetings. Posters must be displayed throughout the duration of the Meeting and should be already mounted in the morning of the first day and removed at the end of the EASD Meeting. The posters must be accessible at any time

Tuesday, 24 September Tuesday, 24 during the hours of the Annual Meeting. Furthermore, all posters are presented at six one hour Poster Discussion Sessions which will be held on Tuesday, Wednesday and Thursday from 12:30 to 14:45, when no other scientific sessions will take place. These sessions offer an excellent opportunity for direct scientific exchange.

During the Poster Presentation Sessions, the presenting author must be present or make arrangements for somebody with knowledge of the displayed work to be present at the poster. An average of 3 to 5 minutes will allow for each author to present the poster, followed by open discussion of 3 to 5 minutes (depending on the number of abstracts in the poster session). Participants can collect a headset to follow the presentations within the corresponding sessions.

EASD will also make posters available via its Virtual Meeting. Participants are invited to discuss and comment on the posters using the Virtual Conference Tool.

12:30 - 14:45 Poster Events and Lunch

44 fp2_2013__ 15.08.13 10:38 Seite 45

12:30 - 13:30 Poster Event A Page

PS 001 Managing and monitoring diabetes: who does well and who doesn't? 121

PS 007 Basic science: environmental factors 128

PS 013 Genetics: discovering genes 136

PS 019 Risk markers for type 2 diabetes 143

PS 025 Insulin secretion in vitro 150

PS 031 ER stress and apoptosis 157

PS 037 Clinical hypoglycaemia 165

PS 043 Beta cell function in man 173 Tuesday, 24 Tuesday, September PS 049 Mitochondria, ROS and metabolism 181

PS 055 Exercise, muscle and lipid metabolism 189

PS 061 Fatty liver: rodent studies 197

PS 067 Preventing and treating diabetes: the nutrition impact 205

PS 073 SGLT-2 clinical trials 213

PS 079 Novel approaches to treat type 1 and type 2 diabetes 222

PS 085 Hypoglycaemia in type 1 and type 2 diabetes 231

PS 091 Insulin pumps in clinical practice 238

PS 097 Health economics: living better? at what cost? 246

PS 103 Basic science retinopathy: novel in vitro and in vivo findings 254

PS 109 Pregnancy: treatment, efficacy and safety 261

PS 115 Other diabetic complications 269

45 fp2_2013__ 15.08.13 10:38 Seite 46

13:45 - 14:45 Poster Event B Page

PS 002 HbA1c measurement and outcomes 122

PS 008 Genetics: functional studies 129

Tuesday, 24 September Tuesday, 24 PS 014 Nutrition and mechanisms in diabetes: observational studies 137

PS 020 Circulating biomarkers in prediction of diabetes 144

PS 026 Beta cell metabolism and mitochondrial function 152

PS 032 Islet cell toxicity and survival 158

PS 038 Hypoglycaemia mechanism and prevention 166

PS 044 Incretins: secretions and action 174

PS 050 Gender: difference and sex hormones in metabolism 182

PS 056 Adipose tissue: expandability 191

PS 062 Signalling in adipocyte metabolism 198

PS 068 Mechanistic insights: GLP-1-based medications and GPR40 agonists 206

PS 074 SGLT-2 inhibitors: influence on cardiovascular risk factors 215

PS 080 Novel agents: novel mechanisms 223

PS 086 Insulin adjustment and self-management 232

PS 092 Delivering diabetes care 240

PS 098 Inflammation and immunity: links to clinical practice 248

PS 104 Clinical retinopathy 256

PS 110 Pregnancy outcomes in GDM 263

PS 116 Cerebrovascular and peripheral artery disease 270

46 fp2_2013__ 15.08.13 10:38 Seite 47

15:00 - 16:30 Bernard Hall

OP 07 Type 1 diabetes: lifetime impacts

Chair: T.J. Orchard, USA, B. Zinman, Canada

37 A comparison of type 1 diabetes phenotype in a young multi-ethnic urban population T. Brabarupan, S. Misra, N.S. Oliver, UK

38 An international collaboration to compare glycaemic control among people with type 1 diabetes J.A. McKnight, International quality of care for type 1 diabetesgroup, UK

39 The impact of a childhood onset of type 1 diabetes on higher education and labour market outcomes S. Persson, G. Dahlquist, U.G. Gerdtham, K. Steen Carlsson, Sweden Tuesday, 24 Tuesday, September 40 Early retirement in patients with type 1 diabetes: data from a nationwide multicentre survey in Brazil M.B. Gomes, C.A. Negrato, Brazilian Diabetes Type 1 Study Group, Brazil

41 15 year follow-up of quality of life in type 1 diabetes mellitus: no impact of treatment mode (FANTA-1) P.R. Van Dijk, S.J. Logtenberg, K.H. Groenier, N. Kleefstra, H.J. Bilo, Netherlands

42 Explanatory factors of emotional diabetes distress and glycaemic control in type 1 diabetes L.E. Joensen, T. Almdal, I. Willaing, Denmark

47 fp2_2013__ 15.08.13 10:38 Seite 48

15:00 - 16:30 Ramón y Cajal Hall

OP 08 Incretins: what's new?

Chair: V.A. Gault, UK, T. Mandrup-Poulsen, Denmark

Tuesday, 24 September Tuesday, 24 43 GLP-1 and the DPP-IV inhibitor saxagliptin similarly protect human beta cells from palmitate-induced toxicity: potential role of autophagy regulation M. Bugliani, F. Syed, M. Suleiman, F. Olimpico, U. Boggi, M. Masini, P. Masiello, F. Filipponi, L. Marselli, P. Marchetti, Italy

44 Direct enhancement of insulin secretion by dipeptidyl peptidase 4 inhibitors in pancreatic islets: studies in incretin receptor deficient mice B. Omar, L. Ohlsson, Y. Yamada, Y. Seino, B. Ahren, Sweden, Japan

45 Pulsatile secretion of glucagon-like peptide-1(GLP-1) from pancreatic alpha cells: evidence for independent mechanism from intestinal GLP-1 secretion in rodents K. Nakashima, S. Hamamoto, Y. Kimura, M. Shimoda, K. Tawaramoto, H. Hirukawa, T. Kimura, S. Okauchi, K. Kaku, Japan

46 Novel glucagon receptor antagonist peptides help alleviate streptozotocin induced diabetes and preserve beta cell function in mice F.P. O'Harte, L.M. McShane, N. Irwin, UK

47 Exenatide, a GLP-1 receptor agonist, activates glucose transport in L6 muscle cell by an AMPK-dependent mechanism F. Andreozzi, C. Nigro, G.A. Raciti, C. Miele, F. Folli, Italy, USA

48 Oxyntomodulin has significant acute glucoregulatory effects comparable to liraglutide in subjects with type 2 diabetes S.S. Shankar, R. Shankar, L. Mixson, B. Pramanik, S. Stoch, H.O. Steinberg, D.E. Kelley, USA

48 fp2_2013__ 15.08.13 10:38 Seite 49

15:00 - 16:30 Ochoa Hall

OP 09 Retinopathy: risk stratification and novel therapies

Chair: H.-P. Hammes, Germany, M. Porta, Italy

49 Pre-pubertal onset of diabetes may delay development of retinopathy: possible influence of metabolic control and blood pressure F. Schellino, G. Curletto, E. Coppo, A. Raviolo, E. Sitia, S. Albani, P. Dalmasso, F. Cavallo, F. Cerutti, M. Trevisan, M. Trento, M. Porta, Italy

50 Twenty years on from UKPDS: More or less diabetic retinopathy at diagnosis of type 2 diabetes? S.J. Aldington, I.M. Stratton, A. Sallam, M. Histed, P.H. Scanlon, UK

51 Validation of an individualised screening model for diabetic retinopathy I. Walraven, A.A. Van der Heijden, E. Van 't Riet, T. Aspelund, S.H. Lund, P. Elders, A.C. Moll, B.C. Polak, J.M. Dekker, G. Nijpels, Netherlands, Tuesday, 24 Tuesday, September Iceland

52 Polyphenol-enriched cocoa protects the diabetic retina from glial reaction and oxidative stress through the sirtuin (SIRT-1) pathway D.A. Duarte, M.M. Rosales, A. Papadimitriou, K.C. Silva, M. Vitelo, J.B. Lopes de Faria, J.M. Lopes de Faria, Brazil

53 Pioglitazone increases the risk of diabetic macular oedema in patients with type 2 diabetes K. Fujimoto, Y. Hamamoto, S. Honjo, H. Tatsuoka, A. Matsuoka, Y. Wada, H. Ikeda, J. Fujikawa, I. Saito, H. Koshiyama, Japan

54 36-month safety and efficacy of ranibizumab in diabetic macular oedema: the RESTORE extension study (final analysis) A. Boixadera, J. Garcia-Arumi, Spain

49 fp2_2013__ 15.08.13 10:38 Seite 50

15:00 - 16:30 Servet Hall

OP 10 In-patient diabetes: rights and wrongs

Chair: I. Conget, Spain, J.B. Green, USA

Tuesday, 24 September Tuesday, 24 55 Glycaemic variability is not related to postoperative complications in elective cardiac surgery patients on tight glucose control M. Mraz, P. Kopecky, M. Lips, J. Lindner, S. Svacina, J. Blaha, M. Haluzik, Czech Republic

56 Short term continuous subcutaneous insulin infusion (CSII): a boon for type 2 diabetic patients with severe hyperglycaemia undergoing urgent surgical procedures K.P. Singh, H. Chohan, N.C. Raina, A. Jindal, M. Galhotra, India

57 Comparison of inpatient glycaemic control by continuous glucose monitoring (CGM) and capillary point-of-care (POC) testing in general medicine patients with type 2 diabetes A.M. Gomez, G.E. Umpierrez, P. Aschner, F. Herrera, O. Muñoz, Colombia, USA

58 Randomised clinical trial to assess efficacy of two insulin protocols in hospitalised subjects with type 2 diabetes mellitus receiving medium/high dose of corticosteroids: preliminary results M.S. Ruiz de Adana, S. Valdés, N. Colomo, F. García-Torres, M.I. Fontalba, F. Linares, C. Maldonado, R. Fernández, F. Soriguer, Spain

59 The safety and efficacy of a subcutaneous continuous glucose monitoring system compared to point of care measurement in critically ill patients: a randomised controlled trial D.T. Boom, S. Rijkenberg, S. Kreder, M.K. Sechterberger, P.H. Van der Voort, Netherlands

60 Continuous glucose monitoring at the intensive care unit: nursing workload reduction and cost-benefit analysis M.K. Sechterberger, J.H. DeVries, P.H. Van der Voort, Netherlands

50 fp2_2013__ 15.08.13 10:38 Seite 51

15:00 - 16:30 Carrasco Hall

OP 11 Exercise physiology and impact on ageing

Chair: F. Amati, Switzerland, H. Bodansky, UK

61 Effect of chronic exercise on skeletal muscle mitochondria dynamics in older adults C. Greggio, N.T. Broskey, M. Boutant, C. Canto, F. Amati, Switzerland

62 The effect of exercise training on skeletal muscle mitochondrial content in older adults correlates with exercise efficiency and fat oxidation N.T. Broskey, E.-J. Fares, C. Greggio, F. Amati, Switzerland

63 Electrodiab study: impact of bi-quadricipital muscular electrostimulation on insulin sensitivity in type 2 diabetic subjects M. Joubert, L. Metayer, G. Prevost, A. Rod, J. Morera, J. Morera, Y. Reznik, France Tuesday, 24 Tuesday, September

64 Increased IGF-I bioavailability ameliorates the decline in insulin sensitivity that occurs with ageing and type 2 diabetes P. Crossey, D.T. Jones, Ireland

65 Effect of exercise training and resveratrol on HFD-induced changes in skeletal muscle PDHa activity: impact of PGC-1 alpha R.S. Biensø, S. Larson, C.M. Kristensen, N. Brandt, J. Olesen, H. Pilegaard, Denmark

66 Exercise - but not resveratrol - increases performance and oxidative proteins in elderly human skeletal muscle J. Olesen, L. Gliemann, R.S. Biensø, J. Schmidt, Y. Hellsten, H. Pilegaard, Denmark

51 fp2_2013__ 15.08.13 10:38 Seite 52

15:00 - 16:30 Pi i Sunyer Hall

OP 12 FGF21 cures it all?

Chair: M. Stumvoll, Germany, H. Vidal, France

Tuesday, 24 September Tuesday, 24 67 High glucose represses fibroblast growth factor 21 (FGF21) action through peroxisome proliferator-activated receptor gamma in mouse pancreatic islets W.Y. So, Q. Cheng, L. Chen, C.E. Molina, A. Xu, K.S. Lam, P.S. Leung, China, USA

68 Glucagon like peptide 1 (GLP1) in combination with fibroblast growth factor 21 (FGF21) enhances browning of white adipose tissue T. Coskun, L.S. O'Farrell, A.L. Kauffman, A. Efanov, A.C. Adams, USA

69 FGF21 knockdown exacerbates hepatic insulin resistance via STAT3/SOCS3 pathway Y. Lei, L. Li, G. Yang, China

70 Alpha lipoic acid induces hepatic FGF21 expression via up-regulation of Nur77 and CREBH K.-H. Bae, A.-K. Min, K.-G. Park, I.-K. Lee, Korea, Republic of

71 Brown adipose tissue, a sink of glucose disposal? Effects of FGF21 on glucose metabolism in brown adipose cells F. Villarroya, E. Hondares, J. Diaz-Delfin, R. Iglesias, M. Giralt, Spain

72 FGF21 resistance relevant to insulin resistance in skeletal muscle of patients with type 2 diabetes M. Lee, J. Jeon, E. Ha, S.-E. Choi, T. Kim, S.-Y. Ahn, S. Han, H. Kim, D. Kim, Y. Kang, K.-W. Lee, Korea, Republic of

52 fp2_2013__ 15.08.13 10:38 Seite 53 Tuesday, 24 Tuesday, September

53 fp2_2013__ 15.08.13 10:38 Seite 54

CAMILLO GOLGI PRIZE

Camillo Golgi (1843 - 1926) was awarded the Nobel Prize in 1906 for his studies on the nervous system and kidney physiology. The EASD Camillo Golgi Prize is awarded for Tuesday, 24 September Tuesday, 24 outstanding contributions in the field of the histopathology, pathogenesis, preven tion and treatment of the complications of diabetes mellitus, which have been carried out in Europe by a member of EASD normally resident in Europe. The awardee delivers a lecture named in honour of Camillo Golgi at the EASD Annual Meeting in the year of the award.

CAMILLO GOLGI LECTURERS:

1986 Rome G.C. VIBERTI, UK 1987 Leipzig D.J. EWING, UK 1988 Paris C.E. MOGENSEN, DK 1989 Lisbon G.B. BOLLI, IT 1990 Copenhagen P.J. WATKINS, UK 1991 Dublin R. OSTERBY, DK 1992 Prague E. KOHNER, UK 1993 Istanbul K.F. HANSSEN, DK 1994 Düsseldorf J.E. TOOKE, UK 1995 Stockholm R. LANDGRAF, DE 1996 Vienna M.-R. TASKINEN, FI 1997 Helsinki H.-H. PARVING, DK 1998 Barcelona D.R. TOMLINSON, UK 1999 Brussels E. STANDL, DE 2000 Jerusalem U. DI MARIO, IT 2001 Glasgow A. FLYVBJERG, DK 2002 Budapest J. TUOMILEHTO, FI 2003 Paris A. J. M. BOULTON, UK 2004 Munich A. CERIELLO, IT 2005 Athens C. STEHOUWER, NL 2006 Copenhagen M. LAAKSO, FI 2007 Amsterdam P. FIORETTO, IT 2008 Rome A. AVOGARO, IT 2009 Vienna P.-H. GROOP, FI 2010 Stockholm D. ZIEGLER, DE 2011 Lisbon A. BIERHAUS, DE 2012 Berlin G. PUGLIESE, IT

54 fp2_2013__ 15.08.13 10:38 Seite 55

16:45 - 17:45 28TH CAMILLO GOLGI LECTURE Bernard Hall

Chair: A.J.M. Boulton, President, EASD and EFSD P.-H. Groop, Finland Speaker: T. Lauritzen, Denmark

Title: A journey from insulin absorption to screening for type 2 diabetes

Torsten Lauritzen has worked as a general practitioner in Ebeltoft, Denmark since 1983 and has served as Professor in general practice medicine at the University of Aarhus, Department of Public Health since 1996.

Lauritzen started his research career in diabetes in 1975 as a medical student exploring how insulin was absorbed following subcutaneous injections. He Tuesday, 24 Tuesday, September discovered huge intra-individual variation in absorption of intermediate acting insulins like insulin NPH. These variations were associated with considerable intra- individual day-to-day variations in blood glucose. He then demonstrated the pharmacokinetic advantages of multiple injections and insulin pump treatment and became the daily leader of the first randomised controlled trial demonstrating near normalisation of blood glucose with insulin pump treatment compared to routine care. This research became the backbone of his doctoral thesis in 1985. In 1983, he decided to go into general practice and introduced clinical guidelines to general practitioners in Denmark. He served as chairman of the Danish Society for General Practice from 1997 to 1999, introducing clinical guidelines within other disease areas.

As a general practitioner, his main research focus became health tests and health talks for the population, quality improvement in care for people with type 2 diabetes and screening for diabetes. He became chair of the international scientific steering committee for the Anglo-Danish-Dutch study on intensive treatment of people with screen detected diabetes in primary care (ADDITION study). Lauritzen has also served as primary investigator in the LuCamp project which identifies genes associated with the development of diabetes and the effect of pharmacological treatment. Lauritzen has published over 300 articles. Furthermore, he participated as a principal investigator in the first DAWN study.

55 fp2_2013__ 15.08.13 10:38 Seite 56

ALBERT RENOLD PRIZE

The Albert Renold Prize and Lecture honours the memory of A. Renold, the distinguished diabetologist and researcher. The aim of the Lectureship is to recognise an individual's outstanding contribution to the Tuesday, 24 September Tuesday, 24 advancement of knowledge in the field of research on the islets of Langerhans. Not only do many generations of scientists consider A. Renold their principal mentor, but he was also one of the founding fathers of EASD, serving as Honorary Secretary (1965-1969) and President (1974-1977). He trained with the eminent diabetologist, Dr. E.P. Joslin, and was the first full-time director of the Joslin Research Laboratory in the mid- 1950s. In 1963, he returned to Geneva, where he founded the lnstitut de Biochimie Clinique. Under his A. Renold leadership, it became an international centre of 1923 - 1988 excellence in islet research until his death in 1988.

P. Langerhans Jr. was born in Berlin and entered the famous “School of the Grey Monastery” in the same city. He began medical studies at the University of Jena and completed them in Berlin. The discovery of the islets of Langerhans was published in his thesis in 1869. Later he became Professor of Pathology in Freiburg. He also gained fame due to his discovery of the Langerhans cells in the skin. In 1887, while living on the island of Madeira, progressive renal failure brought his medical activities to an end and he died of uraemia in 1888.

ALBERT RENOLD LECTURERS P. Langerhans Jr. 2007 Amsterdam F. ASHCROFT, UK 1847 - 1888 2008 Rome J.-C. HENQUIN, BE 2009 Vienna B. THORENS, CH 2010 Stockholm S. SEINO, JP 2011 Lisbon M. PRENTKI, CA 2012 Berlin D.L. EIZIRIK, BE

56 fp2_2013__ 15.08.13 10:38 Seite 57

16:45 - 17:45 7TH ALBERT RENOLD LECTURE Ramón y Cajal Hall

Chair: P.A. Halban, Switzerland Speaker: P. Rorsman, UK

Title: The pancreatic islet: more than the sum of its parts?

Patrik Rorsman received his Medical Degree from Uppsala University, in his native Sweden, where, in 1986, he also received his PhD from the Department of Medical Cell Biology, for his thesis Patch-clamp characterisation of pancreatic alpha and beta cells. While formally enrolled as a research student at Uppsala University, he undertook additional training in the laboratory of Bert Sakmann (Nobel Prize 1991) at the Max Planck Institute for Biophysical Chemistry, Goettingen, Germany. Tuesday, 24 Tuesday, September

Since 2003 he serves as Professor of Diabetic Medicine at the University of Oxford. He has published more than 200 papers dealing with the function of the pancreatic islet cells and has performed pioneering studies on the cellular and molecular regulation of pancreatic islet hormone secretion, the mechanisms that underlie the ability of the different types of islet cell (beta cells, but also alpha cells and delta cells) to sense changes in the plasma glucose concentration, and how these processes become disrupted in diabetes mellitus (T2DM).

He has provided evidence that dysregulation of glucagon and somatostatin secretion contributes to islet dysfunction in T2DM and, by examining the mode of action of sulphonyureas and glucagon-like peptide 1 (GLP-1) analogues on both alpha and beta cells, he has also made important contributions to our understanding of diabetes therapy. A significant recent contribution is his demonstration of important differences in the functional properties of human and rodent islets.

He holds major international and national research grants and has collaborators worldwide; he welcomes interdisciplinary studies and shares his science generously and with experts in both clinical and biophysical research. His achievements have been recognised by several bodies and he has received numerous awards including the EASD Minkowski Prize in 1996.

57 fp2_2013__ 15.08.13 10:38 Seite 58

16:45 - 18:25 RISING STAR SYMPOSIUM Ochoa Hall

Chair: V. Lyssenko, Sweden, M. Walker, UK

The Rising Star Symposium aims to identify promising and innovative young researchers who are developing their research activities in Europe. Selected

Tuesday, 24 September Tuesday, 24 candidates will have the opportunity to present an overview of their past and ongoing research activities during a multidisciplinary research symposium at the EASD Annual Meeting. Four candidates have been selected. The candidates will receive a commemorative certificate. The candidates must be under the age of 38 on 1 January 2013. Preference will be given to individuals who normally reside in Europe and who have consistently pursued a well defined and innovative research line, leading to several publications in high impact peer reviewed journals.

Speaker: A. Rosengren, Sweden Title: Combining bioinformatics and islet studies to explore the pathophysiology of type 2 diabetes

Speaker: J.A. Pospisilik, Germany Title: Towards understanding the energetic and epigenetic control of beta cell dedifferentiation

Speaker: D.J. Preiss, UK Title: The CAMERA study: investigating the effects of metformin in non-diabetic patients with coronary heart disease

Speaker: G. Sumara, France Title: Signalling cascades in regulation of metabolism

58 fp2_2013__ 15.08.13 10:38 Seite 59 Tuesday, 24 Tuesday, September

59 fp2_2013__ 15.08.13 10:38 Seite 60

9:00 - 10:30 Bernard Hall

UKPDS: 15 years on from Barcelona

Wednesday, 25 25 September Wednesday, Chair: A. Adler, UK, I.W. Campbell, UK

R.R. Holman, UK: Historical perspective

D.R. Matthews, UK: Global impact of UKPDS findings

R.R. Holman, UK: Post trial monitoring results of the UKPDS sulfonylurea plus metformin substudy

Ramón y Cajal Hall Diabetes technology: the search for quality

Chair: A.J.M. Boulton, UK, T.R. Pieber, Austria

J.C. Pickup, UK: From the past to the present

D. Cohen, UK: Do EU regulations for medical devices protect patients' safety?

L. Heinemann, Germany: The European perspective: safety evaluation of diabetes devices

D.B. Sacks, USA: The US perspective: the government and devices in diabetes care

60 fp2_2013__ 15.08.13 10:38 Seite 61

9:00 - 10:30 Ochoa Hall

Neuropathy

Chair: P. Kempler, Hungary, S. Tesfaye, UK

T. Fleming, Germany: Metabolic basis of painful neuropathy (followed by debate)

D. Ziegler, Germany: This house believes that DPN in type 2 diabetes is irreversible (Pro)

R.A. Malik, UK: This house believes that DPN in type 2 diabetes is irreversible (Contra)

Servet Hall Wednesday, September 25 Novel urinary biomarkers of diabetic nephropathy

Chair: R.W. Bilous, UK, P. Rossing, Denmark

C.M. Forsblom, Finland: Do novel biomarkers for diabetic nephropathy outperform albuminuria?

P. Rossing, Denmark: Urinary proteomic profiling for early diagnosis of diabetic nephropathy

K. Sharma, USA: Urinary metabolomic profiling and diabetic kidney disease

61 fp2_2013__ 15.08.13 10:38 Seite 62

9:00 - 10:30 Carrasco Hall Islet G-protein coupled receptors: novel players in beta cell regulation

Wednesday, 25 25 September Wednesday, Chair: S.J. Persaud, UK, E. Renström, Sweden

P.M. Jones, UK: GPR54: Placental kisspeptin and beta cell function in pregnancy

G.A. Bewick, UK: Beta cell function and survival via islet Y1/2 receptors

H. Kim, Korea, Republic of: Role of serotonin receptors in beta cell mass regulation

Pi i Sunyer Hall

The endocannabinoid system in metabolism and beyond

Chair: G. Gruden, Italy, U. Pagotto, Italy

V. Di Marzo, Italy: ECS in type 2 diabetes and obesity

G. Kunos, USA: The peripheral ECS as an emerging therapeutic target for the metabolic syndrome

P.J. Pacher, USA: ECS in diabetic complications

62 fp2_2013__ 15.08.13 10:38 Seite 63

10:45 - 12:15 Bernard Hall

OP 13 Clinical interventions and cardiovascular outcomes

Chair: H.M. Colhoun, UK, M. Diamant, Netherlands

73 Baseline characteristics of participants enrolled in the cardiovascular outcome study of linagliptin versus glimepiride in early type 2 diabetes (CAROLINA) N. Marx, J. Rosenstock, S.E. Kahn, B. Zinman, J.J. Kastelein, J. Lachin, M.A. Espeland, E. Bluhmki, M. Mattheus, S. Patel, O. Johansen, H.-J. Woerle, Germany, USA, Canada, Netherlands, UK

74 Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome and results (LEADER) trial design and methods S.P. Marso, N.R. Poulter, S.E. Nissen, M.A. Nauck, B. Zinman, S. Pocock, R.M. Bergenstal, J.F. Mann, L.S. Ravn, A.C. Moses, J. Buse, USA, UK, Germany, Canada, Denmark Wednesday, September 25 75 Effects of metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus: the CIMT randomised clinical trial L. Lundby-Christensen, The CIMT Trial group, Denmark

76 LV remodelling in patients with type 2 diabetes: determinants of the beneficial effect of olmesartan R.E. Schmieder, L.M. Ruilope, H. Haller, C. Ott, C. Ott, U. Raff, for the ROADMAP trial investigators, Germany, Spain

77 Predictors of congestive heart failure after treatment with an endothelin receptor antagonist: a post-hoc analysis of the ASCEND trial J. Hoekman, H.J. Lambers Heerspink, J. Mann, D. Green, G. Viberti, D. De Zeeuw, Netherlands, Germany, France, UK

78 Effects of bariatric surgery on ectopic fat depositions and cardiovascular function in obese type 2 diabetes patients J.W. Smit, M.A. Sleddering, L.D. Van Schinkel, M.A. Lips, J.T. Jonker, A. De Roos, H. Pijl, H.J. Lamb, I.M. Jazet, Netherlands

63 fp2_2013__ 15.08.13 10:38 Seite 64

10:45 - 12:15 Ramón y Cajal Halll

OP 14 Technologies to transform diabetes

Chair: R. Hovorka, UK, D.B. Sacks, USA Wednesday, 25 25 September Wednesday, 79 The pharmacologic profile of rapid-acting insulin administered by jet- injection in patients with diabetes E.E. Engwerda, B.E. De Galan, C.J. Tack, Netherlands

80 Clinical evaluation of the Imperial College bio-inspired artificial pancreas overnight and after breakfast in adults with type 1 diabetes M. Reddy, P. Herrero, N. Oliver, P. Georgiou, M. El-Sharkawy, P. Pesl, N. Jugnee, H. Thomson, C. Toumazou, D. Johnston, UK

81 Using CGM data to test the hypothesis that higher levels of fear of hypoglycaemia are related to poorer glycaemic control L. Gonder-Frederick, K. Vajda, J. Shepard, C. Wakeman, M. McElwee, B. Kovatchev, USA

82 In type 1 diabetic patients insulin pump treatment is associated with reduced arterial stiffness S. Rosenlund, S. Theilade, T.W. Hansen, P. Rossing, Denmark

83 Interim 12 month results from a post market clinical trial of DJBL treatment outcomes in subjects with type 2 diabetes and/or obesity J. Teare, J. Byrne, J. Mason, J. Kelly, S. Read, D. Thornton, H. Ashrafian, UK

84 Clinical effectiveness and cost-effectiveness of using positive airways pressure to manage sleep apnoea in patients with type 2 diabetes in the UK J.F. Guest, M. Panca, E. Sladkevicius, UK

64 fp2_2013__ 15.08.13 10:38 Seite 65

10:45 - 12:15 Ochoa Hall

OP 15 Neuropathy: peripheral and central mechanisms and outcomes

Chair: A. Odriozola, Spain, V. Spallone, Italy

85 Diabetes induces neuronal loss in the rostroventromedial medulla of streptozotocin-diabetic rats: the preventive effects of antioxidant treatment C. Morgado, A. Miranda, D. Raposo, J. Silva, P. Pereira-Terra, I. Tavares, Portugal

86 Altered baseline brain activity in type 2 diabetes: a resting-state fMRI study W. Xia, Y. Yang, Y. Zhou, P. Wang, Y. Huang, R. Cai, Q. Wei, S. Wang, China

87 Reduced cutaneous Langerhans cell number, endothelial area, and nerve fibre density in recently diagnosed type 2 diabetic subjects

A. Strom, J. Brüggemann, I. Ziegler, B. Ringel, S. Nowak, M. Roden, Wednesday, September 25 D. Ziegler, for the GDS Group, Germany

88 p66Shc mediates bone marrow denervation and impairs stem cell mobilisation in diabetes G. Fadini, M. Albiero, N. Poncina, S. Ciciliot, L. Menegazzo, S. Vigili de Kreutzenberg, M. Giorgio, A. Avogaro, Italy

89 Factors associated with reversibility of erectile dysfunction in men with type 1 diabetes: longitudinal findings from DCCT/EDIC S.K. Holt, R.L. Dunn, A.V. Sarma, J. Goldberg, P. Heagerty, J.M. Hotaling, P.A. Cleary, H. Wessells, USA

90 QTc prolongation is associated with three-year mortality after above ankle amputation in type 2 diabetic patients K. Fagher, P. Katzman, A. Nilsson, A. Sellman, M. Löndahl, Sweden

65 fp2_2013__ 15.08.13 10:38 Seite 66

10:45 - 12:15 Servet Hall

OP 16 Clinical nephropathy: focus on novel biomarkers and improving outcomes

Wednesday, 25 25 September Wednesday, Chair: P. Fioretto, Italy, C.M. Forsblom, Finland

91 Genome-wide association studies of renal diabetes complications E. Ahlqvist, H.A. Deshmukh, N. Sandholm, C. Ladenvall, M. Lajer, L. Marcovecchio, E. Rurali, W.N. Rayner, SUMMIT, Sweden, UK, Finland, Denmark, Italy

92 Predictors of rapid decline in renal function in type 2 diabetes H.C. Looker, I. Brady, M. Colombo, T. Zeller, N. Dalton, M. Wong, C. Turner, C.N. Palmer, M.J. Brosnan, E. Nogoceke, F.V. Agakov, P.M. McKeigue, H.M. Colhoun, on behalf of the SUMMIT Investigators, UK, Germany, USA, Switzerland

93 Urinary proteomics predict onset of microalbminuria in normoalbuminuric type 2 diabetic patients in the DIRECT 2 study M. Lindhardt, F. Persson, P. Zürbig, A. Stalmach, H. Mischak, H. Lambers Heerspink, A. Sjoelie, R. Klein, T. Orchard, M. Porta, J. Fuller, R.W. Bilous, N. Charturvedi, H.-H. Parving, P. Rossing, Denmark, Germany, UK, Netherlands

94 Soluble RAGE predicts progression of late-stage diabetic nephropathy in type 1 diabetes J.M. Söderlund, C. Forsblom, M. Lehto, M. Parkkonen, M. Saraheimo, N. Tolonen, L.M. Thorn, J. Wadén, P.-H. Groop, FinnDiane Study Group, Finland

95 Long-term renal outcome in the Steno 2 study J. Øllgaard, F. Persson, P. Rossing, H.-H. Parving, O.B. Pedersen, P.H. Gæde, Denmark

96 Proteinuria reduction with probucol and telmisartan in patients with type 2 diabetic nephropathy H. Zhu, X. Chen, G. Cai, Y. Zheng, M. Liu, W. Liu, Y. Wang, W. Li, H. Wu, J. Zhang, L. Lun, J. Li, C. Zhou, China

66 fp2_2013__ 15.08.13 10:38 Seite 67

10:45 - 12:15 Carrasco Hall

OP 17 New players in the regulation of insulin secretion

Chair: P. Marchetti, Italy, N.G. Morgan, UK

97 GPR55 deletion is coupled to impaired glucose tolerance and increased islet cell apoptosis B. Liu, S. Song, D. Baker, J. Bowe, Z. Hassan, R. Drynda, P. Jones, S. Persaud, UK

98 Modulation of beta cell function and glucose homeostasis by the bile acid farnesoid X receptor (FXR) B. Schittenhelm, M. Düfer, V. Kähny, R. Wagner, K. Hörth, P. Krippeit-Drews, G. Drews, Germany

99 Intestinal gluconeogenesis controls pancreatic beta cell function M. Soty, A. Sardella, I. Houberdon, G. Mithieux, France Wednesday, September 25 100 Functional role of ERK1 on pancreatic beta cell physiology M. Leduc, J. Richard, G. Bertrand, D. Muller, N. Linck, J.-F. Tanti, S. Dalle, M.A. Ravier, France

101 The orphan receptors GPRC5B and GPRC5C are highly expressed in mouse and human islets of Langerhans and regulate insulin secretion and islet cell survival S. Amisten, A. Soni, P. Rorsman, A. Salehi, S. Persaud, UK, Sweden

102 Membrane raft integrity constrains basal insulin secretion, but is impaired in type 2 diabetes V. Nagaraj, J. Helgeson, C. Lewold, S. Barik, P. Buda, E. Zhang, E. Renström, Sweden

67 fp2_2013__ 15.08.13 10:38 Seite 68

10:45 - 12:15 Pi i Sunyer Hall

OP 18 Central control of metabolism

Chair: T. Rodriguez Castaneda, Germany, B. Thorens, Switzerland Wednesday, 25 25 September Wednesday, 103 Central apelin generates a hypothalamic ROS production that controls hepatic glucose metabolism during the establishment of type 2 diabetes A. Drougard, T. Duparc, A. Fournel, P.D. Cani, P. Valet, C. Knauf, France, Belgium

104 Lipoprotein lipase inhibition into hypothalamus increases glucose tolerance and insulin sensitivity in mice C. Cruciani-Guglielmacci, V.S. Moullé, A. Picard, N. Kassis, S. Luquet, C. Magnan, France

105 Lipoprotein lipase deletion into hippocampus leads to glucose intolerance and impaired insulin secretion in mice E. Laperrousaz, A. Picard, V. Moullé, N. Kassis, S. Luquet, C. Magnan, C. Cruciani-Guglielmacci, France

106 Revealing a functionally-relevant map from the brain to pancreatic islets W. Rosario, I. Singh, A. Wautlet, C. Patterson, J. Flak, T.C. Becker, C.B. Newgard, L. Enquist, M.G. Myers Jr, C.J. Rhodes, USA

107 Hepatic glycogen loading increases the counter-regulatory response to hypoglycaemia by a liver-brain neural connection J.J. Winnick, G. Kraft, J.M. Gregory, B. Farmer, M. Scott, D. Neal, E. Allen, A.D. Cherrington, USA

108 Hypothalamic nesfatin-1 knockdown increases gluconeogenesis by mTOR/STAT3 pathway J. Dai, L. Li, G. Yang, China

68 fp2_2013__ 15.08.13 10:38 Seite 69

12:30 - 14:45 Poster Events and Lunch

12:30 - 13:30 Poster Event C Page

PS 003 Prevalence and incidence of diabetes 123

PS 009 Genetics: candidate gene association studies 130

PS 015 Lifestyle factors as risk factors 138

PS 021 Prediction of complications in type 1 and type 2 diabetes I 147

PS 027 Functional analysis of beta cells 153

PS 033 Experimental immunology 160

PS 039 Insulin resistance improvement 168

PS 045 Insulin secretion and action: using animal models 176 Wednesday, September 25 PS 051 Bariatric surgery 184

PS 057 Autophagy, endoplasmic reticulum and oxidative stresses 192

PS 063 Lipoproteins 199

PS 069 Incretin-based drugs: predictors of clinical outcomes 208

PS 075 SGLT-2 inhibitors: side effects, special populations 216

PS 081 Innovative treatments of type 2 diabetes 225

PS 087 Diabetes self care and adherence 233

PS 093 Type 1 diabetes education 241

PS 099 Nephropathy: epidemiology and clinical correlates 249

PS 105 Autonomic neuropathy 257

PS 111 Pregnancy - GDM: risk factors and delivery outcomes 264

PS 117 Risk factors for cardiovascular disease 272

69 fp2_2013__ 15.08.13 10:38 Seite 70

13:45 - 14:45 Poster Event D Page

PS 004 Type 1 diabetes observational studies 125

PS 010 Genetics: methylation and post transcriptional modification 132 Wednesday, 25 25 September Wednesday, PS 016 Lifestyle interventions 139

PS 022 Prediction of complications in type 1 and type 2 diabetes II 146

PS 028 Islet gene regulation 154

PS 034 Clinical immunology 161

PS 040 Muscle metabolism 169

PS 046 Gut and gut hormones 177

PS 052 Brain metabolism 185

PS 058 Adipose tissue distribution 193

PS 064 Adipokines and secreted proteins in obesity and diabetes 201

PS 070 Incretin-based drugs: treatment strategies 209

PS 076 Metformin: old agent - novel perspectives 218

PS 082 Treatment intensification in type 2 diabetes 226

PS 088 Self blood glucose monitoring: utility and metrics 235

PS 094 Education and motivation in type 2 diabetes 243

PS 100 Nephropathy: clinical risk factors, markers and outcomes 250

PS 106 Neuropathy I: correlates and treatments 258

PS 112 Pregnancy in diabetes 265

PS 118 Non-invasive characterisation of cardiovascular disease 273

70 fp2_2013__ 15.08.13 10:38 Seite 71 Wednesday, September 25

71 fp2_2013__ 15.08.13 10:38 Seite 72

15:00 - 16:30 Bernard Hall

OP 19 State of the art of inhibiting DPP-4

Chair: B. Ahrén, Sweden, C.F. Deacon, Denmark Wednesday, 25 25 September Wednesday, 109 Dipeptidyl peptidase-4 inhibitor sitagliptin preserves islet beta cell function in patients with new-onset latent autoimmune diabetes in adults L. Yang, Y. Zhao, Y. Xiang, L. Liu, G. Huang, Z. Long, R.D. Leslie, X. Wang, Z. Zhou, China, UK, USA

110 Improved glucagon dynamics during hypoglycaemia and food- rechallenge by DPP-4 inhibition by vildagliptin in insulin-treated patients with type 2 diabetes B. Ahrén, J. Farngren, M. Persson, A. Schweizer, J. Foley, Sweden, Switzerland, USA

111 Gemigliptin added to ongoing metformin therapy provides sustained glycaemic control over 52 weeks and was well tolerated in patients with type 2 diabetes E.J. Rhee, K.W. Min, H.C. Jang, C.H. Chung, I.S. Nam-Goong, H.Y. Bae, S.H. Baik, V.K. Shivane, A.R. Sosale, M. Dharmalingam, P. Gandhi, S.K. Gupta, J.Y. Ahn, K.S. Bang, M.K. Lee, Korea, Republic of, India

112 Cardiovascular (CV) safety of linagliptin in patients with type 2 diabetes: a pooled comprehensive analysis of prospectively adjudicated CV events in phase 3 studies O. Johansen, D. Neubacher, T. Seck, S. Patel, H.-J. Woerle, Germany, UK

113 Durability of the efficacy and safety of alogliptin compared to glipizide over 2 years when used in combination with metformin S. Del Prato, R. Camisasca, C. Wilson, C. Wilson, P. Fleck, Italy, UK, USA

114 Comparison of trough dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, and vildagliptin H.L. Katzeff, D.A. Tatosian, Y. Guo, A.K. Schaeffer, N. Gaibu, S. Popa, R.B. Langdon, E. Kauh, USA, Moldova, Republic of

72 fp2_2013__ 15.08.13 10:38 Seite 73

15:00 - 16:30 Ramón y Cajal Hall

OP 20 Inflammation and insulin resistance: switching on and off

Chair: C. Herder, Germany, T.M. Stulnig, Austria

115 Alteration of CD28 T cell costimulatory pathway protects against obesity-induced inflammation and metabolic disorders M. Poggi, S. Morin, F. Peiretti, R. Govers, C. Favre, V. Giroux, D. Bastelica, M. Malissen, D. Olive, J. Nunes, M.-C. Alessi, France

116 Intra-islet inflammation in type 2 diabetes: evidence that the E3 ligase TRAF2 is a key protective factor in beta cells E.K. Malle, S.N. Walters, N.W. Zammit, J. Cantley, R. Brink, S.T. Grey, Australia

117 Delayed intervention with pyridoxamine improves metabolic and vascular function in high-fat diet-induced obese mice

O. Brouwers, K. Gaens, T. Miyata, B.J. Janssen, J.G. De Mey, Wednesday, September 25 C.D. Stehouwer, C.G. Schalkwijk, Netherlands, Japan

118 IL-37 protects against obesity-induced inflammation and insulin resistance D.B. Ballak, J.A. Van Diepen, A.R. Moschen, H.J. Jansen, A. Hijmans, G.-J. Groenhof, P. Bufler, S. Kersten, L.A. Joosten, H. Tilg, C.A. Dinarello, M.G. Netea, C.J. Tack, R. Stienstra, Netherlands, Austria, Germany, USA

119 Fas (CD95) expression in myeloid cells promotes obesity-induced muscle insulin resistance S. Wueest, R. Mueller, M. Blüher, F. Item, A.S. Chin, M. Wiedemann, H. Takizawa, L. Kovtonyuk, A.V. Chervonsky, E.J. Schoenle, M.G. Manz, D. Konrad, Switzerland, Germany, USA

120 Angiopoietin like protein 2 (Angptl2) induced adipose tissue macrophage activation causes impaired glucose tolerance Y. Sasaki, M. Ohta, D. Desai, T. Sugano, M. Yamabi, W. Yano, J. Matsumoto, K. Mizuno, K. Inoue, M. Aikawa, USA

73 fp2_2013__ 15.08.13 10:38 Seite 74

15:00 - 16:30 Ochoa Hall

OP 21 Health economic aspects of diabetes: happy, healthy and prosperous

Chair: P.D. Home, UK, J.A. Johnson, Canada Wednesday, 25 25 September Wednesday, 121 Impact of targeting intensive versus conventional glycaemic control on quality of life in patients with type 2 diabetes: a systematic review B. Hemmingsen, C. Gluud, A. Vaag, T. Almdal, J. Wetterslev, Denmark

122 Long term consequences on annual earnings after childhood onset of type 1 diabetes I. Lovén, K. Steen Carlsson, for the Swedish Childhood Diabetes Study Group, Sweden

123 Health-related quality of life in adults with and without type 2 diabetes: results of a pooled analysis of German population-based cohort studies M. Schunk, P. Reitmeir, C. Meisinger, A. Kluttig, S. Hartwig, S. Schipf, H. Völzke, A. Peters, R. Holle, Germany

124 Diabetes care from the patient's perspective: combining risk factors with patient reported outcomes measures and capabilities in the national diabetes registry in Sweden B. Palaszewski, S. Borg, U.-G. Gerdtham, S. Gudbjörnsdottir, Sweden

125 Factors associated with self-rated health quality in patients with diabetes mellitus O. Rácz, M. Linková, L. Cislakova, P. Takac, K. Jakubowski, Slovakia, Poland

126 Psychometric properties of the hypoglycaemia perspectives questionnaire (HPQ) in type 2 diabetes mellitus A.K. Kawata, S.H. Ong, C. Therapontos, P. Mavrogenis, K. Kulich, W.-H. Chen, K. Coyne, USA, Switzerland, Cyprus

74 fp2_2013__ 15.08.13 10:38 Seite 75

15:00 - 16:30 Servet Hall

OP 22 Drilling down on lipid mechanisms in diabetes

Chair: E. Ferrannini, Italy, B. Ukropcová, Slovakia

127 Intensified LDL-C target of statin therapy and risk of incident diabetes: meta-analysis of randomised statin trials R. Cai, Y. Zhou, Y. Yang, H. Sun, W. Xia, P. Wang, Y. Huang, S. Wang, China

128 Effect of pitavastatin on the incidence of diabetes in Japanese individuals with impaired glucose tolerance M. Odawara, T. Yamazaki, J. Kishimoto, C. Ito, M. Noda, Y. Terauchi, T. Shiba, H. Kitazato, K. Maemura, K. Tobe, Y. Iwamoto, Y. Akanuma, T. Kadowaki, the J-PREDICT study investigators, Japan

129 Serum lipidomic profiling identifies biomarkers associated with

progression to type 2 diabetes in the METSIM study Wednesday, September 25 L. Yetukuri, H. Cederberg, M. Sysi-Aho, T. Hyötyläinen, M. Laakso, M. Orešič, Finland

130 Pleiotropic effects on lipid levels and obesity identified in multi-trait meta-analysis of genome-wide association studies (GWAS) of type 2 diabetes related traits V. Lagou, R. Mägi, I. Surakka, A.-P. Sarin, M. Horikoshi, G. Thorleifsson, S. Hägg, M. Beekman, C. Ladenvall, J.-J. Hottenga, J.S. Ried, M.I. McCarthy, A. Morris, S. Ripatti, I. Prokopenko, UK, Estonia, Finland, Iceland, Sweden, Netherlands, Germany

131 Large-scale genome-wide association meta-analysis of the 1000 genomes project imputed data identifies novel susceptibility loci for glycaemic and obesity traits M. Horikoshi, R. Mägi, I. Surakka, A.-P. Sarin, A. Mahajan, L. Marullo, T. Ferreira, T. Esko, C.M. Lindgren, A.P. Morris, M.I. McCarthy, S. Ripatti, I. Prokopenko, ENGAGE Consortium, UK, Estonia, Finland, Italy, USA

132 DNA methylation changes influence type 2 diabetes M.A. Carless, H. Kulkarni, M.C. Mahaney, H.H. Göring, J.E. Curran, L. Almasy, A.G. Comuzzie, J. Blangero, USA

75 fp2_2013__ 15.08.13 10:38 Seite 76

15:00 - 16:30 Carrasco Hall

OP 23 T cells and autoantigens

Chair: E. Bonifacio, Germany, V. Sordi, Italy Wednesday, 25 25 September Wednesday, 133 MicroRNA profiling of impaired CD4+ T regulatory cells residing in the pancreatic draining lymphnodes of patients with type 1 diabetes G. Sebastiani, C. Morsiani, A. Ferraro, G. Ventriglia, M. Battaglia, F. Dotta, Italy

134 A novel approach for immunotargeting of islet reactive CD8 T cells to prevent diabetes F.S. Wong, L.K. Siew, S. Fishman, G. Gross, UK, Israel

135 A novel immune regulatory peptide, PEPITEM, controls T cell trafficking during inflammation, a tonic inhibitory pathway that is lost in type 1 diabetes mellitus C. Myriam, H.M. McGettrick, C.M. Yates, A. Kennedy, A. Martin, F. Barone, L.S. Walker, C.D. Buckley, G. Nash, G.E. Rainger, P. Narendran, UK

136 Identification of two distinct patterns of immune cell infiltration in the insulitic lesions in human type 1 diabetes P. Leete, A. Willcox, S.J. Richardson, A.J. Bone, A.K. Foulis, N.G. Morgan, UK

137 Mafa knockout NOD mice are protected from type 1 diabetes despite accelerated infiltration of lymphocytes into islets S. Noso, N. Babaya, Y. Hiromine, Y. Kawabata, H. Ikegami, Japan

138 Relationships between major epitopes on the IA-2 autoantigen in type 1 diabetes C.C. Richardson, M.R. Christie, K.A. McLaughlin, UK

76 fp2_2013__ 15.08.13 10:38 Seite 77

15:00 - 16:30 Pi i Sunyer Hall

OP 24 Basic nephropathy: novel mechanisms and potential therapies

Chair: S. Hadjadj, France, A. Solini, Italy

139 The mechanism of action of the splice variant VEGF165b in decreasing proteinuria in mouse models of type 1 diabetic nephropathy M. Stevens, Y. Qiu, J. Ferguson, A. Salmon, D. Bates, S. Harper, S. Oltean, UK

140 Clusterin/apolipoprotein J attenuates angiotensin II-induced renal fibrosis G.-S. Jung, Y.-A. Jung, M.-K. Kim, K.-H. Bae, I.-K. Lee, K.-G. Park, Korea, Republic of

141 Pivotal involvement of CX3CL1-CX3CR1 system in the pathogenesis of diabetic nephropathy in streptozotocin-treated mice

M. Furuta, Y. Shimizu, A. Yamana, M. Ueyama, S. Morita, A. Doi, Y. Ishida, Wednesday, September 25 M. Nosaka, T. Kondo, T. Sanke, Japan

142 PDK1 protects podocytes from apoptosis P.H. Saurus, M. Ristola, C. Fogharty, M. Lehto, M. Saleem, P.-H. Groop, H. Holthöfer, S. Lehtonen, Finland, UK

143 Linagliptin and the angiotensin II receptor blocker telmisartan show comparable efficacy but different renoprotective pathways in rats with 5/6 nephrectomy B. Hocher, O. Tsuprykov, M. Alter, K. Von Websky, L. Chaykovska, V. Antonenko, J. Rahnenführer, T. Klein, C. Reichetzeder, Germany, Switzerland

144 Luseogliflozin (TS-071), a novel SGLT2 inhibitor, protects against diabetic nephropathy in diabetic db/db mice Y. Takiyama, K. Agatsuma, M. Yasuda-Kobayashi, J. Honjo, Y. Fujita, T. Yanagimachi, H. Kitsunai, Y. Makino, M. Haneda, Japan

77 fp2_2013__ 15.08.13 10:38 Seite 78

16:45 - 18:15 Bernard Hall

Incretin-based medications: areas of active research and unanswered questions Wednesday, 25 25 September Wednesday, Chair: S.C.L. Gough, UK, M.A. Nauck, Germany

S.C.L. Gough, UK: Towards a better exploitation of GLP-1's potential to treat type 2 diabetes: Where do current developments of GLP-1 receptor agonists aim?

U. Kielgast, Denmark: Potential use of DPP-4 inhibitors and GLP-1 receptor agonists in type 1 diabetes?

B. Ahrén, Sweden: Understanding the mode of action of DPP-4 inhibitors: recent insights

Ramón y Cajal Hall

Inflammation and type 2 diabetes

Chair: U. Smith, Sweden, M. Walker, UK

V.D. Dixit, USA: Role of the inflammasome in type 2 diabetes

A. Rosengren, Sweden: SFRP4: link between inflammation and type 2 diabetes

U. Smith, Sweden: Obesity and inflammation: Where are the treatment targets?

78 fp2_2013__ 15.08.13 10:38 Seite 79

16:45 - 18:15 Ochoa Hall

Psychosocial issues in diabetes

Chair: R.I.G. Holt, UK, A. Nicolucci, Italy

R.V. García-Mayor, Spain: Disordered eating in type 1 diabetes

M. Peyrot, USA: An overview of the DAWN2 study

F. Pouwer, Netherlands: DAWN2: Psychosocial adaptation and quality of life

Servet Hall Wednesday, September 25

Diabetes epigenetics

Chair: F. Beguinot, Italy, G.A. Hitman, UK

P. Gluckman, New Zealand: DNA methylation and the origin of complex disorders

R. Natarajan, USA: The role of epigenetics in diabetes complications

R. Barrès, Denmark: Exercise and diet on the remodelling of DNA methylation

79 fp2_2013__ 15.08.13 10:38 Seite 80

16:45 - 18:15 Carrasco Hall Activating the diabetogenic T cell: key players in presentation of islet antigens

Wednesday, 25 25 September Wednesday, Chair: E. Bonifacio, Germany, F.S. Wong, UK

B. Calderon, USA: Intra-islet dendritic cells in the regulation of diabetogenic T-cells

S.F. Wong, UK: Role of B cells in autoantigen presentation

M.R. Christie, UK: B cell/T cell collaboration in the autoimmune response to IA-2

Pi i Sunyer Hall

ChREBP, a master switch linking glucose and lipid metabolism

Chair: M. Blüher, Germany, C. Postic, France

K. Uyeda, USA: The story of carbohydrate responsive element-binding protein (ChREBP): more than history?

C. Postic, France: ChREBP dissociates hepatic steatosis from insulin resistance

B.B. Kahn, USA: A new role of ChREBP in fat tissue

80 fp2_2013__ 15.08.13 10:38 Seite 81

MUSEUM NIGHT 19:00 - 22:00

EASD is very grateful to the City Council and the Barcelona Convention Bureau for the opening of the Museums (MNAC, CaixaForum and Mies Van der Rohe). Admission is free for registered delegates. Please bring your badge. All museums are located on Montjuïc, accessible from Plaça Espanya.

The Museu Nacional d’Art de Catalunya (MNAC) is housed within the Palau Nacional, built for the 1929 Barcelona International Exhibition. Boasting “one museum, 1000 years of art”, the Museu Nacional provides its visitors with a comprehensive overview of Catalan art history. Its Romanesque and Gothic collections are particularly impressive, with most of © Imagen M.A.S. - Museu the constituent works, including fresco painting, Nacional d'Art de Catalunya sculpture, and enamel, gold and silver pieces.

The CaixaForum is located in a unique example of Wednesday, September 25 Catalan Art-Nouveau industrial architecture of the early twentieth century. The building, designed by Josep Puig i Cadafalch and completed in 1911. CaixaForum was born in 2002, after “la Caixa” savings bank acquired the building and decided to renovate it into a social, cultural and educational centre for the © Marc Llimargas - CaixaForum benefit of the public. The centre has hosted many Barcelona exhibits, concerts, film screenings and lectures.

The Mies van der Rohe Pavilion, a masterpiece by the German-American architect Ludwig Mies van der Rohe, is a stunning example of 20th-century architecture. The German Pavilion was originally designed for the 1929 Barcelona International Exhibition but was dismantled. It was reconstructed in

1983 by the Barcelona City Hall. Inside the Pavilion, © Pepo Segura- Fundacio Mies visitors can view the renowned Barcelona Chair, a van der Rohe-Barcelona hallmark of contemporary design, and also Alba (Dawn), a work by German figure sculptor Georg Kolbe. The Pavilion is managed by the Mies van der Rohe Foundation, which fosters the study and dissemination of modern and contemporary architecture.

81 fp2_2013__ 15.08.13 10:38 Seite 82

9:00 - 10:30 Bernard Hall

DPP-4 inhibitors and CVD

Chair: J.J. Holst, Denmark, C. Tack, Netherlands Thursday, 26 September Thursday,

W.B. White, USA: Results from EXAMINE

S.R. Heller, UK: Results from EXAMINE

I. Raz, Israel: Results from SAVOR

D.L. Bhatt, USA: Results from SAVOR

N. Sattar, UK: Commentator

Ramón y Cajal Hall

EASD/ESC Symposium: heart failure and diabetes: a deadly intersection

Chair: B.M. Fisher, UK, J.J. McMurray, UK

J.J. McMurray, UK: Why diabetologists need to get serious about heart failure

D.K. McGuire, USA: Evidence-based management of heart failure in diabetes patients

B.M. Fisher, UK: Managing dysglycaemia in heart failure patients: what therapies are safe?

82 fp2_2013__ 15.08.13 10:38 Seite 83

9:00 - 10:30 Ochoa Hall

Pathophysiological phenotypes in type 2 diabetes

Chair: H. Beck-Nielsen, Denmark, S. Del Prato, Italy

H. Beck-Nielsen, Denmark: Phenotypes in type 2 diabetes based on a national survey

S. Del Prato, Italy: Treatment of type 2 diabetes based on pathophysiological knowledge

L. Groop, Sweden: Can genotyping aid in the choice of anti-diabetic therapy?

Servet Hall Thursday,September 26

EASD/JDRF Symposium: cell-based therapy in the treatment of type 1 diabetes

Chair: P.M. Jones, UK, R.A. Insel, USA

N.B. Nardi, Brazil: Therapeutic potential of mesenchymal stem cells

V. Sordi, Italy: Use of mesenchymal stem cells to improve islet function for transplantation

H. Semb, Sweden: Current status of artificial cell production for replacement therapies

83 fp2_2013__ 15.08.13 10:38 Seite 84

9:00 - 10:30 Carrasco Hall Gene-environment interactions: why heredity is not destiny

Chair: T.O. Kilpeläinen, Denmark, N.J. Wareham, UK

Thursday, 26 September Thursday, G. Paré, Canada: How can we detect gene-environment interactions in human populations?

T.O. Kilpeläinen, Denmark: Is type 2 diabetes a disease caused by gene- environment interactions?

M.-F. Hivert, Canada: Foetal programming in obesity and type 2 diabetes

Pi i Sunyer Hall

New pathways in insulin action and resistance

Chair: H. Al-Hasani, Germany, A. Bouloumié, France

U. Eriksson, Sweden: Regulation of endothelial fatty acid transport by VEGF-B and its role in insulin resistance

C.F. Semenkovich, USA: De novo lipogenesis and insulin resistance

G.D. Cartee, USA: The TBC1D1/4 story

84 fp2_2013__ 15.08.13 10:38 Seite 85

10:45 - 12:15 Bernard Hall

OP 25 Novel therapeutic agents and insights

Chair: C.J. Bailey, UK, S. Del Prato, Italy

145 Dissociation between metformin plasma exposure and its glucose- lowering effect: a novel gut-mediated mechanism of action A. Baron, R. DeFronzo, J. Buse, T. Kim, S. Skare, M. Fineman, USA

146 Efficacy of bile acid sequestrant treatment for glycaemic control in type 2 diabetes - systematic review with meta-analysis of randomised controlled trials M. Hansen, D.P. Sonne, K.H. Mikkelsen, L.L. Gluud, T. Vilsbøll, F.K. Knop, Denmark

147 A new anti-inflammatory and immune-modulatory peptide therapeutic improves glycaemic control and beta cell function in the db/db and STZ diabetes models Thursday,September 26 S. Mogelsvang, D. Austin, A. Turner, C. Gelber, USA

148 Effect of a dual agonist of glucagon-like peptide-1/glucose-dependent insulinotropic peptide (MAR701) on insulin secretion rate and gastric emptying in healthy volunteers M. Hompesch, L. Morrow, K. Win, L. Vignati, J. Hauptmann, USA

149 Pharmacogenetic study of selected gene variants related to the pharmacodynamics of metformin with response to metformin treatment in type 2 diabetes M. Javorsky, L. Klimcakova, Z. Schroner, E. Babjakova, M. Stolfova, H. Hermanova, M. Kozarova, I. Tkac, Slovakia

150 The novel glucagon-neutralising Spiegelmer NOX-G15 ameliorates hyperglycaemia in murine models of type 1 and type 2 diabetes A. Vater, S. Sell, P. Kaczmarek, C. Maasch, K. Buchner, E. Pruszynska- Oszmalek, P. Kolodziejski, W.G. Purschke, K.W. Nowak, M.Z. Strowski, S. Klussmann, Germany, Poland

85 fp2_2013__ 15.08.13 10:38 Seite 86

10:45 - 12:15 Ramón y Cajal Hall

OP 26 Incretins: mechanisms of cardiovascular protection

Chair: I. Raz, Israel, W.B. White, USA

Thursday, 26 September Thursday, 151 Inhibition of DPP-4 activity: potential role of non-GLP-1-mediated cardioprotection in the post MI diabetes setting K.A. Connelly, J. Desjardins, G. Kabir, M. Mitchell, Y. Zhang, K. Thai, S. Advani, A. Advani, R.E. Gilbert, Canada

152 Insights into the mechanism of action of linagliptin in reducing ischaemic brain damage following stroke in diabetic and non-diabetic mice V. Darsalia, A. Olverling, T. Nyström, H. Ortsäter, H. Rosenbrock, Å. Sjöholm, T. Klein, C. Patrone, Sweden, Germany

153 The suppressive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to the action of incretin in both non- diabetic and diabetic mice M. Terasaki, M. Nagashima, K. Nohtomi, K. Kohashi, M. Tomoyasu, K. Shinmura, Y. Nogi, K. Sato, F. Itoh, T. Watanabe, T. Hirano, Japan

154 The DPP-IV inhibitor saxagliptin inhibits palmitate-induced apoptosis of human endothelial cells and cardiac progenitor cells L. Laviola, M. Incalza, M.R. Orlando, C. Caccioppoli, A. Leonardini, R. D'Oria, V. Andrulli Buccheri, A. Natalicchio, S. Perrini, F. Giorgino, Italy

155 Exendin-4 counteracts palmitate-induced apoptosis by inhibiting de novo production of ceramides in human cardiac progenitor cells A. Leonardini, L. Laviola, R. D'Oria, M. Incalza, V. Andrulli Buccheri, M.R. Orlando, A. Natalicchio, S. Perrini, F. Giorgino, Italy

156 Incretin-based treatments suppress human macrophage foam cell formation and VSMCs migration and proliferation contributing to atherosclerosis prevention M. Tomoyasu, T. Watanabe, J.R. Kaneyama, M. Terasaki, K. Nohtomi, K. Sato, F. Itoh, A. Miyazaki, T. Hirano, Japan

86 fp2_2013__ 15.08.13 10:38 Seite 87

10:45 - 12:15 Ochoa Hall

OP 27 Pregnancy: GDM diagnosis and foetal outcomes

Chair: H.-U. Häring, Germany, H.R. Murphy, UK

157 Gestational diabetes mellitus (GDM) using the new IADSPG criteria: relative importance of different abnormal glucose values and evaluation of risk factors V. Vasileiou, L. Spanou, A. Papadimitriou, A. Saltiki, M. Alevizaki, E. Anastasiou, Greece

158 Maternal insulin resistance affects foetal brain activity K. Linder, F. Schleger, C. Ketterer, L. Fritsche, I. Kiefer-Schmidt, A. Hennige, H.-U. Häring, H. Preißl, A. Fritsche, Germany

159 Maternal glucose variability and neonatal metabolic outcome in women with pregnancy complicated with type 1 diabetes E. Wender-Ozegowska, A. Zawiejska, J. Brazert, Poland Thursday,September 26

160 Parameters of maternal glucose variability as predictors of birth weight and neonatal metabolic status in pregnancy complicated with gestational diabetes mellitus A. Zawiejska, E. Wender-Ozegowska, J. Brazert, Poland

161 Decreased cord blood serum dipeptidyl-peptidase 4 (DPP4) enzymatic activity in gestational diabetes mellitus O. Hadarits, Z. Al-Aissa, K. Rosta, J. Harreiter, A. Zóka, D. Bancher-Todesca, A. Patócs, J. Rigó, A. Somogyi, A. Kautzky-Willer, G. Firneisz, Hungary, Austria

162 Earlier management with continuous monitoring blood glucose decrease gestational weight gain in gestational diabetes mellitus: a randomised clinical trial Q. Wei, S. Wang, Y. Yang, Z. Sun, China

87 fp2_2013__ 15.08.13 10:38 Seite 88

10:45 - 12:15 Servet Hall

OP 28 Replacement of beta cell mass and function

Chair: K. Maedler, Germany, T. Otonkoski, Finland

Thursday, 26 September Thursday, 163 Conditional expression of a constitutively active EGF-R in beta cells protects against diabetes E. Hakonen, J. Ustinov, D.L. Eizirik, P.J. Miettinen, T. Otonkoski, Finland, Belgium

164 PTP1B a key player in the improvement of survival of transplanted islet grafts H. Figueiredo, A. Garcia, R. Fernandez, H.S. Farghaly, R. Gomis, R. Malpique, Spain, Egypt

165 Acetyl-CoA carboxylase 1 is a critical regulator of beta cell mass J. Cantley, P.T. Whitworth, A. Davenport, K.L. Hoehn, D.E. James, T.J. Biden, Australia, USA

166 The LRH-1 agonist BL001 improves human islet survival and blunts development of hyperglycaemia in the RIP-B7.1 mouse model of experimental autoimmune diabetes N. Cobo-Vuilleumier, M. Baquié, M. Bugliani, D. Bosco, G. Parnaud, M. Cejudo-Guillén, A. Spyrantis, P. Marchetti, B. Boehm, D. Pozo, L. St-Onge, B.R. Gauthier, Spain, Switzerland, Italy, Germany

167 Insulin receptor internalisation and Erk signalling require caveolin-1 in pancreatic beta cells J.D. Johnson, T. Albrecht, G.E. Lim, M. Piske, S. Li, I.R. Nabi, P. Gilon, Canada, Belgium

168 Protection from diabetes in mice with genetically engineered K-cells expressing modified proinsulin M. Mojibian, S. Sassani, A. Asadi, R. Baker, T. Kieffer, Canada

88 fp2_2013__ 15.08.13 10:38 Seite 89

10:45 - 12:15 Carrasco Hall

OP 29 Genetics of renal and cardiovascular complications

Chair: M. Marre, France, L. Tarnow, Denmark

169 Genome-wide association studies for renal complications of type 1 diabetes N. Sandholm, H. Deshmukh, E. Ahlqvist, N.W. Rayner, C. Ladenvall, C. Forsblom, V. Harjutsalo, L. Marcovecchio, FinnDiane Study Group, SUMMIT, Finland, UK, Sweden

170 The haptoglobin 1 allele correlates with corpus callosum hyperintensities in individuals with type 1 diabetes T. Costacou, C. Rosano, H. Aizenstein, T.M. Hughes, R.E. Ferrell, T.J. Orchard, USA

171 Known SNPs in ADAMTS7, the 9p21 region and UBE2E interact with type 2 diabetes status to modify the risk of coronary artery disease in large Thursday,September 26 populations N.R. Van Zuydam, B. Voight, C. Ladenvall, R. Strawbridge, S. Willems, J. Hartiala, E. Vlacholpoulou, E. Mihailov, L. Kwee, L. Qu, A. Goel, J. Kumar, S. Kanoni, CARDIoGRAMplusC4D, SUMMIT, UK, USA, Sweden, Netherlands, Finland, Estonia

172 ADAMTS17 interacts with smoking status to increase the risk of lower extremity arterial disease in non-smokers and also increases the risk of LEAD in patients with diabetes H. Colhoun, G. Þorleifsson, S. Grétarsdóttir, A. Paterson, C. Palmer, N. Van Zuydam, SUMMIT, UK, Iceland, Canada

173 Genome-wide association study for circulating levels of soluble receptor for advanced glycation end-products (sRAGE) H. Deshmukh, P.M. McKeigue, H.C. Looker, N. Van Zuydam, E. Ahlqvist, G.A. Hitman, C.N. Palmer, H.M. Colhoun, The CARDS Executive Committee, The SUMMIT Investigators, UK, Sweden

174 Circulating microRNAs and micro/macrovascular complications of type 1 diabetes F. Barutta, S. Grimaldi, N. Chaturvedi, P. Cavallo Perin, G. Bruno, J.H. Fuller, G. Gruden, Italy

89 fp2_2013__ 15.08.13 10:38 Seite 90

10:45 - 12:15 Pi i Sunyer Hall

OP 30 Insulin signalling and myokines

Chair: M. Benito, Spain, K. Bouzakri, Switzerland

Thursday, 26 September Thursday, 175 Deletion of both Rab-GTPase activating proteins TBC1D1 and TBC1D4 in mice eliminates insulin- and AICAR-stimulated glucose transport A. Chadt, A. Immisch, C. De Wendt, Z. Zhou, T. Peter, J. Loffing, D. Loffing-Cueni, H.-G. Joost, H. Al-Hasani, Germany, Switzerland

176 Role for SREBP-1c in inducing skeletal muscle insulin resistance via repressing IRS-1 transcription and promoting inflammatory response Y. Bi, Y. Chen, W. Wu, M. Cai, H. Liang, D. Zhu, China

177 Potent anti-inflammatory properties of adiponectin on the skeletal muscle M. Abou-Samra, O. Schakman, E. Culot, L. Noel, P. Gailly, S. Brichard, Belgium

178 Fractalkine is a novel myokine which protects myotubes from TNF-alpha induced insulin resistance P. Plomgaard, J. Hansen, V. Bianda, B.K. Pedersen, K. Bouzakri, Denmark, Switzerland

179 G-CSF, a novel fatty acid-dependent myokine A.-M. Ordelheide, N. Gommer, H.-U. Häring, H. Staiger, Germany

180 Evidence against a beneficial effect of irisin in humans H. Gassenhuber, S. Raschke, M. Elsen, M. Sommerfeld, U. Schwahn, B. Brockmann, T. Romacho, K. Eckardt, J. Eckel, Germany

90 fp2_2013__ 15.08.13 10:38 Seite 91

12:30 - 14:45 Poster Events and Lunch

12:30 - 13:30 Poster Event E Page

PS 005 What predicts type 1 diabetes? 126

PS 011 Genetics: monogenic forms 133

PS 017 Body composition and diabetes aetiology in epidemiology 140

PS 023 Receptor regulation of islet function 148

PS 029 Quantification of beta cell mass 155

PS 035 Islet transplantation 162

PS 041 Insulin resistance biomarkers 170

PS 047 Exercise: physiology and clinical benefits 178 Thursday,September 26 PS 053 Inflammation in obesity and type 2 diabetes 187

PS 059 Cancer and metabolism 195

PS 065 Myeloid cells and type 2 diabetes 202

PS 071 Incretin-based drugs: potential risk and use in special populations 211

PS 077 Oral anti-diabetic agents 219

PS 083 Novel insulin preparations: pharmakinetics and pharmacodynamics 228

PS 089 New devices for glucose monitoring and insulin delivery 236

PS 095 Psychosocial aspects of diabetes 244

PS 101 Nephropathy basic science: from profiling to targets 251

PS 107 Neuropathy II: large fibres, small fibres, peripheral and central 259

PS 113 Mechanisms of vascular disease 267

PS 119 Diabetes in childhood 274

91 fp2_2013__ 15.08.13 10:38 Seite 92

13:45 – 14:45 Poster Event F Page

PS 006 Epidemiology: social and environmental factors 127

PS 012 Genetics: gene-lifestyle interactions and pharmacogenetics 134

Thursday, 26 September Thursday, PS 018 Obesity and diabetes 141

PS 024 Beta cell signal transduction 149

PS 030 Beta cell mass expansion and survival 156

PS 036 Insulin is not the only islet player 164

PS 042 Weight loss and caloric modulation 172

PS 048 Liver metabolism 180

PS 054 Fatty acids and triglyceride storage: impact on inflammation and glucose metabolism 188

PS 060 4atty liver: human studies 196

PS 066 Nutrition and weight loss 203

PS 072 Incretin-based agents: assessing the risk-benefit ratio 212

PS 078 Effects of glucose-lowering therapy on cardiovascular risks 220

PS 084 Insulin therapies: basal and novel combination 229

PS 090 Closed loops and CGMS 237

PS 096 Good news for depression in diabetes? 245

PS 102 Hypertension: from experimental evidence to bedside 253

PS 108 Diabetic foot: epidemiology, risk factors and outcomes 260

PS 114 Sleep apnoea, cognitive function and musculoskeletal complications 268

92 fp2_2013__ 15.08.13 10:38 Seite 93 Thursday,September 26

9393 fp2_2013__ 15.08.13 10:38 Seite 94

15:00 - 16:30 Bernard Hall

OP 31 Glucose down the drain

Chair: L. Czupryniak, Poland, G. Schernthaner, Austria Thursday, 26 September Thursday, 181 Dapagliflozin-induced weight loss impacts 24 week HbA1c and blood pressure levels C.D. Sjöström, M. Hashemi, J. Sugg, A. Ptaszynska, E. Johnsson, Sweden, USA

182 Canagliflozin demonstrates durable glycaemic improvements over 104 weeks compared with glimepiride in subjects with type 2 diabetes mellitus on metformin G. Langslet, W.T. Cefalu, L.A. Leiter, K.-H. Yoon, P. Arias, J. Xie, D. Balis, D. Millington, F. Vercruysse, W. Canovatchel, G. Meininger, Norway, USA, Canada, Korea, Republic of, Argentina, Belgium

183 The sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin improves glycaemic control in patients with type 1 diabetes: a single-arm clinical trial B.A. Perkins, D.Z. Cherney, H. Partridge, N. Soleymanlou, H. Tschirhart, B. Zinman, N. Fagan, S. Kaspers, H.-J. Woerle, U.C. Broedl, O. Johansen, Canada, USA, Germany

184 Luseogliflozin, a selective SGLT2 inhibitor, added on to glimepiride for 52 weeks improves glycaemic control with no major hypoglycaemia in Japanese type 2 diabetes patients N. Inagaki, Y. Seino, T. Sasaki, A. Fukatsu, M. Ubukata, H. Umeuchi, S. Sakai, Y. Samukawa, Japan

185 Efficacy and safety of tofogliflozin administered for 52 weeks as monotherapy or combined with other oral hypoglycaemic agents in Japanese patients with type 2 diabetes Y. Tanizawa, E. Araki, K. Tobe, Y. Terauchi, K. Utsunomiya, Y. Iwamoto, H. Watada, K. Kaku, for the Tofogliflozin 004 and 005 Study group, Japan

186 Favourable gastrointestinal and genitourinary safety profile of LX4211 added-on to metformin in a Phase 2b study G.-L. Ye, I. Ogbaa, P. Lapuerta, B. Zambrowicz, P. Banks, K. Frazier, A. Sands, USA

9494 fp2_2013__ 15.08.13 10:38 Seite 95

15:00 - 16:30 Ramón y Cajal Hall

OP 32 Hypoglycaemia: balancing glucose control

Chair: S.R. Heller, UK, P.A. Senior, Canada

187 Lower rates of overall, nocturnal and severe hypoglycaemia during maintenance treatment with IDegAsp vs biphasic insulin aspart 30 in patients with type 2 diabetes mellitus: a meta-analysis A. Vaag, J.S. Christiansen, L. Niskanen, S. Rasmussen, T. Johansen, G. Fulcher, Denmark, Finland, Australia

188 Retrospective analysis of the burden of drug-induced hypoglycaemia in diabetes (SIMEU study) G. Marchesini, G. Veronese, G. Forlani, G. Forlani, A. Fabbri, the Italian Association of Emergency Medicine (SIMEU) Study Group, Italy

189 The effect on insulin analogues on the risk of severe hypoglycaemia in patients with type 1 diabetes and recurrent severe hypoglycaemia: the Thursday,September 26 HypoAna trial U. Pedersen-Bjergaard, P.L. Kristensen, H. Beck-Nielsen, K. Nørgaard, H. Perrild, J.S. Christiansen, T. Jensen, P. Hougaard, H.-H. Parving, B. Thorsteinsson, L. Tarnow, Denmark

190 Exercise-related hypoglycaemia occurs at similar frequency with insulin degludec and insulin glargine D.S. Oyer, S. Heller, S.C. Gough, K.H. Jensen, O. Kinduryte, A. Philis-Tsimikas, USA, UK, Denmark

191 A prospective, randomised study in patients with type 1 diabetes on the need for additional carbohydrates with standardised physical activity to prevent hypoglycaemia H. Frenzke, A. Varnhorn, H. Schulze, M.A. Nauck, Germany

192 Which algorithms best reduce the risk of hypoglycaemia during exercise for patients with type 1 diabetes on pump therapy? S. Franc, M.H. Petit, O. Juy, E. Pussard, A. Daoudi, L. Boursiquot, C. Petit, A. Pochat, P. Dupont, L. Canipel, F. Koukoui, G. Charpentier, France

95 fp2_2013__ 15.08.13 10:38 Seite 96

15:00 - 16:30 Ochoa Hall

OP 33 Mitochondrial metabolism

Chair: M. Roden, Germany, C.B. Wollheim, Switzerland

Thursday, 26 September Thursday, 193 Participation of CDK4 in the regulation of mitochondrial metabolism and energy homeostasis I.C. Lopez-Mejia, C. Chavey, S. Lagarrigue, E. Gari, L. Fajas, Switzerland, France, Spain

194 Dissociation between mitochondrial dysfunction and insulin resistance in adipose-specific PGC-1beta knockout mice J.A. Villena, N. Enguix, R. Pardo, A. González, R. Simó, A. Kralli, Spain, USA

195 Lack of PGC-1α is associated with dysregulation of AICAR mediated AMPK regulation of ACC and PDH A. Gudiksen, R.S. Biensø, H. Pilegaard, Denmark

196 Effects of the mtAtp-8 OXPHOS mutation on susceptibility to diet- induced lipoinflammation in conplastic B6-mtFVB mice F. Koch, H. Weiss, J. Niemann, S. Baltrusch, M. Tiedge, Germany

197 Effects of the mt-Cytb mutation in the B6-mt129S1/SvlmJ strain on metabolism, ROS defence and OXPHOS proteins after high fat diet H. Weiss, L. Oesterwinter, F. Koch, M. Borchert, J. Niemann, S. Baltrusch, M. Tiedge, Germany

198 Hepatic mitochondrial function in human obesity: association with insulin sensitivity and oxidative stress C. Koliaki, J. Szendroedi, K. Kaul, T. Jelenik, P. Nowotny, M. Dubiak, M. Krausch, W. Knoefel, F. Jankowiak, M. Schlensak, M. Roden, Germany

96 fp2_2013__ 15.08.13 10:38 Seite 97

15:00 - 16:30 Servet Hall

OP 34 Impact of treatment and genetic susceptibility to comorbidities and mortality

Chair: D. Eurich, Canada, E.R. Pearson, UK

199 Cardiovascular mortality in type 2 diabetes patients with incident exposure to long-acting insulin analogues S. Ioacara, C. Guja, C. Ionescu-Tirgoviste, S. Fica, A. Reghina, O. Georgescu, M. Roden, Romania, Germany

200 Combination therapy with metformin plus sulfonylureas versus metformin plus DPP-4 inhibitors and risk of all-cause mortality C.J. Currie, S. Jenkins-Jones, J. Mukherjee, C.L. Morgan, UK, USA

201 Association between first-line monotherapy with sulfonylurea versus metformin and risk of all-cause mortality S. Jenkins-Jones, C.J. Currie, J. Mukherjee, C.L. Morgan, UK, USA Thursday,September 26

202 Myocardial infarction in subjects using anti-diabetic and/or anti- depressant agents compared to non-users: a nationwide register study in Sweden K. Rådholm, A.-B. Wiréhn, M. Falk, J. Marcusson, C. Östgren, Sweden

203 KCNJ11 E23K polymorphism increases susceptibility for cardiovascular mortality in patients with type 2 diabetes S. Alkayyali, G. Hindy, M. Åkerlund, M. Lajer, D. Pasko, A. Hattersley, T. Frayling, P. Rossing, L. Groop, M. Orho-Melander, V. Lyssenko, Sweden, Denmark, UK, Finland

204 Diabetes, incretin therapy, pancreatitis and pancreas cancer: meta- analyses P. Boyle, M. Bota, J. Rosenstock, France, USA

97 fp2_2013__ 15.08.13 10:38 Seite 98

15:00 - 16:30 Carrasco Hall

OP 35 Diabetes prediction: is stratification the solution?

Chair: J.W.J. Beulens, Netherlands, N.G. Forouhi, UK

Thursday, 26 September Thursday, 205 Genetic variation near SEPSECS/LGI2 associated with metformin treatment failure N. Van Leeuwen, G. Nijpels, J.M. Dekker, E. Van 't Riet, K. Zhou, E. Pearson, L.M. 't Hart, Netherlands, UK

206 Biomarkers of cardiac stress and risk of microvascular events in patients with type 2 diabetes: results from the ADVANCE trial P. Welsh, M. Woodward, G. Hillis, J. Chalmers, N. Sattar, UK, Australia

207 Durability of oral hypoglycaemic agents in drug naïve patients with type 2 diabetes: observational study from the Swedish National Diabetes Register (NDR) N. Ekström, M. Miftaraj, A.-M. Svensson, K. Andersson Sundell, K. Eeg-Olofsson, J. Cederholm, B. Zethelius, S. Gudbjörnsdottir, B. Eliasson, Sweden

208 Estimating the interval between onset and diagnosis of type 2 diabetes from the time-course of retinopathy prevalence M. Porta, G. Curletto, E. Coppo, A. Raviolo, E. Sitia, S. Albani, F. Schellino, M. Trevisan, M. Trento, P. Dalmasso, F. Cavallo, Italy

209 A population-based study of diabetes incidence by ethnicity and age: support for the development of ethnic-specific prevention strategies M.I. Creatore, G.L. Booth, R. Moineddin, D. Manuel, R.H. Glazier, Canada

210 Long term age-related trajectories of cardiovascular risk factors are affected by cohort effects: the Whitehall II study D.R. Witte, A. Hulmán, T.A. Nyári, M. Kivimäki, A.G. Tabák, E.J. Brunner, Luxembourg, Hungary, UK

98 fp2_2013__ 15.08.13 10:38 Seite 99

15:00 - 16:30 Pi i Sunyer Hall

OP 36 Islet cell development and plasticity

Chair: H. Semb, Denmark, M. Vallejo, Spain

211 ARX knockout hESCs show biased pancreatic endocrine specification to unihormonal somatostatin cells B.K. Gage, A. Asadi, R.K. Baker, T.D. Webber, T.J. Kieffer, Canada

212 Efficient generation of definitive endoderm from human embryonic stem cells by GSK3 beta inhibition and nodal signalling O. Naujok, U. Diekmann, S. Lenzen, Germany

213 NADPH oxidase promotes pancreatic endocrine cell differentiation via mediation of SOX9 J. Liang, P.S. Leung, China

214 Contribution of Ins+GLUT2- progenitor cells to endocrine pancreas Thursday,September 26 regeneration after streptozotocin ablation in the neonatal mouse C.A. Beamish, B.J. Strutt, D.J. Hill, Canada

215 Foxo1 ablation increases endocrine progenitor cells in the adult pancreas C. Talchai, D. Accili, USA, Thailand

216 LKB1 and AMPK differentially regulate pancreatic beta cell fate G.A. Rutter, G. Sun, T.J. Pullen, M. Kone, J. Ferrer, M. Ibberson, B. Thorens, A. Swisa, Y. Dor, T. Hildebrandt, I. Uphues, UK, Switzerland, Israel, Germany

99 fp2_2013__ 15.08.13 10:38 Seite 100

16:45 - 18:15 Bernard Hall Risks and benefits of drugs

Chair: C.J. Bailey, UK, M. Stumvoll, Germany,

Thursday, 26 September Thursday, S. Kaul, USA: Update on the evaluation of SGLT2 inhibitors

J.J. Meier, Germany: GLP-1 based therapies and pancreatic disease: what's the clinical evidence?

F. Gorelick, USA: GLP-1 based therapies and pancreatic disease: review of potential mechanisms

Ramón y Cajal Hall EASD/ADA symposium: The DCCT/EDIC study: 30 years of progress and contributions

Chair: O.B. Crofford, Australia, D.M. Nathan

B. Zinman, Canada: Introduction and overview

W.V. Tamborlane, USA: Microvascular update

T.J. Orchard, USA: Cardiovascular update

G.M. Lorenzi, USA: The future

100 fp2_2013__ 15.08.13 10:38 Seite 101

16:45 - 18:15 Ochoa Hall Bariatric surgery in type 2 diabetes: an update

Chair: R. Taylor, UK, J. Vidal, Spain

D.J. Pournaras, UK: Methods and results of bariatric surgery

L. Sjöström, Sweden: Diabetes remission and prevention after usual care and bariatric surgery. Results over 15 years in the Swedish Obese Subjects trial

E. Ferrannini, Italy: Pathophysiology of bariatric surgery

Servet Hall

Lipid-lowering in diabetes: current controversies? Thursday,September 26

Chair: H.N. Ginsberg, USA, N. Sattar, UK

H.N. Ginsberg, USA: LDL lowering beyond statins: will future agents make the grade?

D.J. Preiss, UK: Should we worry about raised triglycerides? The controversy continues

M.J. Chapman, France: HDL-C raising and CVD risk: weak rationale or poor interventions?

101 fp2_2013__ 15.08.13 10:38 Seite 102

16:45 - 18:15 Carrasco Hall Genetics meets metabolomics en route to personalised therapies

Chair: J.C. Florez, USA, E.R. Pearson, UK Thursday, 26 September Thursday,

J.C. Florez, USA: Do genetic and molecular biomarkers help prevention of type 2 diabetes - or not?

C.B. Newgard, USA: Metabolic signatures in the development of insulin resistance

A.J. Butte, USA: Systems biology approaches for individualised medicine

Pi i Sunyer Hall Pancreas regeneration and development: lessons from model systems

Chair: J. Ferrer, UK, N. Hanley, UK

S.K. Kim, USA: New islet-cell regulators revealed by in vitro models of pancreas development

C.V.E. Wright, USA: Mouse genetic analysis of pancreatic cell plasticity

A. Hattersley, UK: Human genetic insight into pancreas development

18:30 Pi i Sunyer Hall

EASD GENERAL ASSEMBLY

102 fp2_2013__ 15.08.13 10:38 Seite 103

MUSEUM NIGHT 19:00 - 22:00

The CaixaForum is located in a unique example of Thursday,September 26 Catalan Art-Nouveau industrial architecture of the early twentieth century. The building, designed by Josep Puig i Cadafalch and completed in 1911. CaixaForum was born in 2002, after “la Caixa” savings bank acquired the building and decided to renovate it into a social, cultural and educational centre for the ©Marc Llimargas - CaixaForum benefit of the public. The centre has hosted many Barcelona exhibits, concerts, film screenings and lectures.

103 fp2_2013__ 15.08.13 10:38 Seite 104

9:00 - 10:00 Bernard Hall

Michael Berger debate: new basal insulins - the longer the better?

Chair: M. Diamant, Netherlands, C. Kloos, Germany Friday, 27 September L.F. Meneghini, USA: Pro

P.D. Home, UK: Contra

Ramón y Cajal Hall

Dogmata in diabetes: albuminuria is a surrogate endpoint for cardiorenal disease

Chair: P.H. Groop, Finland, H.-H. Parving, Denmark

D. de Zeeuw, Netherlands: Pro

G. Viberti, UK: Contra

Ochoa Hall

Metabolic imaging: looking to the future

Chair: H.-U. Häring, Germany, M. Roden, Germany

M. Gotthardt, Netherlands: Imaging of the beta cell

P. Nuutila, Finland: Brown (and beige) fat imaging

104104 fp2_2013__ 15.08.13 10:38 Seite 105

9:00 - 10:00 Servet Hall

From gene loci to function: what have we learnt?

T.M. Frayling, UK, E. Ingelsson, Sweden

J.A. Todd, UK: From genes to mechanism-based intervention

M.A. Nóbrega, USA: TCF7L2 and mechanisms of diabetes risk

Carrasco Hall

Nutritional epidemiology

Chair: N.G. Forouhi, UK, A. Spijkerman, Netherlands Friday, September 27 N.G. Forouhi, UK: Food and nutrition in relation to the development of type 2 diabetes: insights from the EPIC-InterAct Study

J. Mann, New Zealand: Nutrition in the treatment of diabetes: carbohydrate quality

Pi i Sunyer Hall

Tissue cross-talk

Chair: K. Bouzakri, Switzerland, A.M. Gomez-Foix, Spain

B.K. Pedersen, Denmark: Myokines: role in health and diseases

P. Boström, Sweden: Irisin: a new myokine

105 fp2_2013__ 15.08.13 10:38 Seite 106

10:15 - 11:15 Bernard Hall

OP 37 Insulin in type 2 diabetes: earlier? dangerous? stronger?

Chair: F. Holleman, Netherlands, M. Serrano Rios, Spain

217 The effect of early intensive diabetes treatment on long-term glycaemic Friday, 27 September control in newly diagnosed type 2 diabetes: multicentre randomised parallel trial S. Chon, S. Chin, S. Rhee, S. Oh, J.-T. Woo, Y. Kim, K. Ahn, S. Baik, Y. Park, M. Nam, K. Lee, S. Yoo, G. Koh, Korea, Republic of

218 Exogenous insulin and risk of all-cause mortality in type 2 diabetes: a dose-response association S.E. Holden, G. Schernthaner, S. Jenkins-Jones, C.J. Currie, UK, Austria

219 IDegLira, a novel fixed-ratio combination of insulin degludec and liraglutide, is efficacious and safe in subjects with type 2 diabetes: a large, randomised phase 3 trial S.C. Gough, J.B. Buse, V.C. Woo, H.W. Rodbard, S. Linjawi, P. Poulsen, L.H. Damgaard, B.W. Bode, UK, USA, Canada, Australia, Denmark

220 New insulin glargine formulation: glucose control and hypoglycaemia in people with type 2 diabetes using basal and mealtime insulin (EDITION I) M.C. Riddle, G.B. Bolli, M. Ziemen, I. Muehlen-Bartmer, F. Bizet, P.D. Home, USA, Italy, Germany, France, UK

106 fp2_2013__ 15.08.13 10:38 Seite 107

10:15 - 11:15 Ramón y Cajal Hall

OP 38 Hypertension: towards an individualised assessment

Chair: P.-H. Groop, Finland, K. Strojek, Poland

221 Frailty and the relationship between blood pressure and mortality in elderly patients with type 2 diabetes (ZODIAC-34) K.J. Van Hateren, G.W. Landman, N. Kleefstra, S.T. Houweling, H.J. Bilo, Netherlands

222 Resistant hypertension: clinical correlates and association with complications in subjects with type 2 diabetes A. Solini, G. Penno, E. Bonora, C. Fondelli, E. Orsi, G. Zerbini, R. Trevisan, M. Vedovato, F. Cavalot, L. Laviola, S. Morano, G. Pugliese, Italy

223 Antihypertensive treatment in patients with type 1 diabetes according to the stages of diabetic nephropathy Friday, September 27 R. Lithovius, V. Harjutsalo, C. Forsblom, M. Saraheimo, P.-H. Groop, Finland

224 Prognostic impact of treatment resistant hypertension on clinical events during 2-year follow-up in outpatients with diabetes and hypertension: results of the 3A Registry S. Schmidt, R.E. Schmieder, R. Dechend, T. Riemer, I. Hagedorn, U. Zeymer, Germany

107107 fp2_2013__ 15.08.13 10:38 Seite 108

10:15 - 11:15 Ochoa Hall

OP 39 Lipids: prediction and functional studies

Chair: C.J. Tack, Netherlands, M.-R. Taskinen, Finland

225 Association of hypertriglyceridaemia with complications in subjects with Friday, 27 September type 2 diabetes G. Penno, A. Solini, G. Zoppini, C. Fondelli, E. Orsi, G. Zerbini, R. Trevisan, M. Vedovato, G. Gruden, O. Lamacchia, M.G. Baroni, G. Pugliese, Italy

226 Relationship between serum cholesterol efflux capacity and glucose tolerance status in Japanese-Americans M. Kubota, M. Hirano, S. Maeda, M. Yoneda, T. Awaya, S. Nakanishi, Japan

227 Influence of HDL cholesterol levels on endothelial progenitor cells function in patients with type 2 diabetes mellitus D. Lucchesi, S.G. Popa, V. Sancho Bornez, L. Pucci, E. Russo, M. Garofolo, R. Russo, A. Dardano, L. Giusti, R. Miccoli, G. Penno, S. Del Prato, M. Mota, Italy, Romania

228 Hypoxia exacerbates the up-regulatory effect of electronegative LDL on cardiomyocyte intracellular triglyceride accumulation V. Llorente-Cortés, R. Cal, L. Nasarre, M. Estruch, S. Benitez, J. Sanchez-Quesada, Spain

108 fp2_2013__ 15.08.13 10:38 Seite 109

10:15 - 11:15 Servet Hall

OP 40 Beta cell function in vivo

Chair: A. Mari, Italy, E. Montanya, Spain

229 Effects of a small protein and lipid preload on oral glucose tolerance in subjects with normal and impaired glucose tolerance D. Trico', A. Tulipani, S. Baldi, S. Trifiro', S. Frascerra, M.P. Macedo, A. Mari, E. Ferrannini, A. Natali, Italy, Portugal

230 Metabolic shift with impaired perfusion of pancreas in type 2 diabetes: positron emission tomography study H. Honka, J.C. Hannukainen, H. Karlsson, V. Lepomäki, M. Soinio, P. Salminen, V. Oikonen, R. Parkkola, N. Kudomi, A. Mari, P. Iozzo, P. Nuutila, Finland, Japan, Italy

231 Pancreatic islet cell function before and after Roux-en-Y gastric bypass Friday, September 27 in glucose tolerant individuals C. Dirksen, K.N. Bojsen-Møller, N.B. Jørgensen, S.H. Jacobsen, V.B. Kristiansen, L.S. Naver, D.L. Hansen, D. Worm, J.J. Holst, S. Madsbad, Denmark

232 Beta cell function and insulin sensitivity after Roux-en-Y gastric bypass in patients with type 2 diabetes and normal glucose tolerance K.N. Bojsen-Møller, C. Dirksen, S.H. Jacobsen, N.B. Jørgensen, D. Worm, D.L. Hansen, A.K. Serup, J.J. Holst, E.A. Richter, S. Madsbad, Denmark

109 fp2_2013__ 15.08.13 10:38 Seite 110

10:15 - 11:15 Carrasco Hall

OP 41 Short- and long-term impact of nutrition

Chair: A.F.H. Pfeiffer, Germany, D.R. Witte, Luxembourg

233 The effect of frequency of meals on beta cell function in subjects with Friday, 27 September type 2 diabetes H. Kahleova, L. Belinova, A. Tura, M. Hajek, M. Dezortova, M. Hill, T. Pelikanova, Czech Republic, Italy

234 The effect of carbohydrate intake on glycaemic control in patients with type 1 diabetes treated with insulin pumps M.L. James, L. Green, S.A. Amiel, P. Choudhary, UK

235 Effect of whey protein concentrate on blood glucose, insulin and C- peptide serum levels following a high glycaemic index breakfast in patients with type 2 diabetes D. Jakubowicz, M. Boaz, Z. Landau, Z. Matas, T. Ganz, M. Efremashvili, J. Wainstein, Israel

236 Dietary sodium intake and incidence of diabetic complications in Japanese patients with type 2 diabetes: analysis of the Japan Diabetes Complications Study (JDCS) C. Horikawa, Y. Yoshimura, C. Kamada, S. Tanaka, S. Tanaka, T. Yamada, A. Suzuki, O. Hanyu, A. Araki, A. Tanaka, Y. Ohashi, Y. Akanuma, N. Yamada, H. Sone, The Japan Diabetes Complications Study (JDCS), Japan

110110110 fp2_2013__ 15.08.13 10:38 Seite 111

10:15 - 11:15 Pi i Sunyer Hall

OP 42 SIRT1: the good guy?

Chair: S. Schenk, USA, J.-F. Tanti, France

237 AAV8-mediated Sirt1 overexpression in the liver prevents high- carbohydrate diet induced NAFLD L. Vilà, I. Elias, C. Roca, A. Ribera, A. Casellas, R. Lage, T. Ferré, F. Bosch, Spain

238 MicroRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT and SIRT1 genes S. Choi, T. Fu, S. Seok, D.-H. Kim, K.-W. Lee, Y. Kang, B. Kemper, J. Kemper, Korea, Republic of, USA

239 Lack of SIRT1 attenuated the effect of Exenatide to ameliorate liver steatosis in mice Friday, September 27 F. Xu, Z. Li, H. Liu, H. Liang, Z. Chen, J. Weng, China

240 High-fat diet-induced impairment of skeletal muscle insulin action is not prevented by SIRT1 overexpression S. Schenk, A.T. White, USA

111 fp2_2013__ 15.08.13 10:38 Seite 112

11:30 - 12:30 Bernard Hall

OP 43 Defining strategies for the treatment of type 2 diabetes

Chair: V. Pirags, Latvia, B.H.R. Wolffenbuttel, Netherlands

241 Inadequate plasma adiponectin response characterises non- Friday, 27 September responsiveness to pioglitazone in individuals with impaired glucose tolerance: results from the ACT NOW study D. Tripathy, D.C. Schwenke, M. Banerji, G.A. Bray, T.A. Buchanan, S.C. Clement, R.R. Henry, A.E. Kitabchi, S. Mudaliar, R.E. Ratner, F.B. Stentz, N. Musi, P.D. Reaven, R.A. DeFronzo, USA

242 The efficacy of metformin-based OAD is not inferior to insulin glargine in newly diagnosed type 2 diabetes mellitus patients with severe hyperglycaemia after short-term intensive insulin therapy Y. Shumin, Q. Cheng, C. Zhao, P. Ye, Q. Li, Z. Liu, China

243 Initiation of new injectable treatment introduced after anti-diabetic therapy with oral-only regimens (INITIATOR) study: an interim analysis J. Chu, W. Wei, E. Buysman, S. Thayer, L. Brekke, W.H. Crown, M. Grabner, S. Raparla, R.A. Quimbo, M.J. Cziraky, W. Hu, A. Vlajnic, P. Levin, USA

244 Initial triple combination therapy is more effective and safer than stepwise add on conventional therapy in newly diagnosed type 2 diabetes mellitus R.A. DeFronzo, C. Puckett, J. Adams, E. Cersosimo, C. Triplitt, M. Abdul-Ghani, USA

112 fp2_2013__ 15.08.13 10:38 Seite 113

11:30 - 12:30 Ramón y Cajal Hall

OP 44 Hypoglycaemia

Chair: M.L. Evans, UK, J.-M. Servitja, Spain

245 Brain glutamate falls during hypoglycaemia in controls but not in type 1 diabetes mellitus subjects with hypoglycaemia associated autonomic failure E.R. Seaquist, M. Terpstra, A. Moheet, A. Kumar, L. Eberly, G. Oz, USA

246 Myocardial glucose metabolism: impact of GLP-1 in healthy men during normo- or hypoglycaemia M. Gejl, S. Lerche, B. Brock, N. Møller, J.J. Holst, A. Gjedde, H.E. Bøtker, S.B. Hansen, J. Rungby, Denmark

247 Glucose-dependent insulinotropic polypeptide protects against hypoglycaemia in type 1 diabetes A.H. Sparre-Ulrich, M. Christensen, S. Calanna, P.L. Kristensen, F. Purrello, Friday, September 27 J.J. Holst, T. Vilsbøll, F.K. Knop, Denmark, Italy

248 DPP-4 inhibition protects from insulin-induced hypoglycaemia: results from a novel graded hyperinsulinaemic hypoglycaemic clamp in mice S. Malmgren, B. Ahrén, Sweden

113113 fp2_2013__ 15.08.13 10:38 Seite 114

11:30 - 12:30 Ochoa Hall

OP 45 Brown fat: feel the heat?

Chair: S. Herzig, Germany, D. Konrad, Switzerland

249 The novel adipokines BMP4 and BMP7 promote browning of primary Friday, 27 September human adipose-derived stem cells M. Elsen, S. Raschke, H. Sell, N. Tennagels, T. Romacho, J. Eckel, Germany

250 Role IGF1R in the regulation of brown fat function and energy balance V. Viana-Huete, I. Nieto-Vazquez, A. Talavera-Pardo, G. Garcia-Gomez, M. Benito, Spain

251 Presence of brown adipocytes in white adipose tissue and its role in obesity resistance and insulin sensitivity A.-L. Poher, C. Veyrat-Durebex, X. Montet, A. Caillon, J. Altirriba, F. Rohner Jeanrenaud, Switzerland

252 18F-fluorodeoxyglucose uptake in brown adipose tissue during insulin- induced hypoglycaemia in non-diabetic adults F. Holleman, J.E. Schopman, W.M. Admiraal, B.M. Frier, H.J. Verberne, J.B. Hoekstra, Netherlands, UK

114 fp2_2013__ 15.08.13 10:38 Seite 115

11:30 - 12:30 Servet Hall

OP 46 Beta cells under attack

Chair: M. Cnop, Belgium, M. Tiedge, Germany

253 Pro-apoptotic Bax and Bak control beta cell death and early ER stress signalling under glucolipotoxic stress S.A. White, L. Zhang, J.D. Johnson, D.S. Luciani, Canada

254 The transcription factor JunB protects pancreatic beta cells from lipotoxicity by induction of the ER stress response gene XBP1 and AKT signalling D.A. Cunha, E.N. Gurzov, F. Ortis, N. Naamane, M. Bugliani, P. Marchetti, D.L. Eizirik, M. Cnop, Belgium, Italy

255 Involvement of Pannexin-2 in the regulation of pancreatic beta cell function and apoptosis Friday, September 27 L.A. Berchtold, S.V. Pedersen, M. Miani, D.L. Eizirik, R. Bergholdt, F. Pociot, J. Størling, Denmark, Belgium

256 Contribution of long non-coding RNAs to beta cell dysfunction in type 1 diabetes A. Motterle, S. Gattesco, D. Caille, P. Meda, R. Regazzi, Switzerland

115115115 fp2_2013__ 15.08.13 10:38 Seite 116

11:30 - 12:30 Carrasco Hall

OP 47 Metabolic programming and reprogramming

Chair: P.W. Franks, Sweden, M.-F. Hivert, Canada

257 Genes associated with obesity or type 2 diabetes display altered levels Friday, 27 September of DNA methylation in human adipose tissue in response to exercise T. Rönn, P. Volkov, A.H. Olsson, E. Hall, T. Dayeh, M. Dekker Nitert, K.-F. Eriksson, L. Groop, C. Ling, Sweden, Australia

258 Methylation of SCD gene promoter and LINE-1 repeat region are associated with weight gain: a study of primary prevention of diabetes S. Morcillo, G.M. Martín-Núñez, R. Cabrera-Mulero, G. Rojo-Martínez, E. García-Escobar, S. Valdés, L. Castaño, F. Soriguer, Spain

259 Intrauterine undernutrition alters patterns of DNA methylation in the next generation offspring through the male line D. Martinez, T. Pentinat, C. Davidaud, S. Ribo, J. Cebria, R. Diaz, J. Tost, J.C. Jimenez-Chillaron, Spain, France

260 Repeated measurements of 25-hydroxyvitamin D and vitamin D-binding protein throughout pregnancy and risk of type 1 diabetes in the offspring I.M. Sørensen, G. Joner, P.A. Jenum, A. Eskild, C. Brunborg, P.A. Torjesen, L.C. Stene, Norway

116 fp2_2013__ 15.08.13 10:38 Seite 117

11:30 - 12:30 Pi i Sunyer Hall

OP 48 Mechanisms of atherogenesis

Chair: G.M. Lorenzi, USA, K. Sharma, USA

261 In vivo inhibition of Nuclear Factor of Activated T cells (NFAT) leads to atherosclerotic plaque regression in diabetic IGF-II/LDLR-/-ApoB100/100 mice F. Blanco, S. Heinonen, E. Gurzeler, L.M. Berglund, A.-C. Jönsson- Rylander, S. Ylä-Herttuala, M.F. Gomez, Sweden, Finland

262 Circulating myeloid calcifying cells have anti-angiogenic activity via thrombospondin-1 overexpression L. Menegazzo, M. Albiero, R. Milioni, S. Tolin, G. Arrigoni, N. Poncina, P. Tessari, A. Avogaro, G. Fadini, Italy

263 Myeloid calcifying cells promote atherosclerotic calcification in apolipoprotein-E knock-out mice Friday, September 27 M. Albiero, M. Rattazzi, L. Menegazzo, E. Boscaro, R. Cappellari, E. Pagnin, E. Bertacco, N. Kraenkel, U. Landmesser, C. Agostini, A. Avogaro, G. Fadini, Italy, Switzerland

264 Selenoprotein P as a diabetes-associated hepatokine that impairs angiogenesis by inducing VEGF resistance in vascular endothelial cells K. Ishikura, H. Misu, M. Kumazaki, H. Takayama, H. Ando, Y. Takeshita, K. Kato, S. Kaneko, T. Takamura, Japan

117 fp2_2013__ 15.08.13 10:38 Seite 118

CLAUDE BERNARD LECTURE

The Claude Bernard Lectureship recognises contri butions to the ad vancement of knowledge in the field of diabetes mellitus and related metabolic diseases. The Claude Bernard Award

Friday, 27 September is presented to the lecturer by the President of the EASD at the Award Ceremony immediately preceding this lecture.

CLAUDE BERNARD LECTURERS

1969 Montpellier C. DE DUVE, BE 1992 Prague P.H. BENNETT, US 1970 Warsaw E.W. SUTHERLAND, US 1993 Istanbul D. ANDREANI, IT 1971 Southampton M. DEROT, FR 1994 Düsseldorf G. REAVEN, US 1972 Madrid K. LUNDBAEK, DK 1995 Stockholm M. BERGER, DE 1973 Brussels A.E. RENOLD, CH 1996 Vienna J.D. WARD, UK 1974 Jerusalem T.R. FRASER, UK 1997 Helsinki C.E. MOGENSEN, DK 1975 Munich R.G. SPIRO, US 1998 Barcelona C. WOLLHEIM, CH 1976 Helsinki H.G. HERS, BE 1999 Brussels J.P. ASSAL, CH 1977 Geneva D.L. COLEMAN, US 2000 Jerusalem W. MALAISSE, BE 1978 Zagreb W. CREUTZFELDT, DE 2001 Glasgow P.E. CRYER, US 1979 Vienna D.A. PYKE, UK 2002 Budapest M.R. TASKINEN, FI 1980 Athens R.H. UNGER, US 2003 Paris M. BROWNLEE, US 1981 Amsterdam G.R.E. MEYER-SCHWICKERATH, DE 2004 Munich C.R. KAHN, US 1982 Budapest J. MIROUZE, FR 2005 Athens J.J. HOLST, DK 1983 Oslo C. HELLERSTRÖM, SE 2006 Copenhagen L. GROOP, SE 1984 London P.J. LEFEBVRE, BE 2007 Amsterdam E. VAN OBBERGHEN, FR 1985 Madrid E.F. PFEIFFER, DE 2008 Rome R.A. DEFRONZO, US 1986 Rome W. K. WALDHÄUSL, AT 2009 Vienna O. PEDERSEN, DK 1987 Leipzig H. KEEN, UK 2010 Stockholm M. KASUGA, JP 1988 Paris T. DECKERT, DK 2011 Lisbon E. FERRANNINI, IT 1989 Lisbon G. TCHOBROUTSKY, FR 2012 Berlin D.J. DRUCKER, CA 1990 Copenhagen K.G.M.M. ALBERTI, UK 1991 Dublin E. SHAFRIR, IL

118 fp2_2013__ 15.08.13 10:38 Seite 119

12:45 - 14:00 ANNOUNCEMENT OF EFSD ACTIVITIES Bernard Hall INDUCTION OF HONORARY MEMBERS A.J.M. Boulton, President, EASD and EFSD followed by

45TH CLAUDE BERNARD LECTURE

Chair: A.J.M. Boulton, President, EASD and EFSD Speaker: M. Laakso, Finland

Title: From one family to 10,000 men: Genes meet phenotypes in diabetes

Markku Laakso, MD, PhD, has been Professor of Medicine at the Department of Medicine, University of Eastern Finland, Kuopio and Chief Physician of the Department of Medicine, Kuopio University Hospital since 1995. Friday, September 27

He worked as a visiting scientist at the Department of Medicine, Veterans Administration Hospital, University of Southern California, San Diego, from 1987 to 1989 (Research Fellowship from the Fogarty International Center, NIH), and at the Department of Medicine, Division of Medical Genetics, University of Washington, Seattle, from 1993 to1994.

Since 2005, he has been Academy Professor at the Academy of Finland and at the University of Eastern Finland, Kuopio. He was Associate Editor for Diabetologia from 1997 to1999 and from 2008 to 2013, and a member of Editorial Board for Diabetes Care from 1997 to 1999 and for the Journal of Clinical Endocrinology and Metabolism from 2007 to 2010. His main research interests are cardiovascular complications of type 2 diabetes and genetics of insulin resistance, type 2 diabetes and cardiovascular disease.

He has received several international awards, including Novo Nordisk Foundation Award in 2003, Castelli Pedroli Prize (the European Association for the Study of Diabetes) in 2007, and Kelly West Award (American Diabetes Association) in 2008.

119 fp2_2013__ 15.08.13 10:38 Seite 120

14:00 CLOSING CEREMONY Foyer of Bernard Hall

FAREWELL RECEPTION

All participants are invited to join the Farewell Reception. Friday, 27 September

120 fp3_2013__ 15.08.13 10:41 Seite 121

Poster Event A, Tuesday, 12:30 - 13:30

PS 001 Managing and monitoring diabetes: who does well and who doesn't?

Chair: A.M. Wägner, Spain

265 Metformin - a therapeutic option for prevention of type 2 diabetes in persons with normal glucose tolerance, metabolic syndrome and hyperinsulinaemia P. Kamenova, I. Atanasova, G. Kirilov, Bulgaria

266 Reasons for non-intensification of therapy in type 2 diabetes patients uncontrolled by oral monotherapy in general practice in France: the

DIAttitude study Posters B. Balkau, S. Halimi, J. Blickle, C. Attali, A. Avignon, E. Amelineau, I. Chartier, M.-A. Geoffroy, B. Verges, France

267 C-peptide levels not affected by duration of diabetes in a telemedicine based long-term follow up programme G. Krishnan, P.S. Pillai, A. Shankar, S. Jothydev, J. Kesavadev, India

268 Accuracy of self-measured blood glucose (SMBG) in 11317 adult diabetes patients based on Clark Error Grid, Parkes Error Grid, ISO 15197 and Bland-Altman-plot M. Flechtner-Mors, C. Boettcher, K. Doering, A. Dost, D. Krakow, E. Molz, C. Wagner, A. Zimmermann, R.W. Holl, for the DPV Initiative and the BMBF Competence Network Diabetes, Germany

269 Monitoring and management of type 2 diabetes patients with renal disease: gap between knowledge and real-life practices S. Dejager, J.-F. Blicklé, B. Fiquet, A. Penfornis, France

270 Meta-analysis of studies examining medication adherence to oral antihyperglycaemic agents in type 2 diabetes K. Tunceli, S.E. Cartier, V.M. Rosen, V. Zarotsky, K. Iglay, S.N. Rajpathak, L. Radican, USA

271 How are patients with type 2 diabetes and renal disease monitored and managed in France? Results from the OreDia 2012 survey J.-F. Blicklé, A. Penfornis, B. Fiquet, S. Dejager, France

121 fp3_2013__ 15.08.13 10:41 Seite 122

272 Prevalence of inadequate metabolic control: results from a provincial wide survey in 1,461 patients with type 1 diabetes in China D. Yang, J. Li, J. Yan, J. Weng, China

273 Sex differences in glycaemic control among people with type 1 diabetes S. Wild, International quality of care for type 1 diabetesgroup, UK

274 Glycaemic control is not affected by age and gender: results from a large cohort study (EDGE) M. Ratzinger, H. Brath, A. Kautzky-Willer, G. Bader, Austria, Switzerland Posters

Poster Event B, Tuesday, 13:45 - 14:45

PS 002 HbA1c measurement and outcomes

Chair: A. Adler, UK

275 The use of HbA1c to diagnose type 2 diabetes in a multiethnic and diverse socioeconomic population: results from the South London Diabetes study (SOUL-D) M. Azam, L. Marwood, K. Ismail, T. Evans, K. Winkley, S.A. Amiel, UK

276 Identification of HbA1c cut-off for pre-diabetes from incidence of diabetes in a Japanese population T. Yuki, T. Nakagami, J. Oya, Y. Yamamoto, Y. Hasegawa, M. Kurita, Y. Endo, Y. Uchigata, Japan

277 Phenotypes and biochemical characteristics of new diabetes patients diagnosed based upon different criteria: HbA1c recognises people at a more advanced diabetic stage S. Ilhan, Y. Tutuncu, S. Gedik, F. Turker, N. Dinccag, K. Karsidag, B. Omer, S. Kalaca, A. Telci, S. Genc, T. Yilmaz, B. Cakir, J. Tuomilehto, The TURDEP-II Study Group, Turkey, Austria

278 Prediction of diabetes mellitus using HbA1c: Does HbA1c more efficiently predict onset than plasma glucose concentration? N. Tanabe, M. Yamamoto, T. Momotsu, K. Suzuki, K. Sanpei, H. Sone, Japan

122 fp3_2013__ 15.08.13 10:41 Seite 123

279 Average glucose and respective glycated haemoglobin values in patients with type 2 diabetes: reappraisal of the ADAG study E. Franek, J. Rzeszotarski, P. Bijos, J. Jozwiak, A. Zonenberg, M. Masierek, Poland

280 Relationship between haemoglobin and glycated HbA1c in a Japanese population T. Nakagami, J. Oya, Y. Yamamoto, Y. Hasegawa, M. Kurita, Y. Tanaka, T. Kasahara, Y. Uchigata, Japan

281 'Tracking' of metabolic parameters in patients with diabetes: Are we making a difference? J. Sangha, P. Narendran, UK Posters 282 The threshold of glycated haemoglobin and diabetic complications: a community-based screening programme in Shanghai C. Pang, X. Hou, Y. Bao, Y. Zuo, S. Jiang, W. Jia, China

283 Seasonal variation in HbA1c in adult Portuguese patients M.T. Pereira, D. Lira, C. Bacelar, A.C. Carvalho, Portugal

284 Difference of seasonal variation between glycated albumin and glycated HbA1c K. Tanaka, S. Meguro, T. Kawai, M. Tanaka, J. Irie, Y. Saisho, H. Itoh, Japan

Poster Event C, Wednesday, 12:30 - 13:30

PS 003 Prevalence and incidence of diabetes

Chair: M.B. Schulze, Germany

285 Incidence and risk factors of new-onset diabetes mellitus after lung transplantation S. Thilmany, J. Jamart, P. Evrard, J.E. Donckier, Belgium

286 20 years of type 1 diabetes registry of Catalonia C. Castell, N. Lara, A. Daroca, R. Milà, C. Cabezas, Spain

123 fp3_2013__ 15.08.13 10:41 Seite 124

287 The incidence of type 1 diabetes mellitus in Romanian children aged 0- 17 years increased significantly between 2002 and 2011 A. Vlad, V. Serban, R. Timar, B. Timar, A. Sima, M. Rosu, ONROCAD Study Group, Romania

288 Undiagnosed diabetes and prediabetes in the Bangladeshi population M. Das, K. Islam, M. Sahabuddin, Z. Hassan, M. Khalequzzaman, L. Ali, Bangladesh

289 Undiagnosed type 2 diabetes remains an important health problem Posters disproportionately affecting Irish males: the diabetes mellitus and vascular health initiative (DMVhi) M. Sinnott, A. Jackson, B. Kinsley, C. Walsh, T. O'Grady, P. Gaffney, G. Boran, J.J. Nolan, C. Kelleher, B. Carr, Ireland, Denmark

290 Regional differences in the incidence of known type 2 diabetes mellitus in 45-74 years old individuals: results from five population-based studies in Germany S. Schipf, T. Ittermann, T. Tamayo, W. Maier, C. Meisinger, K.H. Greiser, G. Mueller, S. Moebus, H. Völzke, Germany

291 New estimates of diabetes prevalence in the Netherlands, based on information from 5 million subjects (DUDE-1) S.T. Houweling, N. Kleefstra, M. Meulepas, A. Romeijnders, M. Klomp, H.J. Bilo, Netherlands

292 Evaluation of two screening methods for newly diagnosed diabetes in China: a cost-effectiveness study Y. Zhang, J. Sun, Z. Pang, W. Gao, H. Sintonen, A. Kapur, Q. Qiao, Finland, China, Denmark

293 Screening for people with glucose metabolism disorders within the framework of the Demojuan project in Barranquilla, Colombia N.C. Barengo, T. Acosta, A. Arrieta, C. Ricaurte, D. Mayor, J. Tuomilehto, Colombia, Spain, Austria

294 Prevalence of carbohydrate metabolism disorders in patients with acromegaly A.V. Dreval, I.V. Trigolosova, B.H. Wolffenbuttel, I.V. Misnikova, Y.A. Kovaleva, R.S. Tishenina, I.A. Barsukov, A.V. Vinogradova, Russian Federation, Netherlands

124 fp3_2013__ 15.08.13 10:41 Seite 125

Poster Event D, Wednesday, 13:45 - 14:45

PS 004 Type 1 diabetes observational studies

Chair: A.G. Ziegler, Germany

295 Antibodies against the Epstein-Barr virus Nuclear Antigen (EBNA-1) in patients with autoimmune diabetes mellitus E. Sipter, D. Csuka, Z. Prohászka, P. Pánczél, Á. Szilágyi, I. Karádi, G. Füst, N. Hosszúfalusi, Hungary

296 The risk of type 1 diabetes mellitus in offspring of immigrants in Sweden

H.I. Hussen, S. Cnattingius, M. Persson, T. Moradi, Sweden Posters

297 Non-HLA genes and familial predisposition to autoimmune diseases in families with a child affected by type 1 diabetes A. Parkkola, A.-P. Laine, T. Härkönen, S.J. Ryhänen, J. Ilonen, M. Knip, the Finnish Pediatric Diabetes Register, Finland

298 Mortality and having offspring in type 1 diabetes L. Sjöberg, L. He, J. Tuomilehto, R. Kaaja, J. Pitkäniemi, Finland, Austria

299 Quality of life, age at onset of type 1 diabetes and metabolic control in a cohort of patients followed for 16 years M. Trevisan, E. Coppo, A. Raviolo, P. Passera, M. Zanone, F. Cavallo, M. Porta, M. Trento, Italy

300 50 years of childhood type 1 diabetes: clinical characteristics of survivors from the Pittsburgh Epidemiology of Diabetes Complications study (EDC) T.J. Orchard, R.G. Miller, USA

301 Life expectancy in type 1 diabetes: a Scottish Registry Linkage study S.J. Livingstone, on behalf of the Scottish Diabetes Research Network epidemiology group, UK

302 Excess mortality in early adulthood in a population-based cohort of childhood onset type 1 diabetes M.N. Cooper, N.H. De Klerk, T.W. Jones, E.A. Davis, Australia

125 fp3_2013__ 15.08.13 10:41 Seite 126

303 Associations of genetic variants in thioredoxin (TXN) and mitochondrial thioredoxin reductase (TXNRD2) genes with kidney disease in type 1 diabetes T.A. Patente, M.B. Monteiro, M. Queiroz, M. Nery, M.J. Azevedo, L.H. Canani, E.J. Pavin, M.C. Parisi, U.F. Machado, M. Passarelli, D. Giannella-Neto, M.L. Côrrea-Giannella, Brazil

304 Experimental gene therapy of type 1 diabetes mellitus: dose-dependent effects on glucose levels in blood plasma of mice and rats M. Tronko, L.N. Kalynska, O.I. Kovzun, I.P. Paster, O.K. Toropova, Posters T.P. Gulko, V.A. Kordium, Ukraine

Poster Event E, Thursday, 12:30 - 13:30

PS 005 What predicts type 1 diabetes?

Chair: A.-M. Madec, France

305 Foetal transfer of preproinsulin through the neonatal Fc receptor protects from type 1 diabetes S. Culina, R. Boisgard, N. Gupta, S. Lacroix-Desmazes, R. Mallone, France

306 Lower physical activity in children with persistent islet autoantibodies than in matched controls M. Rewers, K. Waugh, K. Barriga, J. Norris, J. Snell-Bergeon, USA

307 Prognostic and diagnostic relevance of ZnT8 antibodies in autoimmune diabetes K. Wilhelm, K. Tornow, V. Lampasona, U. Walschus, I. Rjasanowski, W. Kerner, M. Schlosser, Germany, Italy

308 Levels of 12-HETE are elevated in patients with newly diagnosed but not with established type 1 diabetes E. Hennessy, A. Rakovac Tisdall, N. Murphy, A. Carroll, C. Clarke, M. Clynes, P. Dowling, S. Sreenan, Ireland

309 Relationship of serum cytokines and proinflammatory markers to development of type 1 diabetes K. Siewko, M. Szelachowska, A. Poplawska-Kita, D. Lipinska, A. Nikolajuk, M. Gorska, Poland

126 fp3_2013__ 15.08.13 10:41 Seite 127

310 Targeting IL-15 for immunotherapy in autoimmune diabetes S. Ramanathan, D. Bobbala, M. Mayhue, S. Ilangumaran, Canada

311 Non-diabetic first degree relatives of type 1 diabetics vs recent-onset type 1 diabetics: insulin secretion and insulin sensitivity changes at onset of type 1 diabetes T. Milicic, N. Lalic, A. Jotic, I. Markovic, K. Lalic, L. Lukic, N. Rajkovic, M. Macesic, J. Seferovic, J. Stanarcic, Serbia

312 Validation of insulin dose-adjusted HbA1c (IDAA1c) in 129 Danish children with new-onset type 1 diabetes M.-L.M. Andersen, S. Pörksen, L.B. Nielsen, J. Svensson, J. Thomsen, N.T. Hertel, J. Vikre-Jørgensen, J.S. Petersen, L. Hansen, P. Hougaard,

H.B. Mortensen, Denmark Posters

Poster Event F, Thursday, 13:45 - 14:45

PS 006 Epidemiology: social and environmental factors

Chair: J.B.L. Hoekstra, Netherlands

313 Ethnic disparities in conversion from impaired fasting plasma glucose to type 2 diabetes W. Admiraal, F. Holleman, M. Snijder, R. Peters, L. Brewster, J. Hoekstra, K. Stronks, I. Van Valkengoed, Netherlands

314 Impact of parental socio-economic resources on excess mortality in subjects with childhood onset type 1 diabetes Y.T. Berhan, M. Eliasson, A. Mollsten, I. Waernbaum, G.G. Dahlquist, the Swedish Childhood Diabetes Study Group, Sweden

315 Factors associated with sustained poor glycaemic control in Chinese patients with type 2 diabetes in Hong Kong J.M. Yin, R. Yeung, Y. Zhang, Y. Sui, N. Brown, A. Kong, R. Ozaki, A. Luk, R.C. Ma, W. Chan, P. Tong, W. So, J. Chan, China

316 Age, glycaemic control and social deprivation independently predict 10- year mortality in a UK type 1 diabetes cohort S. Thomas, L. Yassa, D. Simpson, T. Evans, S. Amiel, A. Simonds, D. Hopkins, UK

127 fp3_2013__ 15.08.13 10:41 Seite 128

317 Does birth weight affect insulin sensitivity and secretion and the prevalence of diabetes in a Japanese general population? J. Oya, T. Nakagami, M. Kurita, Y. Yamamoto, Y. Hasegawa, Y. Tanaka, Y. Endo, Y. Uchigata, Japan

318 Predictive ability of simple clinical information without blood tests for future incident diabetes: a meta-analysis S. Yoshizawa, S. Kodama, K. Fujihara, C. Horikawa, A. Sugawara, Y. Heianza, Y. Yachi, S. Tanaka, S. Minakawa, T. Yamada, A. Suzuki, O. Hanyu, H. Sone, Japan Posters 319 Increased incidence of disorders of carbohydrate metabolism and metabolic syndrome in persons exposed to ionising radiation O.V. Kaminskyi, D.E. Afanasyev, O.V. Tepla, I.O. Kiselova, Ukraine

320 Social network and development of prediabetes and type 2 diabetes in middle-aged Swedish women and men A. Hilding, C. Shen, C.-G. Östenson, Sweden, China

Poster Event A, Tuesday, 12:30 - 13:30

PS 007 Basic science: environmental factors

Chair: N.G. Morgan, UK

321 A chronic exposure to a mixture of low-dosed food contaminants predisposes to the risk of developing metabolic disorders B. Le Magueresse-Battistoni, N. Vega, C. Pinteur, E. Labaronne, C. Luquain-Costaz, H. Vidal, D. Naville, France

322 Foodborne cereulide causes beta cell dysfunction and apoptosis R. Vangoitsenhoven, D. Rondas, I. Crèvecoeur, W. D'Hertog, G. Bomfim Ferreira, C. Matthys, M. Maris, M. Andjelkovic, J. Van Loco, L. Overbergh, C. Mathieu, B. Van der Schueren, Belgium

323 Pancreatic islet expression of enteroviral receptors and dsRNA sensors in human type 1 diabetes I. Spagnuolo, S.J. Richardson, G. Sebastiani, F. Mancarella, A. Patti, N.G. Morgan, F. Dotta, Italy, UK

128 fp3_2013__ 15.08.13 10:41 Seite 129

324 Therapies which lower advanced glycation end products influence experimental autoimmune diabetes in a time dependent manner D.J. Borg, F.Y. Yap, A.K. Fotheringham, B.E. Harcourt, D. McCarthy, M. Ward, R. Slattery, M.T. Coughlan, P. Kantharidis, J.M. Forbes, Australia

325 Increased degradation of insulin granule proteins, caspase-like activity and MHC class I in Coxsackievirus infected insulin producing cells A. Petzold, K.-P. Knoch, E. Töpfer, A. Sönmez, C. Wegbrod, C. Münster, M. Roivainen, M. Solimena, Germany, Finland

326 Effect of nanopowder (TiO2 and CO3O4) on circulating angiogenic cell viability, function and inflammatory response M. Cito, V. Spigoni, M. Pinna, S. Pinelli, R. Alinovi, M. Goldoni, I. Zavaroni,

A. Mutti, A. Dei Cas, Italy Posters

327 DNA methylation analysis in adipose tissue after long term high-fat diet- induced obesity in mice L. Parrillo, V. Costa, R. Esposito, G.A. Raciti, C. Legault, C. Nigro, V. Vastolo, A. Ciccodicola, C. Miele, F. Beguinot, Italy

Poster Event B, Tuesday, 13:45 - 14:45

PS 008 Genetics: functional studies

Chair: G.A. Rutter, UK

328 Functional analyses of the type 2 diabetes associated 12-bp deletion in repin1 J. Krüger, K. Weidle, M. Kern, B. Enigk, I. Müller, M. Prellberg, D. Schleinitz, J. Breitfeld, A. Tönjes, M. Stumvoll, M. Blüher, P. Kovacs, N. Klöting, Germany

329 Regulation of alternative splicing in human obesity loci D. Kaminska, S. Venesmaa, P. Käkelä, H. Gylling, M. Laakso, J. Pihlajamäki, Finland

330 Defective glucose homeostasis in mice inactivated selectively for Tcf7l2 in the adult beta cell with an Ins1-controlled Cre G. Da Silva Xavier, A. Mondragon, R. Mitchell, D.J. Hodson, J. Ferre, B. Thorens, J.A. McGinty, P.M. French, G.A. Rutter, UK, Switzerland

129 fp3_2013__ 15.08.13 10:41 Seite 130

331 Functional characterisation of the transcriptional machinery bound across the type 2 diabetes associated TCF7L2 intronic variant, rs7903146 S.F. Grant, S. Deliard, C.-X. Yuan, M.E. Johnson, Q. Xia, USA

332 The type 2 diabetes-associated gene ADCY5 modulates glucose- stimulated network connectivity and insulin secretion from human islets R.K. Mitchell, M. Bugliani, P. Marchetti, D. Bosco, P. Johnson, S. Hughes, W.-H. Li, D. Li, D.J. Hodson, G.A. Rutter, UK, Italy, Switzerland, USA

333 Effects of functional polymorphisms in GLIS3 and a putative target gene Posters on insulin secretion S. Calderari, C. Gérard, M. Ria, P.J. Kaisaki, D. Gauguier, France, UK

334 Functional analysis of MODY2 mutations in the nuclear export signal of glucokinase M.-A. Navas, A. Gutierrez-Nogués, C.M. Garcia-Herrero, J. Oriola, R. Casamitjana, O. Vincent, Spain

Poster Event C, Wednesday, 12:30 - 13:30

PS 009 Genetics: candidate gene association studies

Chair: F. Bosch, Spain

335 Usefulness of genetic risk score constructed from 49 loci for type 2 diabetes in Japanese individuals M. Imamura, M. Iwata, H. Maegawa, H. Watada, H. Hirose, Y. Tanaka, K. Tobe, K. Kaku, A. Kashiwagi, R. Kawamori, S. Maeda, Japan

336 A genetic risk score comprising common variants associated with fasting insulin is associated with OGTT- and clamp-based indices of whole body insulin sensitivity R.A. Scott, D. Pasko, T. Fall, H. Yaghootkar, A. Barker, S.J. Sharp, M. Walker, N.J. Wareham, E. Ingelsson, T. Frayling, C. Langenberg, UK, Sweden

130 fp3_2013__ 15.08.13 10:41 Seite 131

337 Type 2 diabetes genetic risk score is more strongly associated with basal insulin secretion and insulin requirement than family history in Japanese type 2 diabetic patients M. Iwata, S. Maeda, Y. Kamura, A. Takano, H. Kato, S. Murakami, K. Higuchi, R. Temaru, H. Oda, S. Asamizu, Y. Fukushima, K. Fukuda, K. Yamazaki, I. Usui, K. Tobe, Japan

338 Loss of function mutation carriers (long QT type 1 patients) of the type 2 diabetes gene KCNQ1 have reactive hyperinsulinaemia and postprandial hypoglycaemia S.S. Torekov, J.K. Kanters, E.P. Iepsen, M. Christiansen, A. Linneberg, O. Pedersen, J.J. Holst, T. Hansen, Denmark

339 PROX1 type 2 diabetes predisposing genetic variant is associated with Posters visceral fat accumulation and lower carbohydrate oxidation K. Maliszewska, A. Kretowski, A. Citko, N. Wawrusiewicz-Kurylonek, E. Adamska, J. Goscik, D. Lipinska, M. Waszczeniuk, M. Gorska, Poland

340 The BDNF, NEGR1 and TMEM18 genetic variants are associated with body fat content and components of metabolic syndrome in humans A. Citko, A. Kretowski, N. Wawrusiewicz-Kurylonek, M. Waszczeniuk, E. Adamska, J. Goscik, K. Maliszewska, J. Wilk, D. Lipinska, J. Pliszka, M. Ciborowski, M. Gorska, Poland

341 Association of mitochondrial respiratory chain polymorphisms with type 2 diabetes in the Spanish population G.O. De Marco Solar, M.L. Mansego, G. Rojo-Martínez, R. Carmena, F.J. Chaves, S. Morcillo, M. Pineda-Alonso, G.M. Martín-Núñez, J.C. Martín Escudero, J. Redon, F. Soriguer, M. Serrano-Rios, Spain

342 Association of mitochondrial respiratory chain polymorphisms with the presence of obesity and their impact in type 2 diabetes mellitus development in the Spanish population F.J. Chaves, G.O. De Marco Solar, M. Pineda-Alonso, G. Rojo-Martínez, S. Morcillo, G.M. Martín-Núñez, J.C. Martín Escudero, J. Redon, F. Soriguer, R. Carmena, M. Serrano-Rios, M.L. Mansego, Spain

131 fp3_2013__ 15.08.13 10:41 Seite 132

Poster Event D, Wednesday, 13:45 - 14:45

PS 010 Genetics: methylation and post transcriptional modification

Chair: L. Eliasson, Sweden

343 Role of microRNAs in pancreatic beta cell dysfunction associated with ageing K. Tugay, R. Regazzi, Switzerland Posters 344 Genome-wide DNA methylation analysis identifies epigenetic alterations in pancreatic islets from patients with type 2 diabetes T. Dayeh, P. Volkov, S. Salo, E. Hall, E. Nilsson, A.H. Olsson, L. Eliasson, K. Bacos, T. Ronn, C. Ling, Sweden

345 Identification of SNPs associated with DNA methylation in human pancreatic islets and its role in the pathogenesis of type 2 diabetes A.H. Olsson, P. Volkov, T. Dayeh, E. Hall, E.A. Nilsson, C. Ladenvall, T. Rönn, C. Ling, Sweden

346 Genome-wide analysis of DNA methylation variations caused by chronic glucolipotoxicity in beta cells Y. Hu, X.H. Xu, T.T. Feng, X.M. Mao, China

347 Implication of insulin-like growth factor binding protein 1 DNA methylation and protein variation for type 2 diabetes T. Gu, H.F. Gu, A. Hilding, L.K. Sjöholm, L. Kärvestedt, C.-G. Östenson, T.J. Ekström, K. Brismar, Sweden

348 DNA methylation, cardio metabolic risk and type 2 diabetes in south Asians and Europeans H.R. Elliott, T. Tillin, N. Chaturvedi, A.D. Hughes, W. McArdle, G. Davey Smith, T.M. Frayling, S. Ebrahim, C.L. Relton, UK, India

349 Maternal transmission of variants in the THADA gene to offspring with type 2 diabetes R.B. Prasad, A. Lessmark, P. Almgren, W. Poon, M. Sterner, G. Gremsperger, T. Tuomi, L. Groop, Sweden, Finland

132 fp3_2013__ 15.08.13 10:41 Seite 133

350 DOLCE: new cohort to study the effects of famine on the risk of diabetes and its complications W. Poon, S. Alkayyali, L. Cherviakova, N. Khalimon, T. Svietleisha, T. Buldenko, H. Vasylkova, V. Lyssenko, Sweden, Ukraine, Denmark

Poster Event E, Thursday, 12:30 - 13:30

PS 011 Genetics: monogenic forms

Chair: L.A. Castaño Gonzalez, Spain

351 Clinical widened diagnostic criteria and prediction models identify

"MODY-X" patients who should benefit from new specific genetic screening Posters C. Leroy, I. Fajardy, DIAMENORD Study Group, M. Vaxillaire, P. Froguel, P. Fontaine, A. Vambergue, France

352 Reclassification of diabetes aetiology in a family with multiple diabetes phenotypes F.K. Kavvoura, A. Raimondo, G. Thanabalasingham, A. Barrett, A.L. Webster, N. Mann, S. Ellard, A.L. Gloyn, K.R. Owen, UK

353 Detection of PAX4 mutations in Japanese patients with maturity-onset diabetes of the young M. Takizawa, N. Iwasaki, M. Ogata, R. Ide, Y. Uchigata, Japan

354 Phenotypic heterogeneity in Japanese patients with hepatocyte nuclear factor-1b mutations N. Iwasaki, M. Takizawa, T. Yamamoto, M. Ogata, R. Ide, Y. Uchigata, Japan

355 No attenuation of CRP response to acute inflammation is seen in HNF1A-MODY K.R. Owen, S.A. Mughal, S. Beatty, T.J. James, M.I. McCarthy, UK

356 Cellular re-uptake of secreted carboxyl-ester lipase protein in CEL- MODY, a syndrome of diabetes and pancreatic exocrine dysfunction A. Molven, J. Torsvik, B.B. Johansson, M. Marie, K. Fjeld, S. Johansson, J. Saraste, P.R. Njølstad, Norway

133 fp3_2013__ 15.08.13 10:41 Seite 134

357 Preserved postprandial GLP-1 and GIP responses in patients with maturity onset diabetes of the young J.I. Bagger, S.H. Østoft, T. Hansen, O. Pedersen, J.J. Holst, F.K. Knop, T. Vilsbøll, Denmark

358 Differential glucagon responses to glucose in maturity onset diabetes of the young type 2 and 3 S.H. Østoft, J.I. Bagger, T. Hansen, O. Pedersen, J.J. Holst, F.K. Knop, T. Vilsbøll, Denmark

Posters 359 A case of Transient Neonatal Diabetes (TND) in a young woman with Beckwith-Wiedemann Syndrome (BWS) and a molecular diagnosis of Hypomethylation of Multiple Loci (HIL) N.I. Wreglesworth, D. Mackay, K. Chokkalingam, UK

360 Diabetes mellitus and intestinal ulcers: it’s a Wolfram Syndrome 2? E. Mozzillo, M. Delvecchio, R. Genesio, R. Nugnes, V. Fattorusso, E. De Nitto, A. Franzese, Italy

Poster Event F, Thursday, 13:45 - 14:45

PS 012 Genetics: gene-lifestyle interactions and pharmacogenetics

Chair: P. Kovacs, Germany

361 Dietary polyunsaturated fatty acids and the Pro12Ala polymorphisms of PPARG regulate serum lipids through divergent pathways: a randomised crossover clinical trial J.A. Pihlajamäki, U. Schwab, D. Kaminska, M. Kolehmainen, J. Paananen, M. Laakso, M. Uusitupa, Finland

362 High heritability and genetic correlation of intravenous glucose- and tolbutamide-induced insulin secretion A. Jonsson, M. Hornbak, A.P. Gjesing, K.H. Allin, C.T. Ekstrøm, H. Eiberg, O. Pedersen, T. Hansen, Denmark

134 fp3_2013__ 15.08.13 10:41 Seite 135

363 The CTRB1/CTRB2/BCAR1 locus is associated with GLP-1 stimulated insulin secretion and DPP-4 inhibitor treatment response L.M. 't Hart, A. Fritsche, N. Van Leeuwen, G. Nijpels, L.A. Donnelly, J.M. Dekker, J. Fadista, L. Groop, F. Carlotti, E.J. De Koning, D.I. Boomsma, E.J. De Geus, E.M. Eekhoff, E.R. Pearson, M. Diamant, Netherlands, Germany, UK, Sweden

364 Polymorphisms associated with serum 25-hydroxyvitamin D concentration and their impact on subclinical atherosclerosis in patients with type 2 diabetes A. Deleskog, R. Strawbridge, O. Piksasova, J. Öhrvik, K. Gertow, C.-G. Östenson, A. Hamsten, the IMPROVE Study Group, Sweden

365 TCF7L2 gene polymorphisms may influence decreased postprandial Posters glucose oxidation - looking for personalised nutrition for obesity/type 2 diabetes mellitus prevention E. Adamska, A. Kretowski, J. Goscik, M. Waszczeniuk, J. Wilk, A. Golonko, N. Wawrusiewicz-Kurylonek, A. Citko, M. Ciborowski, D. Lipinska, J. Pliszka, K. Maliszewska, M. Gorska, Poland

366 Interaction between vitamin D receptor gene variants and dairy intake: effects on incident metabolic syndrome and incident IFG/type 2 diabetes in the D.E.S.I.R. study F. Fumeron, A. Lamri, L. Rozenblum, A. Nicolas, N. Bellili, O. Lantieri, B. Balkau, G. Velho, M. Marre, France

367 Several type 2 diabetes associated variants in genes involved in WNT- signalling interact with dietary fibre intake on type 2 diabetes incidence G. Hindy, I.G. Mollet, G. Rukh, U. Ericson, M. Orho-Melander, Sweden

368 Genetic variants within AKR1B10 may influence human eating behaviour K. Rohde, M. Federbusch, A. Horstmann, A. Tönjes, A. Villringer, M. Stumvoll, P. Kovacs, Y. Böttcher, Germany

135 fp3_2013__ 15.08.13 10:41 Seite 136

Poster Event A, Tuesday, 12:30 - 13:30

PS 013 Genetics: discovering genes

Chair: T. Hansen, Denmark

369 The search for the variant explaining type 2 diabetes linkage on chromosome 9 E. Ottosson Laakso, P. Vikman, A. Kvist, H. Mattisson, L. Sarelin, P. Almgren, B. Isomaa, L. Groop, Sweden, Finland Posters

370 Novel gene-bases and pathway analysis GWAS methods for the identification of new candidate genes and pathways for type 2 diabetes J.M. Mercader, C. Voichita, M. Donato, F. Sánchez, S. Bonàs, A.L. Tarca, S. Draghici, D. Torrents, Spain, USA

371 Identification of new genetic associations to type 2 diabetes through accurate genotype imputation with 1000 Genomes reference panel S. Bonàs, F. Sánchez, J.M. Mercader, D. Torrents, Spain

372 Large-scale genome-wide association meta-analysis of the 1000 genomes project imputed data identifies 19 novel lipid loci and new variants in previously known loci I. Prokopenko, I. Surakka, A.-P. Sarin, R. Mägi, M. Horikoshi, T. Ferreira, L. Marullo, G. Thorleifsson, A. Mahajan, M.I. McCarthy, A.P. Morris, S. Ripatti, for the ENGAGE Consortium, UK, Finland, Estonia, Italy, Iceland

373 Pleiotropic effects of obesity-susceptibility loci on metabolic traits: a meta-analysis of up to 37,874 individuals J.V. Van Vliet-Ostaptchouk, M. Den Hoed, J. Luan, J. Zhao, K. Ong, A. Wong, R. Hardy, D. Kuh, M. Van der Klauw, M. Bruinenberg, K.-T. Khaw, B. Wolffenbuttel, N. Wareham, H. Snieder, R. Loos, Netherlands, UK, Sweden, USA

374 Dissecting the pleiotropic effects of established type 2 diabetes and other cardiometabolic trait loci to define pathways and gene networks involved in type 2 diabetes pathogenesis L. Marullo, B. Voight, C. Fuchsberger, C. Scapoli, J. Dupuis, J.B. Meigs, A.P. Morris, I. Prokopenko, Italy, UK, USA

136 fp3_2013__ 15.08.13 10:41 Seite 137

Poster Event B, Tuesday, 13:45 - 14:45

PS 014 Nutrition and mechanisms in diabetes: observational studies

Chair: N. Katsilambros, Greece

375 Anti-obesity and anti-diabetic effect of chronic coffee consumption in mice I. Rustenbeck, V. Lier-Glaubitz, M. Willenborg, U. Engelhardt, A. Jörns, Germany

376 Dietary intake of carbohydrates and risk of type 2 diabetes: European Prospective Investigation into Cancer in Norfolk study

S. Ahmadi Abhari, R.N. Luben, N. Powell, A. Bhaniani, N.J. Wareham, Posters N.G. Forouhi, K.-T. Khaw, UK

377 The association between dietary flavonoid and lignan intakes and incident type 2 diabetes in European populations: the EPIC-InterAct study R. Zamora-Ros, InterAct Consortium, UK, Spain

378 Glucosinolates for the prevention of type 2 diabetes? Reduction of glucose production and induction of protective principles V. Guzman, C. Bumke-Vogt, A. Borchert, M. Schreiner, I. Mewis, A.F. Pfeiffer, Germany

379 Effects of 12 weeks of trichosanthis kirilowii and manitolatodimolybdate in the treatment of Hispanic prediabetic patients J.A. Rojas Jiménez, G.C. Levin Pick, S. Albarrán Echeverría, E.R. Romero Gutiérrez, Mexico

380 A short-term high-cholesterol diet deteriorates glucose tolerance to a different extent and through different mechanisms in controls and type 2 diabetes offspring S. Trifiro', C. Morgantini, S. Baldi, D. Trico', E. Barsotti, E. Ferrannini, A. Natali, Italy

381 Lipopolysaccharide is negatively correlated with beta cell function S. Liang, S. Liu, Y. Li, X. Gan, Y. Liang, F. Li, China

137 fp3_2013__ 15.08.13 10:41 Seite 138

Poster Event C, Wednesday, 12:30 - 13:30

PS 015 Lifestyle factors as risk factors

Chair: N.J. Wareham, UK

382 Smoking and risk of type 2 diabetes: the EPIC-InterAct study A.M. Spijkerman, D.L. Van der A, P.M. Nilsson, E. Ardanaz, D. Gavrila, on behalf of the InterAct Consortium, Netherlands, Sweden, Spain Posters 383 Low birth weight is associated with alterations in dietary intake in later life independent of genetic factors S. Doornweerd, R.G. IJzerman, P.J. Weijs, M. Diamant, E.J. De Geus, D.I. Boomsma, Netherlands

384 Adherence to predefined dietary patterns and incident type 2 diabetes in European populations: EPIC-InterAct study J. Kröger, InterAct Consortium, Germany

385 Fatty fish is associated with a reduced risk of latent autoimmune diabetes in adults (LADA) and type 2 diabetes J. Edwall Löfvenborg, M. Dorkhan, L. Groop, T. Tuomi, A. Wolk, S. Carlsson, Sweden, Finland

386 The influence of the duration of exposure to westernised lifestyle and childhood environment on development of lifestyle-related diseases in Japanese-Americans M. Shiwa, S. Nakanishi, M. Yoneda, Japan

387 Chewing betel-quid and its association with metabolic disease, cardiovascular disease, and all-cause mortality: a meta-analysis of observational studies T. Yamada, K. Hara, T. Kadowaki, Japan

388 Association between urinary phthalate metabolites and diabetes mellitus: a pilot study M. Medić-Stojanoska, B. Vuković, J. Novaković-Paro, I. Bajkin, T. Ičin, N. Ćurić, N. Miljić, A. Milankov, B. Kovačev-Zavišić, Serbia

138 fp3_2013__ 15.08.13 10:41 Seite 139

389 Alcohol consumption is associated with a reduced risk of latent autoimmune diabetes in adults (LADA) and type 2 diabetes: the ESTRID case-control study B. Rasouli, V. Grill, L. Groop, T. Tuomi, T. Andersson, M. Dorkhan, S. Carlsson, Sweden, Norway, Finland

Poster Event D, Wednesday, 13:45 - 14:45

PS 016 Lifestyle interventions

Chair: G.E.H. Rutten, Netherlands

390 Barriers to participation in a community-based lifestyle intervention Posters programme to prevent type 2 diabetes following gestational diabetes mellitus A. O'Dea, J.J. Infanti, I. Gibson, E. Noctor, B.E. McGuire, L.G. Glynn, F.P. Dunne, Galway Diabetes Research Centre (GDRC) - NUIG, Ireland

391 Prevention of type 2 diabetes; a systematic review and meta-analysis of different intervention strategies C. Merlotti, A. Morabito, A.E. Pontiroli, Italy

392 Effectiveness of an intervention in primary care to prevent type 2 diabetes in people with impaired fasting glucose, a cluster-randomised controlled trial A.E. Hesselink, H.J. Bilo, G.E. Rutten, S.M. Slootmaker, I. De Weert, M. Martens, R. Jonkers, Netherlands

393 Sustained weight loss and risk reduction following lifestyle intervention in the community: results of the Rethinking Eating and ACTivity study (REACT) G.A. Piatt, M. Seidel, J.C. Zgibor, USA

394 Feasibility of a controlled intervention with physical activity in individuals with impaired glucose tolerance, recruited by FINDRISC M.I. Hellgren, M. Petzold, H. Bertéus Forslund, P.-A. Jansson, U. Lindblad, Sweden

139 fp3_2013__ 15.08.13 10:41 Seite 140

395 Characteristics of smoking behaviour in patients with diabetes attending a tertiary referral centre R.J. Smyth, A. Mohamed, M. Bell, Ireland

396 Six month follow-up results from a registry observing Duodenal-Jejunal Bypass Liner treatment outcomes in subjects with type 2 diabetes and/or obesity P. Koehestanie, B. Betzel, I. Janssen, F. Berends, H. De Boer, A. Escalona, D.T. Araya, H. Frydenburg, K. Fogarty, Netherlands, Chile, Australia

Posters 397 Duodenal-Jejunal Bypass Sleeve for obesity and type 2 diabetes: systematic review with meta-analysis of clinical studies N. Hedbäck, U. Rohde, L.L. Gluud, T. Vilsbøll, F.K. Knop, Denmark

398 Bariatric surgery in France in 2011 and temporal trends since 2006 A. Fagot-Campagna, M. Paita, S. Czernichow, A. Weill, S. Rican, D. Nocca, J.C. Thalabard, E. Fery-Lemonnier, M. Marty, M.H. Rodde-Dunet, A. Basdevant, B. Millat, France

Poster Event E, Thursday, 12:30 - 13:30

PS 017 Body composition and diabetes aetiology in epidemiology

Chair: M. Laakso, Finland

399 Association between changes in body composition and risk of developing type 2 diabetes in Koreans C.-H. Kim, E.-H. Kim, S.-J. Bae, H.-K. Kim, Korea, Republic of

400 Ethnicity-specific obesity cut-points in the development of incident diabetes: a prospective study including three ethnic groups in the United Kingdom T. Tillin, N. Sattar, I.F. Godsland, E. Coady, D. Key, C. Tuson, A.D. Hughes, N. Chaturvedi, N.G. Forouhi, UK

401 Body fat distribution, glucose tolerance and metabolic profile in young adult twins: an exploration of sex differences S.M. Kaye, L.H. Bogl, A. Rissanen, A.J. Kangas, P. Soininen, A. Ortega- Alonso, M. Ala-Korpela, J. Kaprio, K.H. Pietiläinen, Finland

140 fp3_2013__ 15.08.13 10:41 Seite 141

402 Waist circumference and blood pressure are associated with microvascular vasomotion in a healthy population: the Maastricht study D. Muris, M. Schram, A. Houben, C. Stehouwer, Netherlands

403 The differences between serum fingerprints of healthy and pre-diabetic humans are dependent on BMI M. Ciborowski, A. Kretowski, E. Adamska, A. Citko, M. Waszczeniuk, J. Wilk, A. Golonko, J. Pliszka, D. Lipinska, J. Goscik, J. Teul, J. Godzien, S. Angulo, C. Barbas, M. Gorska, Poland, Spain

404 A propensity-matched comparison of insulin secretion and resistance between subjects from 1990's and 2000's in a Korean population H. Yang, J.-H. Lee, H. Kwan, J. Cho, K. Yoon, Korea, Republic of Posters 405 Association of body fat mass and liver fat content with insulin resistance in euglycaemic Chinese middle-aged and elderly adults M. Xia, H. Lin, X. Li, H. Yan, H. Bian, X. Chang, L. Zhang, X. Gao, China

406 The impact of reproductive factors on glucose metabolism in postmenopausal women: Korean National Health and Nutrition Examination Survey 2008-2010 K. Jin Hwa, J. So, S. Kim, H. Bae, Korea, Republic of

407 Sarcopenic obesity was associated with decreased renal function in elderly, diabetic Koreans: from KNHANES 2008-2010 S. Lee, H. Kwon, O. Hong, J. Son, M. Kim, K. Han, S. Kim, S. Yoo, Korea, Republic of

Poster Event F, Thursday, 13:45 - 14:45

PS 018 Obesity and diabetes

Chair: M. Stumvoll, Germany

408 In the grey zone of type 2 diabetes prediction: Can we separate poorly discriminated incident cases and non-cases? B. Kowall, W. Rathmann, B. Bongaerts, C. Meisinger, A. Peters, C. Huth, A. Zierer, K.-H. Ladwig, R. Holle, Germany

141 fp3_2013__ 15.08.13 10:41 Seite 142

409 Obesity paradox in diabetes mellitus: mortality and cardiovascular morbidity over 15 years of 12,025 patients P. Costanzo, P. Pellicori, D. Hepburn, E. Kilpatrick, J.F. Cleland, S.L. Atkin, UK

410 Evidence of reverse epidemiology between obesity and all-cause mortality in whites with type 2 diabetes from Italy R. Di Paola, A. Marucci, A. Fontana, C. Menzaghi, L. Salvemini, M. Copetti, F. Pellegrini, S. De Cosmo, V. Trischitta, Italy

Posters 411 Overweight is associated with LADA among women but not in men: results from ESTRID, a Swedish case-control study R. Hjort, L. Groop, T. Tuomi, M. Dorkhan, S. Carlsson, Sweden, Finland

412 Comparison of abdominal obesity indicators and body mass index as a predictor of mortality among Europeans X. Song, S. Söderberg, P. Jousilahti, C.D. Stehouwer, J.S. Yudkin, A. Onat, T. Laatikainen, R. Dankner, R. Morris, J. Tuomilehto, Q. Qiao, Finland, Sweden, Netherlands, UK, Turkey, Israel

413 Are we failing to capture the relationship between body mass index and cardiovascular disease and mortality in subjects with type 2 diabetes? D.M. Grant, P. McEwan, V. Foos, J. Palmer, A. Lloyd, UK, Switzerland

414 Trajectory of body mass index before the development of type 2 diabetes in Japanese men: Toranomon hospital health management centre study (TOPICS) Y. Heianza, Y. Arase, S. Hara, K. Fujihara, S. Hsieh, A. Sugawara, A. Suzuki, O. Hanyu, K. Saito, S. Kodama, H. Shimano, H. Sone, Japan

415 Thinness in childhood, weight gain over adolescence and risk of type 2 diabetes: a generational perspective M. Jacota, A. Forhan, E. Eschwège, A. Basdevant, M.-A. Charles, France

416 Adiposity and all-cause mortality in individuals with type 1 diabetes E. Fagerholm, C. Forsblom, V. Harjutsalo, L. Thorn, N. Tolonen, S. Hägg, M. Saraheimo, D. Gordin, J. Wadén, P.-H. Groop, FinnDiane Study Group, Finland

142 fp3_2013__ 15.08.13 10:41 Seite 143

417 The development of age-related time-to-event epidemiological models: the importance of age of type 2 diabetes diagnosis by gender and BMI E.L. Badrick, I. Buchan, M. Sperrin, M. Carr, A. Renehan, UK

Poster Event A, Tuesday, 12:30 - 13:30

PS 019 Risk markers for type 2 diabetes

Chair: C. Herder, Germany

418 Age at menarche and type 2 diabetes risk: the EPIC-InterAct study C. Elks, The InterAct Consortium, UK Posters 419 Type 2 diabetes and cardiovascular risks are present in adolescent girls with polycystic ovaries morphology M.I. Bak, M. Walewska-Wolf, J. Szufladowicz-Wozniak, Poland

420 Cluster of insulin resistance and other metabolic risk factors predicts AMI morbidity in a Swedish population C.A. Larsson, B. Daka, M. Hellgren, J. Eckner, L. Råstam, U. Lindblad, Sweden

421 Predictors of normalisation of prediabetes and of persistence of normal glucose tolerance T.G. Dzebisashvili, Russian Federation

422 Comparison between indexes of insulin sensitivity for risk prediction of cardiovascular diseases or development of type 2 diabetes B. Zethelius, J. Cederholm, Sweden

423 Plasma fibrinogen level as a predictor of incident metabolic syndrome in a community-based prospective study in Hong Kong Chinese C.Y. Yeung, E.Y. Hui, T.H. Lam, W.S. Chow, Y.C. Woo, C.H. Fong, A. Xu, B.M. Cheung, K.S. Lam, Hong Kong

424 Polymorphisms of the AGER gene are related to serum levels of soluble receptor for advanced glycation end products and autoantibody frequencies in children with type 1 diabetes K.M. Salonen, S. Ryhänen, J.M. Forbes, A.-P. Laine, J. Ilonen, P.-H. Groop, M. Knip, The Finnish Pediatric Diabetes Register, Finland, Australia

143 fp3_2013__ 15.08.13 10:41 Seite 144

425 The serum activity of p53 in people with and without type 2 diabetes mellitus and its relation to the diabetes duration J. Drzewoski, J. Kasznicki, M. Kosmalski, I. Majsterek, A. Śliwinska, Poland

426 Retrospective analysis of the Japanese diabetes risk score for incident diabetes and urinary albumin excretion in 2084 subjects and comparison with fatty liver markers S. Katoh, H. Takahashi, M. Kaji, M. Zeniya, Y. Sakamoto, K. Utsunomiya, Japan

Posters 427 Fatty liver disease accompanies loss of glycaemic control on the 5 years follow-up of a previously non-diabetic population R.T. Ribeiro, M.P. Macedo, L. Gardete-Correia, R. Duarte, J.M. Boavida, I. Correia, Z. Peerally, F.O. Martins, J.F. Raposo, Portugal

Poster Event B, Tuesday, 13:45 - 14:45

PS 020 Circulating biomarkers in prediction of diabetes

Chair: N. Sattar, UK

428 Metabolomic profiling identifies biomarkers associated with dysglycaemia and incident type 2 diabetes in the METSIM study J. Cobb, H. Cederberg, K. Pappan, M. Mitchell, K.-P. Adam, P. Gunst, J. Kuusisto, M. Laakso, USA, Finland

429 Low serum total osteocalcin levels is associated with high risk of metabolic syndrome in Korean men C.-H. Park, Korea, Republic of

430 Advanced glycation end products (AGEs) increases renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN) H. Sun, Y. Yuan, China

431 Effect of fasting plasma glucose combined advanced glycation endproducts-peptide on screening for diabetes mellitus and pre-diabetes in Chinese high-risk population J. He, Z. Sun, Z. Xie, S. Qiu, Y. Zhou, China

144 fp3_2013__ 15.08.13 10:41 Seite 145

432 Serum peroxiredoxin 4 as novel biomarker of oxidative stress and the risk of incident type 2 diabetes: the PREVEND study A. Abbasi, E. Corpeleijn, D. Postmus, R.T. Gansevoort, R.O. Gans, L.T. De Jong-van den Berg, J. Struck, H.L. Hillege, P. Van der Harst, R.P. Stolk, G. Navis, S.J. Bakker, Netherlands, Germany

433 Fasting plasma neurotensin and risk of type 2 diabetes according to dietary fat content U. Ericson, C.-A. Schulz, A. Bergmann, O. Melander, M. Orho-Melander, Sweden, Germany

434 Differential role of chronic inflammation in the development of glucose intolerance: relationship between HbA1c and lower adiposity or insulin

secretory function in women Posters S. Okahata, K. Sakamoto, M. Yano, T. Mitsumatsu, Y. Ishizaka, M. Yamakado, T. Shiba, Japan

435 Serum protein concentration predicts incident diabetes: the Insulin Resistance Atherosclerosis study S.M. Haffner, A.J. Hanley, C. Lorenzo, USA, Canada

436 Higher serum bilirubin level as a protective factor for the development of diabetes in healthy Korean men: a 4 year retrospective longitudinal study M. Lee, J. Jang, C. Jung, W. Lee, K.-U. Lee, J.-Y. Park, Korea, Republic of

437 Circulating levels of selenoprotein P predict future hyperglycaemia in non-diabetic Japanese people H. Misu, T. Kanamori, Y. Takeshita, Y. Saito, M. Tanaka, S. Kaneko, T. Takamura, Japan

Poster Event C, Wednesday, 12:30 - 13:30

PS 021 Prediction of complications in type 1 and type 2 diabetes I

Chair: J.J. Nolan, Denmark

438 CARING: diabetes mellitus and risk of cancer - a systematic review and meta-analysis J. Starup-Linde, P. Vestergaard, O. Karlstad, S.A. Eriksen, H.K. Bronsveld, F. De Vries, A. De Boer, M.L. De Bruin, Denmark, Norway, Netherlands

145 fp3_2013__ 15.08.13 10:41 Seite 146

439 Autonomic neuropathy, sexual dysfunction and urinary incontinence in women with type 1 diabetes: findings from the DCCT/EDIC J.M. Hotaling, A. Sarma, R. Pop-Busui, P. Cleary, R. Dunn, H. Wessells, USA

440 The risk of acute pancreatitis with GLP-1 receptor agonists and DPP-4 inhibitors: a retrospective observational cohort study C.E. Koro, M.O. Sowell, M. Stender, P. Chhabra, J.K. Allen, H.J. Krzywy, USA, UK

Posters 441 Serum levels of pancreatic regenerating protein indicate the development of type 2 diabetes and diabetic chronic complications J. Yang, Z. Sun, R. Graf, L. Li, China, Switzerland

442 Haemorrheological approach for early detection of diabetic angiopathy S. Lee, Korea, Republic of

443 Semi-automatic analyses of skin capillary density: proof of principle and validation Ü. Karaca, E.H. Gronenschild, D.M. Muris, M.T. Schram, C.D. Stehouwer, A.J. Houben, Netherlands

444 Natural history of heart rate variability by glycaemic status in the Whitehall II cohort C.S. Hansen, E.J. Brunner, A. Tabák, M. Kivimäki, A. Britton, D.R. Witte, J. Fleischer, M.E. Jørgensen, D. Vististen, Denmark, UK, Luxembourg

445 The triglycerides-to-HDL-cholesterol ratio and cardiovascular disease risk in obese patients with type 2 diabetes: a report from the Swedish national diabetes register K. Eeg-Olofsson, S. Gudbjörnsdottir, B. Eliasson, B. Zethelius, J. Cederholm, Sweden

Poster Event D, Wednesday, 13:45 - 14:45

PS 022 Prediction of complications in type 1 and type 2 diabetes II

Chair: C.D.A. Stehouwer, Netherlands

146 fp3_2013__ 15.08.13 10:41 Seite 147

446 Short term mortality in people with diabetes: results from the national diabetes audit in England and Wales N. Holman, B. Young, UK

447 Does the association of diabetes with mortality vary by sex? Results from a pooled cohort analysis A.P. Carson, S.E. Badon, L. Zhao, C.E. Lewis, M.L. Biggs, S.H. Golden, J.S. Pankow, C.S. Fox, V.G. Vimalananda, L.H. Kuller, P.D. De Chavez, M.R. Carnethon, USA

448 Total mortality by elevated transferrin saturation and haemochromatosis genotype in individuals with diabetes from two general population studies C. Ellervik, T. Mandrup-Poulsen, A. Tybjærg-Hansen, B.G. Nordestgaard, Denmark Posters

449 Prosomatostatin and mortality in patients with type 2 diabetes mellitus (ZODIAC-35) H. Joosten, L. Van Essen, P.R. Van Dijk, K.H. Groenier, S.J. Bakker, H.J. Bilo, N. Kleefstra, Netherlands

450 Predicting macro- and microvascular complications in type 2 diabetes: the Japan diabetes complications study / the Japanese elderly diabetes intervention trial risk engine S. Tanaka, S. Tanaka, S. Iimuro, H. Yamashita, S. Katayama, Y. Akanuma, N. Yamada, A. Araki, H. Ito, H. Sone, Y. Ohashi, Japan

451 Association between sodium and potassium urinary concentrations and cardiovascular and renal complications in a French cohort of type 2 diabetes patients P. Saulnier, R. Roussel, A. De Hauteclocque, R. Marechaud, P. Sosner, S. Ragot, S. Hadjadj, France

452 Albuminuria and renal function as predictors of cardiovascular events and mortality in type 2 diabetes: nationwide observational study B. Eliasson, J. Cederholm, B. Zethelius, M. Svensson, S. Gudbjornsdottir, Sweden

453 Type 2 diabetes and risk of recurrent cardiovascular event following acute coronary syndrome (ACS): longitudinal analysis 2006-2011 V.S. Reddy, R. Luthra, Y. Xu, M. Fisher, T. Power, K. Wilhelm, M. Cziraky, USA

147 fp3_2013__ 15.08.13 10:41 Seite 148

Poster Event E, Thursday, 12:30 - 13:30

PS 023 Receptor regulation of islet function

Chair: J. Bowe, UK

454 The chemokine CCL5 is expressed by islets and regulates beta cell function through activation of GPR75 Z. Hassan, B. Liu, S. Amisten, G.C. Huang, S.A. Amiel, P.M. Jones, S.J. Persaud, UK Posters

455 Fractalkine, a new factor protecting beta cell function and survival R. Dusaulcy, S. Rutti, P. Plomgaard, B.K. Pedersen, P.A. Halban, K. Bouzakri, Switzerland, Denmark

456 Epigenetic regulation of chemokine CXCL12 gene transcription influences its prosurvival effect on pancreatic beta cells M. Vidakovic, A. Tolic, J. Markovic, N. Grdovic, S. Dinic, A. Uskokovic, M. Djordjevic, J. Arambasic, M. Mihailovic, G. Poznanovic, N. Martinet, Serbia, France

457 Role of GPR55 in the regulation of insulin secretion and islet survival S. Song, B. Liu, J.E. Bowe, D. Baker, G.C. Huang, S.A. Amiel, P.M. Jones, S.J. Persaud, UK

458 Effect of in vitro and in vivo hyperglycaemia on muscarinic M3 receptor expression and activation in islets A.C. Hauge-Evans, Z. Franklin, A. Kerby, S. Amisten, A.J. King, S.J. Persaud, P.M. Jones, UK

459 Receptor-mediated effects of melatonin on insulin secretion in INS-1 832/13 beta cells P. Singh, H. Mulder, Sweden

460 Inhibition of small-Maf function in pancreatic beta cells attenuates the effect of GLP-1 receptor agonist on improvement of glucose tolerance H. Nomoto, T. Kondo, N. Fujimori, H. Miyoshi, T. Atsumi, Japan

148 fp3_2013__ 15.08.13 10:41 Seite 149

461 Cannabinoid CB1 receptors and mTORC1 signalling pathway interact to modulate glucose homeostasis F.J. Bermudez-Silva, S.Y. Romero-Zerbo, M. Haissaguerre, I. Ruz- Maldonado, A. Tabarin, G. Marsicano, D. Cota, Spain, France

462 Angiogenic factors regulate beta cell function P. Shah, J. Olerud, J. Kerr-Conte, P.-O. Carlsson, K. Maedler, Germany, Sweden, France

Poster Event F, Thursday, 13:45 - 14:45

PS 024 Beta cell signal transaction Posters Chair: D.S. Muller, France

463 FFAR1 is involved in both the acute and chronic effects of palmitate on insulin secretion H. Kristinsson, D. Smith, P. Bergsten, E. Sargsyan, Sweden

464 Inhibition of the mitogen activated protein kinase pathway accentuates the pro-apoptotic effect of fatty acids but does not alter the fatty acid-induced insulin secretion M. Panse, F. Gerst, G. Kaiser, C.-A. Teutsch, E. Christiansen, T. Ulven, H.-U. Häring, S. Ullrich, Germany, Denmark

465 Withdrawn

466 Prolonged exposure to palmitate deteriorates glucose-induced cAMP generation and pulsatile insulin secretion G. Tian, E.-R.M. Sol, Y. Xu, A. Tengholm, Sweden

467 Acute exposure of beta cells to low concentrations of IL-1beta improves insulin secretion through focal adhesion and actomyosin remodelling C. Arous, P.A. Halban, Switzerland

468 Relationship between islet angiogenesis and the positive effect of islet neogenesis-associated protein pentadecapeptide (INGAP-PP) upon beta cell function L.E. Flores, C.L. Román, B. Maiztegui, J.J. Gagliardino, Argentina

149 fp3_2013__ 15.08.13 10:41 Seite 150

469 INGAP effect on pancreatic islet function: its potential molecular mechanism B. Maiztegui, C. Román, J. Gagliardino, Argentina

470 Increased hexosamine biosynthetic pathway flux alters cell-cell adhesion in INS-1E cells and murine islets B. Di Jeso, S. Turco, V. La Pesa, A.S. Treglia, D.D. Lofrumento, F. De Nuccio, L. Ulianich, C. Miele, M. Longo, R. Spinelli, L. Parrillo, G. Nicolardi, C. Garbi, F. Beguinot, Italy

Posters 471 Effects of the inhibitor of anoctamin 1, tannic acid, on insulin-producing cells W.J. Malaisse, R. Crutzen, N. Bulur, M. Virreira, A. Rzajeva, P.E. Golstein, A. Sener, R. Beauwens, Belgium

472 Sphingosine kinase 1 interacting protein (SKIP) inhibits insulin secretion from beta cells through regulation of protein kinase A activity Y. Wang, S.-I. Harashima, S. Yamane, K. Suzuki, N. Harada, Y.-Y. Liu, N. Inagaki, Japan

Poster Event A, Tuesday, 12:30 - 13:30

PS 025 Insulin secretion in vitro

Chair: P. Rorsman, UK

473 Effects of high extracellular KCl on insulin secretion beyond plasma membrane depolarisation M. Willenborg, M. Belz, K. Schumacher, I. Rustenbeck, Germany

474 Differential role of NO in the control of insulin secretion in human pancreatic islets F. Castex, A. Chalançon, J. Leroy, K. Mezghenna, G. Parnaud, A. Wojtusciszyn, C. Broca, D. Bosco, R. Gross, A.-D. Lajoix, France, Switzerland

150 fp3_2013__ 15.08.13 10:41 Seite 151

475 Regulation of miR-335 expression contributes to orchestrate insulin secretion at the level of exocytosis in insulin secreting INS-1 832/13 cells V.A. Salunkhe, S.A. Andersson, J.L. Esguerra, I.G. Mollet, A. Wendt, L. Eliasson, Sweden

476 Involvement of heparan sulfate proteoglycan syndecan-4 in the mouse beta cell proliferation and insulin secretion I. Takahashi, S. Sato, W. Sakai, K. Ohashi, K. Nata, Japan

477 Flavanol metabolites produced by colonic microbiota improve glucose- stimulated insulin secretion and protect pancreatic beta cells against oxidative damage M.A. Martin, E. Fernández-Millán, C. Alvarez, L. Bravo, S. Ramos, L. Goya, Spain Posters

478 Insulin secretion and ZnT8 gene expression are decreased by ZnT3 overexpression K. Smidt, K.S. Sørensen, A. Larsen, J. Prætorius, P.M. Martensen, J. Rungby, Denmark

479 Zinc buffering by exogenous Zn7-metallothionein-2A affects insulin production, insulin secretion and intracellular zinc regulation in beta cells S.B. Nygaard, N. Lund, N. Pedersen, A. Larsen, J. Rungby, K. Smidt, Denmark

480 Modulation of incretin actions in pancreatic beta cells by metformin K. Shinmura, T. Negoro, Y. Nakano, T. Hirano, Japan

481 The DPP-IV inhibitor, sitgliptin enhances glucose-stimulated insulin secretion from mouse isolated islets A. Clark, C.C. Baker, P. Rorsman, R. Ramracheya, UK

482 Anti-diabetic effect of oral borapetol B, isolated from the plant tinospora crispa, by stimulating insulin release in type 2 diabetic Goto-Kakizaki rats E.F. Lokman, H.F. Gu, W. Wan Mohamood, M. Yusof, L. Meng, C.-G. Östenson, Sweden, Malaysia

151 fp3_2013__ 15.08.13 10:41 Seite 152

Poster Event B, Tuesday, 13:45 - 14:45

PS 026 Beta cell metabolism and mitochondrial function

Chair: S.E. Baltrusch, Germany

483 Nutrient regulation of thiols redox state in the mitochondrial matrix of rat pancreatic islet cells: dynamic measurements using redox-sensitive GFP2 fused to GRX-1 H.K. Takahashi, L.P. Roma, J. Duprez, J.-C. Jonas, Belgium Posters

484 Influence of KATP channel inhibition on ROS production in pancreatic beta cells A. Edalat, C. Bauer, P. Krippeit-Drews, G. Drews, M. Düfer, Germany

485 The role of the reactive oxygen species producing NADPH oxidase 5 (NOX5) as a regulator of islet function I. Szanto, K. Bouzakri, D. Bosco, T. Berney, Switzerland

486 Oxidative stress and activation of the intrinsic pathway of apoptosis cause beta cell loss in Friedreich's ataxia M. Igoillo-Esteve, E. Gurgul-Convey, S. Lenzen, D.L. Eizirik, M. Cnop, Belgium, Germany

487 Glucose causes a pronounced activation of ATP-synthase dependent respiration in pancreatic beta cells A. Wiederkehr, Switzerland

488 MICU2 modulates nutrient-sensing and insulin secretion in INS-1 832/13 cells A. Bagge, B. Valtat, V.K. Mootha, H. Mulder, Sweden, USA

489 The mitochondrial fission proteins Fis1 and Drp1 are important for proper glucose-induced insulin secretion in INS1 832/13 cells J. Schultz, F. Reinhardt, R. Waterstradt, M. Tiedge, S. Baltrusch, Germany

490 Activation of glutamate dehydrogenase stimulates insulin secretion and implicates a metabolic pathway in beta cell stimulus-secretion coupling B. Valtat, I. Göhring, A.P. Danielsson, S.G. Straub, G.W. Sharp, P. Spégel, H. Mulder, Sweden, USA

152 fp3_2013__ 15.08.13 10:41 Seite 153

Poster Event C, Wednesday, 12:30 - 13:30

PS 027 Functional analysis of beta cells

Chair: M. Solimena, Germany

491 DNA methylation of the glucagon-like peptide-1 receptor (GLP1R) in human pancreatic islets E. Hall, T. Dayeh, C.L. Kirkpatrick, C.B. Wollheim, M. Dekker Nitert, C. Ling, Sweden, Switzerland, Australia

492 Targeting pancreatic alpha and beta cells with adeno-associated viruses (AAVs)

E. Tudurí, M.M. Glavas, A. Asadi, G. Soukhatcheva, R.K. Baker, Posters C.B. Verchere, T.J. Kieffer, Canada

493 Microelectrode array (MEA) technology allows functional analysis of human and mouse pancreatic islets S. Schönecker, U. Kraushaar, W. Barthlen, U. Lendeckel, R. Walther, M. Düfer, E. Guenther, G. Drews, P. Krippeit-Drews, Germany

494 Syndapin I is a key regulator of beta cell endocytosis and plasma membrane protein homeostasis Y. Shi, G. Yang, J. Yu, B. Qualmann, M. Kessels, L. Yu, P.-O. Berggren, S.-N. Yang, Sweden, China, Germany

495 Stimulus secretion coupling in a human beta cell line - EndoC-betaH1 L.E. Andersson, B. Valtat, V.V. Sharoyko, D.G. Nicholls, P. Spégel, H. Mulder, Sweden, USA

496 Interaction of incretin and sulfonylurea through Epac2A signalling in insulin secretion H. Takahashi, T. Shibasaki, S. Hidaka, A. Ono, T. Takahashi, S. Seino, Japan

497 Central role of osteopontin in pancreatic islets: regulation by glucose and incretin hormones Y. De Marinis, M. Cai, A. Balhuizen, J.R. Acosta, M. Laakso, L. Groop, Sweden, Finland

153 fp3_2013__ 15.08.13 10:41 Seite 154

498 Effects of glucose and potassium depolarisation on the granule mobility in the submembrane space of insulin-secreting MIN6 cells K. Schumacher, M. Matz, K. Baumann, I. Rustenbeck, Germany

499 Autocrine signals mediate plasma membrane translocation of protein kinase C in insulin-secreting cells A. Tengholm, A. Wuttke, Sweden

Poster Event D, Wednesday, 13:45 - 14:45 Posters

PS 028 Islet gene regulation

Chair: J.-M. Servitja, Spain

500 The clock gene Rev-erb alpha regulates glucagon secretion in mouse pancreatic alpha cells E. Vieira, L. Marroquí, A. C. Figueroa, B. Merino, R. Fernández Ruiz, A. Nadal, T. Burris, R. Gomis, I. Quesada, Spain, USA

501 Roles of the type 2 diabetes-associated gene products Arap1 and StarD10 in the control of insulin secretion G.R. Carrat, G. Meur, G.A. Rutter, UK

502 Identification of mitochondrial targets in human islets exposed to high glucose or fatty acids T. Brun, N. Li, D. Bosco, T. Berney, P. Maechler, Switzerland

503 TCF7L2 is the master regulator or proinsulin expression through ISL1, MAFA and NEUROD1 Y. Zhou, J. Su, E. Ottosson-Laakso, T. Thevenin, E. Zhang, A. Brazma, J. Rung, L. Groop, E. Renstrom, O. Hansson, Sweden, UK

504 cAMP mediated regulation of miR-212/132 expression in insulin secreting cells acts through CREB-regulated transcription co-activator 1 (CRTC1) H.A. Malm, I. Mollet, J.L. Esguerra, M. Orho-Melander, L. Eliasson, Sweden

505 GLP-1 rescued dysregulated miRNA by hyperglycaemia in diet-induced obese mice I. Lee, K. Park, K.-J. Yang, J. Lee, Y. Jang, H. Kim, Korea, Republic of

154 fp3_2013__ 15.08.13 10:41 Seite 155

506 Differences in microRNA expression between embryonic stem cells and induced pluripotent stem cells during differentiation to a pancreatic lineage N.A. Francis, M. Moore, G.A. Rutter, C.J. Burns, UK

Poster Event E, Thursday, 12:30 - 13:30

PS 029 Quantification of beta cell mass

Chair: M. Gotthardt, Netherlands

507 Dual modal MR/fluorescent zinc sensing probes for in vivo beta cell imaging

G.J. Stasiuk, F. Minuzzi, M. Sae-Heng, N.J. Long, G.A. Rutter, UK Posters

508 111In-exendin for non-invasive quantification of beta cell mass in patients with type 1 diabetes and healthy controls W. Van der Weg, M. Brom, M.J. Janssen, M. Béhe, W.J. Oyen, C.J. Tack, O.C. Boerman, M. Gotthardt, Netherlands, Switzerland

509 Towards clinical imaging with 18F-labelled exendin-4, synthesised via click chemistry K. Mikkola, C.-B. Yim, P. Lehtiniemi, V.-V. Elomaa, T. Ishizu, J. Rajander, P. Nuutila, O. Solin, Finland

510 19F-mannoheptuloses as contrast agents for the non-invasive imaging of GLUT2-expressing cells: in vivo and ex vivo MRI studies K. Louchami, S. Liang, E. Hupkens, W.J. Malaisse, J. Thimm, A. Sener, U. Himmelreich, Belgium, Germany

511 Are we overestimating the loss of beta cells in type 2 diabetes? L. Marselli, M. Suleiman, M. Masini, M. Bugliani, F. Olimpico, F. Syed, P. Masiello, F. Filipponi, U. Boggi, P. Marchetti, Italy

512 Effects of altered insulin sensitivity on islet morphology in humans T. Mezza, G. Muscogiuri, G. Sorice, G. Clemente, A. Giaccari, R.N. Kulkarni, USA, Italy

513 Islet number rather than islet size may be a major determinant of beta cell mass in non-diabetic humans K. Kou, Y. Saisho, S. Sato, T. Yamada, H. Itoh, Japan

155 fp3_2013__ 15.08.13 10:41 Seite 156

514 Slow and minimal decline of beta cell mass associated with ageing in non-diabetic Japanese and lack of compensatory islet hyperplasia in obesity H. Mizukami, K. Takahashi, W. Inaba, K. Kamata, K. Tsuboi, O. Uehara, S. Yagihashi, Japan

515 Beta and alpha cell trajectories during development and after high fat programming in neonate, weanling and adolescent Wistar rats M.E. Cerf, C.S. Chapman, J. Louw, South Africa

Posters Poster Event F, Thursday, 13:45 - 14:45

PS 030 Beta cell mass expansion and survival

Chair: K. Maedler, Germany

516 Molecular mechanism of pancreatic islet proliferation during the neonatal development in mice X. Wu, J. Zhu, X. Wang, Y. Xu, Y. Lv, J. Zhang, Q. Zhang, China

517 Modulation of C/EBP beta expression via AMPK regulates pancreatic beta cell mass H. Takahashi, T. Matsuda, Y. Mieda, S.-I. Asahara, E. Terashi, A. Kanno, M. Koyanagi, A. Bartolomé, S. Seino, Y. Kido, Japan

518 The in-vitro effects of glucagon-like peptide-1 (GLP-1) and gastrin combination therapy on pancreatic beta cell proliferation and islet cell survival J. Skarbaliene, T.S. Neerup, K. Fosgerau, N. Billestrup, Denmark

519 Dopamine could be involved in the maintenance of rat pancreatic beta cells controlling insulin secretion and cellular proliferation M.J. Garcia-Barrado, E.J. Blanco, M.C. Iglesias-Osma, M. Carretero- Hernandez, D.J. Burks, J. Carretero, Spain

520 Differentiation of human adult pancreatic duct cells into insulin- producing cells M. Pairó, N. Téllez, C. García, M. Núñez, M. Nacher, E. Montanya, Spain

156 fp3_2013__ 15.08.13 10:41 Seite 157

521 DPP-4 (CD26) is expressed by ductal and islet cells in human adult pancreas P. Augstein, G. Naselli, T. Loudovaris, P. Campbell, E.M. Bandala-Sanchez, P. Heinke, W.J. Hawthorne, L.C. Harrison, Germany, Australia

522 Effects of pharmacological glucokinase activation on beta cell survival and function in rat islets cultured for one week in a low, intermediate or high glucose concentration J.-C. Jonas, L.P. Roma, J. Duprez, Belgium

523 Pancreatic stellate cells induce beta cell failure in vivo M. Zha, L.Z. Sun, China

524 Unfermented aqueous honeybush extract (Cyclopia maculata) Posters attenuates STZ-induced beta cell cytotoxicity N. Chellan, C.J. Muller, E. Joubert, H.G. Strijdom, J. Louw, South Africa

525 Effect of liraglutide on apoptosis and tissue factor activity on Rin-m5f, in response to microparticles: interest in islet transplantation C. Gleizes, A.A. Constantinescu, F. Zobairi, F. Moreau, F. Toti, L. Kessler, France

Poster Event A, Tuesday, 12:30 - 13:30

PS 031 ER stress and apoptosis

Chair: D.L. Eizirik, Belgium

526 Chaperones ameliorate hIAPP-induced ER stress in beta cells L. Cadavez, J. Montane, G. Alcarraz-Vizán, M. Visa, R. Gasa, A. Novials, Spain

527 The translocon, a functional reticular calcium leak channel in human islets: towards a new way of protecting pancreatic beta cells from lipotoxicity R. Cassel, F. Van Coppenolle, S. Ducreux, M.-A. Chauvin, J. Rieusset, C. Thivolet, A.-M. Madec, France

528 Endoplasmic reticulum stress induces ATF4 and CHOP expression independently of PERK/eIF2alpha pathway in pancreatic beta cells X. Zhao, O. Omikorede, T.P. Herbert, UK

157 fp3_2013__ 15.08.13 10:41 Seite 158

529 HDAC3 inhibition rescues pancreatic beta cells from glucolipotoxicity and improves insulin secretion in obese diabetic rats M. Lundh, T. Galbo, F.F. Wagner, D.P. Christensen, D. Walpita, J.P. Gale, Y.-L. Zhang, J.M. Hooker, G.I. Shulman, T. Mandrup-Poulsen, E.B. Holson, B.K. Wagner, Denmark, USA, Sweden

530 Suppression of NO-induced beta cell death by (-)-DHMEQ via activation of Nrf2-ARE pathway and alteration of MAPK activity K. Umezawa, T. Ukaji, A. Ogasawara, S. Simizu, I. Takei, Japan

Posters 531 PKBalpha but not PKBbeta can protect human islets from IL-1beta- induced apoptosis M.G. Dietrich, R.A. Zuellig, B.A. Hemmings, G.A. Spinas, R. Lehmann, O. Tschopp, M. Niessen, Switzerland

532 IL-17 increases the expression and release of pro-inflammatory chemokines by human pancreatic islets F.A. Grieco, F. Moore, F. Vigneron, I. Santin, L. Marselli, D. Rondas, L. Overbergh, F. Dotta, C. Mathieu, P. Marchetti, D.L. Eizirik, Belgium, Italy

533 Identification of a JNK3 module required for adaptation of beta cells in response to obesogenic and gestational environment A. Abderrahmani, N. Beeler, C. Jacovetti, R. Marenzoni, T. Boockenooghe, S. Gargani, G. Sisino, P. Froguel, G. Waeber, P. Fontaine, J. Kerr-Conte, A. Vambergue, R. Regazzi, F. Pattou, H. Ezanno, France, Switzerland

534 Effect of angiotensin-(1-7) on apoptosis of insulin-secreting cell line NIT- 1 induced by high glucose W. Xiao-yun, X. Ming-tong, R. Meng, L. Xiu-hong, Y. Li, China

535 Role of muscle PGC-1α in the effects of resveratrol and exercise training on high fat diet induced changes in pancreas in mice N. Brandt, S. Larsson, C.M. Kristensen, R.S. Biensø, J. Olesen, H. Pilegaard, Denmark

Poster Event B, Tuesday, 13:45 - 14:45

PS 032 Islet cell toxicity and survival

Chair: L. Marselli, Italy

158 fp3_2013__ 15.08.13 10:41 Seite 159

536 c-Src regulates the phosphorylation status of STAT3 in pancreatic beta cells and modulates their response to interleukin-6 M.A. Russell, N.G. Morgan, UK

537 Long-term overexpression of c-Kit negatively impacts beta cell function and survival via capillary and inflammatory recruitment in the islet Z.-C. Feng, J. Li, J. Silverstein, A. Popell, S.-P. Yee, R. Wang, Canada, USA

538 Fibrin modulates αvbeta3 integrin expression and FAK signalling to mediate islet cell differentiation, function, proliferation and survival M. Riopel, J. Li, W. Stuart, R. Wang, Canada

539 AMPK regulates ER morphology and function in stressed pancreatic beta cells via phosphorylation of DRP1 Posters G. Leibowitz, J.D. Wikstrom, T. Israeli, E. Bachar-Wikstrom, Y. Ariav, E. Cerasi, Israel

540 Pathways involved in the GLP-1-mediated protection against cytokine- induced beta cell dysfunction and death in human islets: a proteomic approach D. Rondas, M. Bugliani, W. D'Hertog, M. Massini, E. Waelkens, P. Marchetti, C. Mathieu, L. Overbergh, Belgium, Italy

541 Mechanisms underlying compensatory islet response to insulin resistance A. El Ouaamari, J.-Y. Zhou, E. Dirice, C. Liew, J.-S. Kim, R. Smith, W.-J. Qian, R. Kulkarni, USA

542 Reduced availability of glucose during culture attenuates hypoxia- induced reduction in cellular viability and function in pancreatic beta cells V. Grill, I. Hals, R. Singh, Z. Ma, A. Björklund, Norway, Sweden

543 Cytokines and histone deacetylase inhibition differentially regulate the expression of beta cell inflammasomes M.S. Dahllöf, D.P. Christensen, L. Perruzza, M. Lundh, L. Chatenoud, F. Grassi, T. Mandrup-Poulsen, Denmark, Switzerland, France, Sweden

544 NLRP3 inflammasome is expressed and regulated in human islets V.J. Lavallard, G. Parnaud, P. Morel, B. Bédat, D. Bosco, T. Berney, Switzerland

159 fp3_2013__ 15.08.13 10:41 Seite 160

545 Human serum vs human serum albumin for human islet culture M. Nacher, A. Garcia, E. Estil.les, B. Nadal, M. Pairó, C. Garcia, J. Busquets, A. Novials, E. Montanya, Spain

Poster Event C, Wednesday, 12:30 - 13:30

PS 033 Experimental immunology

Chair: C. Mathieu, Belgium Posters 546 Prevention of type 1 diabetes in NOD mice by targeting dipeptidyl peptidase IV is associated to modification of both central and peripheral T- cell subsets N. Alonso, P. Correa, A. Teniente, R. Colobran, M. Julián, P. Monge, M. Fernández, M. Vives-Pi, M. Puig-Domingo, Spain

547 Changes in the circadian rhythmicity of energy metabolism and cerebral cFos expression at diabetes onset in NOD mice V. Burkart, A. Reinbeck, M. Ingenwerth, G. Sequaris, A. Stahr, H.-J. Partke, C. Von Gall, M. Roden, Germany

548 Differential requirement for endogenous IL-15 and IL-21 in activating diabetogenic CD8+ T cells in a virus-induced model of autoimmune type 1 diabetes S. Ilangumaran, D. Bobbala, S. Ramanathan, Canada

549 Alterations of lipid homeostasis and insulin sensitivity in TLR4-deficient non-obese diabetic mice A. Reinbeck, H.-J. Partke, H. Al-Hasani, V. Burkart, M. Roden, Germany

550 CD26/DPPIV inhibition alters the expression of immune related genes in the thymus of NOD mice M. Julián, N. Alonso, R. Colobrán, C. Paula, A. Sanchez, A. Teniente, I. Pujol-Autonell, M. Vives-Pí, M. Puig-Domingo, Spain

551 Immunomodulatory effects of efferocytosis: a key role in the suppression of autoimmunity to beta cells I. Pujol-Autonell, R.-M. Ampudia, A. Serracant, A. Garcia, E. Aguilera, M. Puig-Domingo, J. Verdaguer, M. Vives-Pi, Spain

160 fp3_2013__ 15.08.13 10:41 Seite 161

552 Correlation of islet infiltration to gene expression of blood mononuclear cells and pancreas draining lymph nodes in the LEW.1AR1-iddm rat model of autoimmune diabetes T. Schoeppe, H. Weiss, D. Wedekind, R. Schmidt, M. Tiedge, Germany

553 In depth lipidomic characterisation of the early stages of the type 1 diabetes pathogenesis A. Overgaard, C. Haase, P. Meikle, F. Pociot, Denmark, Australia

554 Carbon monoxide-releasing molecule CORM-A1 ameliorates islet- directed autoimmunity in mice I. Nikolic, T. Saksida, M. Vujicic, I. Stojanovic, F. Nicoletti, S. Stosic-Grujicic, Serbia, Italy Posters 555 Identification of a targetable pathway that controls plasmacytoid dendritic cells and the interferon response J. Agudo, A. Ruzo, N. Tung, A. Baccarini, M. Leboeuf, D. Hashimoto, C. Becker, L.-A. Garrett-Sinha, C. Kuo, B. Brown, USA

Poster Event D, Wednesday, 13:45 - 14:45

PS 034 Clinical immunology

Chair: F. Wong, UK

556 Insulin resistance, beta cell function and the effect of non-HLA genetic variants in Finnish DIPP study children with HLA-conferred risk for type 1 diabetes M.K. Koskinen, R. Hermann, J. Matomäki, J. Mykkänen, M. Vähä-Mäkilä, T. Simell, S. Simell, M. Mäkinen, V. Simell, M. Saarinen, J. Ilonen, M. Knip, O. Simell, Finland

557 Better glycaemic control but similar diabetes associated complications in LADA compared to type 2 diabetes in the DPV cohort in Germany and Austria N.C. Schloot, K. Badenhoop, W. Kerner, H.-R. Engels, A. Dapp, J. Bayer, G. Goetz, A. Zimmermann, I. Schuetz-Fuhrmann, R. Holl, for the DPV initiative and BMBF competence net Diabetes mellitus, Germany, Austria

161 fp3_2013__ 15.08.13 10:41 Seite 162

558 Incidence of autoimmune antibodies in diabetes type 1 patients with long diabetes duration: the JEVIN-Trial T. Heller, C. Kloos, R. Schiel, G. Wolf, U.A. Müller, Germany

559 Subgroup analysis of DIA-AID 1, an immune intervention phase 3 study in newly diagnosed type 1 diabetes patients P. Pozzilli, I. Raz, T. Linn, F. Bonnici, D. Elias, A. Avron, M. Tamir, R. Eren, S. Dagan, Italy, Israel, Germany, South Africa

560 Long term safety and efficacy of DiaPep277® - initial results of an Posters extension study to DIA-AID 1 O. Mosenzon, I. Raz, Z. Landau, L. De Vries, R. Eren, D. Elias, A. Avron, M. Tamir, S. Dagan, J. Wainstein, Israel

561 Serum vitamin D may modulate fetuin-A, cytokines and insulin resistance across the spectrum of glycaemia D. Dutta, S.A. Mondal, A.H. Reza, A. Sinha, S. Chakraborty, S. Mukhopadhyay, India

562 25-hydroxy vitamin D and thyroid autoimmunity in patients with type 2 diabetes mellitus and controls K.A. Toulis, X. Tsekmekidou, M. Yavropoulou, E. Papanastassiou, A. Papazisi, A. Gotzamani-Psarakou, J. Yovos, K. Kotsa, Greece

563 Expression of circulating CD4+CD5+FOXP3+ regulatory T cells in obese patients T.T. Che, Y. Ren, S.F. Liu, China

Poster Event E, Thursday, 12:30 - 13:30

PS 035 Islet transplantation

Chair: E. Montanya Mias, Spain

564 Acute hypoxia impacts similarly on encapsulated and non-encapsulated human pancreatic islets I. Hals, A. Rokstad, B.L. Strand, V. Grill, Norway

565 Improved siRNA delivery to pancreatic islets using R3V6 peptide carrier S.-H. Ihm, M.-G. Choi, H.-J. Yoo, M. Lee, J. Ihm, Korea, Republic of

162 fp3_2013__ 15.08.13 10:41 Seite 163

566 Zinc oxide nanoparticles for the protection of human beta cells F. Syed, M. Bugliani, C. Riggio, M. Masini, P. Masiello, M. Suleiman, L. Marselli, U. Boggi, F. Filipponi, D. Focosi, F. Scatena, V. Raffa, P. Marchetti, Italy

567 Role of oxidative stress in the pro-angiogenic effect of liraglutide on rat pancreatic islets A. Langlois, S. Dal-Ros, W. Bietiger, C. Mura, E. Seyfritz, C. Dollinger, M. Pinget, N. Jeandidier, S. Sigrist, France

568 Islet survival and function following intramuscular vs intraportal autotransplantation in the minipig T. Hubert, L. Quintane, A. Sterkers, V. Gmyr, M.-C. Vantyghem, J. Kerr- Conte, R. Caiazzo, F. Pattou, France Posters

569 Coronary artery disease in diabetic patients long-term after simultaneous pancreas and kidney transplantation compared with kidney transplantation alone J.P. Lindahl, K. Endresen, A. Günther, A. Hartmann, T. Jenssen, Norway

570 Long-term effects of pancreas transplantation in type 1 diabetes M. Occhipinti, F. Vistoli, M. Barsotti, G. Amorese, U. Boggi, P. Marchetti, Italy

571 Alpha-1 antitrypsin is associated with long term graft function markers after clinical islet transplantation M.-C. Vantyghem, A.-S. Balavoine, M. Costeur, M. Balduyck, F. Zerimech, V. Desforges, C. Noel, J. Kerr-Conte, F. Pattou, France

572 Improvement of sensory nerve conduction correlates with CGMS mean glucose and variability reduction five years after islet transplantation for type 1 diabetes D. Quintin, V. Raverdy, R. Caiazzo, C. Noel, J. Kerr-Conte, F. Pattou, M.-C. Vantyghem, France

573 Reduction of fat mass and leptin with the mTOR inhibitor, sirolimus, in humans: From transplantation to lipodystrophies? E. Parent, F. Defrance, S. Boury, G. Lion, R. Caiazzo, I. Wolowczuk, P. Mathurin, J. Kerr-Conte, F. Pattou, M.-C. Vantyghem, France

163 fp3_2013__ 15.08.13 10:41 Seite 164

Poster Event F, Thursday, 13:45 - 14:45

PS 036 Insulin is not the only islet player

Chair: S. Amisten, UK

574 Specific measurement of the proglucagon-derived peptide glicentin in human samples E. Ludvigsen, C. Gäredal, L. Grufman, R. Boman, H. Ritzén, M. Simonsson, A. Carlsson, R. Gunnarsson, Sweden Posters

575 A novel glucagon receptor antagonist improves hyperglycaemia in both hyperinsulinaemic and relatively insulin-deficient db/db mice K. Sasaki, E. Ohki, M. Shiraishi, Y. Watanabe, N. Abe, S. Nomura, Japan

576 A euglycaemic clamp pilot study assessing the effects of the glucagon receptor antagonist LY2409021 on 24-hour insulin requirement in patients with type 1 diabetes mellitus C. Kapitza, P. Garhyan, Y. Ding, R.P. Kelly, T.A. Hardy, C.M. Kazda, Germany, USA, Singapore, France

577 Mice deficient in glucagon gene exhibit impaired glucose tolerance and the resistance to obesity on high-fat diet feeding N. Ozaki, Y. Takagi, K. Kinoshita, Y. Seino, Y. Oshida, Y. Murata, Y. Hayashi, Japan

578 Secretion and effects of GLP-1 on pancreatic alpha cell V. Sancho Bornez, R. Lupi, G. Faro, D. Lucchesi, S. Del Guerra, A. Dardano, S. Del Prato, Italy

579 Exploring the Somatostatin axis in primary murine mixed islet cultures A.E. Adriaenssens, G. Tolhurst, F. Reimann, F. Gribble, UK

580 GPR120 is expressed preferentially in the delta cells of murine islets of Langerhans and regulates glucose-induced somatostatin secretion V.M. Stone, S. Dhayal, K.J. Brocklehurst, C. Lenaghan, M. Bjursell, X. Xu, T. Admyre, D.M. Smith, N.G. Morgan, UK, Sweden

164 fp3_2013__ 15.08.13 10:41 Seite 165

581 Human bone marrow- and pancreatic islet- derived mesenchymal stem cells: effects of hyperglycaemia and gastrointestinal peptides A. Carpanetto, E. Favaro, S. Lamorte, S. Bruno, R. Granata, P. Cavallo Perin, M. Porta, E. Ghigo, G. Camussi, M.M. Zanone, Italy

582 Intravenous injection of valsartan augmented pancreatic blood flow without affecting in vivo insulin secretion in male GK rats H. Chao, L. Wu, Y. Hu, China

583 Human islet amyloid polypeptide improves hepatic insulin signalling M. Zhou, A. Cheng, G. Xu, China, Hong Kong

Poster Event A, Tuesday, 12:30 - 13:30 Posters

PS 037 Clinical hypoglycaemia

Chair: B. Eliasson, Sweden

584 Nocturnal hypoglycaemia: effect of insulin analogues compared to human insulin in type 1 diabetic patients prone to severe hypoglycaemia C. Bay, P. Lommer Kristensen, U. Pedersen-Bjergaard, L. Tarnow, B. Thorsteinsson, Denmark

585 Effect of insulin analogues on frequency of mild hypoglycaemia in patients with type 1 diabetes and recurrent severe hypoglycaemia: the prospective, controlled HypoAna trial R.M. Agesen, P.L. Kristensen, H. Beck-Nielsen, K. Nørgaard, H. Perrild, J.S. Christiansen, T. Jensen, P. Hougaard, H.-H. Parving, B. Thorsteinsson, L. Tarnow, U. Pedersen-Bjergaard, Denmark

586 Patients with type 1 diabetes treated with insulin pumps do not experience a reduced risk of severe hypoglycaemia in a real life setting C.S. Frandsen, P.L. Kristensen, H. Beck-Nielsen, K. Nørgaard, H. Perrild, J.S. Christiansen, T. Jensen, H.-H. Parving, B. Thorsteinsson, L. Tarnow, U. Pedersen-Bjergaard, Denmark

165 fp3_2013__ 15.08.13 10:41 Seite 166

587 Relationship between glycaemic control and hypoglycaemia using insulin glargine versus premixed insulin in type 2 diabetes: a subanalysis of GALAPAGOS B. Sethi, A. Comlekci, F. Gomez-Peralta, W. Landgraf, M.-P. Dain, V. Pilorget, P. Aschner, India, Turkey, Spain, Germany, France, Colombia

588 The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study A. Hassoun, M. Al-Arouj, R. Medlej, M.F. Pathan, I. Shaltout, M.S. Chawla, P. Geransar, S. Hristoskova, S. DiTommaso, M.Y. Kadwa, United Arab Posters Emirates, Kuwait, Lebanon, Bangladesh, Egypt, India, UK, Switzerland

589 Hypoglycaemia is associated with retinopathy in French type 2 diabetic patients at inclusion in the Gerodiab cohort J.-P. Le Floch, J. Doucet, B. Bauduceau, C. Verny, the SFD / SFGG Intergroup, France

590 Glucose variability and hypoglycaemic excursions in elderly type 2 diabetic patients treated with insulin V.V. Klimontov, A.I. Tsiberkin, O.N. Fazullina, M.A. Prudnikova, N.V. Tyan, V.I. Konenkov, Russian Federation

591 Hypoglycaemia among 3048 insulin-treated patients in real life: frequency and predictive factors: results from the prospective DIALOG study B. Cariou, M. Lièvre, D. Huet, B. Charbonnel, C. Sert, D. Gouet, France

592 Global prevalence of hypoglycaemia: association to treatment factors, self-management education and quality-of-life measurements N. Hermanns, A. Nicolucci, M. Comaschi, M. Davies, M. Escalante, A. Forbes, R.I. Holt, S. Kalra, A. Kokoszka, E. Menéndez-Torre, N. Munro, F. Pouwer, I. Tarkun, M. Peyrot, DAWN2 Study Group, Germany, Italy, UK, Mexico, India, Poland, Spain, Netherlands, Turkey, USA

Poster Event B, Tuesday, 13:45 - 14:45

PS 038 Hypoglycaemia mechanism and prevention

Chair: M.L. Evans, UK

166 fp3_2013__ 15.08.13 10:41 Seite 167

593 Hypoglycaemia promotes thrombosis and inflammation for at least one week in patients with type 2 diabetes E.Y. Chow, A. Iqbal, F. Phoenix, S.R. Heller, R. Ajjan, UK

594 Experimental hypoglycaemia decreases cardiac vagal function for between 7 to 30 days in patients with type 2 diabetes A. Bernjak, E.Y. Chow, E. Walkinshaw, A. Lubina-Solomon, P.J. Sheridan, S.R. Heller, UK

595 Insulin prevents counter-regulatory glucagon secretion by stimulation of somatostatin release P. Rorsman, E. Vergari, M. Brereton, Q. Zhang, B. Hastoy, R. Ramracheya, A. Salehi, A. Clark, F.M. Ashcroft, UK, Sweden Posters 596 Pharmacokinetics and pharmacodynamics of a chemically stable micro- dosed glucagon in a diabetic swine model of type 1 diabetes B. Newswanger, S. Prestrelski, N. Scott, E.R. Damiano, J. Jiang, F.H. El- Khatib, K.M. McKeon, S.J. Russell, P. Sluss, USA

597 Preclinical pharmacology study of stabilised liquid glucagon S.J. Prestrelski, B.J. Newswanger, USA

598 Effects of RAS blockade on ECG and EEG during hypoglycaemia in patients with type 1 diabetes L.H. Færch, B. Thorsteinsson, L. Tarnow, T.W. Kjær, J. Kanters, C. Larroude, U. Pedersen-Bjergaard, Denmark

599 Effects of 6 weeks treatment with sitagliptin on counterregulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes J.E. Schopman, J.B. Hoekstra, B.M. Frier, J.J. De Sonnaville, A.M. Stades, R. Zwertbroek, J.J. Holst, F.K. Knop, F. Holleman, Netherlands, UK, Denmark

600 Risk factor assessment for irreversible brain damage in patients with drug-induced severe hypoglycaemia T. Iwakura, M. Kondo, S. Sasaki, N. Matsuoka, T. Ishihara, Japan

167 fp3_2013__ 15.08.13 10:41 Seite 168

601 Hypoglycaemia related events due to falls in elderly diabetics (H.E.A.L.E.D) study in US veterans Y. Zhao, S. Kachroo, H. Kawabata, S.A. Colilla, L. Shi, J. Mukherjee, U. Iloeje, V. Fonseca, USA

Poster Event C, Wednesday, 12:30 - 13:30

PS 039 Insulin resistance improvement

Posters Chair: J.-F. Tanti, France

602 Cocoa flavonoids attenuate high glucose-induced insulin signalling blockade and enhance glucose uptake and production in human HepG2 hepatic cells S. Ramos, I. Cordero-Herrera, L. Bravo, M.A. Martin, L. Goya, Spain

603 Can carotid sinus nerve resection be a therapeutic approach for the treatment of insulin resistance? M.J. Ribeiro, J.F. Sacramento, M.P. Guarino, S.V. Conde, Portugal

604 GRK2 is a novel modulator of insulin cardioprotective pathway during ageing and diet-induced insulin resistance E. Lucas, M. Jurado-Pueyo, R. Vila Bedmar, J.J. Lazcano, M.A. Fortuño, S. Fernandez-Veledo, L.J. Jiménez-Borreguero, E. Gao, G. Frühbeck, W.J. Koch, J. Díez, F. Mayor Jr, C. Murga, Spain, USA

605 Therapeutic properties of the vanadium compound, VO(dmpp)2, by ex vivo and in vivo studies in diabetic GK rats J. Pelletier, N. Domingues, C.-G. Ostenson, M.M. Castro, Sweden, Portugal

606 Insulin receptor-sensitising polyaminosterols as a novel therapeutic approach for the treatment of type 2 diabetes R. Govers, T. Gonzalez, N. Zaarour, M. Berenguer, Y. Le Marchand-Brustel, J.-F. Tanti, F. Bost, V. Corcelle, J. Zhang, T. Xu, J.M. Brunel, France, China

607 Dapagliflozin improves muscle glucose uptake and increases hepatic glucose production in type 2 diabetes mellitus individuals M. Abdul-Ghani, A. Merovci, C. Solis, R. Eldor, D. Tripathy, D. Giuseppe, R. DeFronzo, USA

168 fp3_2013__ 15.08.13 10:41 Seite 169

608 ISIS PTP-1BRX, a novel protein tyrosine phosphatase antisense inhibitor, improves both insulin and leptin action and increases HMW adiponectin levels in obese subjects Q. Liu, S. Xia, W. Cheng, R. Geary, S. Bhanot, USA

609 The novel myokine YKL-40 is increased by exercise and inhibits TNFalpha-induced inflammation and insulin resistance in human skeletal muscle cells S.W. Görgens, J. Jensen, K.B. Holven, N. Tennagels, K. Eckardt, J. Eckel, Germany, Norway

610 The effects of long-term valsartan treatment on skeletal muscle fatty acid handling in humans with impaired glucose metabolism

G.H. Goossens, C.C. Moors, N.J. Van der Zijl, M. Diamant, E.E. Blaak, Posters Netherlands

611 Low dose pioglitazone-induced reduction in skeletal muscle TACE activity and TNFalpha is associated with an improvement of glycaemic control in type 2 diabetic patients T.V. Fiorentino, G. Daniele, D. Tripathy, Z. Perez-Cadena, A. Chavez- Velasquez, S. Kamath, F. Andreozzi, A. Davalli, M.L. Hribal, G. Sesti, M. Federici, R.A. DeFronzo, F. Folli, USA, Italy

Poster Event D, Wednesday, 13:45 - 14:45

PS 040 Muscle metabolism

Chair: K. Bouzakri, Switzerland

612 Effect of exercise on fatty acid and glucose metabolism in cultured human myotubes E.T. Kase, J. Lund, Y.Z. Feng, T.M. Langleite, V. Aas, J. Jensen, K.I. Birkeland, H.L. Gulseth, C.A. Drevon, A.C. Rustan, G.H. Thoresen, Norway

613 DNA demethylation enhances myoblasts hypertrophy during the late phase of myogenesis activating the IGF-1 pathway N. Mazzocchi, P. Senesi, L. Luzi, A. Montesano, I. Terruzzi, Italy

614 Knockout of STAT3 in skeletal muscle does not enhance insulin action A.T. White, S. Schenk, USA

169 fp3_2013__ 15.08.13 10:41 Seite 170

615 Determination of glucose metabolic fluxes in live myoblasts by microfluidic nanosensing and data analysis A. Zoso, A. Zambon, C. Luni, W.B. Frommer, N. Elvassore, Italy, USA

616 High fat diet induces selective alterations in microRNA expression profile in rat skeletal muscle D.K. Andersen, J.A. Timmons, M.E. Cleasby, UK

617 Debio 0930, a novel direct AMPK activator, improves glycaemic control and lipid profile in metabolic disease models Posters P. Muzzin, M. Von Holtey, M. Barbier, R. Lysek, A. McAllister, Switzerland

618 Effects of chronic variable stress on insulin sensitivity, inflammation and plasma hormone levels S. Müller-Lühlhoff, T. Jelenik, E. Brandt, S. Hartwig, S. Lehr, P. Nowotny, M. Roden, T.R. Castañeda, H. Al-Hasani, Germany

619 Glucose as a significant predictor of irisin levels in children A.-D. Nasser, O. Al-Attas, K. Alkharfy, S. Ur-Rahman, O. Amer, P. Milan, P. McTernan, A. Harte, M. Alokail, Saudi Arabia, UK

620 A single mechanism underlies glucose kinetics in euglycaemic and hyperglycaemic clamps and oral glucose tolerance tests R. Bizzotto, A. Natali, A. Gastaldelli, E. Muscelli, E. Ferrannini, A. Mari, Italy

621 Insulin-mediated suppression of lipolysis in adipose tissue and skeletal muscle of obese type 2 diabetic and normal glucose tolerant men J.W. Jocken, G.H. Goossens, H. Boon, R.R. Mason, Y. Essers, B. Havekes, M.J. Watt, L.J. Van Loon, E.E. Blaak, Netherlands, Australia

622 Characterisation of PIMT KO mice: a model of deficient protein repair Y. Brito-Casillas, J.C. Wiebe, L. López-Ríos, R.M. Sánchez-Hernández, J.F. Arbelo-Galván, M. Monzón-Mayor, M.M. Romero-Alemán, J. Nóvoa- Mogollón, A.M. Wägner, Spain

Poster Event E, Thursday, 12:30 - 13:30

PS 041 Insulin resistance biomarkers

Chair: C. Guay, Switzerland

170 fp3_2013__ 15.08.13 10:41 Seite 171

623 Search for biomarkers that predict the development of type 2 diabetes N. Yokoi, R. Hoshikawa, M. Beppu, S. Hidaka, M. Shinohara, S. Seino, Japan

624 Elevated ferritin in skeletal muscle and insulin resistance in patients with type 2 diabetes mellitus T. Kim, E. Ha, S.-Y. Ahn, M. Lee, J. Jeon, S. Han, H. Kim, D. Kim, S. Choi, Y. Kang, K.-W. Lee, Korea, Republic of

625 Uric acid is a biomarker of beta cell function in patients with newly diagnosed type 2 diabetes C. Brangani, L. Boselli, M. Dauriz, R.C. Bonadonna, E. Bonora, M. Trombetta, Italy Posters 626 Plasma soluble leptin receptor levels are associated with beta cell function in patients with type 2 diabetes T. Morioka, M. Emoto, Y. Yamazaki, H. Urata, S. Imamura, R. Numaguchi, K. Motoyama, K. Mori, S. Fukumoto, T. Shoji, M. Inaba, Japan

627 Plasma concentrations of the methylglyoxal metabolite D-lactate are independently associated with insulin resistance: the CODAM study D.E. Maessen, I. Ferreira, M.M. Van Greevenbroek, C.J. Van der Kallen, J.L. Scheijen, K.H. Gaens, C.D. Stehouwer, C.G. Schalkwijk, Netherlands

628 The association between serum prothymosin-α concentrations and insulin resistance in subjects with or without diabetes mellitus H.-Y. Ou, H.-T. Wu, F.-H. Lu, H.-C. Hung, J.-S. Wu, Y.-C. Yang, C.-J. Chang, Taiwan

629 ZEBD3 3 is associated with obesity and insulin resistance in humans Y. Ren, L. Li, G. Yang, China

630 TIMP3 regulates metabolism acting on different pathways: studies with a metabolomics approach M. Mavilio, M. Cavalera, V. Marchetti, V. Casagrande, M. Fabrizi, R. Menghini, M. Federici, Italy

631 Improvement of metabolite risk profile for type 2 diabetes and cardiovascular disease by weight loss and weight maintenance A.P. Danielsson, M. Magnusson, N. Geidenstam, L.E. Reinius, H. Mulder, O. Melander, M. Ridderstråle, Sweden, Denmark

171 fp3_2013__ 15.08.13 10:41 Seite 172

632 Gene-metabolite networks reveal the regulation of clock genes by insulin N.N. Rudovich, O. Pivovarova, J. Mazuch, S. Wendt, V. Murahovschi, A. Erban, V.J. Nikiforova, C. Sticht, M. Kruse, F. Keyhani Nejad, A.-C. Seltmann, Ö. Gögebakan, L. Willmitzer, A. Kramer, A.F. Pfeiffer, Germany

Poster Event F, Thursday, 13:45 - 14:45

PS 042 Weight loss and caloric modulation Posters

Chair: R. Taylor, UK

633 Effect of an isocaloric reduced protein intake on glucose metabolism and fatty liver in ovariectomised rat C.L. Fournier, S. Sacco, M.-N. Horcajada, K. Bouzakri, L.G. Karagounis, E. Offord, P. Ammann, Switzerland

634 Middle-aged overweight male south Asians exhibit a different metabolic adaptation to short-term caloric restriction compared to Caucasians L.E. Bakker, B. Guigas, T.C. Streefland, G.C. Van der Zon, H. Pijl, A.E. Meinders, I.M. Jazet, Netherlands

635 Obesogenic effect of hypercaloric diet on early undernourished rats: changes in central and peripheral insulin sensitivity E. Lizárraga-Mollinedo, J. De Toro-Martín, E. Fernández-Millán, M. García- San Futos, T. Fernández-Agulló, M. Ros, C. Álvarez, F. Escrivá, Spain

636 Effects of a hypercaloric snacking diet on liver fat and insulin sensitivity in lean men M.J. Serlie, K.E. Koopman, A.J. Nederveen, M.T. Ackermans, E. Fliers, S.E. La Fleur, Netherlands

637 Forced catch-up growth after early food-restriction alters the entero- insular axis programme leading to glucose intolerance in adult female rats J. De Toro-Martín, E. Fernández-Millán, E. Lizárraga-Mollinedo, P. Serradas, F. Escrivá, C. Álvarez, Spain, France

172 fp3_2013__ 15.08.13 10:41 Seite 173

638 Effects of phentermine and topiramate extended-release (PHEN/TPM ER) on weight loss (WL) and glycaemic parameters by gender, race, and baseline body mass index (BMI) H. Toplak, S. Rössner, R. Dvorak, Austria, Sweden, USA

639 Lorcaserin HCl phase 3 trials in obese and overweight patients: week 52 outcomes for those achieving at least 5% weight loss at week 12: a per prescribing information analysis N. Finer, S. Smith, M. Sanchez, K. Fraher, S. Stubbe, C. Turner, B. Raether, D. Halliday, J. Krolikowski, R. Fain, W.R. Shanahan, UK, USA

640 Beneficial oxytocin effects in adipose tissue of obese/diabetic leptin- deficient mice J. Altirriba Gutiérrez, A. Caillon, A. Poher, C. Veyrat-Durebex, D. Arsenijevic, Posters A. Dulloo, F. Rohner-Jeanreaud, Switzerland

641 A long-acting oxyntomodulin derivative exerts superior body weight lowering to GLP1R agonism in monkeys A. Pocai, B. Hansen, R. DiMarchi, J. Lao, USA

642 Differences in the metabolic response to an oral glucose tolerance test between adult lean and obese individuals N. Geidenstam, P. Spégel, H. Mulder, K. Filipsson, M. Ridderstråle, A.P. Danielsson, Sweden, Denmark

Poster Event A, Tuesday, 12:30 - 13:30

PS 043 Beta cell function in man

Chair: A. Mari, Italy

643 In patients with newly-diagnosed type 2 diabetes beta cell function is an independent predictor of glucose control evolution over 18 months G. Fainelli, R.C. Bonadonna, M. Trombetta, L. Boselli, S. Bonetti, V. Stoico, C. Negri, M. Dauriz, E. Bonora, Italy

644 Cross-sectional and longitudinal analyses of factors contributing to the progressive loss of beta cell function in type 2 diabetes H. Nakayama, T. Kato, S. Nakayama, H. Kaku, K. Muraishi, I. Tokubuchi, K. Hara, S. Shigemoto, J. Kameo, M. Oho, Y. Tajiri, K. Yamada, Japan

173 fp3_2013__ 15.08.13 10:41 Seite 174

645 Predictors of beta cell dysfunction in type 2 diabetes: the Beta Decline study G.T. Russo, A. Arcangeli, S. Cercone, A. Corda, D. Cucinotta, S. De Cosmo, L. Gentile, S. Leotta, A. Nicolucci, M. Pellegrini, G. Vespasiani, C.B. Giorda, Italy

646 CSII therapy should be stopped for accurate evaluation of beta cell function in type 2 diabetic patients Y. Tan, W. Xu, S. Luo, J. Yan, B. Yao, J. Weng, China

Posters 647 Liver transplantation improves both beta cell function and insulin sensitivity and may induce reversal of type 2 diabetes mellitus in cirrhotic patients V. Grancini, M.E. Lunati, L. Boselli, D. Zimbalatti, P. Beck-Peccoz, R.C. Bonadonna, E. Orsi, Italy

648 Modelled response to a meal is a useful method to characterise beta cell function (BCF) across the glucose tolerance (GT) spectrum: correlation with FSIGT D. Chen, C. Dalla Man, C. Cobelli, D.A. Fryburg, R.H. Raymond, D.S. Lee, R.N. Bergman, D. Stefanovski, for the Beta Cell Project Team of the FNIH Biomarkers Consortium, USA, Italy

649 Pramlintide improves insulin action and worsens beta cell responsivity in healthy adults: a minimal model study A. Mallad, M. Schiavon, L. Hinshaw, C. Dalla Man, R. Basu, A. Basu, C. Cobelli, Y. Kudva, USA, Italy

650 Adaptive insulin response to increasing caloric load in healthy subjects W. Alsalim, L. Ohlsson, G. Pacini, B. Ahrén, Sweden, Italy

Poster Event B, Tuesday, 13:45 - 14:45

PS 044 Incretins: secretions and action

Chair: J.J. Meier, Germany

174 fp3_2013__ 15.08.13 10:41 Seite 175

651 CART is expressed in L-cells and K-cells in humans, regulates GIP and GLP-1 expression in vitro, and potentiates glucose stimulated GIP secretion in vivo in mice L. Shcherbina, A.-H. Thoren Fischer, S.E. Falkmer, N. Wierup, Sweden

652 Identification of novel GPR39 agonists that stimulate insulin and GLP-1 secretion in vitro using StaR® technology O.J. Mace, S. Andrews, A.J. Brown, S. Brown, M. Congreve, A. Jazayeri, J. Patel, R. Prihandoko, B. Tehan, F. Marshall, UK

653 Peptide sensing by glucagon-like peptide-1 secreting L cells E. Diakogiannaki, R. Pais, H. Parker, G. Tolhurst, A. Ramzan, J. Horscroft, H. Daniel, F. Gribble, F. Reimann, UK, Germany Posters 654 Distribution of fatty acid binding receptors in GIP-secreting K cells in the small intestine K. Mori, N. Harada, K. Suzuki, S. Yamane, A. Hamasaki, K. Sasaki, D. Nasteska, E. Joo, K. Shibue, T. Harada, N. Inagaki, Japan

655 Temporal profiles of hormone expression in mouse enteroendocrine cells P. Richards, F. Reimann, F.M. Gribble, UK

656 Loss of GIP responsiveness in human adipocytes from an obesity context: potential therapeutic implications S. Fernandez-Veledo, V. Ceperuelo-Mallafre, X. Duran, K. Roche, N. Vilarasa, V. Vicente, J. Vendrell, Spain

657 Glucose-dependent insulinotropic polypeptide: blood glucose stabilising effects around fasting glycaemia in patients with type 2 diabetes M. Christensen, S. Calanna, J.J. Holst, T. Vilsbøll, F.K. Knop, Denmark, Italy

658 GLP-1 response after oral glucose overload test in patients with a history of gestational diabetes M.J. Picon Cesar, A. Muñoz Garach, S. Maraver Selfa, A.M. Gomez Perez, I.M. Cornejo Pareja, F. Tinahones Madueño, Spain

659 Time course of the incretin effect across the spectrum of glucose tolerance assessed by modelling analysis A. Tura, E. Muscelli, A. Gastaldelli, E. Ferrannini, A. Mari, Italy

175 fp3_2013__ 15.08.13 10:41 Seite 176

660 High glycaemic index (GI) diet induced hepatic fat accumulation and insulin resistance is associated with high glucose-dependent insulinotropic polypeptide (GIP) secretion F. Keyhani-Nejad, F. Isken, A.L. Birkenfeld, M. Irmler, J. Beckers, A.F. Pfeiffer, Germany

Poster Event C, Wednesday, 12:30 - 13:30

PS 045 Insulin secretion and action: using animal models Posters

Chair: S.J. Persaud, UK

661 The non-hematopoietic erythropoietin analogue, ARA290, improves glucose tolerance by stimulating insulin secretion in spontaneously type 2 diabetic Goto-Kakizaki rats C. Muller, K. Yassin, L.-S. Li, M. Palmblad, P.-O. Berggren, A. Cerami, C.-G. Östenson, Sweden, Netherlands, USA

662 Effects of exogenous DLK1-Fc treatment on insulin secretion and insulin sensitivity in an animal model of diet-induced obesity M.-R. Yun, H. Kim, B. Jeon, I. Kwon, H. Seok, J. Huh, B.-W. Lee, E. Kang, H. Lee, B. Cha, Korea, Republic of

663 Favourable effects of PERK reduction on insulin secretion in autophagy- deficient pancreatic beta cells H.S. Jung, M.J. Kim, O.K. Choi, S.S. Chung, D.-S. Ham, J.-W. Kim, K.H. Yoon, I.-S. Park, M. Komatsu, K. Tanaka, J.C. Bell, K.S. Park, Korea, Republic of, Japan, Canada

664 Beta cell CART overexpression in mice increases insulin secretion, enhances beta cell survival and attenuates insulin sensitivity M. Abels, M. Riva, E. Banke, P. Spégel, L. Shcherbina, A.-H. Thorén Fischer, H. Mulder, E. Degerman, N. Wierup, Sweden

665 Impaired islet function and structure in mice with hereditary predisposition to high fat diet-induced glucose intolerance M. Nagao, A. Asai, W. Inaba, M. Kawahara, H. Sugihara, S. Yagihashi, S. Oikawa, Japan

176 fp3_2013__ 15.08.13 10:41 Seite 177

666 Evaluation of the effect of liraglutide on beta cell fate in alloxan diabetic mice by tamoxifen-inducible Cre/loxP system K. Tamura, K. Minami, H. Takahashi, M. Kudo, H. Kitanoya, S. Seino, Japan

667 A role for kisspeptin in islet function during pregnancy J. Bowe, C. Pilgrim, S. Persaud, P. Jones, UK

668 Maternal high fat diet induced insulin resistance and deterioration of pancreatic beta cell function with a gender difference in mature offspring H. Yokomizo, T. Inoguchi, N. Sonoda, Y. Sakaki, R. Takayanagi, Japan

669 Attenuated hyperinsulinaemia protects female mice with reduced Insulin2 gene dosage from diet-induced obesity N.M. Templeman, X. Hu, A.E. Mehran, J.D. Johnson, Canada Posters

670 Characterisation of glucose homeostasis in a novel rat model of leptin deficiency A.M. D'souza, A. Asadi, S.D. Covey, T.J. Kieffer, Canada

671 Hypothalamic nitric oxide regulates peripheral insulin bioavailability F.O. Martins, S. Tovar, S. Pérez-Sieira, D. Gonzalez-Touceda, J.G. Jones, A. Natali, C. Diéguez, M. Macedo, Portugal, Spain, Italy

Poster Event D, Wednesday, 13:45 - 14:45

PS 046 Gut and gut hormones

Chair: E. Ferrannini, Italy

672 Continuous glucose monitoring (CGM) discloses high glycaemic variability in patients with "late dumping" after RYGB K. Rett, D. Wagenknecht, E. Fischer, K. Krieger, E. Weitz, R. Chandra, C. Stier, Germany

673 Mechanisms of diabetes remission after bariatric surgery: role of the gut M. Nannipieri, S. Baldi, D. Colligiani, A. Mari, D. Guarino, R. Berta, S. Camastra, M. Anselmino, E. Ferrannini, Italy

177 fp3_2013__ 15.08.13 10:41 Seite 178

674 Intestinal lipogenesis in morbidly obese subjects is higher in those with high insulin resistance E. Garcia-Escobar, C. Gutierrez-Repiso, S. Garcia-Serrano, F. Soriguer, J. Garcia-Arnes, S. Valdes, M. Gonzalo, J.L. Gallego-Perales, E. Garcia- Fuentes, Spain

675 Eradication of gut bacteria: effect on postprandial glucose metabolism K.H. Mikkelsen, M.F. Nielsen, U.S. Jensen, M. Tvede, T. Hansen, O.B. Pedersen, J.J. Holst, T. Vilsbøll, F.K. Knop, Denmark

Posters 676 Evidence for a leaky gut in type 2 diabetes J. Wright, F. Horton, P. Hinton, L. Smith, M. Robertson, UK

677 Postprandial plasma glycine-conjugated deoxycholic acid levels correspond with plasma insulin levels in healthy subjects S. Van Nierop, R. Achterbergh, L.A. Ten Berg-Lammers, H.M. Eggink, F.M. Vaz, R.A. Mathot, J.A. Romijn, M.R. Soeters, Netherlands

678 Activation of renal GLP-1 receptors located in the afferent arteriole causes an increase in renal blood flow E.P. Jensen, C.M. Sorensen, C. Deacon, H. Kissow, S.S. Poulsen, N.-H. Holstein-Rathlou, J.J. Holst, Denmark

679 Up-regulated insulin secretion during insulin resistance involves enhanced GLP-1 response and signalling L. Ahlkvist, G. Pacini, B. Ahrén, Sweden, Italy

680 Exendin-4 and rosiglitazone reduced beta cell degeneration and islet inflammation in male Zucker diabetic fatty rats M. Sörhede Winzell, A. Ahnmark, H.B. Jones, D.M. Smith, D. Lindén, Sweden, UK

Poster Event E, Thursday, 12:30 - 13:30

PS 047 Exercise: physiology and clinical benefits

Chair: R. Barrès, Denmark

178 fp3_2013__ 15.08.13 10:41 Seite 179

681 Effects of a training programme at the crossover point on the metabolic abnormalities and cardiovascular risk factors in obese women with metabolic syndrome J.B. Coquart, G. Boitel, B. Borel, R. Matran, C. Mounier-Vehier, M. Garcin, France

682 Exercise training improves insulin sensitivity in abdominal adipose tissue but not in brown adipose tissue in healthy, sedentary, middle aged men K.K. Motiani, A. Savolainen, J.J. Eskelinen, K.A. Virtanen, P. Boström, J. Jensen, R. Parkkola, V. Saunavaara, J. Knuuti, P. Nuutila, K.K. Kalliokoski, J.C. Hannukainen, Finland, Sweden, Norway

683 Eccentric endurance exercise significantly improves both fasting and Posters postchallenge metabolism in overweight and obese individuals P. Rein, C.H. Saely, A. Vonbank, S. Geller-Rhomberg, H. Drexel, Austria, Liechtenstein, USA

684 Glucose requirements for prevention of hypoglycaemia during exercise in individuals with type 1 diabetes mellitus V.B. Shetty, P.A. Fournier, R.J. Davey, A.J. Retterath, N. Paramalingam, H.C. Roby, E.A. Davis, T.W. Jones, Australia

685 Preventing hypoglycaemia by heavily reducing pre- and post-exercise rapid-acting insulin dose may cause hyperglycaemia, but not hyperketonaemia in type 1 diabetes patients M.D. Campbell, M. Walker, M.I. Trenell, S. Luzio, G. Dunseath, E.J. Stevenson, R.M. Bracken, D. Turner, S.C. Bain, D.J. West, UK

686 The role of interleukin 6 in regulation of liver metabolism during exercise J.G. Knudsen, R.S. Biensø, A.H. Jacobsen, H. Adser, J. Hidalgo, H. Pilegaard, Denmark, Spain

687 Resistance exercise induces increases in circulating interleukin-6 in type 1 diabetes individuals D. Turner, B.J. Gray, S. Luzio, S.C. Bain, G. Dunseath, M.D. Campbell, D.J. West, R.M. Bracken, UK

688 Altered follistatin secretion profile during exercise in type 2 diabetes J. Hansen, B. Pedersen, P. Plomgaard, Denmark

179 fp3_2013__ 15.08.13 10:41 Seite 180

689 Physical activity, blood glucose and C-peptide in healthy school children: a substudy of the prospective longitudinal ABIS cohort J. Ludvigsson, K. Huus, A. Raustorp, L. Åkerman, Sweden

Poster Event F, Thursday, 13:45 - 14:45

PS 048 Liver metabolism

Chair: C. Postic, France Posters

690 GLP-1-derived nonapeptide GLP-1(28-36)amide represses hepatic gluconeogenesis and improves pyruvate tolerance in high fat diet fed mice W. Ip, W. Shao, Y.-T. Chiang, T. Jin, Canada

691 Reduction of hepatic glucagon receptor expression with an antisense drug (ISIS-GCGRRX) increases total GLP-1 levels without affecting cholesterol or BP in normal subjects E. Morgan, C. Bethune, L. Watts, S. Xia, M. McDonnell, R. Geary, S. Bhanot, USA, Canada

692 Liver fructokinase: a new target for GLP-1 receptor agonists F. Francini, M.L. Massa, M.C. Castro, M.P. Polo, J.J. Gagliardino, Argentina

693 Metformin reverses FOXO3-induced hyperactivation of hepatic gluconeogenesis and catabolic pathways Y. Sunami, S. Gul, K.-H. Holzmann, F. Leithäuser, H. Maier, M. Vogel, T. Luedde, B.O. Boehm, P. Strnad, T. Wirth, Germany

694 Cyclin-dependent kinase 4 inhibits hepatic gluconeogenesis A. Giralt, P.-D. Denechaud, S. Lagarrigue, I. Lopez, S. Huré, C. Chavey, L. Fajas, Switzerland, France

695 AICAR regulates G6Pase independently of SRC-2/RORα A. Madsen, J.-I. Bjune, G. Mellgren, J.V. Sagen, Norway

696 Significance of hepatic AMPK in metabolic regulation by sympathetic nervous system L. Miyamoto, Y. Tomida, A. Kawasaki, T. Yamaoka, M. Yamane, M. Kono, K. Tsuchiya, Japan

180 fp3_2013__ 15.08.13 10:41 Seite 181

697 Redox as a master regulator of liver function L. Nocito, E. Yoo, B. Corkey, USA

698 ISIS-GCCRRX, a novel glucocorticoid receptor antisense drug reduces CHOL,TG, attenuates dexamethasone induced hepatic IR without systemic GC antagonism in normal subjects S. Bhanot, E. Morgan, C. Bethune, R. Larouche, S. Xia, R. Geary, USA, Canada

699 Effect of resveratrol in hepatic and renal expression of the glucose transporters GLUT2 and SGLT2 in diabetic rats H.S. Freitas, E.P. Machado, A. David-Silva, M.M. Okamoto, U.F. Machado, Brazil Posters

Poster Event A, Tuesday, 12:30 - 13:30

PS 049 Mitochondria, ROS and metabolism

Chair: V.B. Schrauwen-Hinderling, Netherlands

700 Cytochrome C oxidase activity in islets and lymphocytes is directly correlated to glucose stimulated insulin secretion in Cohen diabetes rats fed different diets S.W. Zangen, L. Romero-Afrima, G. Aharon-Hananel, T. Aouizerat, A. Saada, I. Raz, Israel

701 Study of key proteins in the newly identified mitochondrial target of thiazolidinediones (mTOT): a new target for insulin sensitisers W.G. McDonald, S.L. Cole, D.D. Holewa, A.S. Brightwell-Conrad, C.L. Wolfe, J.S. Wheeler, K.R. Coulter, P.M. Kilkuskie, J.R. Colca, R.F. Kletzien, USA

702 In situ detection of mitochondria-endoplasmic reticulum interactions by proximity ligation assay: defective organelle interactions cause hepatic insulin resistance E.L. Tubbs, P. Theurey, A. Bravard, N. Bendridi, G. Vial, M.-A. Chauvin, F. Zoulim, M. Ovize, H. Vidal, J. Rieusset, France

181 fp3_2013__ 15.08.13 10:41 Seite 182

703 An mtDNA mutation in the cytochrome-c oxidase impacts age-related processes in liver, muscle and brain J. Niemann, C. Johne, L. Wuchert, F. Koch, M. Tiedge, S. Baltrusch, Germany

704 Liver mitochondrial function in Zucker diabetic fatty rats during the early stages of the diabetes disease G. Vial, M. Le Guen, F. Lamarche, D. Detaille, C. Cécile Cottet-Roussel, L. Demaison, I. Hininger-Favier, D. Crouzier, J.-C. Debouzy, H. Dubouchaud, France Posters 705 Role of peroxiredoxin 6 in the pathogenesis of diabetes mellitus F. Pacifici, R. Arriga, G.P. Sorice, B. Capuani, D. Pastore, A. Coppola, S. Caratelli, A. Bellia, G. Donadel, M. Federici, P. Sbraccia, G. Sconocchia, A. Giaccari, A. Orlandi, D. Lauro, Italy

706 Effect of association between insulin and PPAR agonists on renal cortex glucose transporters and gluconeogenic enzymes expression in diabetic rats M.M. Okamoto, A. David-Silva, M.F. Marques, R. Sabino Silva, H.S. Freitas, U.F. Machado, Brazil

707 A new mutation in SLC5A2 causing familial renal glycosuria in individuals with impaired glucose control P. Vikman, E. Ottosson-Laaksso, M. Gullström, P.-H. Groop, L. Groop, Sweden

708 The impact of reduced kidney mass on adipose tissue metabolism and whole-body glucose homeostasis in mice S.H. Chin, F. Item, S. Wueest, M.S. Wiedemann, E.J. Schoenle, D. Konrad, Switzerland

709 Early insulin treatment preserved beta cell function by alleviating local oxidative stress in db/db mice Y. Shen, X. Lai, G. Xu, L. Xie, X. Xia, H. Liang, J. Weng, China

182 fp3_2013__ 15.08.13 10:41 Seite 183

Poster Event B, Tuesday, 13:45 - 14:45

PS 050 Gender: difference and sex hormones in metabolism

Chair: J.B. Ruige, Belgium

710 Withdrawn

711 Hyperandrogenaemia in morbidly obese women is associated with increased risk of metabolic syndrome, dysglycaemia and dyslipidaemia T.G. Valderhaug, J.K. Hertel, N. Norstrand, L.K. Johnson, P.O. Dale, D. Hofsø, J. Hjelmesæth, Norway

712 Testosterone replacement in 181 obese, hypogonadal men leads to Posters continuous weight loss and over 5 years and improved glucose homeostasis F. Saad, A. Haider, G. Doros, L. Gooren, Germany, United Arab Emirates, USA, Netherlands

713 Weight loss and beneficial effects on the metabolic syndrome as a result of testosterone treatment for up to 16 years in 381 hypogonadal men M. Zitzmann, F. Saad, S. Kliesch, E. Nieschlag, Germany, United Arab Emirates

714 Increased free testosterone levels following bariatric surgery are related to weight loss and glycaemic control in men with type 2 diabetes: analysis from a RCT S.R. Kashyap, P. Schauer, D.L. Bhatt, M. Gupta, K. Wolski, C. Pothier, J. Kirwan, S. Brethauer, L. Kennedy, USA

715 Comparison of carotid intima-medium thickness, endothelial function and C-reactive protein in male patients with type 2 diabetes with normal and low testosterone levels J.M. Farias, M. Khoury, M. Tinetti, Argentina

716 Association of glypican-4 with body fat distribution, insulin resistance and non-alcoholic fatty liver disease H. Yoo, H. Hong, H. Choi, J. Ryu, Y. Kim, N. Kim, J. Ahn, H. Kim, S. Kim, N. Kim, S. Baik, K. Choi, Korea, Republic of

183 fp3_2013__ 15.08.13 10:41 Seite 184

717 Gender differences in the HPA axis are abolished in type 2 diabetes L. Arnetz, N. Rajamand Ekberg, K. Brismar, M. Alvarsson, Sweden

718 Exenatide improved sperm quality and promoted testosterone metabolism in high-fat-diet induced obese C57BL/6J mice E. Zhang, F. Xu, Z. Li, J. Yan, X. Xing, Z. Chen, H. Liang, J. Weng, China

719 Impaired GLUT4-mediated glucose uptake in skeletal muscle plays a key role in the development of glucose intolerance induced by testosterone deficiency Posters T. Senmaru, M. Fukui, K. Mitsuhashi, T. Fukuda, H. Okada, M. Tsujikawa, H. Obayashi, M. Tanaka, M. Asano, M. Yamazaki, G. Hasegawa, N. Nakamura, Japan

Poster Event C, Wednesday, 12:30 - 13:30

PS 051 Bariatric surgery

Chair: D.J. Pournaras, UK

720 Laparoscopic sleeve gastrectomy ameliorates mRNA expression of inflammation-related genes in subcutaneous adipose tissue but not in peripheral monocytes of obese patients P. Trachta, M. Mraz, I. Dostalova, Z. Lacinova, D. Haluzikova, P. Kavalkova, M. Kasalicky, S. Svacina, M. Haluzik, Czech Republic

721 Laparoscopic greater curvature plication improves metabolic control and modulates adipose tissue inflammation in obese type 2 diabetic patients during a 6-month follow-up J. Drapalova, P. Kavalkova, K. Dolezalova, M. Urbanova, P. Trachta, Z. Lacinova, S. Svacina, M. Fried, M. Mraz, M. Haluzik, Czech Republic

722 Bile acids: key actors of metabolic improvement after gastric bypass? D. Goncalves, A. Barataud, F. De Vadder, J. Vinera, C. Zitoun, A. Duchampt, G. Mithieux, France

723 Improvements in insulin sensitivity after gastric bypass is not due to changes in physical fitness M. Hansen, M. T. Lund, M. Palsøe, A. Floyd, J. W. Helge, F. Dela, Denmark

184 fp3_2013__ 15.08.13 10:41 Seite 185

724 GLP-1 Antagonism alters the rate of gastrointestinal transit but not the rate of meal appearance after Roux-en-Y Gastric Bypass in diabetic and non-diabetic subjects M. Shah, J.H. Law, F. Piccinini, C. Dalla Man, M. Sathananthan, P.D. Giesler, M. Camilleri, R.A. Rizza, C. Cobelli, A. Vella, USA, Italy

725 Insulin secretion before and after gastric bypass operation in morbidly obese subjects with and without type 2 diabetes M.T. Lund, M. Hansen, S. Skaaby, S. Dalby, A. Floyd, J.J. Holst, J.W. Helge, F. Dela, Denmark

726 Implantation of an endoscopically deployed Duodenal-Jejunal Bypass Liner in obese type 2 diabetes subjects: 8 months follow up of ten subjects Y. Krepak, B. Stratmann, M. Hauber, Y.H. Lee-Barkey, M. Fischer, Posters D. Tschoepe, Germany

727 Influence of severe obesity on circulating endothelial progenitor cells levels and effects of bariatric surgery A. Ciccarone, D. Lucchesi, L. Pucci, V. Sancho Bornez, E. Russo, M. Garofolo, R. Bellante, R. Russo, I. Crisci, S.G. Popa, L. Giusti, M. Mota, R. Miccoli, G. Penno, S. Del Prato, Italy, Romania

728 Effects of gastric bypass surgery on glucose homeostasis, pancreatic islet and gut morphology, and metabolite profile in a porcine model N. Wierup, P. Spégel, M. Ekelund, K. Szwiec, S. Pierzynowski, H. Mulder, J. Hedenbro, L. Groop, A. Lindqvist, Sweden

Poster Event D, Wednesday, 13:45 - 14:45

PS 052 Brain metabolism

Chair: B. Thorens, Switzerland

729 Variation in the obesity risk gene FTO determines the postprandial cerebral processing of food stimuli M. Heni, S. Kullmann, R. Veit, C. Ketterer, F. Machicao, H. Staiger, H.-U. Häring, H. Preissl, A. Fritsche, Germany

185 fp3_2013__ 15.08.13 10:41 Seite 186

730 Six weeks of hypercaloric high-fat-high-sugar snacking decreases diencephalic serotonin transporters, but not dopamine transporters, in lean men K.E. Koopman, J. Booij, E. Fliers, M.J. Serlie, S.E. La Fleur, Netherlands

731 Increasing HOMA-IR modulates brain responses to meal ingestion in insulin sensitive men: a continuous arterial spin labelling functional magnetic resonance imaging study Y.S. Cheah, S. Lee, B.M. Wilson, L.J. Reed, M.J. Brammer, F.O. Zelaya, S.A. Amiel, UK Posters 732 The brain's response to food ingestion in insulin sensitive and insulin resistant obesity: a [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) study K.F. Hunt, J.T. Dunn, A.M. Pernet, L.J. Reed, P.K. Marsden, S.A. Amiel, UK

733 Early Alzheimer-type dementia and type 2 diabetes: analysis using Voxel-based specific regional analysis system for Alzheimer's disease (VSRAD) M. Yoshida, N. Yamamoto, E. Ohshima, A. Saeki, M. Sugino, T. Kuzuya, N. Ohsawa, S. Yoshida, T. Hanafusa, Japan

734 Does sleep loss induce diabetes? S. Harada, S. Chikahisa, N. Shimizu, T. Shiuchi, H. Séi, Japan

735 Effect of feeding rhythm on sleep/wake regulation K. Oura, T. Shiuchi, N. Shimizu, S. Chikahisa, H. Séi, Japan

736 The effects of brain insulin action on hepatic glucose metabolism, glucagon secretion and lipolysis in the absence of somatostatin infusion D.S. Edgerton, G. Kraft, M. Smith, B. Farmer, D.W. Neal, P. Williams, C.J. Ramnanan, A.D. Cherrington, USA, Canada

737 Alx3 deficient mice exhibit hypothalamic dysfunction and altered energy expenditure A. Fernández-Pérez, M. Mirasierra, B. Lizarbe, S. Cerdán, M. Vallejo, Spain

738 Insulin action in the brain depends on whole-body insulin sensitivity T. Sartorius, M. Heni, P. Schöpfer, A. Peter, A. Fritsche, M. Synofzik, H.-U. Häring, W. Maetzler, A.M. Hennige, Germany

186 fp3_2013__ 15.08.13 10:41 Seite 187

Poster Event E, Thursday, 12:30 - 13:30

PS 053 Inflammation in obesity and type 2 diabetes

Chair: A. Bouloumié, France

739 The interleukin-1 receptor antagonist anakinra improves beta cell function in subjects with impaired glucose tolerance P.C. Van Poppel, E.V. Van Asseldonk, M.G. Netea, C.J. Tack, Netherlands

740 Activation of the inflammasome in glomerular cells aggravates experimental diabetic nephropathy K. Shahzad, F. Bock, C. Wacker, H. Wang, S. Ranjan, J. Wolter,

S. Stoyanov, K. Reymann, M. Thati, B. Isermann, Germany Posters

741 Protection of beta cell function by therapy with interleukin-1beta antibody in the Cohen diabetes-sensitive rat G. Aharon-Hananel, S. Lenzen, A. Jörns, I. Raz, S. Weksler-Zangen, Israel, Germany

742 Pivotal role of TNFalpha in mediating ET-1 vasocostrictive effects in small arteries of obese patients A. Virdis, C. Rossi, E. Duranti, U. Dell'Agnello, E. Santini, M. Anselmino, M. Chiarugi, S. Taddei, A. Solini, Italy

743 Plasma levels of Nε-(Carboxymethyl)lysine are inversely associated with BMI and inflammation, and explain a part of the obesity-related increases in inflammation K.H. Gaens, I. Ferreira, M.M. Van Greevenbroek, C.J. Van der Kallen, M.P. Van de Waarenburg, S.S. Rensen, W.A. Buurman, J.M. Greve, C.D. Stehouwer, C.G. Schalkwijk, Netherlands

744 Increased leukotriene production is associated with metabolic syndrome in obese subjects A. Sultan, A. Avignon, F. Stanke-Labesque, C. Boegner, V. Attalin, E. Leprieur, M. Back, France, Sweden

187 fp3_2013__ 15.08.13 10:41 Seite 188

745 Dipeptidyl peptidase 4 (DPP4) induces inflammation and proliferation of human smooth muscle cells by activation of the ERK and NF-kB signalling pathway N. Wronkowitz, L.A. Villalobos, C.F. Sánchez-Ferrer, C. Peiro, H. Sell, J. Eckel, Germany, Spain

746 ITCH deficiency protects from diet induced obesity A. Marino, M. Fabrizi, V. Casagrande, M. Mavilio, R. Menghini, G. Melino, R. Lauro, M. Federici, Italy

Posters 747 Parasitic nematode Trichinella infection improves obesity-induced diabetes H. Okada, K. Kajita, M. Yamauchi, T. Ikeda, Y. Uno, H. Morita, T. Ishizuka, Japan

748 Obesity and inflammation: molecular pathways involved in CCL5 chemokine regulation in adipocytes F. Passaretti, V. D'Esposito, C. Padrone, R. Valentino, M.R. Ambrosio, L. Albano, F. Beguinot, P. Formisano, Italy

Poster Event F, Thursday, 13:45 - 14:45

PS 054 Fatty acids and triglyceride storage: impact on inflammation and glucose metabolism

Chair: M. Foti, Switzerland

749 Plasma acylcarnitine levels have limited predictive value for metabolic characteristics as insulin sensitivity and energy expenditure M.R. Soeters, M.G. Schooneman, S.M. Houten, S.R. Miller, S. Virtue, A. Vidal-Puig, A. Napolitano, D.J. Nunez, UK, Netherlands, USA

750 Plasma acylcarnitines poorly reflect tissue acylcarnitine metabolism N. Achterkamp, M.G. Schooneman, M.R. Soeters, S.M. Houten, Netherlands

751 γ-Butyrobetaine impairs glucose tolerance in mice on a high carbohydrate diet M.G. Schooneman, F.M. Vaz, C.E. Hollak, M.R. Soeters, S.M. Houten, Netherlands

188 fp3_2013__ 15.08.13 10:41 Seite 189

752 Relationship between inflammatory phenotype of human macrophages and the lipid storage in lipid droplets K. Cho, H. Miyoshi, T. Kondo, T. Atsumi, Japan

753 Coordinated effects of macrophages and free fatty acids on the inflammatory gene expression in pancreatic islets H. Inoue, J. Shirakawa, K. Orime, Y. Togashi, Y. Terauchi, Japan

754 Early over-nutrition and dietary fat induce beta cell failure in Swiss Webster mice M.M. Glavas, Q. Hui, E. Tuduri, J.K. Fox, X. Hu, J.D. Johnson, T.J. Kieffer, Canada

755 Fatty acid composition in adipose triglyceride in high-fat fed rats treated Posters with pioglitazone D. Sato, K. Oda, M. Kusunoki, A. Nishina, Z. Feng, T. Nakamura, Japan

756 Intramuscular triglyceride synthesis rate influences skeletal muscle DAG localisation in humans B.C. Bergman, L. Perreault, D.M. Hunerdosse, A. Kerege, M.C. Playdon, S. Bacon, A. Strauss, R.H. Eckel, USA

757 Involvement of the endocrine factor FGF21 in the beneficial effects of dietary long-chain n-3 polyunsaturated fatty acids J. Villarroya, P. Flachs, I. Redondo, M. Giralt, F. Villarroya, J. Kopecky, A. Planavila, Spain, Czech Republic

758 Effect of carnitine palmitoyltransferase (CPT) 1A activity regulation on the control of the food intake D. Serra, P. Mera, J.F. Mir, K. Makowski, M.I. Malandrino, M. Weber, N. Steiner, B. Losilla, H. Petri, X. Ariza, L. Herrero, G. Asins, J. García, F.G. Hegardt, Spain, Austria, Netherlands

Poster Event A, Tuesday, 12:30 - 13:30

PS 055 Exercise, muscle and lipid metabolism

Chair: H. Bodansky, UK

189 fp3_2013__ 15.08.13 10:41 Seite 190

759 Serum irisin after moderate exercise test in obese and non-obese adolescent boys B. Skowrońska, M. Fichna, A. Gertig, E. Niechciał, I. Krzyśko, P. Fichna, Poland

760 Serum FGF21 relation to nutritional status and physical activity in adolescent boys P. Fichna, B. Skowrońska, M. Fichna, A. Gertig, E. Niechciał, I. Krzyśko, Poland

Posters 761 Skeletal muscle mitochondrial uncoupling induces a metabolic rescue cycle involving FGF21 as a myokine M. Ost, S. Keipert, J. Dokas, M. Portero-Otin, E.M. Van Schothorst, J. Keijer, S. Klaus, Germany, Spain, Netherlands

762 Specific changes in plasma lipidome in obesity and type 2 diabetes are associated with physical inactivity and muscle mitochondrial function T. Kurdiova, B. Ukropcova, M. Balaz, G. Liebisch, M. Vician, M. Vlcek, M. Srbecky, J. Olejnik, R. Imrich, V. Belan, I. Klimes, G. Schmitz, D. Gasperikova, J. Ukropec, Slovakia, Germany

763 Effects of resveratrol and exercise training on HFD induced changes in white adipose tissue; role of muscle PGC-1α S.B. Larsson, N. Brandt, C.M. Kristensen, R.S. Biensø, J. Olesen, H. Pilegaard, Denmark

764 Effects of a combined aerobic and resistance exercise programme on C1q/TNF-related protein-3(CTRP3) and CTRP-5 levels J. Ryu, H. Hong, H. Choi, Y. Kim, N. Kim, J. Ahn, H. Kim, H. Yoo, S. Kim, N. Kim, S. Baik, B.-S. Youn, K. Park, K. Choi, Korea, Republic of

765 Effect of exercise and rosiglitazone on neprilysin protein expression in db/db diabetic mice K.M. Elased, S. Gutta, L.F. Alawi, H.K. Somineni, G.P. Boivin, USA

766 Maturation of AMP-activated protein kinase in skeletal muscle in pre- weaning mice J. Hansikova, P. Janovska, J. Kopecky, Czech Republic

767 Different feeding rhythm affects hypothalamic regulation of fatty acid metabolism in skeletal muscle T. Shiuchi, S. Chikahisa, K. Oura, N. Shimizu, H. Séi, Japan

190 fp3_2013__ 15.08.13 10:41 Seite 191

Poster Event B, Tuesday, 13:45 - 14:45

PS 056 Adipose tissue: expandability

Chair: M. Rydén, Sweden

768 Bip/GRP78 inhibits adipogenesis through Wnt/beta catenin signalling Y. Nie, G. Xu, China, Hong Kong

769 WISP1 (Wnt1 inducible signalling pathway protein 1) is a novel marker of adipose tissue differentiation and obesity V. Murahovschi, I. Ilkavets, O. Pivovarova, R. Dmitrieva, S. Döcke, C. Von Loeffelholz, S. Dooley, A.F. Pfeiffer, N. Rudovich, Germany, Russian

Federation Posters

770 The potential role of iron and endogenous transferrin biosynthesis in human and 3T3-L1 adipocyte differentiation J.M. Fernández-Real, J. Moreno-Navarrete, M.G. Novelle, V. Catalán, F. Ortega, M. Moreno, J. Gomez-Ambrosi, G. Xifra, M. Serrano, E. Guerra, G. Frühbeck, C. Diéguez, W. Ricart, Spain

771 Impaired leptin regulation by epigenetic methylation as a marker of immature preadipocyte function in low birth weight subjects N. Schultz, C. Broholm, L. Gilberg, B. Pedersen, A. Vaag, Denmark

772 Bivalent histone modification of the promoter and its resolution contribute to the epigenetic regulation of PPARγ gene expression and adipocyte differentiation T. Yamauchi, J. Yu, H. Waki, T. Kadowaki, Japan

773 Dual effects of inflammation and insulin resistance on markers of renewal of adipose tissue G. Pardo, F.J. Ortega Delgado, J. Moreno-Navarrete, N. Pueyo, M. Sabater, M. Serrano, D. Mayas, M. Serino, J.I. Rodriguez-Hermosa, W. Ricart, R. Burcelin, F.J. Tinahones, G. Frühbeck, G. Mingrone, J. Fernández-Real, Spain, France, Italy

774 A novel role of Opa-interacting protein 5 in obesity K. Inoue, N. Maeda, T. Mori, M. Yamaoka, R. Sekimoto, Y. Tsushima, H. Nishizawa, T. Funahashi, I. Shimomura, Japan

191 fp3_2013__ 15.08.13 10:41 Seite 192

775 Adipocyte morphology and implications for metabolic derangements in obesity S. Heinonen, L. Saarinen, J. Naukkarinen, A. Rodríguez, G. Frühbeck, A. Hakkarainen, J. Lundbom, N. Lundbom, P. Arner, S. Hautaniemi, A. Suomalainen, J. Kaprio, A. Rissanen, K. Pietiläinen, Finland, Spain, Sweden

776 Blockade of lysophosphatidic acid receptors reduces adipose tissue fibrosis and improves insulin resistance C. Rancoule, S. Gres, P. Valet, J.S. Saulnier Blache, France

Posters 777 Collagen VI mRNA expression is regulated by leptin: a potential physiological feedback mechanism regulating adipose tissue expandability L.J. McCulloch, T.J. Rawling, E.J. Price, B. Knight, N.H. Liversedge, K. Kos, UK

Poster Event C, Wednesday, 12:30 - 13:30

PS 057 Autophagy, endoplasmic reticulum and oxidative stresses

Chair: M. Cormont, France

778 PPARβ/δ attenuates palmitate-induced endoplasmic reticulum stress and provokes autophagy in human cardiac cells X. Palomer, E. Capdevila-Busquets, G. Botteri, M.M. Davidson, L. Michalik, W. Wahli, M. Vázquez-Carrera, Spain, USA, Switzerland

779 Deletion of hepatic ROCK1 prevents steatosis by reducing lipid synthesis and activating autophagic flux in diet-induced obese mice I.S. Lima, H. Huang, S.-H. Lee, I. Jarak, J.G. Jones, M.P. Macedo, Y.-B. Kim, USA, Portugal, Korea, Republic of

780 The PPARβ/δ agonist GW501516 inhibits endoplasmic reticulum stress- induced inflammation in skeletal muscle cells L. Salvadó Serra, A. Gómez-Foix, M. Vázquez-Carrera, Spain

781 Inhibition of autophagic flux is associated with increased endoplasmic reticulum stress during the development of non-alcoholic fatty liver disease Á. González-Rodríguez, R. Mayoral, N. Agra, V. Pardo, M.E. Miquilena- Colina, J. Vargas-Castrillón, C. García-Monzón, P. Martín-Sanz, Á.M. Valverde, Spain

192 fp3_2013__ 15.08.13 10:41 Seite 193

782 Correction of intermittent hypoxia with CPAP improves cardio-metabolic abnormalities, systemic inflammation, and adipose tissue ER stress in obese subjects with OSA S. Perrini, M. Barbaro, A. Ciavarella, S. Kounaki, V. Quaranta, P. Nigro, R. Ficarella, A. Cignarelli, A. Peschechera, A. Natalicchio, L. Laviola, G. De Pergola, O. Resta, F. Giorgino, Italy

783 Differential effects of oleate and palmitate on beta cell autophagy K.-Y. Chu, L. O'Reilly, C. Bartley, T.J. Biden, Australia

784 DNAJB3/HSP-40 cochaperone role in obesity A. Jehad, M. Abufarha, F. Al-Ghimlas, I. Alkhairi, P. Cherian, N. Elkum, J. John, S. Kavalakatt, A. Khadir, A. Tiss, S. Warsame, S. Dermime, K. Behbehani, M. Dehbi, Kuwait Posters

785 Des-acyl ghrelin protects microvascular endothelial cells from oxidative stress-induced apoptosis through sirtuin 1 signalling pathway H. Furuta, T. Shimada, A. Doi, M. Nishi, H. Sasaki, T. Akamizu, Japan

786 Plasma URB protein is positively associated with human obesity and URB gene expression is inversely regulated by hydrogen peroxide and IL- 1beta in cultured adipocytes O. Osorio-Conles, M. Guitart, X. Escoté, J. Moreno-Navarrete, J. Fernández- Real, J. Vendrell, A. Gómez-Foix, Spain

787 Palmitate induced repression of GLUT4 protein involves activation of nuclear factor-kappa B (NF-kB) P.E. Silva, A. David-Silva, M.M. Okamoto, H.S. Freitas, U.F. Machado, Brazil

Poster Event D, Wednesday, 13:45 - 14:45

PS 058 Adipose tissue distribution

Chair: M. Blüher, Germany

788 MicroRNA-196a is a potential regulator of body fat distribution in humans C.Z. Hilton, M. Neville, K. Pinnick, K. Mackay, F. Karpe, UK

193 fp3_2013__ 15.08.13 10:41 Seite 194

789 Depot-specific changes of fat metabolism with ageing in a type 2 diabetic animal S. Park, C.-Y. Park, M. Lee, J. Kim, W. Jeon, E.-J. Rhee, W. Lee, K. Oh, S. Park, H. Lee, B. Cha, Korea, Republic of

790 Role of PGC-1alpha in exercise induced regulation of inflammatory markers in visceral and subcutaneous adipose tissue J.F. Halling, A. Lundgaard, S. Ringholm, H. Pilegaard, Denmark

791 Identification of CCDC3 as a possible novel biomarker for visceral Posters adiposity S. Maeda, S. Ugi, Y. Kawamura, M. Kobayashi, M. Imamura, M. Rokushima, O. Sekine, K. Morino, T. Yoshizaki, H. Yamamoto, T. Tani, A. Kashiwagi, H. Maegawa, Japan

792 Perihilar fat: another specialised and functionally very active perivascular fat tissue which differs from subcutaneous and visceral fat D.I. Siegel-Axel, M. Guthoff, N. Stefan, S. Nadalin, K. Rittig, H.-E. Schaller, N. Heyne, H.-U. Häring, Germany

793 Effect of high FFA level on the anti-contractile response of perivascular adipose tissue in rat aorta X. Sun, N. Hou, F. Han, China

794 Impact of the peripancreatic adipose tissue on beta cell adaptation to obesity: an integrated, multi-platform analysis R. Malpique, H. Figueiredo, S. Rebuffat, M. Vinaixa, O. Yanes, X. Correig, S. Barceló, S. Kalko, R. Gomis, Spain

795 In vivo AAV-mediated genetic engineering of white and brown adipose tissue in adult mice V. Jimenez, S.A. Munoz, E. Casana, C. Mallol, I. Elias, A. Ribera, T. Ferre, S. Franckhauser, F. Bosch, Spain

796 Brown adipose tissue metabolic activity assessed with FDG-PET/CT correlates with BMI and glucose tolerance in insulin resistant subjects M.S. Buchsbaum, L. Morrow, D. Meyers, A. Krentz, G. Peterson, T. Swan, A. DeCastro, M. Hompesch, D. Laurent, USA, Switzerland

194 fp3_2013__ 15.08.13 10:41 Seite 195

797 The effect of cold exposure on hepatic fatty acid uptake and brown adipose tissue function: relations to glycaemic control J.R. Raiko, T. Saari, P. Nuutila, K. Virtanen, Finland

Poster Event E, Thursday, 12:30 - 13:30

PS 059 Cancer and metabolism

Chair: A. Renehan, UK

798 Insulin glargine does not increase breast cancer growth in an animal model

E.J. Gallagher, A. Tobin-Hess, J. Blank, N. Buffin, A. Polin, N. Tennagels, Posters U. Werner, D. LeRoith, USA, Germany

799 Insulin glargine (GLA) metabolites do not stimulate cell growth in human cancer initiating cells (CICs) C. Belda-Iniesta, R. Perona, O. Arrizabalaga Garde, M. Cortés-Sempere, E. Holgado, O. Pernía, Spain

800 Use of glucose lowering drugs and the risk of adenocarcinoma among patients with type 2 diabetes: a case-control study in the Netherlands A.C. Simon, G.W. 't Jong, V.E. Valkhoff, M. Sturkenboom, J.B. Hoekstra, F. Holleman, Netherlands

801 Metformin decreases the tumour death ratio accelerated by a high calorie diet in the RasH2 mouse, a model for evaluating and designing tumour prevention or regression therapies S. Otabe, X. Yuan, T. Fukutani, M. Migita, H. Nakao, S. Shigemoto, J. Kameo, M. Harada, K. Tanaka, N. Wada, T. Hashinaga, S. Kakino, H. Nakayama, Y. Tajiri, K. Yamada, Japan

802 Direct inhibition of hexokinase II underlies a new anticancer property of metformin B. Salani, C. Marini, A. Del Rio, S. Ravera, M. Massollo, A. Orengo, A. Amaro, M. Passalacqua, S. Maffioli, U. Pfeffer, G. Sambuceti, R. Cordera, D. Maggi, Italy

195 fp3_2013__ 15.08.13 10:41 Seite 196

803 Hyperglycaemia and hyperinsulinaemia promote fibrogenesis: increased risk of pancreatic cancer L. Li, Z. Sun, J. Yang, R.T. Waldron, A. Lugea, S.J. Pandol, China, USA

Poster Event F, Thursday, 13:45 - 14:45

PS 060 Fatty liver: human studies

Chair: N. Stefan, Germany Posters

804 Impaired gastrointestinal-mediated glucose disposal in patients with non-alcoholic fatty liver disease A.E. Junker, L.L. Gluud, F.K. Knop, T. Vilsbøll, Denmark

805 Marked reductions in hepatic fat after a cardiovascular prevention programme persist after one year despite weight regain S. Jenni, T. Tillin, L. Thomas, K. March, C. Tuson, C. Park, M.D. Baker, J. Bell, S.B. Connolly, D.A. Wood, A.D. Hughes, N. Chaturvedi, UK, Switzerland

806 The relationship between liver fat content in patients with type 2 diabetes and liver disease outcome L. Zhang, X. Gao, China

807 The change in plasma triglycerides during an OGTT strongly predicts non-alcoholic fatty liver disease and the effectiveness of a lifestyle intervention to reduce liver fat K. Kantartzis, I. Rettig, J. Machann, F. Schick, A. Fritsche, L. Scheja, H.-U. Häring, N. Stefan, Germany

808 Alteration in lipid metabolism after an oral fat load in subjects with NAFLD A. Gastaldelli, M. Gaggini, L. Mezzabotta, C. Rosso, F. Carli, D. Ciociaro, R. Gambino, S. Carenzi, F. Saba, M. Cassader, E. Bugianesi, Italy

809 Interaction between obesity status and dietary intakes of sucrose and ω- 6/ω-3-polyunsaturated fats and the Ile148Met in the PNPLA3 gene I.A. Stojkovic, U. Ericson, G. Rukh, S. Romeo, M. Orho-Melander, Sweden

196 fp3_2013__ 15.08.13 10:41 Seite 197

810 Organ-specific fat accumulation and insulin resistance among the liver, skeletal muscle and adipose tissue in people with non-alcoholic fatty liver disease T. Takamura, K.-I. Kato, H. Misu, Y. Takeshita, S. Kaneko, Japan

811 TWEAK/Fn14 in human hepatic steatosis: sTWEAK reduces triglyceride accumulation in human liver cells M.R. Chacón, E. Maymó-Masip, J. Fernández Real, A. Lecube, J. Moreno- Navarrete, J. Vendrell, A.H. Patel, J. Garcia-Fontgivell, M. Rodríguez, Spain, UK

Poster Event A, Tuesday, 12:30 - 13:30 Posters PS 061 Fatty liver: rodent studies

Chair: G. Pugliese, Italy

812 A chronic apelin treatment improves hepatic steatosis in obese and insulin resistant mice by modulating de novo lipogenic pathway C. Bertrand, A. Batut, E. Wanecq, K. Louche, C. Moro, P. Valet, I. Castan- Laurell, France

813 P2X7 receptor deficiency attenuates non-alcoholic steatohepatitis (NASH) induced by high-fat diet: possible role of the NLRP3 inflammasome G. Pugliese, C. Blasetti Fantauzzi, S. Menini, C. Ricci, C. Rossi, E. Santini, C. Iacobini, A. Solini, Italy

814 Beta cryptoxanthin improves hepatic insulin resistance and inflammation through alternative activation of macrophages in diet-induced non-alcoholic fatty liver disease M. Nagashimada, Y. Ni, F. Zhuge, N. Nagata, M. Kobori, M. Sugiura, S. Kaneko, T. Ota, Japan

815 Dysfunctional adipose tissue-liver crosstalk contributes to short-term HFD-induced insulin resistance M.S. Wiedemann, S. Wueest, I. Flurin, E.J. Schoenle, D. Konrad, Switzerland

197 fp3_2013__ 15.08.13 10:41 Seite 198

816 Dietary lipids do not contribute to fructose induced hepatic triglyceride accumulation in mice P.M. Nunes, A.J. Wright, A. Veltien, J.J. Van Asten, C.J. Tack, J.G. Jones, A. Heerschap, Netherlands, Portugal

817 Depletion of S-adenosylmethionine promotes non-alcoholic steatohepatitis by upregulating sphingomyelin synthase 1 K.-U. Lee, S. Woo, J. Leem, J. Jang, M. Lee, E. Koh, I.-K. Lee, Korea, Republic of

Posters 818 Protection of high-fat diet induced non-alcoholic steatohepatitis with the combination of n-3 polyunsaturated fatty acids and IgY targeted for NPC1L1 J.-S. Bae, E.-H. Kim, K.-B. Hahm, B.-C. Oh, J.-Y. Cha, Korea, Republic of

819 Liver overexpression of GLUT2 and Slc2a2 are associated with non- alcoholic steatohepatitis in obese diabetic mice A.D. Silva, R.R. Favaro, D.T. Furuya, M.M. Okamoto, P. Silva, H.S. Freitas, F. Barrence, T.M. Zorn, U.F. Machado, Brazil

820 Implication of mitochondria associated membranes regulation in insulin resistant and fatty liver P. Theurey, E. Tubbs, G. Vial, N. Bendridi, H. Vidal, J. Rieusset, France

Poster Event B, Tuesday, 13:45 - 14:45

PS 062 Signalling in adipocyte metabolism

Chair: H. Staiger, Germany

821 Involvement of Tpl2 kinase in COX-2 expression and prostaglandin production in adipocytes F. Berthou, F. Ceppo, K. Dumas, M. Cormont, J.-F. Tanti, France

822 Bombesin receptor subtype-3: expression/function/role in cell signalling pathway and glucose transport, in adipose tissue from human and animal model Z. Moreno-Villegas, I. Ramos-Álvarez, R. Sanz, S. Portal-Núñez, N. González, R.T. Jensen, Spain, USA

198 fp3_2013__ 15.08.13 10:41 Seite 199

823 CDK4 is an essential insulin effector in adipocytes L. Fajas, S. Lagarrigue, C. Chavey, S. Hure, Switzerland, France

824 Down-regulation of calcineurin-like phosphoesterase domain containing 1 (CPPED1) expression improves glucose metabolism in vitro in adipocytes M. Vaittinen, M. Kolehmainen, J. Pihlajamäki, M. Uusitupa, L. Pulkkinen, Finland

825 Role of ChREBP and PPARa in the regulation of glucose and lipid metabolism in brown adipocytes K. Iizuka, W. Wu, T. Hattori, Y. Horikawa, M. Saito, J. Takeda, Japan

826 Unsuppressed lipolysis in adipose tissues by insulin is critical for glucose homeostasis under high fat diet Posters E. Lee, K. Sakurai, C. Toda, Y. Minokoshi, T. Miki, Japan

827 Cyclosporin A and tacrolimus impair dynamics of GLUT4 traffic in insulin-responsive cells M.J. Pereira, J. Palming, M. Rizell, M. Aureliano, E. Carvalho, M.K. Svensson, J.W. Eriksson, Sweden, Portugal

828 Amyloid beta42 administration impairs energy metabolism in vivo and in vitro J.K. Czeczor, T. Connor, A.J. Genders, K. Walder, S. McGee, Australia

829 Metabolic profiling of cultured human adipocytes from metabolically malign versus benign obese individuals A.A. Böhm, A. Halama, J. Adamski, H.-U. Häring, M. Hrabe de Angelis, H. Staiger, Germany

Poster Event C, Wednesday, 12:30 - 13:30

PS 063 Lipoproteins

Chair: P. Plomgaard, Denmark

830 Protective effect of physical activity on atherogenic lipoproteins in type 1 diabetes L. Brugnara, R. Mallol, M. Guardiola, M. Vinaixa, M.A. Rodríguez, J.C. Vallvé, M. Gonzalez, S. Murillo, M. Balfegó, X. Correig, J. Ribalta, A. Novials, Spain

199 fp3_2013__ 15.08.13 10:41 Seite 200

831 Anti-oxidant and anti-inflammatory properties of HDL are inhibited by apolipoprotein A-I antibodies isolated from type 2 diabetes patients J.R. Batuca, F. Paula, C. Favas, M.C. Amaral, J. Delgado Alves, Portugal

832 VLDL-Apo B 100 fractional synthesis rate (FSR) is decreased in type 2 diabetes mellitus patients with diabetic nephropathy and hypertriglyceridaemia: possible defect in VLDL-Apo B 100 removal P. Tessari, M. Vettore, R. Barazzoni, G.M. Toffolo, I. Cortella, E. Manesso, C. Gabelli, M. Zanetti, Italy

Posters 833 LDL receptor knock-out mice impaired spatial cognition with hippocampal vulnerability to apoptosis and synapse Y. Huang, W.-Q. Xia, Y. Zhou, P. Wang, Y. Yang, R.-R. Cai, S.-H. Wang, China

834 Early improvement of postprandial lipaemia after bariatric surgery in obese type 2 diabetic patients E. Griffo, R. Lupoli, G. Nosso, G. Saldalamacchia, M. Cotugno, G. Vitagliano, L. Angrisani, P.P. Cutolo, A.A. Rivellese, B. Capaldo, Italy

835 Short-term changes of HDL-C related parameters during transition from insulin to GLP-1 in type 2 diabetics K. Yagi, A. Nohara, J. Kobayashi, O. Miyazaki, J. Liu, Y. Mori, A. Obatake, S. Okazaki, Y. Takeda, M. Yamagishi, Japan

836 Comparison of the HDL-C-raising effects of statins in high-risk hypercholesterolaemia with diabetes: TOHO-LIP diabetes sub-analysis for 96 weeks T. Shiba, S. Okahata, K. Sakamoto, T. Mitsumatsu, T. Ikeda, J. Yamazaki, T. Hirose, Y. Iwasaki, S. Yamamura, K. Sugi, T. Fujioka, H. Noike, I. Tatsuno, K. Shirai, Japan

837 JAZF1 improves hepatic insulin resistance in C57bl/6j mice and attenuates atherosclerosis in apoE-knockout mice W. Ran, L. Li, G. Yang, China

838 Cholesterol as a novel activator of HIF-1 pathway in hepatocytes under hypoxia S. Anavi, S. Sofer, Z. Madar, O. Tirosh, Israel

200 fp3_2013__ 15.08.13 10:41 Seite 201

839 Deficiency of clusterin aggravates insulin resistance in high fat fed mice S.-Y. Park, M. Kwon, T. Ju, Y.-W. Kim, J.-Y. Kim, K.-C. Won, J. Dan, H.-J. Kim, Korea, Republic of

Poster Event D, Wednesday, 13:45 - 14:45

PS 064 Adipokines and secreted proteins in obesity and diabetes

Chair: H. Sell, Germany

840 In vivo proteomics reveals increased galectin-1 levels in subcutaneous interstitial fluid in newly diagnosed type 2 diabetes patients

E. Fryk, T. Larsson, L. Strindberg, J. Perman, J. Borén, P.A. Jansson, Posters Sweden

841 Circulating chemerin level is associated with arterial stiffness in patients with type 2 diabetes H. Park, H. Kim, D. Byun, K. Suh, M. Yoo, Korea, Republic of

842 Serum omentin significantly predicts cardiovascular events both in patients with the metabolic syndrome and in subjects who do not have the metabolic syndrome A. Muendlein, C.H. Saely, A. Leiherer, A. Vonbank, D. Zanolin, K. Geiger, P. Rein, H. Drexel, Austria, Liechtenstein, USA

843 Ghrelin and its relationship with insulin resistance markers in myocardial infarction complicated with acute heart failure O. Barbarash, E. Uchasova, O. Gruzdeva, E. Belik, Y. Dyleva, E. Shurygina, Russian Federation

844 Alterations in the levels of the endocrine factors FGF21 and FGF19, and in the expression of their receptors, are associated with impaired glucose homeostasis in obese patients J.M. Gallego-Escuredo, J. Gómez-Ambrosi, V. Catalan, P. Domingo, M. Giralt, G. Fruhbeck, F. Villarroya, Spain

845 Circulating osteopontin levels are associated with whole body insulin resistance in type 2 diabetes mellitus in humans G. Daniele, T. Fiorentino, R. Guardado Mendoza, F. Andreozzi, D. Winnier, C. Jenkinson, A. Davalli, R. DeFronzo, D. Tripathy, F. Folli, USA, Italy

201 fp3_2013__ 15.08.13 10:41 Seite 202

846 DPP4 shedding is mediated by ADAM17 and is upregulated by severe hypoxia D. Röhrborn, J. Eckel, H. Sell, Germany

847 Serum follistatin is reduced in gestational diabetes mellitus: association with anthropometric parameters in offspring S. Näf, X. Escote, M. Ballesteros, R.E. Yañez, I. Simón-Muela, P. Gil, G. Albaiges, J. Vendrell, A. Megia, Spain

848 The novel role of oncostatin m, a GP130 cytokine secreted in adipose Posters tissue, in the development of obesity and type 2 diabetes D. Sanchez-Infantes, R.F. Morrison, E. Ravussin, J.M. Stephens, Spain, USA

849 LBP is not merely a liver acute phase reactant: adipose tissue is an important source of this proinflammatory adipokine J. Moreno-Navarrete, J. Vendrell, D. Langin, M.-C. Michalski, M. Laville, P. Domingo, W. Ricart, G. Frühbeck, F. Villarroya, G. Mingrone, A. Zorzano, H. Vidal, R. Burcelin, A. Vidal-Puig, J. Fernández-Real, Spain, France, Italy, UK

Poster Event E, Thursday, 12:30 - 13:30

PS 065 Myeloid cells and type 2 diabetes

Chair: A. Körner, Hungary

850 Deletion of myeloid-cell protein tyrosine phosphatase-1B improves glucose tolerance and suppresses inflammatory responses in high-fat fed and endotoxaemic mouse models M. Delibegovic, L. Grant, K. Shearer, A. Czopek, E. Lees, C. Owen, A. Agouni, H. Wilson, N. Mody, UK

851 Siglec-7 is down-regulated in inflamed islets and activated peripheral mononuclear cells and restores beta cell function and survival G. Dharmadhikari, J. Kerr-Conte, S. Kelm, K. Maedler, Germany, France

852 The relationships between macrophage infiltration and amyloid deposition in the islets of humans with type 2 diabetes S. Dhayal, S.J. Richardson, N.G. Morgan, UK

202 fp3_2013__ 15.08.13 10:41 Seite 203

853 TIMP3 modulates CD11c+ recruitment through IL6/Il6Ralpha complex in a model of metabolic disease V. Marchetti, M. Mavilio, M. Fabrizi, M. Cavalera, M. Federici, Italy

854 Fructose supplementation exacerbates glucose intolerance and causes adipose tissue inflammation in PPARb/d-deficient mice E. Barroso, R. Rodríguez-Rodríguez, X. Palomer, L. Salvadó, L. Michalik, W. Wahli, M. Vázquez-Carrera, Spain, Switzerland

855 Obesity induces CD11c+ macrophages in murine adipose tissue which are distinctive from, but resemble, dendritic cells K. Wouters, E. Wijnands, J.J. Van Wegberg, E.A. Biessen, C.D. Stehouwer, C.G. Schalkwijk, Netherlands Posters 856 Ubc13 haploinsufficiency protects against high-fat diet-induced insulin resistance via TRAF-mediated inflammatory responses E. Joo, T. Fukushima, S.-I. Matsuzawa, J.C. Reed, T. Hayashi, K. Tsuda, N. Inagaki, Japan, USA

857 Obesity-associated macrophage infiltration has a paracrine effect to induce skeletal muscle insulin resistance N.A. Talbot, C.P. Wheeler-Jones, M.E. Cleasby, UK

858 Characterisation of macrophage infiltration and polarisation in adipose tissue of children D. Rockstroh, K. Landgraf, R. Tauschert, I. Wagner, J. Gesing, S. Weise, M. Blüher, W. Kiess, H. Till, M. Wojan, A. Körner, Germany

859 Circadian regulation of MCP1 serum levels and expression in monocytes and adipose tissue upon switching from high to low carb diets with replacement by fat in humans O. Pivovarova, S. Hornemann, M. Kruse, Y. Lu, A.-C. Seltmann, J. Mazuch, N. Rudovich, A. Kramer, A. Busjahn, A.F. Pfeiffer, Germany

Poster Event F, Thursday, 13:45 - 14:45

PS 066 Nutrition and weight loss

Chair: N.G. Forouhi, UK

203 fp3_2013__ 15.08.13 10:41 Seite 204

860 A community-based intervention for diabetes risk reduction in inner-city obese adolescents M. Savoye, S. Caprio, J. Dziura, A. Camp, F. Li, M. Shaw, B. Pierpont, F. Depourcq, G. Kim, W.V. Tamborlane, USA

861 Big breakfast rich in protein improved glycaemic control and satiety feeling in adults with type 2 diabetes mellitus H. Rabinovitz, M. Boaz, T. Ganz, Z. Madar, D. Jakubowicz, J. Wainstein, Israel

Posters 862 The impact of high fat meal frequency on metabolic profile and energy expenditure in obese subjects M.K. Piya, N. Reddy, A. Harte, A. Campbell, J. Hattersley, L. Halder, A.A. Tahrani, G. Tripathi, S.A. Aftab, T.M. Barber, P.G. McTernan, S. Kumar, UK

863 Combining dietary polyphenols increase energy expenditure and improve parameters of adipose tissue and skeletal muscle in healthy overweight humans J. Most, G.H. Goossens, J.W. Jocken, E.E. Blaak, Netherlands

864 Combination naltrexone/bupropion therapy resulted in clinically meaningful improvements in weight and quality of life (QOL): integrated analysis of four phase 3 trials R.L. Kolotkin, C. Burns, B. Walsh, P. Klassen, USA

865 An integrated analysis of weight loss with combination naltrexone/bupropion therapy by BMI (obesity) classification B. Walsh, C. Burns, K. Taylor, C. Apovian, USA

866 Early improvement in control of eating is associated with long-term weight loss: integrated analysis of four phase 3 trials of combination naltrexone/bupropion treatment K. Fujioka, C. Burns, B. Walsh, P. Klassen, USA

867 Oral formulation of UGP302, a novel amylin and calcitonin dual receptor agonist, exerts anti-obesity effects in diet-induced obese (DIO) rats K.V. Andreassen, M. Feigh, S.T. Hjuler, N. Mehta, W. Stern, S. Gydesen, I.A. Ottosen, M.A. Karsdal, K. Henriksen, Denmark, USA

204 fp3_2013__ 15.08.13 10:41 Seite 205

868 Beneficial effect of lingonberry, blackcurrant and bilberry consumption on weight gain and adiposity in C57BL/6J mice L. Heyman, U. Axling, A. Gormand, C. Holm, K. Berger, Sweden

869 Proteomic analysis in type 2 diabetes patients before and after a very low calorie diet reveals disease state and intervention specific biomarkers M.A. Sleddering, A.J. Markvoort, H.K. Dharuri, S. Jeyakar, M. Snel, P. Juhasz, M. Lynch, W. Hines, X. Li, I.M. Jazet, A. Adourian, P.A. Hilbers, J.W. Smit, K. Willems van Dijk, Netherlands, USA

Poster Event A, Tuesday, 12:30 - 13:30

PS 067 Preventing and treating diabetes: the nutrition impact Posters

Chair: A.F.H. Pfeiffer, Germany

870 Consuming snacks at mid-afternoon reduced the incremental area under the glucose curve after dinner in patients with type 2 diabetes S. Imai, M. Fukui, N. Ozasa, S. Kajiyama, Japan

871 Effects of vitamin D supplementation on insulin sensitivity and secretion in subjects with type 2 diabetes: a randomised controlled trial H.L. Gulseth, C. Wium, E.F. Eriksen, K.I. Birkeland, Norway

872 Vitamin D is positively related to the increase of pulse wave velocity during 4 years in men with type 2 diabetes while PTH levels are related to less such arteriosclerosis in women F.H. Nystrom, H. Guldbrand, T. Lindström, P. Jennersjö, T. Länne, C. Östgren, Sweden

873 Randomisation to a low-carbohydrate diet improves health related quality of life compared with a low-fat diet at similar weight loss in type 2 diabetes T. Lindström, M. Bachrach-Lindström, H. Guldbrand, B. Dizdar, B. Bunjaku, C. Östgren, F.H. Nyström, Sweden

874 Nutritional screening in elderly type 2 diabetic patients admitted in a ward M.C. Carvalho, T. Santos, I. Silva, R. Carvalho, H. Figueiredo, Portugal

205 fp3_2013__ 15.08.13 10:41 Seite 206

875 Higher urinary sodium excretion is weakly associated with albuminuria, but not with retinopathy in type 1 diabetes: the EURODIAB study L. Engelen, S.S. Soedamah-Muthu, J.M. Geleijnse, N. Chaturvedi, J.H. Fuller, C.G. Schalkwijk, C.D. Stehouwer, Netherlands, UK

876 Breastfeeding and the risk of developing type 1 diabetes or islet autoimmunity N.A. Lund-Blix, L. Frost Andersen, K. Skjold Rønningen, Norway

877 Effect of omega 3/ALA supplementation on inflammatory markers and Posters ER stress in diabetic rats M.C. Foss-Freitas, T.R. Vidal, T.N. Griffo, N.B. Gonçalves, M.A. Ferreira, M.C. Foss, Brazil

Poster Event B, Tuesday, 13:45 - 14:45

PS 068 Mechanistic insights: GLP-1-based medications and GPR40 agonists

Chair: T. Vilsbøll, Denmark

878 Glucose tolerance and gastrointestinal-mediated glucose disposal in women with previous gestational diabetes mellitus S. Foghsgaard, L. Vedtofte, E.R. Mathiesen, J.A. Svare, P. Damm, F.K. Knop, T. Vilsbøll, Denmark

879 The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects N.A. Rhee, S.H. Østoft, J.J. Holst, T. Vilsbøll, F.K. Knop, Denmark

880 Substantial posprandial appearance of active GLP-1 in the gut lymphatics in mice with marked increase after DPP-4 inhibition L. Ohlsson, A.B. Kohan, P. Tso, B. Ahrén, Sweden, USA

881 Effects of miglitol, sitagliptin and combination of both on plasma incretins’ responses to a mixed meal and visceral fat in over-weight Japanese type 2 diabetic patients T. Narita, H. Yokoyama, R. Yamashita, M. Suzuki, Y. Horikawa, A. Mikada, K. Tsukiyama, Y. Yamada, Japan

206 fp3_2013__ 15.08.13 10:41 Seite 207

882 Pharmacological characterisation of a novel long-acting CarboCarrier® D-Ala8GLP-1 for treatment of type 2 diabetes S. Patterson, M. De Kort, W.H. Dokter, E.S. Bos, A.M. Miltenburg, P.R. Flatt, UK, Netherlands

883 Long-term effects of liraglutide on pancreatic beta cell function and glycaemic control in type 1 diabetes with residual insulin secretion Y. Hamamoto, S. Honjo, Y. Kawasaki-Ogita, H. Tatsuoka, K. Fujimoto, A. Matsuoka, H. Ikeda, Y. Wada, H. Koshiyama, Japan

884 Dipeptidyl peptidase-4 inhibitors improve glycaemic control in latent autoimmune diabetes in adults (LADA) patients insufficiently controlled despite insulin therapy

O. Araki, R. Nakahara, K. Ujiie, K. Tsunekawa, T. Aoki, T. Morimura, Posters T. Kimura, M. Nara, H. Sumino, T. Ogiwara, M. Murakami, Japan

885 Exenatide blunts hyperactivation in CNS reward and satiety circuits elicited by viewing food cues in obese individuals L. Van Bloemendaal, R.G. IJzerman, J.S. Ten Kulve, F. Barkhof, D.J. Veltman, M. Diamant, Netherlands

886 Liraglutide is applicable in elective perioperative patients with type 2 diabetes I. Nakadaira, K. Hamano, N. Katagiri, Y. Tahara, Y. Sato, S. Kaneko, Japan

887 Pharmacokinetics (PK) and pharmacodynamics (PD) of the GPR40 agonist fasiglifam (TAK-875) and glimepiride following co-administration in type 2 diabetes subjects P. Viswanathan, M. Tsai, R.D. Lee, M. Vakilynejad, W. Zhang, J. Marcinak, X. Peng, USA

888 Efficacy and safety of fasiglifam (TAK-875), a GPR40 selective agonist, in Japanese type 2 diabetes mellitus patients: a phase 3, double-blind, placebo controlled, comparative study K. Kaku, K. Enya, R. Nakaya, T. Ohira, R. Matsuno, Japan

207 fp3_2013__ 15.08.13 10:41 Seite 208

Poster Event C, Wednesday, 12:30 - 13:30

PS 069 Incretin-based drugs: predictors of clinical outcomes

Chair: B. Gallwitz, Germany

889 Markers of insulin resistance and beta cell function do not predict response to incretin based treatments in type 2 diabetes A.G. Jones, A.V. Hill, J. Stewart, B.M. Shields, T.J. McDonald, B.A. Knight, A.T. Hattersley, UK Posters

890 "Real-life" experience in use of dipeptidyl peptidase 4 inhibitors at a large Scottish teaching hospital A.L. Brown, G. Jones, C. Sainsbury, UK

891 INdividualised Treatment targets for EldeRly patients using Vildagliptin Add-on or Lone therapy (INTERVAL) study W. David Strain, V. Lukashevich, W. Kothny, M.-J. Hoellinger, P. Paldánius, UK, USA, Switzerland

892 Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in patients with type 2 diabetes J. Lee, S. Durán-Garcia, H. Yki-Järvinen, J. Rosenstock, U. Hehnke, S. Thiemann, S. Patel, H.-J. Woerle, Germany, Spain, Finland, USA, UK

893 Predictors of attaining a composite endpoint with exenatide once weekly (EQW): recursive partitioning analysis V. Aroda, M. Zhou, L. Shen, L. MacConell, J. Han, USA

894 Diabetes duration and background diabetes therapies in predicting liraglutide treatment response: data from the post-marketing EVIDENCE study A. Penfornis, P. Gourdy, L. Martinez, S. Madani, G. Charpentier, E. Eschwège, J.-F. Gautier, France

895 The effect of liraglutide on HbA1c and body weight is largely independent of baseline diabetes duration J.R. Seufert, T. Bailey, C. Svendsen, M. Donsmark, M.A. Nauck, Germany, USA, Denmark

208 fp3_2013__ 15.08.13 10:41 Seite 209

896 Efficacy of lixisenatide in patients with different levels of beta cell function as assessed by C-peptide/glucose ratio J.J. Meier, D. Yabe, E. Wang, J. Lin, J. Rosenstock, B. Ahrén, Germany, Japan, USA, Sweden

897 Effectiveness of prandial insulin and glucagon-like peptide-1 treatment regimens in patients with type 2 diabetes on basal insulin in a real-world setting in the United States A. DiGenio, S. Karve, S.D. Candrilli, M.R. Dalal, USA

898 Adding rapid-acting insulin or GLP-1 receptor agonist to basal insulin in patients with type 2 diabetes: real-world health care costs from a US managed care setting M. Dalal, L. Xie, O. Baser, A. DiGenio, USA Posters

Poster Event D, Wednesday, 13:45 - 14:45

PS 070 Incretin-based drugs: treatment strategies

Chair: G.A. Spinas, Switzerland

899 Efficacy of the human GLP-1 analogue liraglutide in patients with type 2 diabetes who switched from a DPP-4 inhibitor: 1-year data from the EVIDENCE study G. Charpentier, L. Martinez, E. Eschwège, S. Madani, A. Penfornis, P. Gourdy, J.-F. Gautier, France

900 A randomised trial comparing the addition of liraglutide to high dose intensive insulin therapy vs insulin up-titration in type 2 diabetes J. Rappaport, W. Lane, S. Weinrib, C. Hale, USA

901 A novel fixed-ratio combination of insulin degludec and liraglutide improves postprandial glycaemic control in patients with type 2 diabetes: results from a standardised meal test J.J. Holst, J. Buse, S.C. Gough, H.W. Rodbard, V.C. Woo, S. Linjawi, P. Poulsen, L.H. Damgaard, B.W. Bode, Denmark, USA, UK, Canada, Australia

209 fp3_2013__ 15.08.13 10:41 Seite 210

902 HARMONY 1 results at week 52 primary endpoint: once-weekly albiglutide vs placebo in patients with type 2 diabetes mellitus not controlled on pioglitazone ± metformin J. Reusch, M. Stewart, C. Perkins, P. Ordronneau, J. Ye, C. Perry, R. Reinhardt, B. Bode, USA

903 HARMONY 2 results at week 52 primary endpoint: once-weekly albiglutide monotherapy for patients with type 2 diabetes mellitus inadequately controlled with diet and exercise R. Reinhardt, M.A. Nauck, M. Stewart, C. Perkins, A. Jones-Leone, F. Yang, Posters C. Perry, M. Rendell, USA, Germany

904 HARMONY 4: 52-week efficacy of albiglutide vs insulin glargine in patients with type 2 diabetes mellitus R. Pratley, M. Stewart, D. Cirkel, J. Ye, C. Perry, M.C. Carr, USA, UK

905 52-week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in patients with type 2 diabetes: HARMONY 5 study M. Stewart, P. Home, F. Yang, C. Perry, M.C. Carr, USA, UK

906 HARMONY 8: once-weekly glucagon-like peptide 1 receptor agonist albiglutide vs sitagliptin for patients with type 2 diabetes with renal impairment: week 26 results L. Leiter, M.C. Carr, M. Stewart, A. Jones-Leone, F. Yang, Y. Handelsman, Canada, USA

907 Meta-analysis of GLP-1 agonist lixisenatide use in patients insufficiently controlled with OADs D. Raccah, A. Ceriello, P. Gourdy, L. Sagnard, J. Lin, J. Rosenstock, France, Spain, USA

908 Meta-analysis of randomised controlled trials of lixisenatide as add-on to basal insulin and/or oral anti-diabetic drugs in patients with type 2 diabetes mellitus M.L. Puig Domingo, V. Fonseca, E. Wang, J. Lin, M. Davies, F.J. Tinahones, B. Charbonnel, Spain, USA, UK, France

210 fp3_2013__ 15.08.13 10:41 Seite 211

Poster Event E, Thursday, 12:30 - 13:30

PS 071 Incretin-based drugs: potential risk and use in special populations

Chair: H. Sourij, Austria

909 Effect of metformin on glycotoxic intermediate-methylglyoxal metabolism in patients with type 2 diabetes Z. Kender, T. Fleming, P. Reismann, K. Rácz, P. Nawroth, Hungary, Germany

910 Gastrointestinal tolerability with twice-daily or once-weekly exenatide formulations was not predicted by concentration with long-term treatment

B. Cirincione, J. Edwards, M. Aisporna, L. MacConell, USA Posters

911 Chronic palmitate excess results in reduced exendin-4 action and signalling via CREB and Akt in pancreatic beta cells A. Natalicchio, G. Biondi, N. Marrano, F. Tortosa, R. Labarbuta, S. Perrini, L. Laviola, F. Giorgino, Italy

912 MK0626, a DPP-4 inhibitor for use in mice, in combination with low-dose systemic anti-CD3 stably reverses new-onset diabetes in non-obese diabetic mice L. Ding, T. Takiishi, H. Korf, C. Gysemans, C. Mathieu, Belgium

913 Renal safety and outcomes with linagliptin: meta-analysis of individual data for 5466 patients with type 2 diabetes M. Von Eynatten, M. Cooper, V. Perkovic, J. Rosenstock, C. Wanner, U. Hehnke, H.-J. Woerle, USA, Australia, Germany

914 Linagliptin versus placebo followed by glimepiride in type 2 diabetes patients with moderate to severe renal impairment P.-H. Groop, M. Laakso, J. Rosenstock, U. Hehnke, I. Tamminen, S. Patel, M. Von Eynatten, H.-J. Woerle, Finland, USA, Germany, UK

915 Efficacy and safety of alogliptin in subjects with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 study in mainland China, Taiwan and Hong Kong Q. Ji, P. Han, C. Li, J. Lu, J. Yang, W. Li, J. Zeng, A.-T. Hsieh, J. Chan, C. Pan, China, Taiwan, Hong Kong

211 fp3_2013__ 15.08.13 10:41 Seite 212

916 Continuous infusion of lixisenatide or exenatide in mice stimulates calcitonin and GLP-1 receptor gene expression but does not induce thyroid C-cell proliferation G. Dietert, X. Palazzi, M. Borne, M. Dorau, G. Hadour, F. Levai, S. Nellen, S. Ratering, T. Kissner, Germany, France

917 GLP-1 receptor expression in human C-cell carcinomas and human thyroid glands without C-cell pathology T. Kissner, M. Dorau, A. Perren, A. Blank, M. Heinrichs, G. Dietert, Germany, Switzerland Posters 918 Occurrence of spontaneous pancreatic lesions in normal and diabetic rats may confound the non-clinical assessment of glucagon-like peptide (GLP)-1-elevating therapies K.D. Chadwick, D. Roy, A. Fletcher, C. Parrula, A.-M. Bergholm, N. Neef, R. Mangipudy, E. Janovitz, M. Graziano, T.P. Reilly, USA, Sweden

Poster Event F, Thursday, 13:45 - 14:45

PS 072 Incretin-based agents: assessing the risk-benefit ratio

Chair: S. Del Prato, Italy

919 Efficacy and safety of dulaglutide versus placebo and exenatide in type 2 diabetes (AWARD-1) C. Wysham, T. Blevins, R. Arakaki, G. Colon, P. Garcia, C. Atisso, D. Kuhstoss, J. Scism-Bacon, M. Lakshmanan, USA, Puerto Rico, Mexico

920 Safety and efficacy of dulaglutide vs sitagliptin after 104 weeks in type 2 diabetes (AWARD-5) B. Guerci, R.S. Weinstock, G. Umpierrez, M.A. Nauck, K. Boleyn, Z. Skrivanek, Z. Milicevic, France, USA, Germany, Austria

921 Efficacy and safety of dulaglutide vs sitagliptin after 52 weeks in type 2 diabetes (AWARD‑5) M.A. Nauck, R.S. Weinstock, G. Umpierrez, B. Guerci, K. Boleyn, Z. Skrivanek, Z. Milicevic, Germany, USA, France, Austria

212 fp3_2013__ 15.08.13 10:41 Seite 213

922 Efficacy and safety of lixisenatide in elderly type 2 diabetes mellitus patients: subanalysis from the GetGoal programme M. Hanefeld, R. Berria, J. Lin, R. Aronson, P. Darmon, M. Evans, L. Van Gaal, Germany, USA, Canada, France, UK, Belgium

923 Effectiveness and tolerability with liraglutide among patients with type 2 diabetes. 1-year data from EVIDENCE: a 2-year, prospective, follow-up, post-marketing study P. Gourdy, A. Penfornis, G. Charpentier, S. Madani, L. Martinez, E. Eschwège, J.-F. Gautier, France

924 Quantification of the benefit-risk relationship between glycaemic control and hypoglycaemia: a comparison of exenatide once weekly with titrated insulin glargine Posters J. Han, M. Zhou, J. Malloy, L. Shen, USA

925 Efficacy and safety of low-dose sitagliptin (25 mg) in elderly (≥70 years old) Japanese patients with type 2 diabetes H. Ikeda, K. Ida, M. Usami, H. Koshiyama, M. Ikeda, Japan

926 Renal safety of linagliptin in elderly patients with type 2 diabetes: analysis of pooled patient data from 7 phase 3 clinical trials S. Patel, G. Schernthaner, A.H. Barnett, U. Hehnke, M. Von Eynatten, H.-J. Woerle, UK, Austria, Germany, USA

927 Clinical experience with vildagliptin in patients ≥ 75 years with type 2 diabetes mellitus and moderate or severe renal impairment A. Schweizer, S. Dejager, Switzerland, France

928 Treat 4 Ramadan trial: a randomised control trial comparing liraglutide vs a sulphonylurea as add-on to metformin in patients with established type 2 diabetes E.M. Brady, M.J. Davies, L.J. Gray, M.A. Saeed, W. Hanif, K. Khunti, UK

Poster Event A, Tuesday, 12:30 - 13:30

PS 073 SGLT-2 clinical trials

Chair: J. Rosenstock, USA

213 fp3_2013__ 15.08.13 10:41 Seite 214

929 Verification of the efficacy and safety of tofogliflozin, a novel SGLT2 inhibitor, in Japanese patients with type 2 diabetes mellitus: results from a phase 2/3 clinical study E. Araki, K. Kaku, H. Watada, Y. Iwamoto, K. Utsunomiya, Y. Terauchi, K. Tobe, Y. Tanizawa, for the Tofogliflozin 003 Study group, Japan

930 Safety and efficacy of empagliflozin monotherapy in a 52-week study in Japanese patients with type 2 diabetes mellitus H.J. Woerle, T. Kadowaki, M. Haneda, N. Inagaki, A. Taniguchi, M. Sakamoto, K. Koiwai, H. Rattunde, U.C. Broedl, Germany, Japan Posters 931 Empagliflozin as add-on to basal insulin for 78 weeks improves glycaemic control with weight loss in insulin-treated type 2 diabetes mellitus J. Rosenstock, A. Jelaska, F. Wang, G. Kim, U.C. Broedl, H.J. Woerle, USA, Germany

932 Metabolic response to sodium-glucose transporter 2 (SGLT2) inhibition with empagliflozin in patients with type 2 diabetes E. Ferrannini, E. Muscelli, S. Frascerra, S. Baldi, A. Mari, T. Heise, U.C. Broedl, H.-J. Woerle, Italy, Germany

933 Canagliflozin added on to dipeptidyl peptidase-4 inhibitors or glucagon- like peptide-1 agonists with or without other antihyperglycaemic agents in type 2 diabetes mellitus G. Meininger, C. Wysham, V. Woo, C. Mathieu, G. Capuano, M. Alba, M. Desai, USA, Canada, Belgium

934 Efficacy and safety of canagliflozin in subjects with type 2 diabetes mellitus inadequately controlled with metformin plus sulphonylurea over 52 weeks F. Vercruysse, G. Charpentier, J. Wilding, P. Hollander, G. González Gálvez, C. Mathieu, K. Usiskin, U. Vijapurkar, S. Black, W. Canovatchel, G. Meininger, Belgium, France, UK, USA, Mexico

935 Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise over 52 weeks K. Stenlöf, W.T. Cefalu, K.-A. Kim, E. Jodar, M. Alba, R. Edwards, C. Tong, W. Canovatchel, G. Meininger, Sweden, USA, Korea, Republic of, Spain

214 fp3_2013__ 15.08.13 10:41 Seite 215

936 Durability of dapagliflozin vs glipizide as add-on therapies in type 2 diabetes inadequately controlled on metformin: 4-year data A. Langkilde, M.A. Nauck, S. Del Prato, S. Durán-Garcia, K. Rohwedder, A. Theuerkauf, S.J. Parikh, Sweden, Germany, Italy, Spain, USA

937 Dapagliflozin improves glycaemic control and reduces body weight as add-on therapy to metformin plus sulphonylurea S. Matthaei, K. Rohwedder, A. Grohl, E. Johnsson, Germany, Sweden

938 Dapagliflozin helps reduce HbA1c and body weight in patients with type 2 diabetes as part of triple combination therapy: a subanalysis of four clinical studies S. Jabbour, E. Hardy, T.W. De Bruin, I. Gause-Nilsson, K. Rohwedder,

P. Martin, S. Parikh, USA, Sweden, Germany Posters

Poster Event B, Tuesday, 13:45 - 14:45

PS 074 SGLT-2 inhibitors: influence on cardiovascular risk factors

Chair: P. Fioretto, Italy

939 Combined HbA1c and weight reduction is more frequent with dapagliflozin vs glipizide add-on treatment in patients with type 2 diabetes inadequately controlled on metformin K. Rohwedder, M.A. Nauck, S. Duran-Garcia, M. Hashemi, S.J. Parikh, Germany, Spain, Sweden, USA

940 Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes H.J. Lambers Heerspink, D. De Zeeuw, L. Wei, J.F. List, Netherlands, USA

941 Weight loss related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin S.J. Parikh, A. Ingelgard, A.-M. Langkilde, J. Sugg, S. Grandy, USA, Sweden

942 Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension I. Tikkanen, K. Narko, C. Zeller, A. Green, A. Salsali, U.C. Broedl, H.J. Woerle, Finland, Germany, UK

215 fp3_2013__ 15.08.13 10:41 Seite 216

943 Empagliflozin improves glycaemic parameters and cardiovascular risk factors in patients with type 2 diabetes: pooled data from four pivotal phase III trials T. Hach, J. Gerich, A. Salsali, G. Kim, S. Hantel, H.J. Woerle, U.C. Broedl, Germany, USA

944 Design of the empagliflozin cardiovascular outcome event trial in type 2 diabetes mellitus S.E. Inzucchi, B. Zinman, J.M. Lachin, C. Wanner, R. Ferrari, E. Bluhmki, S. Hantel, O. Johansen, H.-J. Woerle, U.C. Broedl, USA, Canada, Germany, Posters Italy

945 Effects of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in subjects with type 2 diabetes mellitus M. Weir, A. Januszewicz, R. Gilbert, U. Vijapurkar, G. Meininger, USA, Poland, Canada

946 Canagliflozin lowers HbA1c and blood pressure through weight loss- independent and weight loss-associated mechanisms J. Wilding, L. Blonde, J.-L. Chiasson, D. Polidori, G. Meininger, P. Stein, UK, USA, Canada

947 Changes in lipid profiles of patients with type 2 diabetes mellitus on dapagliflozin therapy E. Hardy, A. Ptaszynska, T.W. De Bruin, E. Johnsson, S.J. Parikh, J.F. List, USA, Sweden

948 LX4211, a dual inhibitor of sodium glucose transporters SGLT1 and SGLT2, reduces blood pressure in patients with type 2 diabetes P. Lapuerta, J. Neutel, B. Zambrowicz, I. Ogbaa, P. Banks, K. Frazier, A. Sands, USA

Poster Event C, Wednesday, 12:30 - 13:30

PS 075 SGLT-2 inhibitors: side effects, special populations

Chair: A. Solini, Italy

216 fp3_2013__ 15.08.13 10:41 Seite 217

949 Urinary tract infection with canagliflozin in subjects with type 2 diabetes mellitus K. Usiskin, L. Nicolle, G. Capuano, A. Fung, G. Meininger, USA, Canada

950 Genital mycotic infections with canagliflozin in subjects with type 2 diabetes mellitus K. Ways, P. Nyirjesy, J.D. Sobel, A. Fung, C. Gassmann-Mayer, K. Usiskin, USA

951 Efficacy and safety of canagliflozin in subjects with type 2 diabetes mellitus and chronic kidney disease over 52 weeks J. Nieto, J.-F. Yale, G. Bakris, B. Cariou, E. Wajs, K. Figueroa, J. Jiang, K. Usiskin, G. Meininger, Spain, Canada, USA, France, Belgium Posters 952 Empagliflozin in patients with type 2 diabetes mellitus and stage 3A, 3B and 4 chronic kidney disease (CKD) A. Mithal, A.H. Barnett, J. Manassie, R. Jones, H. Rattunde, H.J. Woerle, U.C. Broedl, India, UK, Germany

953 Canagliflozin is effective and generally well tolerated in subjects with type 2 diabetes mellitus and Stage 3 chronic kidney disease V. Woo, M. Davies, D. De Zeeuw, G. Bakris, V. Perkovic, C. Gassmann- Mayer, U. Vijapurkar, K. Usiskin, G. Meininger, Canada, UK, Netherlands, USA, Australia

954 Safety and efficacy of the SGLT2 inhibitor dapagliflozin in older patients with type 2 diabetes P. Fioretto, T.W. De Bruin, E. Johnsson, A. Ptaszynska, S. Parikh, J.F. List, Italy, USA, Sweden

955 Efficacy and safety of canagliflozin in older subjects with type 2 diabetes mellitus A. Sinclair, B. Bode, S. Harris, U. Vijapurkar, C. Gassmann-Mayer, A. Fung, W. Shaw, K. Usiskin, M. Desai, G. Meininger, UK, USA, Canada

956 Luseogliflozin, a SGLT2 inhibitor, improves glycaemic control and reduces body weight as monotherapy up to 52 weeks in Japanese patients with type 2 diabetes mellitus Y. Seino, T. Sasaki, A. Fukatsu, M. Ubukata, T. Sasaki, Y. Kasai, S. Sakai, Y. Samukawa, Japan

217 fp3_2013__ 15.08.13 10:41 Seite 218

957 Luseogliflozin, a SGLT2 inhibitor, as add-on therapy to 5 types of oral antidiabetic drugs improves glycaemic control and reduces body weight in Japanese patients with type 2 diabetes mellitus M. Haneda, Y. Seino, T. Sasaki, A. Fukatsu, M. Ubukata, Y. Sato, S. Sakai, Y. Samukawa, Japan

Poster Event D, Wednesday, 13:45 - 14:45

PS 076 Metformin: old agent - novel perspectives Posters

Chair: B. Wierusz-Wysocka, Poland

958 Metformin and berberine promote glucose metabolism via inhibiting mitochondrial respiratory chain complex I independently of AMPK activation J. Yin, M. Xu, L. Wei, W. Jia, China

959 Early phase of metformin action in dietary-obese mice: lack of involvement of AMPK and possible interaction with n-3 fatty acids P. Kucharikova, O. Horakova, M. Rossmeisl, J. Kopecky, Czech Republic

960 Metformin extended release compared to metformin immediate release on glycaemic control and patients’ satisfaction in type 2 diabetic patients A. Bonaventura, P. Maffioli, A. D'Angelo, L. Bianchi, D. Romano, G. Derosa, Italy

961 Association between metformin therapy and quantity and quality of sleep in type 2 diabetic patients referred for potential sleep disorders J.-D. Lalau, F. Kajbaf, A. Basille-Fantinato, M. Diouf, D. Rose, S. Fendri, France

962 Metformin therapy improves pregnancy outcome in women with polycystic ovary syndrome M.V. Macesic, A. Jotic, T. Milicic, L. Lukic, M. Gojnic Dugalic, K. Lalic, N. Rajkovic, J. Seferovic Mitrovic, J. Stanarcic Gajovic, N.M. Lalic, Serbia

963 Metformin treatment is associated with increased serum levels of methylmalonic acid in patients with type 2 diabetes treated with insulin: a placebo-controlled 4-year trial A. Kooy, M. Out, P. Lehert, C.G. Schalkwijk, C.D. Stehouwer, Netherlands, Belgium

218 fp3_2013__ 15.08.13 10:41 Seite 219

964 Metformin use in diabetics with reduced kidney function: prescription pattern in 4,414 subjects with type 2 diabetes and different eGFR levels A. Cignarelli, L. Laviola, G. Stefanelli, G. Garruti, F. Logoluso, N. Morea, S. Perrini, A. Natalicchio, R. Giorgino, F. Giorgino, Italy

965 Metformin reduces serum CA199 levels in type 2 diabetic patients with time-effect and gender difference D.D. Zhang, F. Liu, W. Jia, China

966 Improved resistance to exercise in mice treated with metformin I. Terruzzi, P. Senesi, A. Montesano, R. Codella, S. Benedini, L. Luzi, Italy

967 Effect of acarbose compared with metformin on incretins of GIP, PYY, Ghrelin in patients of newly diagnosed type 2 diabetes mellitus Posters H. Ma, Y. Ren, S.F. Liu, H.M. Tian, China

Poster Event E, Thursday, 12:30 - 13:30

PS 077 Oral antidiabetic agents

Chair: M.A. Nauck, Germany

968 SLC47A1 gene rs2289669 G>A variant influences the hypoglycaemic effect of metformin in type 2 diabetes patients F. Liu, D. Zhang, Y. Shen, T.S. Zheng, W. Lu, W.P. Jia, China

969 SNPs related to the glucose lowering effect of metformin: do they affect plasma concentrations of metformin and their effects on insulin requirements? M. Out, A. Kooy, M.L. Becker, R.H. Van Schaik, P. Lehert, C.D. Stehouwer, Netherlands, Belgium

970 Efficacy and safety of acarbose plus metformin fixed-dose combination versus acarbose monotherapy for type 2 diabetes: a randomised, double- blind, parallel-group study J.-S. Wang, C.-N. Huang, Y.-J. Hung, C.-F. Kwok, J.-H. Sun, D. Pei, C.-Y. Yang, C.-C. Chen, C.-L. Lin, W.-H. Sheu, Taiwan

219 fp3_2013__ 15.08.13 10:41 Seite 220

971 Sulfonylureas use among US veterans with type 2 diabetes mellitus at high risk for cardiovascular disease (CVD) or existing CVD-CREST study: comparison to current treatment guidelines L. Shi, S. Kachroo, H. Kawabata, S.A. Colilla, J. Mukherjee, U. Iloeje, V. Fonseca, USA

972 Change in body weight after 24 weeks of vildagliptin therapy as a function of baseline fasting plasma glucose levels in patients with type 2 diabetes J.E. Foley, G. Bader, A. Schweizer, USA, Switzerland Posters 973 Saxagliptin improves glycaemic control and is well tolerated in adult diabetes patients with glutamic acid decarboxylase antibodies R. Buzzetti, P. Pozzilli, R. Frederich, N. Iqbal, B. Hirshberg, Italy, USA

974 Use of pioglitazone and risk of bladder cancer among diabetic patients in Korea: a multicentre retrospective cohort study supported by a nested case-control analysis S.-M. Jin, B.-S. Cha, C. Jung, S. Suh, C.-Y. Park, J. Kim, J. Cho, B.-W. Lee, Korea, Republic of

975 Pioglitazone increases bone marrow fat content I. Lingvay, Q. Yuan, M. Poduri, B. Adams-Huet, X. Li, N. Maalouf, USA

976 Effect of pioglitazone on thyroid stimulating hormone and insulin resistance in hypothyroid patients K.A. Moskva, L.J. Lapovets, O.P. Kikhtyak, Ukraine

977 The glucagon receptor antagonist LY2409021 significantly lowers HbA1c and is well tolerated in patients with type 2 diabetes mellitus: a 24-week phase 2 study C.M. Kazda, S.A. Headlee, Y. Ding, R.P. Kelly, P. Garhyan, T.A. Hardy, A.J. Lewin, France, USA, Singapore

Poster Event F, Thursday, 13:45 - 14:45

PS 078 Effects of glucose-lowering therapy on cardiovascular risks

Chair: E. Bonora, Italy

220 fp3_2013__ 15.08.13 10:41 Seite 221

978 Effects of pioglitazone vs glyburide on endothelial function in type 2 diabetic patients with vascular complications: the SPLENDOR study M. Garofolo, L. Pucci, D. Lucchesi, R. Bruno, E. Russo, V. Sancho Bornez, R. Russo, L. Giusti, A. Dardano, A. Avogaro, L. Ghiadoni, R. Miccoli, C. Di Pietro, G. Penno, S. Del Prato, Italy

979 The comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes and heart failure D.L. Weir, F.A. McAlister, A. Senthilselvan, J.R. Dyck, J.K. Sandhu-Minhas, D.T. Eurich, Canada

980 Efficacy and safety of exenatide once weekly over 5 years L. MacConell, D. Maggs, Y. Li, P. Griffin, C. Wysham, USA Posters 981 Long-term cardiovascular outcomes with exenatide twice daily compared to insulin: a retrospective observational study K. Klein, J.H. Best, S.P. Marso, D. Maggs, S.K. Paul, Australia, USA

982 Impact on cardiovascular risk factors of exenatide BID vs insulin lispro TID added to titrated insulin glargine QD in metformin-treated type 2 diabetes mellitus patients: the 4B trial M. Diamant, M.A. Nauck, R. Shaginian, J. Malone, S. Cleall, D. De Vries, B. Hoogwerf, L. MacConell, B.H. Wolffenbuttel, Netherlands, Germany, USA, UK

983 Cardiovascular effects of anti-diabetic drugs: exendin-4 and liraglutide B. Faricelli, M. Salomonsson, A. Consoli, T. Engstroem, M. Treiman, Italy, Denmark

984 Effects of lixisenatide on survival and cardiac function in a mouse model of chronic myocardial infarction P. Wohlfart, K. Hiss, D. Hein, T. Hübschle, H. Ruetten, U. Werner, Germany

985 Patient-reported outcomes with dulaglutide, exenatide, or placebo (AWARD-1) K. Van Brunt, M. Reaney, M. Yu, M. Lakshmanan, B. Curtis, B. Mitchell, UK, Canada, USA

221 fp3_2013__ 15.08.13 10:41 Seite 222

986 Safety and tolerability of linagliptin in 7400 patients with type 2 diabetes: a pooled comprehensive analysis of prospective safety reporting in placebo- controlled studies M. Lehrke, N. Marx, S. Patel, T. Seck, S. Crowe, M. Von Eynatten, O. Johansen, Germany, UK, USA

987 Metformin safety in the very elderly L. Czupryniak, N. Szyłło, E. Szymańska-Garbacz, M. Pawłowski, M. Saryusz-Wolska, J. Loba, Poland Posters Poster Event A, Tuesday, 12:30 - 13:30

PS 079 Novel approaches to treat type 1 and type 2 diabetes

Chair: P.A. Senior, Canada

988 Metabolic effects of cell therapy based GLP-1 treatment in streptozotocin diabetic mice N. Irwin, S. Vasu, R.C. Moffett, J.T. McCluskey, M.H. Hamid, P.R. Flatt, UK, Malaysia

989 Molecular mechanism of protective effect by pioglitazone and/or liraglutide on beta cell damage with the progression of diabetic morbidity T. Kimura, M. Shimoda, H. Hirukawa, S. Hamamoto, K. Tawaramoto, M. Hashiramoto, K. Kaku, Japan

990 GLP-1 attenuates the acceleration of gastric emptying induced by hypoglycaemia in healthy subjects M.P. Plummer, T.D. Crowhurst, C.E. Annink, C.E. Cousins, R.R. Sardana, J.J. Meier, M.J. Chapman, M. Horowitz, K.L. Jones, A.M. Deane, Australia, Germany

991 GLP-1 and liraglutide increase the platelet inhibitory effects of nitric oxide I. Russo, C. Barale, L. Mattiello, F. Cavalot, M. Trovati, Italy

992 Exploring the potential of dapagliflozin in type 1 diabetes: phase 2a pilot study R.R. Henry, J. Rosenstock, A.-G. Chalamandaris, S. Kasichayanula, A. Bogle, S. Griffen, USA, Belgium

222 fp3_2013__ 15.08.13 10:41 Seite 223

993 Effects of one-year treatment with canagliflozin or sitagliptin on glycaemic control and beta cell function measures in subjects with type 2 diabetes on metformin + sulfonylurea G. Schernthaner, E. Ferrannini, A. Mari, C. Tong, M. Kawaguchi, G. Meininger, D. Polidori, Austria, Italy, USA

994 Synergistic glucose-lowering effects of SGLT1- and ASBT-inhibitor combinations in ZDF rats A.A. Young, Y. Liu, J. McNulty, D. Cowan, J. Collins, B. Dobbins, M. Bishop, L. Chen, USA

995 LX2761, an SGLT1 inhibitor restricted to the intestine, improves glycaemic control in mice D.R. Powell, M. Smith, D. Doree, A. Harris, J. Greer, C. DaCosta, Posters A. Thompson, S. Jeter-Jones, N. Goodwin, B. Harrison, E. Strobel, F. Mseeh, A. Sands, B. Zambrowicz, Z.-M. Ding, USA

996 LX4211, a dual SGLT1/SGLT2 inhibitor, decreases body weight and triglycerides in patients with type 2 diabetes mellitus and elevated baseline values B. Zambrowicz, P. Lapuerta, I. Ogbaa, P. Banks, K. Frazier, K.A. Boehm, M. Kelly, A. Sands, USA

997 The effect of ipragliflozin on the total glucose turnover after OGTT in healthy subjects and patients with type 2 diabetes mellitus R.A. Smulders, S. Leeflang, F. Schliess, T. Jax, E. Kurosaki, T. Kadokura, Netherlands, Germany, Japan

Poster Event B, Tuesday, 13:45 - 14:45

PS 080 Novel agents: novel mechanisms

Chair: C.J. Bailey, UK

998 A novel GLP-1/glucagon co-agonist peptide exhibits improved glucose- lowering and insulinotropic actions in diet induced obese diabetic mice V.A. Gault, V.K. Bhat, P.R. Flatt, UK

223 fp3_2013__ 15.08.13 10:41 Seite 224

999 Apical sodium-dependent bile acid transport inhibitors (ASBTi) exhibit potent anti-diabetic activity in ZDF rats B. Gedulin, S. Nikoulina, G. Gedulin, N. Nazarenkov, B. Keller, USA

1000 HM11260C, a new generation long acting GLP-1R agonist with a unique pharmacokinetic profile improves glucose control and GI tolerability; a phase IIa clinical trial in type 2 diabetes mellitus J. Kang, S. Choi, I. Choi, S. Kwon, M. Trautmann, K. Yoon, J. Son, Korea, Republic of, USA

Posters 1001 Sitagliptin improves blood glucose control by suppressing glucagon secretion in insulin-treated type 2 diabetic patients Y. Otsuka, M. Kosuda, N. Ueno, S. Yamaguchi, M. Nakazaki, H. Ishihara, Japan

1002 Exenatide suspension, a novel exenatide formulation, improves insulin sensitivity 28 days after a single injection in diabetic fatty Zucker rats P. Smith, J. Hoyt, J. Athanacio, C. Villescaz, C. Jodka, D. Parkes, USA

1003 Dose-finding results in an adaptive trial of dulaglutide combined with metformin in type 2 diabetes (AWARD-5) Z. Skrivanek, J.Y. Chien, B. Gaydos, M. Heathman, M. Geiger, Z. Milicevic, USA, Austria

1004 Consistent reduction of postprandial glucagon and insulin by lixisenatide in the GetGoal clinical trial programme C.J. Bailey, R. Berria, W. Stager, J.-F. Gautier, R. Aronson, B. Ahrén, UK, USA, France, Canada, Sweden

1005 Once-daily lixisenatide in combination with basal insulin ± OADs in patients with type 2 diabetes selectively reduces postprandial hyperglycaemic daytime exposure R. Gómez-Huelgas, M.C. Riddle, Y. Seino, B. Cariou, C. Roy-Duval, C. Hecquet, A. DiGenio, J. Rosenstock, Spain, USA, Japan, France

1006 Liraglutide demonstrates similar pharmacokinetic properties in patients with type 1 and type 2 diabetes S. Klim, S.H. Ingwersen, L. Jensen, F. Kiyomi, J. Mader, S. Heller, T.R. Pieber, Denmark, Japan, Austria, UK

224 fp3_2013__ 15.08.13 10:41 Seite 225

1007 Treatment with liraglutide as adjunct to insulin in type 1 diabetes; effects on counter regulatory response to hypoglycaemia: a randomised, double blind, crossover trial T.R. Pieber, S. Deller, M. Brunner, L. Jensen, E. Christiansen, F. Kiyomi, S.R. Heller, Austria, Denmark, Japan, UK

Poster Event C, Wednesday, 12:30 - 13:30

PS 081 Innovative treatments of type 2 diabetes

Chair: S.E. Kahn, USA

1008 Safety and efficacy of lobeglitazone monotherapy in patients with type Posters 2 diabetes mellitus over 52 weeks: a randomised open-label trial S. Kim, S. Kim, D. Kim, J.-T. Woo, H. Jang, C. Chung, K. Ko, J. Park, Y. Park, S. Kim, D. Choi, Korea, Republic of

1009 A novel oral dual-action amylin and calcitonin receptor agonist (UGP302) rebalances insulin and glucagon action to attenuate diabetic hyperglycaemia in Zucker diabetic fatty rats M. Feigh, S.T. Hjuler, K.V. Andreassen, S. Gydesen, I. Ottosen, N. Metha, W. Stern, C. Christiansen, M.A. Karsdal, K. Henriksen, Denmark, USA

1010 Dual-action targeting the amylin and calcitonin receptor by oral salmon calcitonin improves glucose homeostasis and insulin sensitivity in an animal model of type 2 diabetes S.T. Hjuler, M. Feigh, K.V. Andreassen, M.A. Karsdal, K. Henriksen, Denmark

1011 Effect of exogenous glucagon vs spontaneous recovery from hypoglycaemia in subjects with type 2 diabetes treated with a novel glucokinase activator AZD1656 and metformin A. Krentz, L. Morrow, M. Petersson, E. Norjavaara, M. Hompesch, USA, Sweden

1012 Evidence that two divergent mechanisms contribute to blood glucose lowering by imidazoline compounds in mice K. Stadlbauer, Z. Lehner, N. Stamenkovic, L. Surman, I. Rustenbeck, A. Luger, C. Fürnsinn, Austria, Germany

225 fp3_2013__ 15.08.13 10:41 Seite 226

1013 MTBL0036, a promising anti-diabetic candidate, impacts both insulin action and insulin secretion in type 2 diabetic rats M. El Hage, G. Moinet, B. Ferrier, R. Nazaret, G. Baverel, G. Martin, A. Conjard-Duplany, France

1014 A one-week phase 1 trial with the DGAT1 inhibitor AZD7687: lipid handling, hormone secretion and adverse effects in the gut H. Denison, C. Nilsson, L. Löfgren, A. Al-Shurbaji, A. Himmelmann, G. Mårtensson, H. Tornqvist, M. Knutsson, J.W. Eriksson, Sweden

Posters 1015 Metabolic effects and safety of two selective 11β-HSD1 inhibitors (RO5093151 (RO151) and RO5027838 (RO838) in metformin-treated patients with type 2 diabetes S. Fuerst-Recktenwald, T. Heise, M. Hompesch, T. Pieber, H.-U. Haering, C. Kapitza, M. Abt, M. Ramsauer, L. Morrow, Switzerland, Germany, USA, Austria

1016 Pharmacological characterisation of 55P0251, a derivative from a novel class of molecules with distinct antihyperglycaemic activity in rodents C. Fürnsinn, K. Stadlbauer, Z. Lehner, B. Brunmair, I. Adorjan, K. Frobel, A. Luger, L. Bauer, Austria

1017 The effect of diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomised trial F.M. Van der Valk, C.H. Hassing, M.E. Visser, P. Thakkar, K. Pathak, A. Mohanan, C. Dutt, V. Chauthaiwale, M.T. Ackermans, M.J. Serlie, M. Nieuwdorp, E.S. Stroes, Netherlands, India

Poster Event D, Wednesday, 13:45 - 14:45

PS 082 Treatment intensification in type 2 diabetes

Chair: R. Weitgasser, Austria

1018 How many OADS before initiating insulin? A retrospective study of outcomes associated with initiation of basal insulin after failing oral anti- diabetic drugs P. Levin, S. Zhou, W. Wei, E. Durden, A.M. Farr, J. Gill, USA

226 fp3_2013__ 15.08.13 10:41 Seite 227

1019 Delay in starting insulin after failure of other treatments in patients with type 2 diabetes I. Zografou, M. Strachan, J. McKnight, Greece, UK

1020 Durability of therapeutic intensification strategies in patients with uncontrolled type 2 diabetes M. Korytkowski, M. Brooks, D. DeAlmeida, M. Lombardero, J. Kanter, T. Orchard, L. Siminerio, USA

1021 Is assessment of postprandial hyperglycaemia useful in determining whether to initiate prandial therapy after basal insulin fails to achieve glycaemic control? C. Shaefer, T. Reid, A. DiGenio, A. Vlajnic, R. Zhou, USA Posters 1022 Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents P. Home, M.-P. Dain, N. Freemantle, R. Kawamori, M. Pfohl, V. Pilorget, W. Scherbaum, G. Vespasiani, M. Vincent, B. Balkau, UK, France, Japan, Germany, Italy

1023 Is FPG variability linked to dose escalation during basal insulin titration, leading to excess insulin, weight gain and hypoglycaemia in type 2 diabetes mellitus? A.B. King, J. Stewart, A. Vlajnic, J. Liang, USA

1024 Two prandial insulin approaches for achieving adequate glycaemic control in patients not at goal HbA1c on basal insulin plus oral agents alone: the AUTONOMY study S. Edelman, J. Johnson, R. Liu, K. Deschamps, L.C. Glass, USA

1025 Insulin lispro mix 25/75 twice daily (LM25) vs basal insulin glargine once daily and prandial insulin lispro once daily (BP) in type 2 diabetes: insulin intensification F.J. Tinahones, J.L. Gross, A. Onaca, Z. Zhou, S. Cleall, A. Rodriguez, Spain, Brazil, Romania, China, UK

1026 Intensification of basal insulin therapy with step-wise addition of insulin aspart boluses compared with basal-bolus therapy: the FullSTEP study H. Rodbard, V.E. Visco, H. Andersen, L.C. Hiort, D.H. Shu, USA, Argentina, Denmark, Canada

227 fp3_2013__ 15.08.13 10:41 Seite 228

1027 Addition of liraglutide vs addition of a single dose of insulin aspart to insulin degludec plus metformin in patients with type 2 diabetes C. Mathieu, H.W. Rodbard, B. Cariou, Y. Handelsman, A. Philis-Tsimikas, A. Ocampo Francisco, A. Rana, B. Zinman, Belgium, USA, France, Denmark, Canada

Poster Event E, Thursday, 12:30 - 13:30

PS 083 Novel insulin preparations: pharmakinetics and pharmacodynamics Posters

Chair: D.M.C. Carvalho, Portugal

1028 Novel formulations BIOD-238 and BIOD-250 result in more rapid absorption and declines from peak than Humalog® J. Kaye, A. Krasner, L. Canney, P. Pichotta, P. Simms, J. Krishnarajah, E. De Souza, Australia, USA

1029 New insulin glargine formulation has a flat and prolonged steady state profile in subjects with type 1 diabetes T. Jax, T. Heise, R. Dahmen, K. Bergmann, A. Lehmann, J. Tillner, R.H. Becker, Germany

1030 LY2605541 exhibits a flatter glucodynamic profile than insulin glargine at steady state in subjects with type 1 diabetes L.A. Morrow, M. Hompesch, S.J. Jacober, S.L. Choi, Y. Qu, V. Sinha, USA, Singapore

1031 Single dose of new insulin glargine Gla-300 formulation has a flatter and prolonged PK/PD profile than Gla-100 in Japanese subjects with type 1 diabetes M. Shiramoto, T. Eto, A. Watanabe, S. Irie, A. Fukuzaki, K. Bergmann, Y. Takahashi, R. Dahmen, M. Koyama, R.H. Becker, Japan, Germany

1032 Metabolism of insulin glargine in humans is the same regardless of formulation, Gla-100 or Gla-300 A. Steinstraesser, R. Schmidt, K. Bergmann, R. Dahmen, R.H. Becker, Germany

228 fp3_2013__ 15.08.13 10:41 Seite 229

1033 Euglycaemic single dose clamp profile of new insulin glargine formulation in subjects with type 1 diabetes is flat and prolonged J. Tillner, K. Bergmann, L. Teichert, R. Dahmen, T. Heise, R.H. Becker, Germany

1034 Insulin degludec multi-hexamers retain the native protein fold of human insulin D.B. Steensgaard, M. Norrman, J. Bearham, C.B. Andersen, A.V. Friderichsen, H.M. Strauss, G. Schluckebier, I. Jonassen, Denmark

1035 Pharmacokinetics and pharmacodynamics of insulin glargine, changes in glucose and lipid metabolism after either evening or morning injection in type 2 diabetes mellitus F. Porcellati, P. Lucidi, P. Candeloro, P. Cioli, A. Marinelli Andreoli, Posters G.B. Bolli, C.G. Fanelli, Italy

1036 Adipose tissue levels of human insulin and insulin detemir measured with open flow microperfusion (OFM) during constant intravenous infusion C. Höfferer, T.R. Pieber, D. Tutkur, S.I. Mautner, J. Damgaard, H. Naver, C.B. Jeppesen, E. Nishimura, C.L. Brand, C. Fledelius, F. Sinner, Austria, Denmark

1037 Determination of glargine and the metabolites M1 and M2 by using a combination of insulin assays of different specificity J.M. Axelsson, A. Carlsson, E. Karamihos, H. Ritzén, R. Gunnarsson, Sweden

Poster Event F, Thursday, 13:45 - 14:45

PS 084 Insulin therapies: basal and novel combination

Chair: R.A. Ritzel, Germany

1038 Postprandial glycaemic control following a fixed-ratio combination of insulin degludec and liraglutide compared to each component individually in patients with type 2 diabetes J.B. Buse, S.C. Gough, H.W. Rodbard, V.C. Woo, S. Linjawi, P. Poulsen, L.H. Damgaard, B.W. Bode, USA, UK, Canada, Australia, Denmark

229 fp3_2013__ 15.08.13 10:41 Seite 230

1039 A novel concentrated recombinant human insulin formulation with improved ultra-rapid prandial and similar basal absorption as insulin lispro protomine mixes R. Pohl, R. Hauser, B.R. Wilson, M. Li, M. Guinness, P. Reddy, M. Jackson, E. De Souza, USA

1040 IDegAsp shows distinct prandial and basal glucose-lowering effects at steady state in subjects with type 1 diabetes T. Heise, L. Nosek, H. Hastrup, S. Chenji, O. Klein, H. Haahr, Germany, Denmark, India Posters 1041 IDegAsp produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes L. Nosek, T. Heise, O. Klein, H.-V. Coester, C. Roepstorff, A. Svendsen, H. Haahr, Germany, Denmark

1042 Clinical efficacy and safety of insulin glargine as compared to other insulin preparations in the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis P. Wojciechowski, P. Rys, A. Rogoz-Sitek, G. Niesyczynski, A. Syta, J. Lis, M.T. Małecki, Poland

1043 Lower within-subject variability in mean blood glucose concentration with insulin degludec vs insulin glargine: a meta-analysis of patients with type 2 diabetes L.F. Meneghini, S.B. Harris, M. Evans, S. Rasmussen, T. Johansen, T.R. Pieber, USA, Canada, UK, Denmark, Austria

1044 Superior FPG control and reduced hypoglycaemia with IDegAsp vs BIAsp 30 in adults with type 2 diabetes mellitus inadequately controlled on pre/self-mixed insulin: a randomised phase 3 trial G. Fulcher, G. Bantwal, J.S. Christiansen, T. Andersen, H. Mersebach, L.K. Niskanen, Australia, India, Denmark, Finland

1045 Superior FPG control and less nocturnal hypoglycaemia with IDegAsp vs BIAsp 30 in Asian subjects poorly controlled on basal or pre/self-mixed insulin: randomised phase 3 trial J.S. Christiansen, F.C. Chow, D.S. Choi, S. Taneda, K. Hirao, Y. Park, T. Andersen, M.-A. Gall, S. Kaneko, Denmark, China, Korea, Republic of, Japan

230 fp3_2013__ 15.08.13 10:41 Seite 231

Poster Event A, Tuesday, 12:30 - 13:30

PS 085 Hypoglycaemia in type 1 and type 2 diabetes

Chair: S.R. Heller, UK

1046 Temporal variations in hypoglycaemia occurring in hospital in people with diabetes who are at risk of hypoglycaemia R. Rajendran, C. Kerry, S. Mitchell, S. Sharma, A. Rayman, G. Rayman, UK

1047 Frequency and characteristics of iatrogenic hypoglycaemia requiring medical assistance: a multicentre study of tertiary hospitals M. Mylona, S. Kalopita, L. Lanaras, A. Papazafiropoulou, S. Pappas,

S. Karamagkiolis, V. Vazyntari, A. Melidonis, A. Xilomenos, M. Voukali, Posters M. Chryssochoou, D. Kapsalas, N. Aggelis, V. Ntova, S. Liatis, Greece

1048 Diabetic autonomic neuropathy predicts severe hypoglycaemia in patients with type 2 diabetes mellitus: a ten-year follow up study Y. Ahn, S.-H. Ko, S.-H. Ko, S. Moon, J.-S. Yun, Korea, Republic of

1049 Behaviours and impact of hypoglycaemia in type 2 diabetes mellitus C. Therapontos, S.H. Ong, A.K. Kawata, P. Mavrogenis, K. Kulich, W.-H. Chen, K. Coyne, on behalf of the HYPO-Cyprus Study Investigators, Cyprus, Switzerland, USA

1050 Physical health status and nocturnal hypoglycaemia with insulin degludec vs insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes Y. Handelsman, B. Cariou, H.W. Rodbard, B. Zinman, M.L. Wolden, A. Rana, C. Mathieu, USA, France, Canada, Denmark, Belgium

1051 Achieving fasting plasma glucose target without nocturnal hypoglycaemia: a pooled analysis of studies in type 2 diabetes comparing insulin degludec vs insulin glargine B. Zinman, J. Vora, M. Niemeyer, M.-A. Gall, C. Mathieu, Canada, UK, Denmark, Belgium

231 fp3_2013__ 15.08.13 10:41 Seite 232

1052 Higher rates of confirmed hypoglycaemia are associated with greater within-subject variability in fasting blood glucose in type 1 and type 2 diabetes: a meta-analysis B.W. Bode, T. Heise, T.R. Pieber, T. Johansen, S. Rasmussen, D.L. Russell-Jones, USA, Germany, Austria, Denmark, UK

1053 Recurrent severe hypoglycaemia in type 1 diabetes: potential for prevention? M.M. Henriksen, R. Due-Andersen, B. Thorsteinsson, U. Pedersen- Bjergaard, Denmark Posters 1054 Gender differences in personality traits and resilience concerning glycaemic control and hypoglycaemia in patients with type 1 and type 2 diabetes W.C. Keweloh, F. Zillich, K. Wick, N. Müller, C. Kloos, T. Lehmann, G. Wolf, U.A. Müller, Germany

Poster Event B, Tuesday, 13:45 - 14:45

PS 086 Insulin adjustment and self-management

Chair: F. Holleman, Netherlands

1055 Evaluation of a real-time carbohydrate counting course during a clinic setting in the management of diabetes type 1 H. Forde, M.C. Durkan, H. Clarke, Ireland

1056 Which principles patients with diabetes type 1 use for self-adjustment of insulin dose? G. Kramer, N. Müller, C. Kloos, G. Wolf, U.A. Müller, Germany

1057 Carbohydrate counting competency index (C31) is a clinically meaningful measure of carbohydrate counting skills in patients with diabetes: results from ABACUS C.G. Parkin, D.A. Cavan, R. Ziegler, I. Cranston, K. Barnard, J. Ryder, C. Vogel, W. Koehler, I. Vesper, B. Petersen, K. Friedman, M.A. Schweitzer, R.S. Wagner, USA, UK, Germany

232 fp3_2013__ 15.08.13 10:41 Seite 233

1058 Use of an automated bolus advisor may improve carbohydrate counting competence in patients treated with multiple daily insulin injection therapy: results from ABACUS J. Ryder, D.A. Cavan, R. Ziegler, I. Cranston, K. Barnard, C. Vogel, W. Koehler, B. Petersen, I. Vesper, K. Friedman, M.A. Schweitzer, R.S. Wagner, UK, Germany, USA

1059 Use of an automated bolus advisor improves multiple outcomes in patients treated with multiple daily insulin injections: results from ABACUS D.A. Cavan, R. Ziegler, I. Cranston, K. Barnard, C.G. Parkin, W. Koehler, B. Petersen, I. Vesper, M.A. Schweitzer, R.S. Wagner, UK, Germany, USA

1060 Evaluating the patient experience in the Asian Treat to Target Lantus Study (ATLAS): a 24 week randomised, multinational study Posters I.R. Jarek-Martynowa, N. Freemantle, K. Admane, A. Koroleva, ATLAS Study Group, Russian Federation, UK, France

1061 A Smartphone for adjustment of basal insulin dose and for coaching: benefits in terms of glycaemic control for type 2 diabetes patients A. Daoudi, M. Joubert, S. Franc, C. Fagour, P.-Y. Benhamou, Y. Reznik, M. Rodier, B. Boucherie, E. Benamo, P. Schaepelynck, B. Guerci, D. Dardari, A. Penfornis, G. Charpentier, TELEDIAB2 Study Group, France

1062 Determinants of insulin dosing decisions made by diabetes care providers: a vignette study N. Peek, A.C. Simon, J.E. Schopman, J.B. Hoekstra, A. Abu-Hanna, V.E. Gerdes, F. Holleman, Netherlands

Poster Event C, Wednesday, 12:30 - 13:30

PS 087 Diabetes self care and adherence

Chair: T.R. Pieber, Austria

1063 Asian Treat to Target Lantus Study (ATLAS): a 24 week randomised, multinational study K. Admane, S. Garg, M. Odawara, ATLAS Study Group, France, USA, Japan

233 fp3_2013__ 15.08.13 10:41 Seite 234

1064 The SimpleMix study with biphasic insulin aspart 30: a comparison between subject-driven titration vs investigator-driven titration B. Saboo, C. Luquez, J. Råstam, H. Andersen, Y. Gao, India, Argentina, Denmark, China

1065 Glycaemic control and quality of life: Is there any relationship in young patients with type 1 diabetes? E.V. Surkova, O.G. Motovilin, A.Y. Mayorov, J.A. Shishkova, Russian Federation

Posters 1066 Factors affecting non-adherence to drug, diet and physical activity advices among type 1 diabetic subjects B. Banu, Z. Rizvi, A. Basit, L. Ali, Bangladesh, Pakistan

1067 Empowerment and motivation affects HbA1c in subjects with low medical adherence and poor diabetes control G. Andrésdóttir, L. Jelstrup, F. Persson, A.R. Varming, E.H. Petersen, G. Engelund, P. Rossing, Denmark

1068 Early utilisation of daily SMBG in insulin treated type 2 diabetes patients is associated with greater improvement in glycaemic control: results from the COMPASS study Q. Su, L. Ji, B. Feng, Z. Shan, R. Hu, X. Xing, Y. Xue, China

1069 Correlates of patient barriers to medication taking in type 2 diabetes: the BENCH-D study M. Rossi, F. Pellegrini, S. Gentile, G. Lucisano, G. Marra, B. Pintaudi, S. Skovlund, G. Vespasiani, A. Nicolucci, BENCH-D Study Group, Italy, Denmark

1070 Correlates of patients’ attitudes to check their feet as a diabetes self- care activity: the BENCH-D study B. Pintaudi, G. Lucisano, S. Gentile, G. Marra, F. Pellegrini, M. Rossi, S. Skovlund, G. Vespasiani, A. Nicolucci, BENCH-D Study Group, Italy, Denmark

1071 My Diabetes My Way: an electronic personal health record for people with diabetes S.G. Cunningham, D.J. Wake, A.D. Morris, A. Waller, J. Walker, UK

234 fp3_2013__ 15.08.13 10:41 Seite 235

Poster Event D, Wednesday, 13:45 - 14:45

PS 088 Self blood glucose monitoring: utility and metrics

Chair: M. Saraheimo, Finland

1072 Introduction of a recommended SMBG regimen improved glycaemic control in poorly controlled Chinese patients on insulin therapy: results from the COMPASS study L. Ji, Q. Su, B. Feng, Z. Shan, R. Hu, X. Xing, Y. Xue, China

1073 Use of structured 3-day glycaemic profiles impacts glucose control in diabetes patients treated with multiple daily insulin injection therapy: results

from ABACUS Posters C. Vogel, D.A. Cavan, R. Ziegler, I. Cranston, K. Barnard, J. Ryder, C.G. Parkin, W. Koehler, I. Vesper, B. Petersen, M.A. Schweitzer, R.S. Wagner, Germany, UK, USA

1074 Colour record in self-monitoring of blood glucose improves glycaemic control for insulin-treated type 2 diabetes patients A. Nishimura, I. Honda, S. Harashima, Y. Shimizu, K. Hosoda, N. Inagaki, Japan

1075 ExAct study: Integrated strip-free SMBG technology (Accu-Chek® Mobile) improves patient adherence to recommended testing frequency and patterns and glycaemic control A. Maran, D. Tschoepe, M. Di Mauro, W.A. Fisher, K. Loeffler, I. Vesper, O. Mast, S. Bloethner, J. Weissmann, I. Amann-Zalán, I. Cranston, Italy, Germany, Canada, USA, UK

1076 System accuracy evaluation of blood glucose monitoring systems for point of care testing and self monitoring G. Freckmann, A. Baumstark, M. Link, S. Pleus, E. Stolberg, C. Haug, J. Sieber, Germany

1077 Measurement error in estimated average glucose: a new approach M.J. O'Kane, J.E. Given, B.P. Bunting, V.E. Coates, UK

1078 An innovative metric objective evaluation of glucose profiles E. Salzsieder, P. Heinke, L. Vogt, P. Augstein, Germany

235 fp3_2013__ 15.08.13 10:41 Seite 236

1079 Robustness of dynamical real-time estimation of HbA1c using routine self-monitoring of blood glucose (SMBG) data M. Breton, F. Flacke, J. Sieber, B. Kovatchev, USA, Germany

1080 Accuracy of dynamical real-time estimation of HbA1c using routine self- monitoring of blood glucose (SMBG) data B. Kovatchev, F. Flacke, J. Sieber, M. Breton, USA, Germany

Poster Event E, Thursday, 12:30 - 13:30 Posters

PS 089 New devices for glucose monitoring and insulin delivery

Chair: R. Hovorka, UK

1081 Development of a novel microprobe array continuous glucose monitor: pre-clinical validation A.H. El-Laboudi, S. Sharma, N. Oliver, H. Santhanam, A. Cook, J. Carton, T. Cass, D. Johnston, UK

1082 Performance of a novel sensor during induced glucose swings K. Obermaier, M. Schoemaker, J. Jager, G. Schmelzeisen-Redeker, G. Freckmann, E. Zschornack, Germany

1083 Presenting a truly non-invasive glucose monitor for home use A. Gal, I. Harman-Boehm, E. Naidis, Y. Mayzel, N. Goldstein, K. Horman, Israel

1084 Six-month data from a clinical study of an implantable fluorescence- based glucose sensor T. Whitehurst, J. Emken, P. Huffstetler, S. Tankiewicz, X. Wang, S. Rajaraman, M. Mortellaro, R. Rastogi, R. Rastogi, O. Chen, C. Mdingi, K. Lechleiter, A. Dehennis, USA

1085 Catalytic protection from ROS using platinum nanoparticles: enabling a long-term, implantable glucose sensor S.C. Puiu, M.A. Mortellaro, USA

236 fp3_2013__ 15.08.13 10:41 Seite 237

1086 Evaluation of drug efficacy using glucose area under the curve monitoring system without blood sampling K. Kosugi, K. Sakamoto, K. Yoshiuchi, A. Ono, T. Sato, S. Okada, Y. Ohnishi, H. Koga, K. Tokunaga, H. Nakajima, Japan

1087 Very well controlled patients using InsuPad experience reduced insulin requirements and less hypoglycaemic events: results from the real world BARMER study A. Pfützner, K. Funke, N. Hermanns, M. Derwahl, T. Forst, G. Bitton, R. Nagar, A. Karch, T. Haak, Germany, Israel

1088 Proof of reliability of intradermal devices under extended wear basal/bolus infusion conditions E.A. McVey, S.C. Keith, D.E. Sutter, K. Judge, J. Herr, R.J. Pettis, USA Posters

1089 Insulin therapy with a 4mm x 32G pen needle vs larger needles in obese subjects, including those taking high doses and/or glargine L. Hirsch, R. Bergenstal, E. Strock, D. Peremislov, V. Parvu, M. Gibney, USA

1090 Extra thin-wall pen needles: impact on thumb force, insulin flow, time- to-deliver, patient preference and confidence in dosing R. Aronson, M.A. Gibney, K. Oza, J. Berube, K. Kassler-Taub, L. Hirsch, Canada, USA

Poster Event F, Thursday, 13:45 - 14:45

PS 090 Closed loops and CGMS

Chair: T. Battelino, Slovenia

1091 Inpatient evaluation of an automated closed-loop control-to-range system H.C. Zisser, Control To Range Writing Group, USA

1092 Tighter glucose control through a reduction of hyperglycaemia results from closed-loop intra-peritoneal vs subcutaneous insulin delivery in type 1 diabetes E.M. Renard, A. Farret, J.J. Lee, J. Place, E. Dassau, M.-J. Pelletier, R.A. Harvey, F.J. Doyle III, H. Zisser, France, USA

237 fp3_2013__ 15.08.13 10:41 Seite 238

1093 Nocturnal glycaemic control with the MD-Logic artificial pancreas at type 1 diabetes mellitus patient's home I. Muller, R. Nimri, E. Atlas, S. Miller, O. Kordonouri, N. Bratina, C. Tsioli, M. Avbelj Stefanija, T. Danne, T. Battelino, M. Phillip, Israel, Germany, Slovenia

1094 Performance of a new continuous glucose monitoring (CGM) system in youth with diabetes L. Laffel, P. Chase, T. Bailey, B. Buckingham, D. Liljenquist, M. Daniels, K. Nakamura, USA Posters 1095 Effect of repeated continuous glucose monitoring (CGM) profiles on glycaemic control of dialysis patients with diabetes: DIALYDIAB study C. Fourmy, M. Joubert, P. Henri, J. Morera, A. Rod, Y. Reznik, France

1096 A comparison of utilising SMBG vs CGM data to optimise glycaemic profiles and glucose control in patients with type 2 diabetes R.M. Bergenstal, E. Strock, K. Thompson, M.X. Xi, M.L. Johnson, D. Wesley, S. Borgman, S. Borgman, R. Mazze, USA

1097 Improvement of metabolic control after three months use of RT-CGM in type 1 diabetics treated with insulin pump: the multicentre Greek DIAMOND study A.C. Pappas, E. Anastasiou, C. Vasilopoulos, C. Zoupas, C. Manes, A. Tsatsoulis, N. Tentolouris, M. Benroubi, E. Pangalos, A. Gerasimidi- Vazeou, T. Didangelos, Greece

1098 Poor agreement of computerised calculators to calculate the mean amplitude of glycaemic excursions J.B. Hoekstra, M.K. Sechterberger, J.H. DeVries, Netherlands

1099 Continuous glucose monitoring via telemetry in rats R. Brockway, T. Coskun, L.S. O'Farrell, P. Haefner, K. White, C.V. Jackson, R.G. Peterson, USA

Poster Event A, Tuesday, 12:30 - 13:30

PS 091 Insulin pumps in clinical practice

Chair: M.T. Malecki, Poland

238 fp3_2013__ 15.08.13 10:41 Seite 239

1100 Intermittent glucose monitoring in type 1 diabetics on insulin pump: is there difference in glycaemic control between real-time and retrospective analysis? G. Petrovski, T. Milenkovic, B. Jovanovska, I. Ahmeti, I. Bitovska, Macedonia, The Former Yugoslav Republic of

1101 Quantitation of the roles played by the main determinants of meal glucose tolerance in patients with type 1 diabetes on insulin pump therapy M. Trombetta, C. Brangani, L. Boselli, C. Negri, M. Dauriz, I. Rubbo, G. Ceradini, E. Bonora, R.C. Bonadonna, Italy

1102 HbA1c and weight development one year after initiation of continuous subcutaneous insulin injection therapy in adult subjects

H.U. Andersen, E. Hommel, H.-C. Andersen, J.N. Christensen, K. Rytter, Posters A. Hougaard, A. Grynnerup, M. Ridderstråle, Denmark

1103 Factors affecting glycaemic control in adult type 1 diabetic patients treated with personal insulin pumps T. Klupa, B. Matejko, B. Kieć-Wilk, M.T. Malecki, Poland

1104 Carbohydrate-to-insulin ratio in type 1 diabetic patients treated with continuous subcutaneous insulin infusion therapy (CSII) C. Gonzalez, I. Orellana, R. Corcoy, V. Alcantara, A. Chico, Spain

1105 Outcomes in people with type 1 diabetes transferring to insulin pump therapy after structured education P. Mansell, R. Cullum, F. Cole, C. Taylor, D. Cooke, H. Murphy, UK

1106 Dose Adjustment for Normal Eating (DAFNE) structured education is associated with reduced progression to insulin pump among patients considered for pump before enrolment T. Ray, P. Choudhary, P. Mansell, S. Heller, S.A. Amiel, D. Hopkins, UK

1107 Comparison between individually and group-based insulin pump initiation by time-driven activity-based costing M. Ridderstråle, Sweden, Denmark

1108 Experience with V-GO insulin delivery device in clinical practice J.-P. Lock, R. Powell, D.M. Harlan, USA

239 fp3_2013__ 15.08.13 10:41 Seite 240

1109 A feasibility assessment of PaQ®, a simple 3-day basal/bolus insulin delivery device, in patients with type 2 diabetes J.K. Mader, L.C. Lilly, F. Aberer, H. Kojzar, S. Korsatko, E. Strock, R. Mazze, P. Damsbo, T.R. Pieber, Austria, USA

Poster Event B, Tuesday, 13:45 - 14:45

PS 092 Delivering diabetes care Posters Chair: J. Škrha, Czech Republic

1110 Marked improvement of glycaemic control and insulin therapy associated problems of patients with diabetes mellitus after intervention in a diabetes day clinic C.S. Kloos, C. Eckardt, G. Kramer, B. Milke, G. Wolf, U.A. Müller, Germany

1111 How quickly do HbA1c levels respond to a change in oral glucose lowering therapy? Results from a cohort study J.A. Hirst, R.J. Stevens, A.J. Farmer, UK

1112 Use of sulfonylureas in patients with multiple risk factors for CV disease or those with existing CV disease - CREST Study: are we following current ADA/EASD guidelines? S. Kachroo, H. Kawabata, S.A. Colilla, L. Shi, J. Liu, J. Mukherjee, V.A. Fonseca, U. Iloeje, USA

1113 National Diabetes Action Programme: a monitoring study regarding the Dutch care standard for diabetes among health care professionals and patients L.G. Raaijmakers, M.K. Martens, A.E. Hesselink, I. De Weerdt, M.A. Jebbink, S.P. Kremers, Netherlands

1114 Differences in healthcare professionals’ perceptions of diabetes healthcare provision in the DAWN2 study R.I. Holt, K. Kovacs Burns, A. Forbes, N. Hermanns, S. Kalra, B. Kulzer, M. Massi Benedetti, A. Mayorov, N. Munro, A. Nicolucci, S. Skovlund, J. Wens, M. Peyrot, DAWN2 Study Group, UK, Canada, Germany, India, Italy, Russian Federation, Denmark, Belgium, USA

240 fp3_2013__ 15.08.13 10:41 Seite 241

1115 Emergency medical identification use in adults with diabetes P.L. Kapsner, H.P. Nguyen, C.A. Soller, J.P. Torres, USA

1116 Optimal target range for blood glucose in hyperglycaemic patients in a neurocritical care unit P. Wang, Y.-J. Guo, Y. Zhou, S.-Y. Zhang, Q. Wei, Y. Huang, W.-Q. Xia, S.-H. Wang, China

1117 Predictors of medication usage for incident diabetes patients: a SUrveillance PREvention and ManagEment of Diabetes Mellitus (SUPREME-DM) study J. Schmittdiel, J. Steiner, W. Dyer, P. O'Connor, J. Segal, L. Kirschner, E.B. Schroeder, G. Goodrich, M. Butler, M. Raebel, USA Posters 1118 Process- and intermediate outcome indicator results in the 2011 LOK survey (DUDE-2) H.J. Bilo, M. Meulepas, A. Romeijnders, M. Klomp, S.T. Houweling, N. Kleefstra, Netherlands

1119 European vs non-European HCP attitudes and practices: results from DAWN2 S. Kalra, M. Comaschi, A. Forbes, R.I. Holt, E. Menéndez Torre, N. Munro, J. Salles, I. Tarkun, J. Wens, I. Willaing, M. Peyrot, DAWN2 Study Group, India, Italy, UK, Spain, Brazil, Turkey, Belgium, Denmark, USA

Poster Event C, Wednesday, 12:30 - 13:30

PS 093 Type 1 diabetes education

Chair: S.F. Dinneen, Ireland

1120 A randomised controlled trial of an internet-based mentoring programme for type 1 diabetes patients with inadequate glycaemic control S. Suh, S.M. Park, T. Kim, S.M. Jin, J.C. Bae, K.Y. Hur, M.K. Lee, J.H. Kim, Korea, Republic of

1121 The efficiency of telemedicine to optimise metabolic control in patients with type 1 diabetes mellitus E. Esmatjes, M. Jansà, D. Roca, N. Pérez, S. Martinez, M. Ruiz de Adana, F. Vazquez, O. Solà-Morales, Spain

241 fp3_2013__ 15.08.13 10:41 Seite 242

1122 Evaluation of a 5 days education programme by regards to individualised patient target for patients with type 1 diabetes M. Halbron, C. Sachon, T. Obadia, D. Simon, V. Quiniou, A. Grimaldi, A. Hartemann, France

1123 Gender differences in the effect of motivational interviewing and cognitive behavioural therapy in Austrian adolescents with type 1 diabetes G. Berger, F. Brunmayr, M. Muehlehner, T. Waldhoer, C. Wondratsch, M. Koenig, E. Horak, G. Wagner, M. Fritsch, T. Hoertenhuber, B. Rami- Merhar, E. Schober, Austria Posters 1124 Do young adults with poorly controlled type 1 diabetes benefit from a flexible nurse-led guided self-determination intervention? Results of a randomised controlled trial V. Zoffmann, D. Vistisen, M. Due-Christensen, Denmark

1125 A cross country qualitative investigation of structured education programmes for adults with type 1 diabetes M. O' Hara, M. Byrne, J. Lawton, U. Müller, N. Müller, F. Zillich, P. Mansell, I. Lawrence, S.R. Heller, S.F. Dinneen, E. O' Shea, for the Irish DAFNE Study Group, Ireland, UK, Germany

1126 Evaluation of a one day a week re-education course (EDWARD) for type 1 diabetes: 6-year follow up E. Houghton, C. Soar, T. Cooper, S. Carr, W. Jeffcoate, UK

1127 Midterm impact of a specially designed therapeutic education programme in patients transferred from a paediatric to an adult diabetes unit M. Giménez, M. Vidal, M. Jansa, C. Yoldi, A. Gómez, M. Torres, I. Conget, Spain

1128 Influence of basal insulin regimen on outcome from structured education in type 1 diabetes H.E. Hopkinson, R.M. Jacques, I. Lawrence, S.A. Amiel, P. Mansell, UK

1129 Impact of ethnicity and social deprivation on uptake of structured education for type 1 diabetes in a multi-ethnic urban population D. Hopkins, R. Foxcroft, D. Simpson, T. Evans, S. Thomas, A. Simonds, S. Amiel, UK

242 fp3_2013__ 15.08.13 10:41 Seite 243

Poster Event D, Wednesday, 13:45 - 14:45

PS 094 Education and motivation in type 2 diabetes

Chair: M. Trento, Italy

1130 NOTOS: an electronic questionnaire structures individualised diabetes management B. Landers, J. Weissmann, L.C. Steinbrinker, U.A. Kraemer, S. Weinert, H.-J. Lüddeke, Germany, USA

1131 Information seeking behaviour of patients with diabetes mellitus: a cross-sectional study in an outpatient clinic of a university-affiliated hospital

K. Makrilakis, S. Kalantzi, P. Kostagiolas, G. Kachagias, D. Niakas, Greece Posters

1132 The art of creating dialogue and participation in patient education: health educator experiences using a person centred patient education tool kit G. Engelund, R. Torenholt, U. Møller Hansen, I. Willaing, Denmark

1133 Motivation to change towards healthy diet and habitual physical activity in subjects with type 2 diabetes mellitus A.S. Sasdelli, E. Centis, A. Mazzotti, G. Marchesini, the AMD-SID Interassociative Study Group on Physical Activity, Italy

1134 Group-based diabetes self management education for refugees with type 2 diabetes in Sweden: an observational study on short term effects on metabolic control E. Ridderstråle, K. Andersson, K. Balcker, T. Elgzyri, U. Jakobsson, M. Ridderstråle, Sweden, Denmark

1135 Physical activity and life quality in patients with type 2 diabetes mellitus after therapeutic education in “diabetes school” A.V. Petrov, D.V. Logutova, L.G. Strongin, Russian Federation

1136 Exploring diabetes education and information: perspectives of people with diabetes (DAWN2 study) I. Willaing, M. Massi Benedetti, K. Kovacs Burns, M. Comaschi, M. Davies, M. Escalante, A. Forbes, N. Hermanns, B. Kulzer, R. Malek, A. Mayorov, N. Munro, M. Vallis, M. Peyrot, DAWN2 Study Group, Denmark, Italy, Canada, UK, Mexico, Germany, Algeria, Russian Federation, USA

243 fp3_2013__ 15.08.13 10:41 Seite 244

1137 Effect of individual patient education for people with type 2 diabetes mellitus in Bangladesh M.S. Bukht, K.R. Ahmed, Bangladesh

Poster Event E, Thursday, 12:30 - 13:30

PS 095 Psychosocial aspects of diabetes

Chair: N. Hermanns, Germany Posters

1138 Socioeconomic differences in families of children with well and poorly controlled type 1 diabetes B.M. Zdunczyk, K. Piechowiak, A. Szypowska, Poland

1139 Association of personality traits with diabetes-related distress and psychosocial factors in subjects with long duration of type 1 diabetes A. Duda-Sobczak, D. Zozulinska-Ziolkiewicz, B. Wierusz-Wysocka, Poland

1140 Socio-economic status - combination of occupation, education and income level - and diabetes risk: the Hoorn study A. Koopman, F. Rutters, S. Rauh, P.J. Kostense, S.D. Bot, C.A. Baan, C.D. Stehouwer, P. Elders, G. Nijpels, J.M. Dekker, Netherlands

1141 Low self-efficacy and insulin resistance in a Swedish population: a cross-sectional study M. Eriksson, C.A. Larsson, L. Råstam, U. Lindblad, Sweden

1142 Societal discrimination and emotional well-being in people with diabetes: results from DAWN2 J. Wens, A. Nicolucci, S. Kalra, B. Kulzer, M. Massi Benedetti, N. Piana, F. Pouwer, S. Skovlund, M. Peyrot, DAWN2 Study Group, Belgium, Italy, India, Germany, Netherlands, Denmark, USA

1143 Psychosocial stress is associated with higher mortality: the Hoorn study F. Rutters, S. Pilz, A. Koopman, S. Rauh, C. Stehouwer, P. Elders, G. Nijpels, J.M. Dekker, Netherlands, Austria

244 fp3_2013__ 15.08.13 10:41 Seite 245

1144 Qualitative insights into diabetes psychosocial needs and strategies from the perspective of healthcare professionals in DAWN2 H.L. Stuckey, K. Kovacs Burns, H. Ishii, S. Kalra, A. Kokoszka, C. Mullan- Jensen, A. Nicolucci, S. Skovlund, M. Vallis, J. Wens, I. Willaing, M. Peyrot, DAWN2 Study Group, USA, Canada, Japan, India, Poland, Denmark, Italy, Belgium

1145 A psychological support programme for patients with nonalcoholic fatty liver disease (NAFLD) L. Montesi, C. Caselli, E. Centis, C. Nuccitelli, S. Moscatiello, A. Suppini, G. Marchesini, Italy

1146 Eating disorders and food anomalous behaviour in type 2 diabetes adults Posters A. Larrañaga, J. Garcia-Soidan, R.V. Garcia-Mayor, Traconal Study Group, Spain

1147 Study on the support of compatibility between work and medical care and of return to work in diabetic patients in Japan E. Nakashima, T. Sano, A. Watarai, T. Kawamura, H. Ishikawa, M. Omura, M. Nomura, Y. Yamamoto, K. Yaga, K. Kaneko, H. Yatsuya, N. Hotta, Japan

Poster Event F, Thursday, 13:45 - 14:45

PS 096 Good news for depression in diabetes?

Chair: K. Ismail, UK

1148 Multiple analysis of risk factors for depression in Chinese type 2 diabetic patients M. Jia, B. Xie, X.L. Ye, Y.C. Tu, N. Yang, Z.L. Sun, China

1149 Depression and the metabolic control of type 2 diabetes mellitus L. Diaconu, B. Timar, S. Popescu, R. Timar, Romania

1150 Diabetes and depression among pregnant women in Bangladesh: a hospital based study K. Natasha, A. Hussain, Norway, Bangladesh

245 fp3_2013__ 15.08.13 10:41 Seite 246

1151 Diabetologist perceived barriers to addressing psychological matters in diabetes consultations C.B. Johansen, R. Torenholt, E. Hommel, M. Wittrup, I. Willaing, Denmark

1152 Depression in diabetes: the role of diabetes-related distress on incidence and recovery D. Ehrmann, N. Hermanns, B. Kulzer, N. Bergis, B. Maier, T. Haak, Germany

1153 Impact of comorbid depression on glycaemic control and family Posters functioning in treatment-resista nt Japanese patients with type 2 diabetes: a 6-month follow-up study T. Saeki, M. Takaishi, S. Yamawaki, K. Ishida, T. Komo, S. Tazuma, Japan

1154 Low prevalence of depression and burden by diabetes mellitus at secondary care level in Germany N. Kuniß, G. Kramer, N. Müller, C. Kloos, G. Wolf, U.A. Müller, Germany

1155 Depression, anxiety, cognitive impairment and their correlations with clinical and demographic variables in people with type 2 diabetes: a 4-year prospective study M. Trento, M. Raballo, M. Trevisan, P. Passera, F. Schellino, L. Charrier, P. Berchialla, F. Cavallo, M. Porta, Italy

1156 Simple self-reported anger and memory loss as risk factors for the development of type 2 diabetes in Japanese individuals A. Suzuki, Y. Heianza, Y. Arase, S. Hara, S. Hsieh, T. Yamada, K. Fujihara, K. Saito, S. Kodama, O. Hanyu, H. Sone, Japan

1157 Psychological, behavioural and biological changes following treatments of subsyndromal depression in people with type 2 diabetes M. Pibernik-Okanovic, M. Vucic Lovrencic, D. Ajdukovic, M. Sekerija, N. Hermanns, Croatia, Germany

Poster Event A, Tuesday, 12:30 - 13:30

PS 097 Health economics: living better? at what cost?

Chair: D. Mauricio, Spain

246 fp3_2013__ 15.08.13 10:41 Seite 247

1158 Defining the health economic value of avoiding weight gain and hypoglycaemia in type 2 diabetes mellitus A. Lloyd, V. Foos, P. McEwan, D.M. Grant, M. Lamotte, J. Palmer, UK, Switzerland, Belgium

1159 Health-related of quality of life using EQ-5D in patients with type 2 diabetes F. Saleh, F. Ara, S.J. Mumu, M.A. Hafez, F. Khan, L. Ali, Bangladesh

1160 Flexible insulin dosing improves health-related quality of life (HRQoL): a time trade-off survey B. Chubb, M. Evans, H.H. Jensen, M. Bøgelund, J. Gundgaard, K. Khunti, UK, Denmark Posters 1161 Economic models of diabetes mellitus: Are we making decisions on the best available evidence? K. Norrbacka, W.J. Valentine, K.S. Boye, B.H. Curtis, J.P. Bae, L. Timlin, R.F. Pollock, J. Smith-Palmer, B. Hunt, D. Kendall, Finland, Switzerland, USA, UK

1162 Acute coronary syndrome patients with type 2 diabetes had higher healthcare costs vs patients without diabetes in the US population from 2006 to 2011 Y. Xu, M.J. Cziraky, R. Luthra, M.D. Fisher, K. Wilhelm, T.P. Power, V.S. Reddy, USA

1163 Cost predictors in type 2 diabetes mellitus: a retrospective claims database analysis R. Ionescu-Ittu, M. Bron, D. Latremouille-Viau, A. Guerin, J. Samp, E. Wu, USA

1164 Trends in the management of type 2 diabetes and its prescription drug costs in Greece (2006 and 2012) S. Papaoikonomou, A. Melidonis, A. Papazafiropoulou, M. Michael, A. Ganotopoulou, K. Ntinos, S. Bousboulas, A. Xilomenos, V. Vazintari, N. Katsilambros, S. Pappas, S. Liatis, Greece

1165 Cost of diabetes care and its determinants: a hospital based study in Bangladesh A. Afroz, S.G. Choudhury, M.A. Hafez, L. Ali, Bangladesh

247 fp3_2013__ 15.08.13 10:41 Seite 248

1166 The cost of type 2 diabetes: a population-based study in Catalonia I. Vinagre, M. Mata-Cases, J. Franch-Nadal, M. Casajuana, R. Morros, E. Hermosilla, F. Fina, C. Castell, B. Bolivar, D. Mauricio, Spain

1167 Distribution of costs in patients with type 2 diabetes mellitus: a retrospective claims database analysis M. Bron, A. Guerin, D. Latremouille-Viau, R. Ionescu-Ittu, C. Lopez, P. Viswanathan, E. Wu, USA

Posters Poster Event B, Tuesday, 13:45 - 14:45

PS 098 Inflammation and immunity: links to clinical practice

Chair: J.J. Vendrell, Spain

1168 The effect of intensive insulin treatment on plasma level of LP-PLA2 and sPLA2 in patients with newly diagnosed type 2 diabetes X.-H. Lin, M. Xu, F. Li, L. Mai, X. Wang, Y. Li, L. Yan, China

1169 Intensification of antihyperglycaemic treatment with DPP-4 inhibitor: influence on body composition and adipokine level I. Shmushkovich, O. Sukhareva, T. Chernova, A. Ilin, M. Shestakova, A. Aleksandrov, I. Dedov, Russian Federation

1170 Depression in newly diagnosed type 2 diabetes is associated with raised levels of systemic inflammatory markers J.S. Laake, J.C. Pickup, S.A. Amiel, D. Stahl, F. Petrak, K. Ismail, UK, Germany

1171 Relation of the obesity-related gene (FTO) polymorphism with depressive symptoms and quality of life in type 1 diabetic children treated with insulin pumps: a pilot study A. Szypowska, B. Zduńczyk, J. Sendela, A. Ramotowska, A. Bossowski, W. Łuczyński, Poland

1172 Is there a relationship between depression and inflammatory markers in people with type 1 and type 2 diabetes? M. Carreira, M.T. Anarte, M. Guerrero, E. Rubio, N. Colomo, M. Domínguez- López, N. Sánchez, A. Machado, E. Varela, M.S. Ruiz de Adana, Spain

248 fp3_2013__ 15.08.13 10:41 Seite 249

1173 Insulin antibodies are associated with use of protaminated insulin, and the uncommon TNF -857T allele in subjects with type 2 diabetes mellitus K. Takahashi, M. Masaya, T. Takahashi, M. Yamashina, T. Oda, R. Nakagawa, M. Ono, M. Matsui, K. Nagasawa, H. Homma, T. Kajiwara, H. Taneichi, Y. Takahashi, N. Takebe, J. Satoh, Japan

Poster Event C, Wednesday, 12:30 - 13:30

PS 099 Nephropathy: epidemiology and clinical correlates

Chair: F. Bonnet, France

1174 Prevalence of albuminuria and reduced renal function in type 2 Posters diabetes and its association with vascular co-morbidities in a Swedish primary care setting M.K. Svensson, A. Bröijersén, L. Weiss, C. Östgren, Sweden

1175 Albuminuria significantly predicts cardiovascular events in patients with type 2 diabetes independently from the baseline coronary artery state A. Vonbank, D. Zanolin, P. Rein, C.H. Saely, H. Drexel, Austria, Liechtenstein, USA

1176 Impact of morbid obesity on kidney function in type 2 diabetes N. Belhatem, K. Mohammedi, F. Rouzet, N. Matallah, F. Travert, R. Roussel, M. Marre, D. Le Guludec, B. Hansel, France

1177 Heterogeneity of chronic kidney disease (CKD) phenotypes in patients with type 1 diabetes mellitus E. Russo, G. Penno, M. Garofolo, D. Lucchesi, L. Pucci, V. Sancho Bornez, R. Russo, L. Giusti, R. Miccoli, S. Del Prato, Italy

1178 Diabetes increases renovascular impedance in patients with liver cirrhosis G. Privitera, L. Spadaro, G. Fede, S. Calanna, A. Rabuazzo, F. Purrello, Italy

1179 Poor glycaemic control is related with increased nitric oxide activity within the renal circulation of patients with type 2 diabetes mellitus M.P. Schneider, C. Ott, S. Schmidt, I. Kistner, S. Friedrich, R.E. Schmieder, Germany

249 fp3_2013__ 15.08.13 10:41 Seite 250

1180 Haemodialysis-associated hypoglycaemia and inter-day glycaemic variability assessed by continuous glucose monitoring system in patients with type 2 diabetes S. Popa, C. Vaduva, E. Mota, M. Mota, Romania

1181 Glucose profile in patients with type 2 diabetes and ESRD: comparison between haemodialysis sessions and inter-haemodialysis periods A. Smagala, L. Képénékian, F. Chantrel, L. Meyer, L. Kessler, France

Posters Poster Event D, Wednesday, 13:45 - 14:45

PS 100 Nephropathy: clinical risk factors, markers and outcomes

Chair: L. Thorn, Finland

1182 Socioeconomic risk factors for developing end stage renal disease in patients with childhood onset type 1 diabetes: a population based register study C. Toppe, A. Möllsten, G. Dahlquist, S. Schön, The Swedish Childhood Diabetes Study group, Sweden

1183 Smoking increases the incidence of diabetic nephropathy and end stage renal disease in patients with type 1 diabetes M. Feodoroff, V. Harjutsalo, C. Forsblom, L. Thorn, J. Wadén, N. Tolonen, R. Lithovius, P.-H. Groop, Finland

1184 Metabolic risk factors according to albuminuria and chronic kidney disease in apparently healthy Koreans N. Kim, S. Kim, J. Ahn, J. Yu, H. Hong, H. Choi, Y. Kim, H. Yoo, H. Kim, S. Kim, K. Choi, S. Baik, D. Choi, C. Shin, N. Kim, Korea, Republic of

1185 Genome-wide association scan for diabetes associated chronic kidney disease (CKD) in patients with type 1 and type 2 diabetes N.W. Rayner, H. Desmukh, N. Sandholm, C. Ladenvall, E. Ahlqvist, Eurodiab, FinnDiane, SUMMIT, UK, Finland, Sweden

250 fp3_2013__ 15.08.13 10:41 Seite 251

1186 Urinary proteomics predict onset of microalbuminuria in a cohort of normoalbuminuric type 1 diabetic patients in the DIRECT 1 study F. Persson, M. Lindhardt, P. Zürbig, A. Stalmach, H. Mischak, H. Lambers Heerspink, A. Sjoelie, R. Klein, T. Orchard, M. Porta, J. Fuller, R.W. Bilous, N. Charturvedi, H.-H. Parving, P. Rossing, Denmark, Germany, UK, Netherlands

1187 Alkaline phosphatase is independently associated with renal function in normoalbuminuric type 1 diabetic patients T. Bulum, K. Blaslov, K. Zibar, L. Duvnjak, Croatia

1188 Circulating levels of adrenomedullin are elevated in type 1 diabetes with nephropathy and associated with outcome P. Holmager, U. Pedersen-Bjergaard, J. Faber, C. Kistorp, Denmark Posters

1189 Renal depletion of the organic osmolyte, myo-inositol, in hypertension, diabetes and insulin resistance: therapeutic implications for chronic kidney disease K.M. Loomes, H.-H. Chang, H.-N. Chao, B. Choong, C. Walker, New Zealand

1190 Mortality and requirement of renal replacement therapy in people with type 1 diabetes: a 30 years prospective observational study M. Stadler, S. Peric, H. Strohner-Kaestenbauer, R. Kramar, K. Irsigler, T. Kaestenbauer, F. Kronenberg, R. Prager, UK, Austria

1191 Pitavastatin improves the estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes and hypercholesterolaemia treated with sitagliptin S. Kurioka, Japan

Poster Event E, Thursday, 12:30 - 13:30

PS 101 Nephropathy basic science: from profiling to targets

Chair: A. Flyvbjerg, Denmark

251 fp3_2013__ 15.08.13 10:41 Seite 252

1192 Transcriptional profiling of kidney glomerulus in diabetic mouse models G. Genové, J. Norlin, B. Lavina-Siemsen, E. García-Vaz, M.F. Gómez, C. Betsholtz, Sweden

1193 Electron and confocal microscopy of diabetic E1-DN mouse glomeruli revealed thickening of basement membrane and decreased nephrin expression V. Dumont, M.E. Hyvönen, E. Lehtonen, J. Ustinov, J. Tienari, T. Otonkoski, P.J. Miettinen, S. Lehtonen, Finland Posters 1194 Characterisation of transcriptional influences on the coagulation protease-activated protein C pathway in diabetic nephropathy J.G. Schneider, E. Rybacka, T. Madhusudhan, K. Roomp, B.H. Isermann, Luxembourg, Germany

1195 Experimental podocyte injury leads to reduced expression of CD2AP S. Kuusela, P. Saurus, P. Räihä, T. Palmen, M. Saleem, H. Holthöfer, E. Lehtonen, S. Lehtonen, Finland, UK

1196 Senescence marker protein-30 deficiency accelerates diabetic renal injury through tubulointerstitial fibrosis in a mouse model of type 1 diabetes H. Okada, T. Senmaru, M. Asano, M. Yamazaki, M. Fukui, G. Hasegawa, N. Nakamura, Japan

1197 Methylglyoxal induced insulin resistance in podocytes contributes to diabetic kidney disease L.A. Gallo, B.E. Harcourt, A.K. Fotheringham, D. McCarthy, S.A. Penfold, J.M. Forbes, Australia

1198 Unexpected behaviour of aminoguanidine on human embryonic kidney cell (HEK293) exposed to glycated albumin A.I. Serban, L. Stanca, O.I. Geicu, A. Dinischiotu, Romania

1199 Anti-fibrotic peptide AcSDKP restores diabetes-suppressed microRNA- let-7 cluster and exhibits therapeutic effect on kidney fibrosis in diabetes K. Kanasaki, T. Nagai, S.P. Srivastava, M. Kitada, M. Kanasaki, D. Koya, Japan

252 fp3_2013__ 15.08.13 10:41 Seite 253

1200 Theobromine cocoa prevents high glucose-induced extracelular matrix accumulation via activation of NAD+-dependent deacetylase sirtuin-1 in human mesangial cells E.B. Peixoto, A. Papadimitriou, K.C. Silva, J.M. Lopes de Faria, J.B. Lopes de Faria, Brazil

1201 Cocoa enriched in polyphenols is renoprotective in experimental diabetes mellitus by reducing transforming growth factor beta-1 (Tgfbeta-1) signalling A. Papadimitriou, E.B. Peixoto, K.C. Silva, A.M. Faria, J.M. Lopes de Faria, J.B. Lopes de Faria, Brazil

Poster Event F, Thursday, 13:45 - 14:45 Posters

PS 102 Hypertension: from experimental evidence to bedside

Chair: L. Gnudi, UK

1202 Silencing of a disintegrin and metalloproteinase (ADAM)17 enhances ACE2 protein expression and activity in COS7 cells M. Di Fulvio, N.F. Kashkari, E.J. Shah, H.K. Somineni, H. Chodavarapu, M. Almiahuob, R. Singh, N. Grobe, K.M. Elased, USA

1203 Deletion of GIPR (glucose-dependent insulinotropic polypeptide receptor) in mice results in reduced blood pressure and changes in vascular contractility L.M. Berglund, K. Swärd, Y. Seino, D.J. Drucker, L. Groop, M.F. Gomez, Sweden, Japan, Canada

1204 Prevalence of hypertension and its determinants among Bangladeshi type 2 diabetic subjects F. Jasmine, S. Hossain, H. Chowdhuri, Bangladesh

1205 Normal fasting glucose and HbA1c levels and the development of hypertension in Japanese individuals T. Yamada, Y. Heianza, S. Kodama, Y. Arase, K. Saito, A. Suzuki, S. Hara, O. Hanyu, H. Sone, Japan

253 fp3_2013__ 15.08.13 10:41 Seite 254

1206 The effect of pre-measurement rest time on ankle systolic pressures in people with and without diabetes V.H. Chuter, S.L. Casey, Australia

1207 Prognostic value of reading-to-reading blood pressure variability over 24 hours in 584 patients with diabetes from 11 populations T. Hansen, L. Thijs, Y. Liu, K. Asayama, Y. Li, J. Boggia, K. Björklund- Bodegård, E. Dolan, T. Kuznetsova, K. Stolarz-Skrzypek, V. Tikhonoff, S. Malyutina, J.A. Staessen, on behalf of the IDACO Investigators, Denmark, Belgium, China, Uruguay, Sweden, UK, Poland, Italy, Russian Federation Posters 1208 Targeting nocturnal hypertension in type 2 diabetes: bedtime dosing of once-daily antihypertensive drugs reduces night-time BP and 24-h BP N.B. Rossen, S.T. Knudsen, E. Ebbehøj, P.L. Poulsen, K.W. Hansen, Denmark

1209 Arterial stiffness is associated with diabetic complications in type 1 diabetes and normalisation of albuminuria is associated with reduced arterial stiffness S. Theilade, T.W. Hansen, P. Rossing, Denmark

1210 Blood pressure independent effect of renin angiotensin system blockade on soluble klotho levels in patients with type 2 diabetes and albuminuria J. Karalliedde, G. Maltese, G. Viberti, L. Gnudi, UK

1211 Effect of direct renin inhibitor aliskiren on circulating endothelial progenitor cells number in patients with type 2 diabetes mellitus and arterial hypertension M.C. Mazioti, K.P. Markakis, A.E. Raptis, E. Maratou, I. Ikonomidis, D.V. Vlahakos, A. Tsirogianni, S.A. Raptis, G.D. Dimitriadis, Greece

Poster Event A, Tuesday, 12:30 - 13:30

PS 103 Basic science retinopathy: novel in vitro and in vivo findings

Chair: G.M. Lorenzi, USA

254 fp3_2013__ 15.08.13 10:41 Seite 255

1212 The C57BL/KsJ-db/db mouse: an appropriate model for investigating diabetes-induced retinal neurodegeneration R. Simó, P. Bodganov, L. Corraliza, A.R. Carvalho, C. Hernández, Spain

1213 Connexin 43 (Cx43) upregulation rescues retinal endothelial cells from high glucose-induced apoptosis and excess permeability through amelioration of tight junctions S. Roy, K. Barrette, T. Tien, USA

1214 Activation of cell proliferation and VEGF transcription by advanced glycation end-products in hydroquinone-treated human retinal pigment epithelial cells H. Tsujinaka, A. Itaya-Hironaka, A. Yamauchi, S. Sakuramoto-Tsuchida, H. Ota, T. Fujimura, K. Nochioka, K. Shimoyama-Miyata, N. Ogata, S. Posters Takasawa, Japan

1215 Mesenchymal stem cell-derived microvesicles induce pericyte destabilisation in diabetic-like conditions T. Lopatina, E. Beltramo, E. Berrone, M. Porta, Italy

1216 VEGF165b reduces blood vessel dysfunction in diabetic retinas N. Ved, R. Hulse, L.F. Donaldson, J.W. Bainbridge, D.O. Bates, UK

1217 The role of macrophage migration inhibitory factor in a mouse model of diabetic retinopathy J. Wang, Germany

1218 S-nitrosoglutathione eye drop inhibits inducible nitric oxide synthase up-regulation by post-translational modification in experimental diabetic retinopathy M.A. Rosales, K.C. Silva, D.A. Duarte, M.G. De Oliveira, J.B. Lopes de Faria, J.M. Lopes de Faria, Brazil

1219 Neuroprotective effect of fenofibrate on retinal neurodegeneration in an experimental mouse model of type 2 diabetes L. Corraliza, P. Bogdanov, A. Rodrigues-Carvalho, J. García-Arumí, C. Hernández, R. Simó, Spain

255 fp3_2013__ 15.08.13 10:41 Seite 256

Poster Event B, Tuesday, 13:45 - 14:45

PS 104 Clinical retinopathy

Chair: M. Porta, Italy

1220 Epi-retinal membranes, pseudoholes and macular holes in diabetes A.D. Wright, N.K. Bilkhu, E.L. Curtis, M. Clarke, UK

1221 Inflammation and visceral obesity: possible link to pathogenesis of Posters diabetic retinopathy in type 2 diabetes M. Tomic, B. Novak, N. Car, S. Kastelan, S. Ljubic, Croatia

1222 Diabetic retinopathy is associated with arterial stiffness independent of albuminuric status in patients with type 2 diabetes S. Moon, E. Kim, E. Mo, J. Han, S. Moon, Korea, Republic of

1223 Digital retinal imaging: community heath workers as imagers in rural areas versus an ophthamology clinic K.M. Colleran, C. McAuley, E. Harding, G. Zamora, E. McGrew, D. Thomas, G. Axford, P. Soliz, USA

1224 Retinopathy at diagnosis of type 2 diabetes: more or less prevalent at older ages? I.M. Stratton, S.J. Aldington, M. Histed, P.J. Scanlon, UK

1225 Obstructive sleep apnoea predicts the development of preproliferative and proliferative retinopathy in patients with type 2 diabetes: a longitudinal analysis A. Tahrani, P. Dodson, A. Ali, N. Raymond, Q. Altaf, H. Wharton, H. Fellows, R. Hampshire, M. Shah, E. Curtis, J. Miah, A. Barnett, M.J. Stevens, UK

1226 High cystatin C level hints severe retinopathy in type 2 diabetic patients R. He, F. Liu, J. Shen, H. Zeng, L. Li, W. Jia, China

1227 GLP-1 therapy and diabetic retinopathy: temporary progression and the need to monitor L. Varadhan, T. Humphreys, A. Walker, G.I. Varughese, UK

256 fp3_2013__ 15.08.13 10:41 Seite 257

Poster Event C, Wednesday, 12:30 - 13:30

PS 105 Autonomic neuropathy

Chair: P. Kempler, Hungary

1228 Cardiovascular autonomic neuropathy and lower urinary tract symptoms in men with type 1 diabetes R. Pop-Busui, J. Hotaling, H. Wessels, B. Braffett, P. Cleary, R. Dunn, C. Martin, A. Sarma, USA

1229 Prevalence and risk factors of cardiac autonomic nerve dysfunction in the elderly population with diabetes and prediabetes: the KORA S4 survey

D. Ziegler, A. Voss, S. Nowak, M. Scheer, W. Rathmann, S. Perz, M. Roden, Posters A. Peters, C. Meisinger, KORA Study Group, Germany

1230 Associations between postural hypotension and neuropathy in type 2 diabetes: the Fremantle Diabetes study phase II T.M. Davis, A. Knapp, W.A. Davis, Australia

1231 Gastric emptying, glycaemia, and upper GI symptoms are independent factors in diabetic gastroparesis N. Ejskjaer, J. Wo, T. Esfandyari, M. Jamal, G. Dimcevski, L. Tarnow, R. Malik, P. Hellstrom, E. Mondou, E. Mondou, J. Quinn, J. Quinn, F. Rousseau, M. Richard, Denmark, USA, Norway, UK, Sweden

1232 Gastroparesis in adults with type 1 diabetes from the type 1 diabetes exchange clinic registry G. Aleppo, N.C. Foster, K.M. Miller, R.W. Beck, USA

1233 New technologies of fertility restoration in patients with type 1 diabetes mellitus and an autonomic neuropathy Y. Shvarts, D. Kurbatov, G. Galstian, A. Lepetukhin, S. Dubskiy, Russian Federation

1234 Assessment of sudomotor function as a screening tool for microvascular complications in type 2 diabetes V. Eranki, J.-H. Calvet, India, France

257 fp3_2013__ 15.08.13 10:41 Seite 258

1235 Screening for diabetes and its microvascular complications in subjects at risk by a rapid and non-invasive measurement of sweat function J.-H. Calvet, France

1236 Sudomotor dysfunction is associated with increased mortality in patients with chronic kidney disease, with or without diabetes mellitus D.S. Tesic, N. Papanas, S. Vodopivec, B. Malinovic, Serbia, Greece

1236a Sexual dysfunction among Sri Lankan adults: effect of diabetes R.M. Jayawardena, D.A. Lamabadusuriya, P. Ranasinghe, D.H. Punyadasa, Posters R. Sheriff, D.R. Matthews, P. Katulanda, Sri Lanka, UK

Poster Event D, Wednesday, 13:45 - 14:45

PS 106 Neuropathy I: correlates and treatments

Chair: B. Mankovsky, Ukraine

1237 Association between distal arterial calcification and diabetic neuropathy in diabetes mellitus N.A. Molitvoslovova, O.V. Manchenko, M.V. Yaroslavceva, G.R. Galstyan, Russian Federation

1238 Skin microvascular reactivity relates to advanced glycation endproducts accumulation and endothelial activation in patients with diabetes J. Skrha Jr, J. Soupal, L. Landova, J. Kvasnicka, M. Prazny, J. Skrha, Czech Republic

1239 Serum osteoprotegerin levels are associated with peripheral neuropathy in patients with type 2 diabetes I. Eleftheriadou, P. Grigoropoulou, I. Mourouzis, V. Argiana, A. Kokkinos, D. Perrea, N. Katsilambros, N. Tentolouris, Greece

1240 Osteoprotegerin, RANKL, RANK genes polymorphisms in diabetic Charcot neuroosteoarthropathy A. Korzon-Burakowska, B. Bruhn-Olszewska, J. Jakobkieiwcz-Banecka, G. Wegrzyn, Poland

258 fp3_2013__ 15.08.13 10:41 Seite 259

1241 Long-term effect of quinapril or losartan or their combination on diabetic autonomic neuropathy and left ventricular function over a period of 4 years T.P. Didangelos, G. Arsos, E. Moralidis, F. Iliadis, A. Zantidis, A. Hatzitolios, Greece

1242 Amelioration of neuropathic changes with correction of nerve insulin resistance in diabetic Goto-Kakizaki rats treated with DPP-IV inhibitor vildagliptin K. Tsuboi, H. Mizukami, W. Inaba, K. Kamata, S. Ogasawara, S. Yagihashi, Japan

1243 Treatment for chronic pain syndrome of diabetic peripheral neuropathy in type 2 diabetics with thioctic acid and standardised protein-free dialysate Posters of calf blood L.A. Ivanova, O.N. Rostovtseva, Russian Federation

Poster Event E, Thursday, 12:30 - 13:30

PS 107 Neuropathy II: large fibres, small fibres, peripheral and central

Chair: D. Selvarajah, UK

1244 The influence of diabetic neuropathy on imbalance in patients with diabetes mellitus O.S. Fedorova, I.V. Gurieva, I.A. Strokov, L.T. Ahmedzhanova, Russian Federation

1245 Function of large nerve fibres and levels of HSP27 in type 1 diabetes: a longitudinal follow-up K. Pourhamidi, H. Skärstrand, L.B. Dahlin, O. Rolandsson, Sweden

1246 Prevalence of chronic use of metformin-related vitamin B12 deficiency is lower in Asian population H. Chun, Y.-B. Ahn, S. Ko, S. Moon, S.-H. Ko, Korea, Republic of

1247 Pain threshold values of small fibres are associated with the severity of diabetic complications D. Kukidome, M. Sato, S. Shimoda, T. Nishikawa, E. Araki, Japan

259 fp3_2013__ 15.08.13 10:41 Seite 260

1248 Retinal nerve fibre layer thickness is associated with measures of small fibre neuropathy in long-term type 1 diabetes K.A. Sveen, K. Ørstavik, D. Fosmark, K. Dahl-Jørgensen, K.F. Hanssen, Norway

1249 Association of subclinical inflammation with polyneuropathy in the older population: KORA F4 study C. Herder, B.W. Bongaerts, W. Rathmann, M. Heier, B. Kowall, W. Koenig, B. Thorand, M. Roden, C. Meisinger, D. Ziegler, Germany

Posters 1250 Impact of neuropathy severity on brain volume loss in diabetic peripheral neuropathy D. Selvarajah, M. Maxwell, J. Davies, A. Sankar, E. Cachia, R. Gandhi, I. Wilkinson, S. Tesfaye, UK

Poster Event F, Thursday, 13:45 - 14:45

PS 108 Diabetic foot: epidemiology, risk factors and outcomes

Chair: N.C. Schaper, Netherlands

1251 Reduced incidence of lower-extremity amputations in a Danish diabetes population from 2000 to 2012 M.E. Jørgensen, T.P. Almdal, K. Faerch, Denmark

1252 Pre-hospital delay in patients with diabetic foot problems: influencing factors and subsequent quality of care B. Zhou, J. Yan, China

1253 The impact of impaired renal function on the prediction of diabetic foot complications: Should it be included on foot risk classifications? M. Monteiro-Soares, D. Martins-Mendes, M. Dinis-Ribeiro, R. Guimarães, A. Távora, E. Lemos, J. Sobral, I. Duarte, J. Campos-Lemos, D. Brandão, M. Madureira, M. Ribeiro, M. Oliveira, Portugal

1254 Diabetic foot and endothelial precursors cells (EPC): preliminary results of an Italian AIL (Italian Leukaemia Association section of Treviso) research project S. Maria, E. Seganfreddo, A. Paccagnella, A. Furlan, F. Canal, A. Dei Tos, F. Gherlinzoni, Italy

260 fp3_2013__ 15.08.13 10:41 Seite 261

1255 Diabetic foot in patients on renal replacement therapy in Lleida health area (Spain) V. Rosado, R. Pacheco, M. Doria, M. Hernández, B. Àngels, V. Maria, V. Joan, F. Rius, D. Mauricio, Spain

1256 Migratory activity of circulating endothelial progenitor cells predicts mortality in patients with diabetic foot G. Spinetti, O. Fortunato, C. Specchia, E. Sangalli, S. Losa, G. Clerici, M. Caminiti, E. Faglia, P. Madeddu, Italy, UK

1257 Lower-limb risk factors for falls in those with and without diabetes mellitus C. MacGilchrist, L. Paul, B.M. Ellis, T.E. Howe, B. Kennon, J. Godwin, Ireland, UK Posters

1258 Assessment of optimum transcutaneous oxygen pressure to predict diabetic foot ulcer healing and indicate angiography J. Jirkovská, J. Venerová, J. Skibová, A. Jirkovská, L. Fialová, L. Vedralová, J. Faltová, S. Solař, M. Zavoral, Czech Republic

1259 The long-term outcomes of endovascular procedure in diabetic patients with critical limb ischaemia according to chronic kidney disease stage G. Galstyan, O. Bondarenko, N. Ayubova, I. Sitkin, Russian Federation

Poster Event A, Tuesday, 12:30 - 13:30

PS 109 Pregnancy: treatment, efficacy and safety

Chair: H.R. Murphy, UK

1260 Effectiveness of metformin in gestational diabetes: systematic review and meta-analysis

M.O. Khin, M. Vatish, S. Gates, P. Saravanan, UK

1261 Study of the safety and efficacy of the use of insulin and metformin in combination in gestational diabetes D. ODonoghue, G. Adebayo, C.M. McHugh, Ireland

261 fp3_2013__ 15.08.13 10:41 Seite 262

1262 Breaking down misclassifications: not all gestational diabetes needs treatment as not all children need insulin D. Iafusco, A. Napoli, G. Balbi, N. Tinto, L. Sacchetti, C. Giuliani, O. Bitterman, V. Rozzi, A. Zanfardino, F. Stoppoloni, Italy

1263 Preliminary data on pregnancy outcome of diabetic mothers treated with basal insulin lispro-protamine in a multicentre study in northeast of Italy M. Dalfrà, A. Filippi, A. Soldato, P. Moghetti, S. Lombardi, C. Vinci, T. Romanelli, A. Lapolla, Italy

Posters 1264 Insulin treatment in women with gestational diabetes mellitus: Is there a label effect on delivery characteristics? D. Tundidor, A. García-Patterson, M.A. María, J. Ubeda, J.M. Adelantado, A. De Leiva, R. Corcoy, Spain

1265 Type 1 diabetes and pregnancy: continuous subcutaneous insulin infusion systems versus multiple daily injection therapy J. Saraiva, S. Paiva, L. Ruas, L. Barros, C. Baptista, M. Melo, M. Alves, S. Gouveia, C. Moreno, D. Guelho, E. Marta, L. Gomes, P. Moura, F. Carrilho, Portugal

1266 Real-time continuous glucose monitoring in pregnant women with type 1 diabetes at high risk of severe hypoglycaemia E.R. Mathiesen, A.L. Secher, E. Stage, L. Ringholm, C. Barfred, P. Damm, Denmark

1267 Serum levels of the myokine and adipokine irisin are decreased in pregnancies complicated by preeclampsia S. Kralisch-Jäcklein, J. Richter, H. Stephan, J. Hindricks, A. Jank, W. Schaarschmidt, S. Schrey, U. Lössner, B. Jessnitzer, M. Blüher, M. Stumvoll, M. Fasshauer, T. Ebert, Germany

1268 GDm-Health: telehealth for remote monitoring and treatment of gestational diabetes L. Loerup, O.J. Gibson, J.E. Hirst, A.J. Farmer, K. Bartlett, J.E. Blincowe, Y.M. Kenworthy, D.A. Kevat, L.H. MacKillop, L. Tarassenko, J.C. Levy, UK

262 fp3_2013__ 15.08.13 10:41 Seite 263

Poster Event B, Tuesday, 13:45 - 14:45

PS 110 Pregnancy outcomes in GDM

Chair: A.G. Tabák, Hungary

1269 Pregnancy outcome in gestational diabetes mellitus compared to the Swedish birth register C. Nilsson, D. Ursing, H. Strevens, M. Landin-Olsson, Sweden

1270 Maternal prepregnancy body mass index but not gestational diabetes determines postnatal growth from birth to 4 years P. Gil-Lluís, R.E. Yañez, S. Näf, G. Llauradó, M. Ballesteros, J.J. Vendrell,

A. Megía, Spain Posters

1271 Effects of prepregnancy weight on foetal growth in patients with well controlled gestational diabetes mellitus G. Perez Lopez, A. Becerra Fernandez, R. Villar, L. Yus Lopez, M. Menacho Roman, Spain

1272 Maternal glucose levels in early pregnancy, gestational diabetes, prepregnancy BMI and the risk of childhood obesity: the mother child cohort, RHEA study in Crete, Greece L. Chatzi, M. Karachaliou, V. Daraki, V. Georgiou, S. Koinaki, G. Chalkiadaki, A. Pappas, M. Kogevinas, Greece

1273 Predictors of newborn and placental weight and placental ratio in women with gestational diabetes mellitus A.E. Ramos, F. Caimari, I.M. Pujol, A. Garcia Petterson, G. Ginovart, J.M. Adelantado, R. Corcoy, Spain

1274 ATLANTIC DIP: gestational weight gain and pregnancy outcomes in women with pregestational and gestational diabetes mellitus A.M. Egan, M.C. Dennedy, W. Al-Ramli, A. Heerey, F. Dunne, Ireland

1275 Serum interleukin-1-receptor antagonist levels in women with prior gestational diabetes mellitus and in control women Z. Janicsek, E. Szabó, T. Tänczer, V. Ferencz, Á.G. Tabák, Hungary, UK

263 fp3_2013__ 15.08.13 10:41 Seite 264

1276 Metabolic characterisation of women with prior gestational diabetes maintaining normal glucose tolerance up to five years postpartum Y. Winhofer, A. Tura, A. Thomas, T. Prikoszovich, C. Winzer, G. Pacini, A. Luger, A. Kautzky-Willer, Austria, Italy

1277 A multiplatform metabolomics study of gestational diabetes mellitus D. Dudzik, M. Zorawski, M. Skotnicki, W. Zarzycki, G. Kozlowska, K. Bibik- Malinowska, C. Barbas, Spain, Poland

1278 Gestational diabetes mellitus after gestational diabetes mellitus Posters C. Giuliani, O. Bitterman, C. Festa, V. Rozzi, P. Bianchi, L. Mattei, M. Bongiovanni, V. Toscano, A. Napoli, Italy

Poster Event C, Wednesday, 12:30 - 13:30

PS 111 Pregnancy - GDM: risk factors and delivery outcomes

Chair: E. Wender-Ozegowska, Poland

1279 Genetic background of gestational diabetes mellitus in the Czech population D. Vejrazkova, P. Lukasova, M. Vankova, O. Bradnova, T. Halkova, J. Vcelak, V. Cirmanova, K. Andelova, H. Krejci, B. Bendlova, Czech Republic

1280 Daily arsenic contamination associated with gestational diabetes and low Apgar score F. Jebunnesa, B. Banu, L. Ali, Bangladesh

1281 Gestational diabetes screening: new considerations on the recent Italian recommendations B. Arcidiacono, C. Capula, E. Chiefari, V. Ventura, S. Iiritano, A. Vero, L. Puccio, V. Pullano, D. Foti, A. Brunetti, R. Vero, Italy

1282 Prediction for development of gestational diabetes mellitus in the 1st trimester of gestation based on levels of HOMA-IR index Z. Zabarovskaya, S. Pavlukova, O. Zabarovskaya, Belarus

1283 Insulin secretion in addition to insulin resistance predicts gestational diabetes mellitus E.-C. Krzizek, J.M. Brix, G.-H. Schernthaner, G. Schernthaner, Austria

264 fp3_2013__ 15.08.13 10:41 Seite 265

1284 Serum adiponectin levels in women with previous gestational diabetes E. Szabó, Z. Janicsek, Á. Fürst, R. Magenheim, T. Taenczer, J. Kósa, G. Tamás, Á.G. Tabák, Hungary, Germany, UK

1285 Estimation of the postpartum glucose intolerance risk in women with gestational diabetes mellitus using routine glycaemic indices assessed in the mid-trimester of pregnancy K. Kankova, V. Bartakova, D. Maluskova, J. Muzik, J. Belobradkova, Czech Republic

1286 Changes of serum vaspin, adiponectin, MCP-1 and BDNF during course of pregnancy and their association with glucose metabolism L. Bozkurt, C.S. Göbl, K. Leitner, J. Scholz, D. Bancher-Todesca, A. Luger, A. Kautzky-Willer, Austria Posters

1287 The effect of prior gestational diabetes on the shape of the glucose response curve during an oral glucose tolerance test 3 years after delivery T. Tänczer, Z. Janicsek, B. Domján, E. Fazekas, V. Ferencz, Á.G. Tabák, Hungary, UK

1288 The role of HbA1c as a risk predictor for overt diabetes after pregnancy with gestational diabetes mellitus C.S. Göbl, L. Bozkurt, T. Prikoszovich, A. Tura, G. Pacini, A. Kautzky-Willer, Austria, Italy

Poster Event D, Wednesday, 13:45 - 14:45

PS 112 Pregnancy in diabetes

Chair: F.J. Nóvoa, Spain

1289 Fertility in affected and non-affected siblings in families with type 1 diabetes: results from the type 1 diabetes genetics consortium (T1DGC) J.C. Wiebe, Á. Santana, N. Medina Rodríguez, M. Hernández, J. Nóvoa, D. Mauricio, A.M. Wägner on behalf of the T1DGC, Spain

1290 Circadian variation in glucose during diabetic pregnancy is associated with macrosomia in the newborn E.M. Scott, G.T. Ellison, R. Temple, H. Murphy, G.R. Law, UK

265 fp3_2013__ 15.08.13 10:41 Seite 266

1291 In pregnancy maternal active ghrelin levels predict positively neonatal birth waist and negatively cord blood insulin levels G. Valsamakis, D.C. Papatheodorou, A. Naoum, A. Margeli, I. Papassotiriou, E. Kapantais, G. Creatsas, G. Mastorakos, Greece

1292 Risk factors of macrosomia in type 1 diabetes pregnancy: one centre analysis between 1999 and 2012 K. Cyganek, B. Katra, J. Skupien, A. Hebda-Szydło, I. Janas, I. Trznadel- Morawska, M. Szopa, P. Witek, E. Kozek, M.T. Malecki, Poland

Posters 1293 1, 5-Anhydroglucitol (1, 5 AG) and neonatal complications in pregnancy complicated by diabetes L.A. Wright, I.B. Hirsch, T. Gooley, Z. Brown, USA

1294 Pregnancy outcomes in diabetic type 1 patients of an academic centre combining endocrine and obstetric care from before conception to delivery; still not good enough L.B. Hoeks, H.W. De Valk, A.C. De Kat, G.H. Visser, Netherlands

1295 Obesity and gestational weight gain both contribute to the risk of large for gestational age babies in women without gestational diabetes mellitus E. Cosson, P. Valensi, I. Pharisien, M. Nguyen, L. Carbillon, France

1296 Outcome of pregnancies in women with type 1 diabetes M. Landin-Olsson, D. Ursing, H. Strevens, Sweden

1297 Maternal high fat diet alters weight regulation and blood glucose prior to mating but not during gestation, and reduces offspring weight at weaning K. Rooney, K. Fredericks, P. Ruell, Y. Mavros, C. Thompson, S. Ozanne, Australia, UK

1298 Excretion of amino nitrogen and ammonia with the urine in patients with type 1 diabetes, according to the gestational age and the severity of nephropathy Z.R. Alimetova, F.V. Valeeva, Russian Federation

266 fp3_2013__ 15.08.13 10:41 Seite 267

Poster Event E, Thursday, 12:30 - 13:30

PS 113 Mechanisms of vascular disease

Chair: M. Federici, Italy

1299 Endothelial dysfunction induced by dipeptidyl peptidase-4 in isolated mice mesenteric microvessels C.F. Sanchez-Ferrer, T. Romacho, S. Vallejo, L.A. Villalobos, N. Wronkowitz, H. Sell, J. Eckel, C. Peiro, Spain, Germany

1300 Hyperglycaemia-induced resistance to GLP-1 in the endothelium: the possible involvement of NRF2 and PKC pathway

G. Pujadas, L. La Sala, A. Ceriello, Spain Posters

1301 The phosphodiesterase-5 inhibitor tadalafil decreases ET-1 expression in HUVECs and suppresses circulating ET-1 levels type 2 diabetes mellitus patients J. Olausson, L. Sjögren, L. Mattsson Hultén, P.A. Jansson, Sweden

1302 The new role of PDK4 in vascular calcification I.-K. Lee, S.-J. Lee, J. Jeong, K.-U. Lee, Korea, Republic of

1303 FoxO1 compartmentalisation results in different metabolomic profiles in human endothelial cells R. Menghini, V. Casagrande, M. Cardellini, M. Fabrizi, E. Martelli, F. Davato, M. Morelli, M. Mavilio, R. Stoehr, A. Ippoliti, D. Accili, M. Federici, Italy, USA

1304 Monoamine oxidase activity promotes type 1 diabetes-induced mitochondrial dysfunction and cardiac damage N. Kaludercic, N. Paolocci, F. Di Lisa, Italy, USA

1305 Repetitive selective breeding for susceptibility to glucose intolerance accelerates atherosclerotic lesion formation in mice A. Asai, M. Nagao, Y. Shuto, M. Kawahara, H. Sugihara, S. Oikawa, Japan

1306 Histone methyltransferase EZH2 regulates glucose induced VEGF production through H3K27 methylation in retinal endothelial cells M.A. Ruiz, S. Chakrabarti, Canada

267 fp3_2013__ 15.08.13 10:41 Seite 268

1307 Impaired glucose tolerance in rats is associated with a reduced expression of hepatocyte growth factor J. Klimas, L. Pivackova, L. Mesarosova, B. Gajdacova, L. Mensikova, J. Srankova, E. Malikova, K. Galkova, P. Ochodnicky, P. Krenek, Slovakia, Netherlands

Poster Event F, Thursday, 13:45 - 14:45

PS 114 Sleep apnoea, cognitive function and musculoskeletal complications Posters

Chair: P. Diem, Switzerland

1308 Obstructive sleep apnoea is independently associated with arterial stiffness and in-hospital early clinical outcome after first-ever ischaemic stroke in type 2 diabetes C. Voulgari, T. Loukopoulos, K. Fotopoulou, S. Chorepsima, P. Tsiodra, C. Stefanadis, K. Tsioufis, Greece

1309 Characterising sleep apnoea syndrome in type 2 diabetes (Sweet Sleep study) A. Lecube, A. Ciudin, C. Hernández, G. Sampol, O. Romero, J. Mesa, R. Simó, Spain

1310 Association between glycaemic control and impaired lung function in Japanese adults Y. Kabeya, K. Kato, M. Okisugi, M. Kawasaki, M. Tomita, T. Katsuki, Y. Oikawa, A. Shimada, Japan

1311 Type 2 diabetes is an independent risk factor for dementia conversion in mild cognitive impairment patients A. Ciudin, A. Espinosa, A. Ruiz, M. Alegret, C. Hernández, M. Boada, R. Simó, Spain

1312 Selective cognitive decline is related to focal brain volume loss in type 1 diabetes patients with microangiopathy: a 4 year follow-up E. Van Duinkerken, F. Barkhof, M. Klein, F.J. Snoek, R.G. IJzerman, M. Diamant, Netherlands

268 fp3_2013__ 15.08.13 10:41 Seite 269

1313 Hypoglycaemia related events due to falls in elderly diabetics (H.E.A.L.E.D) study using a US commercial database J. Mukherjee, S. Kachroo, H. Kawabata, S.A. Colilla, L. Shi, Y. Zhao, V.A. Fonseca, U. Iloeje, USA

1314 Incidence and predictors of hip fracture in type 2 diabetes: the Fremantle Diabetes study W.A. Davis, E.J. Hamilton, M. Zakaria, T.M. Davis, Australia

1315 Diabetes is not a risk factor for the carpal tunnel syndrome: a case- control study S.H. Hendriks, P.R. Van Dijk, K.H. Groenier, P. Houpt, H.J. Bilo, N. Kleefstra, Netherlands Posters

Poster Event A, Tuesday, 12:30 - 13:30

PS 115 Other diabetic complications

Chair: K.E. Brismar, Sweden

1316 Urologic complications and health-related quality of life in type 1 diabetes: long-term follow-up in the DCCT/EDIC study A.M. Jacobson, B.H. Braffett, P.A. Cleary, R.L. Dunn, M.E. Larkin, H. Wessels, A.V. Sarma, DCCT/EDIC Research Group, USA

1317 Prevalence of urinary tract infection among type 2 diabetes mellitus patients vs non-diabetic patients in Germany S. Yu, C. Zhao, K. Joshi, Y. Qiu, USA

1318 Disease burden of urinary tract infections among type 2 diabetes mellitus patients: a US database study A.Z. Fu, S. Yu, Y. Qiu, S.S. Engel, R. Shankar, S. Rajpathak, K.G. Brodovicz, L. Radican, USA

1319 Statin therapy is associated with development of new onset diabetes after transplantation (NODAT) in liver recipients Y. Cho, E. Choe, Y. Choi, D. Joo, B.-W. Lee, M. Kim, B. Cha, H. Lee, E. Kang, Korea, Republic of

269 fp3_2013__ 15.08.13 10:41 Seite 270

1320 Sex hormone-binding globulin: a new marker of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus Y. Hu, X. Hua, G. Tong, Y. Zhong, W. Wang, L. Li, Y. Sun, China

1321 Low relative skeletal muscle mass is independently associated with NAFLD in Korean women with type 2 diabetes Y.J. Choi, J.S. Lim, S.-H. Jee, E.-J. Lee, S.H. Lee, B.W. Huh, K.B. Huh, Korea, Republic of

1322 Insulin resistance and hepatic steatosis relate to increased cardiac Posters oxidative stress in mice J. Szendroedi, T. Jelenik, U. Floegel, E. Phielix, K. Kaul, P. Nowotny, H. Partke, J. Schrader, M. Roden, Germany

1323 Increased accumulation of skin advanced glycation end products is associated with microvascular complications and insulin resistance in type 1 diabetes A. Araszkiewicz, J. Schlaffke, P. Niedzwiecki, D. Zozulinska-Ziolkiewicz, D. Naskret, B. Wierusz-Wysocka, Poland

1324 Activated Notch1 signalling has repressive effects on wound healing in diabetes S.-B. Catrina, V. Sunkari, I. Botusan, J. Grünler, A. Catrina, F. Radtke, X. Zheng, K. Brismar, Sweden, Switzerland

Poster Event B, Tuesday, 13:45 - 14:45

PS 116 Cerebrovascular and peripheral artery disease

Chair: A. Vaag, Denmark

1325 Impact of established and undiagnosed type 2 diabetes mellitus on acute ischaemic stroke severity and outcome K. Tziomalos, S. Bouziana, M. Spanou, A. Pavlidis, V. Giampatzis, M. Papadopoulou, C. Boutari, D. Magkou, F. Iliadis, C. Savopoulos, A. Hatzitolios, Greece

1326 Falling or static national rates of diabetes-related vascular and renal outcomes from 2006 to 2011 despite a 50% increase in diabetes prevalence P.L. Drury, P.W. Giles, E. Jo, New Zealand

270 fp3_2013__ 15.08.13 10:41 Seite 271

1327 Diabetes mellitus and chronic kidney disease amplify accumulation of tissue advanced glycation end products in patients with peripheral artery disease J.D. Lefrandt, L.C. De Vos, D.J. Mulder, R.P. Dullaart, H.L. Lutgers, H.J. Lambers Heerspink, A.J. Smit, P.W. Kamphuisen, C.J. Zeebregts, Netherlands

1328 Skin autofluorescence as a measure of tissue advanced glycation end products deposition is elevated in diabetic patients with peripheral artery disease L.C. De Vos, D.J. Mulder, R.P. Dullaart, H.L. Lutgers, A.J. Smit, P.W. Kamphuisen, J. Westra, C.J. Zeebregts, J.D. Lefrandt, Netherlands

1329 Relationship between peripheral vascular calcification and accuracy of Posters ankle brachial index and pulse palpation to screen peripheral arterial occlusive disease A. Hartemann, C.E. Aubert, P. Cluzel, S. Kemel, P.-L. Michel, F. Lajat-Kiss, M. Dadon, O. Bourron, France, Switzerland

1330 Statin therapy successfully maintains low LDL-C in type 2 diabetes mellitus and prevents the age-related LDL-C increase H.L. Lutgers, M.M. Van der Klauw, J.V. Van Vliet-Ostaptchouk, S.N. Slagter, A.P. Van Beek, B.H. Wolffenbuttel, Netherlands

1331 The effect of HMG-CoA reductase inhibitor of ischaemic heart disease and cerebrovascular attack in elderly diabetic individuals: difference in risk by age T. Hayashi, H. Nomura, A. Araki, K. Yokote, M. Takemoto, M. Noda, H. Noto, H. Sone, Japan CDM group, Japan

1332 Vitamin D and carotid intima media thickness in 416 Danish patients with type 2 diabetes mellitus at entry into the CIMT trial K. Winckler, T. Boesgaard, L. Tarnow, H. Vestergaard, T. Almdal, L. Lundby- Christensen, A. Vaag, S. Madsbad, C. Gluud, The CIMT Trial Group, Denmark

1333 Improved cardiovascular function after prolonged caloric restriction in obese patients with type 2 diabetes mellitus and cardiac complications L.D. Van Schinkel, J.J. Westenberg, J.T. Jonker, A. De Roos, H.J. Lamb, J.W. Smit, Netherlands

271 fp3_2013__ 15.08.13 10:41 Seite 272

Poster Event C, Wednesday, 12:30 - 13:30

PS 117 Risk factors for cardiovascular disease

Chair: K. Khunti, UK

1334 Diabetes duration rather than the level of metabolic control is a determinant of endothelial damage in type 1 diabetes E. Szymanska-Garbacz, L. Czupryniak, P. Grzelak, M. Podgorski, M. Saryusz-Wolska, M. Pawlowski, J. Loba, L. Stefanczyk, Poland Posters

1335 Prognostic impact of haemoglobin A1c in high-risk type 2 diabetic patients: the Rio de Janeiro type 2 diabetes cohort study C.R. Cardoso, N.C. Leite, G.F. Salles, Brazil

1336 Glycaemic variability is related to duration of diabetes rather than cardiovascular risk factors G. Koh, S.-Y. Yoo, S. Lee, D.-H. Lee, H.-J. Chin, Korea, Republic of

1337 Restenosis after percutaneous transluminal coronary angioplasty in individuals with different categories of glucose tolerance: a 1-year follow-up study L. Zhang, Y. Gu, Y. Dong, X. Zhang, D. Shang, China

1338 Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes S. Paul, B.L. Thorsted, M. Wolden, K. Klein, K. Khunti, Australia, Denmark, UK

1339 Secondary prevention in patients with type 2 diabetes and previous myocardial infarction in Dutch primary care G.E. Rutten, A. Wezendonk, M.J. Kasteleyn, H. Jansen, Netherlands

1340 Significant impact of gender on the association of HbA1c with angiographically diagnosed coronary atherosclerosis C. Malin, A. Vonbank, P. Rein, D. Zanolin, C.H. Saely, H. Drexel, Austria, Liechtenstein, USA

272 fp3_2013__ 15.08.13 10:41 Seite 273

1341 Gender differences in cardiovascular events, cardiovascular and all- cause mortality in type 2 diabetes: lesson from the San Luigi Gonzaga Diabetes study F.L. Cavalot, A. Pagliarino, M. Valle, L. Di Martino, F. Mazzaglia, K. Bonomo, M. Trovati, Italy

1342 Evidence for sex-specific effect of serum total adiponectin on cardiovascular death in patients with type 2 diabetes mellitus C. Menzaghi, M. Xu, L. Salvemini, C. De Bonis, G. Fini, G. Palladino, S. Bacci, L. Qi, V. Trischitta, Italy, USA

Poster Event D, Wednesday, 13:45 - 14:45 Posters PS 118 Non-invasive characterisation of cardiovascular disease

Chair: H.-H. Parving, Denmark

1343 Risk stratification with plasma-NT-proBNP and coronary calcium score predicts all-cause mortality in type 2 diabetic patients B.J. Von Scholten, H. Reinhard, P.G. Jørgensen, S. Theilade, P.R. Hansen, N. Wiinberg, A. Kjær, C.L. Petersen, K. Winther, H.-H. Parving, J.S. Jensen, P.K. Jacobsen, P. Rossing, Denmark

1344 Stress cardiac magnetic resonance imaging reveals hypoperfusion in asymptomatic type 1 diabetes patients, missed by the routine non-invasive evaluation A. Melidonis, K. Bratis, E. Fousteris, P. Gavra, V. Markoussis, G. Kolovou, K. Van Wijk, D. Hautemann, J.H. Reiber, S. Mavrogeni, Greece, Netherlands

1345 Impaired left ventricular diastolic function and increased systolic contractions in type 2 diabetes compared to healthy controls: a case-control study A.P. Ofstad, H. Dalen, K.I. Birkeland, L. Gullestad, S. Urheim, O.E. Johansen, S. Aakhus, Norway

1346 Diabetes and the spectrum of hyperglycaemia adversely affects left ventricular diastolic function and is particularly toxic to South Asians C.M. Park, K. March, S. Jones, C. Tuson, T. Tillin, N. Chaturvedi, A.D. Hughes, UK

273 fp3_2013__ 15.08.13 10:41 Seite 274

1347 Comparison of left ventricular filling pressures in male patients with type 2 diabetes with normal and low testosterone levels M. Tinetti, M. Koury, A. Baranchuk, J.M. Farias, Argentina, Canada

1348 Advanced glycation endproducts are associated with higher pulse wave velocity and 24-hour pulse pressure: preliminary results from the Maastricht study M.G. Van Eupen, M.T. Schram, T.T. Van Sloten, R.M. Henry, A.A. Kroon, A.J. Smit, C.D. Stehouwer, C.G. Schalkwijk, Netherlands

Posters 1349 Postprandial haemodynamic responses are altered in uncomplicated type 2 diabetes M.M. Smits, M.H. Muskiet, M.E. Tushuizen, K.A. Kwa, D.H. Van Raalte, M. Diamant, Netherlands

1350 The co-existence of endothelial dysfunction and deteriorating glucose metabolism or insulin resistance synergistically increases incident CV event risk: the Hoorn study R.M. Henry, T.T. Van Sloten, G. Nijpels, J.M. Dekker, M.T. Schram, C.D. Stehouwer, Netherlands

1351 Metabolic predictors of CVD in type 2 diabetes M. Colombo, F.V. Agakov, I. Brady, H.C. Looker, L. Groop, B. Thorand, A. Hamsten, U. De Faire, C.N. Palmer, E. Nogoceke, L.-M. Gan, V. Salomaa, P.M. McKeigue, H.M. Colhoun, on behalf of the SUMMIT Investigators, UK, Sweden, Germany, Switzerland, Finland

Poster Event E, Thursday, 12:30 - 13:30

PS 119 Diabetes in childhood

Chair: O. Kordonouri, Germany

1352 DKA at diagnosis of type 1 diabetes predicts poor long-term glycaemic control A. Rewers, G. Klingensmith, M. Rewers, USA

274 fp3_2013__ 15.08.13 10:41 Seite 275

1353 The effect of treat-to-target insulin regimen on glycaemic control in overweight/obese type 1 diabetes patients B.U. Nwosu, K. Cullen, L. Maranda, L. Greenman, J. Fleshman, N. McShea, M.M. Lee, USA

1354 Study of circulating microRNAs in prepubertal obesity F.J. Ortega Delgado, A. Prats Puig, J.M. Mercader, J. Moreno-Navarrete, M. Moreno, N. Bonet, W. Ricart, A. López-Bermejo, J. Fernández-Real, Spain

1355 OGTT-modelled beta cell function and incretins in obese youth from normal to pre diabetes to overt type 2 diabetes S.F. Michaliszyn, S. Lee, F. Bacha, H. Tfayli, L. Farchoukh, A. Mari, E. Ferrannini, S. Arslanian, USA, Lebanon, Italy Posters

1356 The AGE methylglyoxal-derived hydroimidazolone and early signs of atherosclerosis in childhood diabetes M. Heier, H. Margeirsdottir, P.A. Torjesen, I. Seljeflot, K. Stensæth, M. Gaarder, C. Brunborg, K.F. Hanssen, K. Dahl-Jørgensen, Norway

1357 Microstructural abnormalities in white and gray matter in obese adolescents with and without type 2 diabetes A. Nouwen, A. Chambers, H.A. Allen, M. Chechlacz, S. Higgs, J. Blissett, T.G. Barrett, UK

1358 Brain responses to food cues in adolescents with and without type 2 diabetes A. Chambers, A. Nouwen, H.A. Allen, M. Chechlacz, S. Higgs, J. Blissett, T. Barrett, UK

1359 Corneal confocal microscopy detects neuropathy before retinopathy and nephropathy in children with type 1 diabetes: a preliminary study M. Tavakoli, R.A. Malik, UK

1360 Prevalence of asthma in children and adolescents with type 1 diabetes in Germany and Austria: Is there an impact on metabolic control? T. Hörtenhuber, E. Schober, E. Fröhlich-Reiterer, K. Raile, S. Wudy, R. Stachow, E. Molz, R. Holl, Austria, Germany

275 fp4_2013__ 15.08.13 10:45 Seite 276

Last name, Initials Pres. number Arcidiacono, B. 1281 Abbasi, A. 432 Arnetz, L. 717

Presenting authors of posterPresenting and presentationsauthors oral Abderrahmani, A. 533 Aroda, V. 893 Abdul-Ghani, M. 607 Aronson, R. 1090 Abels, M. 664 Arous, C. 467 Abou-Samra, M. 177 Asai, A. 1305 Achterkamp, N. 750 Augstein, P. 521 Adamska, E. 365 Axelsson, J. M. 1037 Admane, K. 1063 Azam, M. 275 Admiraal, W. 313 Badrick, E. L. 417 Adriaenssens, A. E. 579 Bae, J.-S. 818 Afroz, A. 1165 Bae, K.-H. 70 Agesen, R. M. 585 Bagge, A. 488 Agudo, J. 555 Bagger, J. I. 357 Aharon-Hananel, G. 741 Bailey, C. J. 1004 Ahlkvist, L. 679 Bak, M. I. 419 Ahlqvist, E. 91 Bakker, L. E. H. 634 Ahmadi Abhari, S. 376 Balkau, B. 266 Ahn, Y. 1048 Ballak, D. B. 118 Ahrén, B. 110 Banu, B. 1066 Albiero, M. 263 Barbarash, O. 843 Aldington, S. J. 50 Barengo, N. C. 293 Aleppo, G. 1232 Baron, A. 145 Alimetova, Z. R. 1298 Barroso, E. 854 Alkayyali, S. 203 Barutta, F. 174 Alonso, N. 546 Batuca, J. R. 831 Alsalim, W. 650 Bay, C. 584 Altirriba Gutiérrez, J. 640 Beamish, C. A. 214 Amisten, S. 101 Belda-Iniesta, C. 799 Anavi, S. 838 Belhatem, N. 1176 Andersen, D. K. 616 Berchtold, L. A. 255 Andersen, H. U. 1102 Bergenstal, R. M. 1096 Andersen, M.-L.M. 312 Berger, G. 1123 Andersson, L. E. 495 Berglund, L. M. 1203 Andreassen, K. V. 867 Bergman, B. C. 756 Andreozzi, F. 47 Berhan, Y. T. 314 Andrésdóttir, G. 1067 Bermudez-Silva, F. J. 461 Annicotte, J.-S. 19 Bernelot Moens, S. J. 24 Araki, E. 929 Bernjak, A. 594 Araki, O. 884 Berthou, F. 821 Araszkiewicz, A. 1323 Bertrand, C. 812

276 fp4_2013__ 15.08.13 10:45 Seite 277

Bhanot, S. 698 Calderari, S. 333 Bi, Y. 176 Calvet, J.-H. 1235 Biensø, R. S. 65 Campbell, M. D. 685 Bilo, H. J. G. 1118 Cantley, J. 165 Bizzotto, R. 620 Cardoso, C. R. L. 1335 Blanco, F. 261 Cariou, B. 591 Blicklé, J.-F. 271 Carless, M. A. 132 Bode, B. W. 1052 Carpanetto, A. 581 Böhm, A. A. 829 Carrat, G. R. 501 Boixadera, A. 54 Carreira, M. 1172 Bojsen-Møller, K. N. 232 Carson, A. P. 447 Bonàs, S. 371 Carvalho, M. C. 874 Bonaventura, A. 960 Casellas, A. 23 Boom, D. T. 59 Cassel, R. 527 Borg, D. J. 324 Castell, C. 286 Bowe, J. 667 Castex, F. 474 Boyle, P. 204 Catrina, S.-B. 1324 Bozkurt, L. 1286 Cavalot, F. L. 1341 Brabarupan, T. 37 Cavan, D. A. 1059 Brady, E. M. 928 Cerf, M. E. 515 Brady, I. 9 Chacón, M. R. 811

Brandt, N. 535 Chadt, A. 175 authorsoralpresentations and Presenting poster of Brangani, C. 625 Chadwick, K. D. 918 Breton, M. 1079 Chambers, A. 1358 Brito-Casillas, Y. 622 Chao, H. 582 Brockway, R. 1099 Charpentier, G. 899 Bron, M. 1167 Chatzi, L. 1272 Broskey, N. T. 62 Chaves, F. J. 342 Brouwers, O. 117 Che, T. Ting. 563 Brown, A. L. 890 Cheah, Y. S. 731 Brugnara, L. 830 Chellan, N. 524 Brun, T. 502 Chen, D. 648 Buchsbaum, M. S. 796 Chin, S. H. 708 Bugliani, M. 43 Cho, K. 752 Bukht, M. S. 1137 Cho, Y. 1319 Bulum, T. 1187 Choi, S. 238 Burkart, V. 547 Choi, Y. J. 1321 Buse, J. B. 1038 Chon, S. 217 Buzzetti, R. 973 Chow, E. Y. K. 593 Cadavez, L. 526 Christensen, M. 657 Cai, R. 127 Christiansen, J. S. 1045

277 fp4_2013__ 15.08.13 10:45 Seite 278

Chu, J. 243 Dalal, M. 898 Chu, K.-Y. 783 Dalfrà, M. 1263

Presenting authors of posterPresenting and presentationsauthors oral Chubb, B. 1160 Daniele, G. 845 Chun, H. 1246 Danielsson, A. P. H. 631 Chuter, V. H. 1206 Daoudi, A. 1061 Ciborowski, M. 403 Darsalia, V. 152 Ciccarone, A. 727 Das, M. 288 Cignarelli, A. 964 David Strain, W. 891 Cinek, O. 29 Davis, T. M. E. 1230 Cirincione, B. 910 Davis, W. A. 1314 Citko, A. 340 Dayeh, T. 344 Cito, M. 326 De Marco Solar, G. O. 341 Ciudin, A. 1311 De Marinis, Y. 497 Clark, A. 481 De Toro-Martín, J. 637 Cobb, J. 428 de Vos, L. C. 1328 Cobo-Vuilleumier, N. 166 DeFronzo, R. A. 244 Colhoun, H. 172 Dejager, S. 269 Colleran, K. M. 1223 Del Prato, S. 113 Colombo, M. 1351 Deleskog, A. 364 Connelly, K. A. 151 Delibegovic, M. 850 Cooper, M. N. 302 Denison, H. 1014 Coquart, J. B. 681 Deshmukh, H. 173 Corraliza, L. 1219 Dharmadhikari, G. 851 Coskun, T. 68 Dhayal, S. 852 Cosson, E. 1295 Di Fulvio, M. 1202 Costacou, T. 170 Di Jeso, B. 470 Costanzo, P. 409 Di Paola, R. 410 Creatore, M. I. 209 Diaconu, L. 1149 Crossey, P. 64 Diakogiannaki, E. 653 Cruciani-Guglielmacci, C. 104 Diamant, M. 982 Culina, S. 305 Didangelos, T. P. 1241 Cunha, D. A. 254 Dietert, G. 916 Cunningham, S. G. 1071 Dietrich, M. G. 531 Currie, C. J. 200 DiGenio, A. 897 Cyganek, K. 1292 Ding, L. 912 Czeczor, J. K. 828 Dirksen, C. 231 Czupryniak, L. 987 Doornweerd, S. 383 da Silva Xavier, G. 330 Drapalova, J. 721 Dahllöf, M. S. 543 Dreval, A. V. 294 Dai, J. 108 Drougard, A. 103 Daka, B. 11 Drury, P. L. 1326

278 fp4_2013__ 15.08.13 10:45 Seite 279

Drzewoski, J. 425 Fainelli, G. 643 D'souza, A. M. 670 Fajas, L. 823 Duarte, D. A. 52 Farias, J. M. 715 Duda-Sobczak, A. 1139 Faricelli, B. 983 Dudzik, D. 1277 Fedorova, O. S. 1244 Dumont, V. 1193 Feigh, M. 1009 Dusaulcy, R. 455 Feng, Z.-C. 537 Dutta, D. 561 Feodoroff, M. 1183 Dzebisashvili, T. G. 421 Fernández-Pérez, A. 737 Eastwood, S. V. 14 Fernández-Real, J. M. 770 Edalat, A. 484 Fernandez-Veledo, S. 656 Edelman, S. 1024 Ferrannini, E. 932 Edgerton, D. S. 736 Fichna, P. 760 Edwall Löfvenborg, J. 385 Figueiredo, H. 164 Eeg-Olofsson, K. 445 Finer, N. 639 Egan, A. M. 1274 Fiorentino, T. Vanessa. 611 Ehrmann, D. 1152 Fioretto, P. 954 Ejskjaer, N. 1231 Flechtner-Mors, M. 268 Ekström, N. 207 Flores, L. E. 468 El Hage, M. 1013 Foghsgaard, S. 878 El Ouaamari, A. 541 Foley, J. E. 972

Elased, K. M. 765 Forde, H. 1055 authorsoralpresentations and Presenting poster of Eleftheriadou, I. 1239 Foss-Freitas, M. C. 877 Eliasson, B. 452 Fourmy, C. 1095 Elks, C. 418 Fournier, C. L. 633 El-Laboudi, A. H. 1081 Franc, S. 192 Ellervik, C. 448 Francini, F. 692 Elliott, H. R. 348 Francis, N. A. 506 Elsen, M. 249 Frandsen, C. S. S. 586 Engelen, L. 875 Franek, E. 279 Engelund, G. 1132 Freckmann, G. 1076 Engwerda, E. E. C. 79 Freitas, H. S. 699 Eranki, V. 1234 Frenzke, H. 191 Ericson, U. 433 Fryk, E. 840 Eriksson, M. 1141 Fu, A. Z. 1318 Esmatjes, E. 1121 Fuerst-Recktenwald, S. 1015 Fadini, G. 88 Fujimoto, K. 53 Færch, L. H. 598 Fujioka, K. 866 Fagerholm, E. 416 Fulcher, G. 1044 Fagher, K. 90 Fumeron, F. 366 Fagot-Campagna, A. 398 Fürnsinn, C. 1016

279 fp4_2013__ 15.08.13 10:45 Seite 280

Furuta, H. 785 Grant, S. F. A. 331 Furuta, M. 141 Greggio, C. 61

Presenting authors of posterPresenting and presentationsauthors oral Gaens, K. H. J. 743 Grieco, F. A. 532 Gage, B. K. 211 Griffo, E. 834 Gal, A. 1083 Grill, V. 542 Gallagher, E. J. 798 Groop, P.-H. 914 Gallego-Escuredo, J. M. 844 Grünberg, J. R. 31 Gallo, L. A. 1197 Gu, T. 347 Galstyan, G. 1259 Gudiksen, A. 195 Garcia-Barrado, M. J. 519 Guerci, B. 920 Garcia-Escobar, E. 674 Guest, J. F. 84 Garofolo, M. 978 Gulseth, H. L. 871 Gassenhuber, H. 180 Guzman, V. 378 Gastaldelli, A. 808 Hach, T. 943 Gault, V. A. 998 Hadarits, O. 161 Gedulin, B. 999 Haffner, S. M. 435 Geidenstam, N. 642 Hägg, S. 7 Gejl, M. 246 Hakonen, E. 163 Genové, G. 1192 Halbron, M. 1122 Gerber, P. A. 22 Hall, E. 491 Gil-Lluís, P. 1270 Halling, J. F. 790 Giménez, M. 1127 Hals, I. 564 Giralt, A. 694 Hamamoto, Y. 883 Giuliani, C. 1278 Han, J. 924 Glavas, M. M. 754 Handelsman, Y. 1050 Gleizes, C. 525 Haneda, M. 957 Göbl, C. S. 1288 Hanefeld, M. 922 Gomes, M. B. 40 Hansen, C. S. 444 Gomez, A. M. 57 Hansen, J. 688 Gómez-Huelgas, R. 1005 Hansen, M. 146 Goncalves, D. 722 Hansen, M. 723 Gonder-Frederick, L. 81 Hansen, T. 1207 Gonzalez, C. 1104 Hansikova, J. 766 González-Rodríguez, Á. 781 Harada, S. 734 Goossens, G. H. 610 Hardy, E. 947 Görgens, S. W. 609 Hartemann, A. 1329 Gough, S. C. L. 219 Hassan, Z. 454 Gourdy, P. 923 Hassoun, A. 588 Govers, R. 606 Hauge-Evans, A. C. 458 Grancini, V. 647 Hayashi, T. 1331 Grant, D. M. 413 He, J. 431

280 fp4_2013__ 15.08.13 10:45 Seite 281

He, R. 1226 Hompesch, M. 148 Hedbäck, N. 397 Honka, H. 230 Heianza, Y. 414 Hopkins, D. 1129 Heier, M. 1356 Hopkinson, H. E. 1128 Heinonen, S. 775 Horikawa, C. 236 Heise, T. 1040 Horikoshi, M. 131 Heller, S. R. 3 Hörtenhuber, T. 1360 Heller, T. 558 Hotaling, J. M. 439 Hellgren, M. I. 394 Houghton, E. 1126 Hemmingsen, B. 121 Houweling, S. T. 291 Hendriks, S. H. 1315 Hu, Y. 1320, 346 Heni, M. 729 Huang, Y. 833 Hennessy, E. 308 Hubert, T. 568 Henriksen, M. M. 1053 Hunt, K. F. 732 Henry, R. M. A. 1350 Hussen, H. I. 296 Henry, R. R. 992 Iafusco, D. 1262 Herder, C. 1249 Igoillo-Esteve, M. 486 Hermanns, N. 592 Ihm, S.-H. 565 Hertle, E. 12 Iizuka, K. 825 Hesselink, A. E. 392 Ikeda, H. 925 Heyman, L. 868 Ilangumaran, S. 548

Hilding, A. 320 Ilhan, S. 277 authorsoralpresentations and Presenting poster of Hilton, C. Z. E. 788 Imai, S. 870 Hindy, G. 367 Imamura, M. 335 Hirsch, L. 1089 Inagaki, N. 184 Hirst, J. A. 1111 Inoue, H. 21 Hjort, R. 411 Inoue, H. 753 Hjuler, S. T. 1010 Inoue, K. 774 Hocher, B. 143 Inzucchi, S. E. 944 Hoekman, J. 77 Ioacara, S. 199 Hoeks, L. B. E. 1294 Ionescu-Ittu, R. 1163 Hoekstra, J. B. L. 1098 Ip, W. 690 Höfferer, C. 1036 Irwin, N. 988 Holden, S. E. 218 Ishikura, K. 264 Holleman, F. 252 Ivanova, L. A. 1243 Holmager, P. 1188 Iwakura, T. 600 Holman, N. 446 Iwasaki, N. 354 Holst, J. J. 901 Iwata, M. 337 Holt, R. I. G. 1114 Jabbour, S. 938 Holt, S. K. 89 Jacobson, A. M. 1316 Home, P. 1022 Jacota, M. 415

281 fp4_2013__ 15.08.13 10:45 Seite 282

Jakubowicz, D. 235 Kalra, S. 1119 James, M. L. 234 Kaludercic, N. 1304

Presenting authors of posterPresenting and presentationsauthors oral Janicsek, Z. 1275 Kamenova, P. 265 Jarek-Martynowa, I. R. 1060 Kaminska, D. 329 Jasmine, F. 1204 Kaminskyi, O. V. 319 Javorsky, M. 149 Kanasaki, K. 1199 Jax, T. 1029 Kang, J. 1000 Jayawardena, R. M. 1236a Kankova, K. 1285 Jebunnesa, F. 1280 Kantartzis, K. 807 Jehad, A. 784 Kapitza, C. 576 Jenkins-Jones, S. 201 Kapsner, P. L. 1115 Jenni, S. 805 Karaca, Ü. 443 Jensen, E. P. 678 Karalliedde, J. 1210 Ji, L. 1072 Kase, E. T. 612 Ji, Q. 915 Kashyap, S. R. 714 Jia, M. 1148 Katoh, S. 426 Jimenez, V. 795 Katzeff, H. L. 114 Jin Hwa, K. 406 Kavvoura, F. K. 352 Jin, S.-M. 974 Kawata, A. K. 126 Jirkovská, J. 1258 Kaye, J. 1028 Jocken, J. W. E. 621 Kaye, S. M. 401 Joensen, L. E. 42 Kazda, C. M. 977 Johansen, C. B. 1151 Kender, Z. 909 Johansen, O. 112 Keweloh, W. C. 1054 Johnson, J. D. 167 Keyhani-Nejad, F. 660 Johnson, S. 5 Khin, M. O. 1260 Jonas, J.-C. 522 Kim, C.-H. 399 Jones, A. G. 889 Kim, N. 1184 Jonsson, A. 362 Kim, S. 1008 Joo, E. 856 Kim, T. 624 Joosten, H. 449 Kimura, T. 989 Jørgensen, M. E. 1251 King, A. B. 1023 Joubert, M. 63 Kissner, T. 917 Julián, M. 550 Klein, K. 981 Jung, G.-S. 140 Klim, S. 1006 Jung, H. Seung. 663 Klimas, J. 1307 Junker, A. E. 804 Klimontov, V. V. 590 Kabeya, Y. 1310 Kloos, C. S. 1110 Kachroo, S. 1112 Klupa, T. 1103 Kahleova, H. 233 Knudsen, J. G. 686 Kaku, K. 888 Koch, F. 196

282 fp4_2013__ 15.08.13 10:45 Seite 283

Koehestanie, P. 396 Laperrousaz, E. 105 Koh, G. 1336 Lapuerta, P. 948 Koliaki, C. 198 Larrañaga, A. 1146 Kolotkin, R. L. 864 Larsson, C. A. 420 Koopman, A. 1140 Larsson, S. B. 763 Koopman, K. E. 730 Lavallard, V. J. 544 Kooy, A. 963 Laviola, L. 154 Koro, C. E. 440 Le Floch, J.-P. 589 Korytkowski, M. 1020 Le Magueresse-Battistoni, B. 321 Korzon-Burakowska, A. 1240 Lecube, A. 1309 Koskinen, M. K. 556 Leduc, M. 100 Kosugi, K. 1086 Lee, E. 826 Kou, K. 513 Lee, I. 505 Kovatchev, B. 1080 Lee, I.-K. 1302 Kowall, B. 408 Lee, J. 892 Kralisch-Jäcklein, S. 1267 Lee, K.-U. 817 Kramer, G. 1056 Lee, M. 436 Krentz, A. 1011 Lee, M. 72 Krepak, Y. 726 Lee, S. 407 Krishnan, G. 267 Lee, S. 442 Kristinsson, H. 463 Lee, Y.-H. 15

Kröger, J. 384 Leete, P. 136 authorsoralpresentations and Presenting poster of Krüger, J. 328 Lefrandt, J. D. 1327 Krzizek, E.-C. 1283 Lehrke, M. 986 Kubota, M. 226 Lei, Y. 69 Kucharikova, P. 959 Leibowitz, G. 539 Kukidome, D. 1247 Leiter, L. 906 Kuniß, N. 1154 Lempainen, J. 26 Kurdiova, T. 762 Leonardini, A. 155 Kurioka, S. 1191 Leroy, C. 351 Kuusela, S. 1195 Levin, P. 1018 Laake, J. S. 1170 Li, L. 803 Laffel, L. 1094 Liang, J. 213 Lagou, V. 130 Liang, S. 381 Lalau, J.-D. 961 Lima, I. S. 779 Lambers Heerspink, H. J. 940 Lin, X.-H. 1168 Landers, B. 1130 Lindahl, J. P. 569 Landin-Olsson, M. 1296 Linder, K. 158 Langkilde, A. 936 Lindhardt, M. 93 Langlois, A. 567 Lindström, T. 873 Langslet, G. 182 Lingvay, I. 975

283 fp4_2013__ 15.08.13 10:45 Seite 284

Liotti, A. 36 Malin, C. 1340 Lithovius, R. 223 Maliszewska, K. 339

Presenting authors of posterPresenting and presentationsauthors oral Liu, B. 97 Mallad, A. 649 Liu, F. 968 Malle, E. K. 116 Liu, Q. 608 Malloy, J. 2 Livingstone, S. J. 301 Malm, H. A. 504 Lizárraga-Mollinedo, E. 635 Malmgren, S. 248 Llorente-Cortés, V. 228 Malpique, R. 794 Lloyd, A. 1158 Mansell, P. 1105 Lock, J.-P. 1108 Maran, A. 1075 Loerup, L. 1268 Marchesini, G. 188 Löffler, D. 34 Marchetti, V. 853 Lokman, E. Faradianna. 482 Maria, S. 1254 Looker, H. C. 92 Marino, A. 746 Loomes, K. M. 1189 Marselli, L. 511 Lopatina, T. 1215 Marso, S. P. 74 Lopez-Mejia, I. C. 193 Martin, M. Angeles. 477 Lorenzo, C. 13 Martinez, D. 259 Louchami, K. 510 Martins, F. O. 671 Lovén, I. 122 Marullo, L. 374 Lucas, E. 604 Marx, N. 73 Lucchesi, D. 227 Mathiesen, E. R. 1266 Ludvigsen, E. 574 Mathieu, C. 1027 Ludvigsson, J. 689 Matthaei, S. 937 Lund, M. T. 725 Mavilio, M. 630 Lund-Blix, N. A. 876 Mazioti, M. C. 1211 Lundby-Christensen, L. 75 Mazzocchi, N. 613 Lundh, M. 529 McCulloch, L. J. 777 Lutgers, H. L. 1330 McDonald, W. G. 701 Ma, H. 967 McKnight, J. A. 38 MacConell, L. 980 McVey, E. A. 1088 Mace, O. J. 652 Medić-Stojanoska, M. 388 Macesic, M. V. 962 Meier, J. J. 896 MacGilchrist, C. 1257 Meininger, G. 933 Mader, J. K. 1109 Melidonis, A. 1344 Madsen, A. 695 Menegazzo, L. 262 Maeda, S. 791 Meneghini, L. F. 1043 Maessen, D. E. M. 627 Menghini, R. 1303 Maiztegui, B. 469 Menzaghi, C. 1342 Makrilakis, K. 1131 Mercader, J. M. 370 Malaisse, W. J. 471 Merlotti, C. 391

284 fp4_2013__ 15.08.13 10:45 Seite 285

Mezza, T. 512 Mylona, M. 1047 Michaliszyn, S. F. 1355 Myriam, C. 135 Mikkelsen, K. H. 675 Nacher, M. 545 Mikkola, K. 509 Näf, S. 847 Milicic, T. 311 Nagao, M. 665 Misu, H. 437 Nagaraj, V. 102 Mitchell, R. K. 332 Nagashimada, M. 814 Mithal, A. 952 Nakadaira, I. 886 Miyamoto, L. 696 Nakagami, T. 280 Mizukami, H. 514 Nakashima, E. 1147 Mogelsvang, S. 147 Nakashima, K. 45 Mojibian, M. 168 Nakayama, H. 644 Molitvoslovova, N. A. 1237 Nannipieri, M. 673 Molven, A. 356 Narita, T. 881 Monnier, V. . 17 Nasser, A.-D. 619 Monteiro-Soares, M. 1253 Natalicchio, A. 911 Montesi, L. 1145 Natasha, K. 1150 Moon, S. 1222 Nauck, M. A. 921 Morcillo, S. 258 Naujok, O. 212 Moreno-Navarrete, J. 849 Navas, M.-A. 334 Moreno-Villegas, Z. 822 Newswanger, B. 596

Morgado, C. 85 Nie, Y. 768 authorsoralpresentations and Presenting poster of Morgan, E. 691 Niemann, J. 703 Mori, K. 654 Nieto, J. 951 Morioka, T. 626 Nikolic, I. 554 Morrow, L. A. 1030 Nilsson, C. 1269 Mosenzon, O. 560 Nishimura, A. 1074 Moskva, K. A. 976 Njolstad, P. R. 33 Most, J. 863 Nocito, L. 697 Motiani, K. Kumar. 682 Nomoto, H. 460 Motterle, A. 256 Norrbacka, K. 1161 Mozzillo, E. 360 Nosek, L. 1041 Mraz, M. 55 Noso, S. 137 Muendlein, A. 842 Nouwen, A. 1357 Mukherjee, J. 1313 Nowak, N. 18 Muller, C. 661 Nunes, P. M. 816 Muller, I. 1093 Nwosu, B. U. 1353 Müller-Lühlhoff, S. 618 Nygaard, S. B. 479 Murahovschi, V. 769 Nystrom, F. H. 872 Muris, D. 402 Obermaier, K. 1082 Muzzin, P. 617 Occhipinti, M. 570

285 fp4_2013__ 15.08.13 10:45 Seite 286

Odawara, M. 128 Papadimitriou, A. 1201 O'Dea, A. 390 Papaoikonomou, S. 1164

Presenting authors of posterPresenting and presentationsauthors oral ODonoghue, D. 1261 Pappas, A. C. 1097 Ofstad, A. P. 1345 Pardo, G. 773 Oh, T. 35 Parent, E. 573 O'Hara, M. 1125 Parikh, S. J. 941 O'Harte, F. P. M. 46 Park, C. M. 1346 Ohlsson, L. 880 Park, C.-H. 429 Okada, H. 747 Park, H. 841 Okada, H. 1196 Park, S. 789 Okahata, S. 434 Park, S.-Y. 839 Okamoto, M. M. 706 Parkin, C. G. 1057 O'Kane, M. J. 1077 Parkkola, A. 297 Olausson, J. 1301 Parrillo, L. 327 Olesen, J. 66 Passaretti, F. 748 Øllgaard, J. 95 Patel, S. 926 Olsson, A. H. 345 Patente, T. A. 303 Omar, B. 44 Patterson, S. 882 Orchard, T. J. 300 Paul, S. 1338 Ordelheide, A.-M. 179 Pedersen-Bjergaard, U. 189 Ortega Delgado, F. J. 1354 Peek, N. 1062 Osorio-Conles, O. 786 Peixoto, E. B. M. 1200 Ost, M. 761 Pelletier, J. 605 Østoft, S. H. 358 Penfornis, A. 894 Otabe, S. 801 Penno, G. 225 Otsuka, Y. 1001 Pereira, M. J. 827 Ottosson Laakso, E. 369 Pereira, M. T. R. 283 Ou, H.-Y. 628 Perez Lopez, G. 1271 Oura, K. 735 Perkins, B. A. 183 Out, M. 969 Perrini, S. 782 Overgaard, A. 553 Persson, F. 1186 Owen, K. R. 355 Persson, S. 39 Oya, J. 317 Petrov, A. V. 1135 Oyer, D. S. 190 Petrovski, G. 1100 Ozaki, N. 577 Petzold, A. 325 Pacifici, F. 705 Pfützner, A. 1087 Pairó, M. 520 Piatt, G. A. 393 Palaszewski, B. 124 Pibernik-Okanovic, M. 1157 Palomer, X. 778 Picon Cesar, M. J. 658 Pang, C. 282 Pieber, T. R. 1007 Panse, M. 464 Pihlajamäki, J. A. 361

286 fp4_2013__ 15.08.13 10:45 Seite 287

Pintaudi, B. 1070 Rasouli, B. 389 Pivovarova, O. 859 Ratzinger, M. 274 Piya, M. K. 862 Rawshani, A. 28 Plomgaard, P. 178 Ray, T. 1106 Plummer, M. P. 990 Rayner, N. W. 1185 Pocai, A. 641 Reddy, M. 80 Poggi, M. 115 Reddy, V. S. 453 Poher, A.-L. 251 Rein, P. 683 Pohl, R. 1039 Reinbeck, A. 549 Poon, W. 350 Reinhardt, R. 903 Popa, S. 1180 Ren, Y. 629 Pop-Busui, R. 1228 Renard, E. M. 1092 Porcellati, F. 1035 Rett, K. 672 Porta, M. 208 Reusch, J. 902 Pourhamidi, K. 1245 Rewers, A. 1352 Powell, D. R. 995 Rewers, M. 306 Pozzilli, P. 559 Rhee, E. Jung. 111 Prasad, R. B. 349 Rhee, N. A. 879 Pratley, R. 904 Ribeiro, M. J. 603 Prestrelski, S. J. 597 Ribeiro, R. T. 427 Privitera, G. 1178 Richards, P. 655

Prokopenko, I. 372 Richardson, C. C. 138 authorsoralpresentations and Presenting poster of Pugliese, G. 813 Ridderstråle, E. 1134 Puig Domingo, M. L. 908 Ridderstråle, M. 1107 Puiu, S. C. 1085 Riddle, M. C. 220 Pujadas, G. 1300 Riopel, M. 538 Pujol-Autonell, I. 551 Rizza, S. 10 Quintin, D. 572 Rockstroh, D. 858 Raaijmakers, L. G. M. 1113 Rodbard, H. 1026 Rabinovitz, H. 861 Rohde, K. 368 Raccah, D. 907 Röhrborn, D. 846 Rácz, O. 125 Rohwedder, K. 939 Rådholm, K. 202 Rojas Jiménez, J. A. 379 Raiko, J. R. H. 797 Rondas, D. 540 Rajendran, R. 1046 Rönn, T. 257 Ramanathan, S. 310 Rooney, K. 1297 Ramos, A. E. 1273 Rorsman, P. 595 Ramos, S. 602 Rosado, V. 1255 Ran, W. 837 Rosales, M. A. B. 1218 Rancoule, C. 776 Rosario, W. 106 Rappaport, J. 900 Rosenlund, S. 82

287 fp4_2013__ 15.08.13 10:45 Seite 288

Rosenstock, J. 931 Savoye, M. 860 Rossen, N. B. 1208 Schellino, F. 49

Presenting authors of posterPresenting and presentationsauthors oral Rossi, M. 1069 Schenk, S. 240 Roy, S. 1213 Schernthaner, G. 993 Rudovich, N. N. 632 Schipf, S. 290 Ruiz de Adana, M. S. 58 Schittenhelm, B. 98 Ruiz, M. . 1306 Schloot, N. C. 557 Ruschke, K. 32 Schmidt, S. 224 Russell, M. A. 536 Schmieder, R. E. 76 Russo, E. 1177 Schmittdiel, J. 1117 Russo, G. T. 645 Schneider, J. G. 1194 Russo, I. 991 Schneider, M. P. 1179 Rustenbeck, I. 375 Schoeppe, T. 552 Rutten, G. E.. H.. 1339 Schönecker, S. 493 Rutter, G. A. 216 Schooneman, M. G. 751 Rutters, F. 1143 Schopman, J. E. 599 Ryder, J. 1058 Schultz, J. 489 Ryu, J. 764 Schultz, N. 771 Saad, F. 712 Schumacher, K. 498 Saboo, B. 1064 Schunk, M. 123 Saeki, T. 1153 Schweizer, A. 927 Saely, C. H. 8 Scott, E. M. 1290 Salani, B. 802 Scott, R. A. 336 Saleh, F. 1159 Seaquist, E. R. 245 Salonen, K. M. 424 Sebastiani, G. 133 Salunkhe, V. A. 475 Sechterberger, M. K. 60 Salvadó Serra, L. 780 Seino, Y. 956 Salzsieder, E. 1078 Selvarajah, D. 1250 Sanchez-Ferrer, C. F. 1299 Senmaru, T. 719 Sanchez-Infantes, D. 848 Serban, A. I. 1198 Sancho Bornez, V. 578 Serlie, M. J. 636 Sandholm, N. 169 Serra, D. 758 Sangha, J. 281 Sethi, B. 587 Saraiva, J. 1265 Seufert, J. R. 895 Sartorius, T. 738 Shaefer, C. 1021 Sasaki, K. 575 Shah, M. 724 Sasaki, Y. 120 Shah, P. 462 Sasdelli, A. S. 1133 Shahzad, K. 740 Sato, D. 755 Shankar, S. S. 48 Saulnier, P. 451 Shcherbina, L. 651 Saurus, P. H. 142 Shen, Y. 709

288 fp4_2013__ 15.08.13 10:45 Seite 289

Shetty, V. B. 684 Solini, A. 222 Shi, L. 971 Song, S. 457 Shi, Y. 494 Song, X. 412 Shiba, T. 836 Sørensen, I. M. 260 Shinmura, K. 480 Sörhede Winzell, M. 680 Shiramoto, M. 1031 Soty, M. 99 Shiuchi, T. 767 Spagnuolo, I. 323 Shiwa, M. 386 Sparre-Ulrich, A. H. 247 Shmushkovich, I. 1169 Spijkerman, A. M. W. 382 Shumin, Y. 242 Spinetti, G. 1256 Shvarts, Y. 1233 Stadlbauer, K. 1012 Siegel-Axel, D. I. 792 Stadler, M. 1190 Siewko, K. 309 Starup-Linde, J. 438 Siljander, H. 27 Stasiuk, G. J. 507 Silva, A. D. 819 Steensgaard, D. B. 1034 Silva, P. E. 787 Steinstraesser, A. 1032 Simó, R. 1212 Stenlöf, K. 935 Simon, A. C. R. 800 Stevens, M. 139 Sinclair, A. 955 Stewart, M. 905 Singh, K. P. 56 Stojkovic, I. A. 809 Singh, P. 459 Stone, V. M. 580

Sinnott, M. 289 Stratton, I. M. 1224 authorsoralpresentations and Presenting poster of Sipter, E. 295 Strom, A. 87 Sjöberg, L. 298 Stuckey, H. L. 1144 Sjöström, C. D. 181 Su, Q. 1068 Skarbaliene, J. 518 Suh, S. 1120 Skärstrand, H. 30 Sultan, A. 744 Skowrońska, B. 759 Sun, H. 430 Skrha Jr., J. 1238 Sun, X. 793 Skrivanek, Z. 1003 Sunami, Y. 693 Sleddering, M. A. 869 Surkova, E. V. 1065 Smagala, A. 1181 Suzuki, A. 1156 Smidt, K. 478 Sveen, K. A. 1248 Smit, J. W. A. 78 Svensson, M. K. 1174 Smith, P. 1002 Syed, F. 566 Smits, M. M. 1349 Szabó, E. 1284 Smulders, R. A. 997 Szanto, I. 485 Smyth, R. J. 395 Szendroedi, J. 1322 So, W. Yan. 67 Szymanska-Garbacz, E. 1334 Söderlund, J. M. 94 Szypowska, A. 1171 Soeters, M. R. 749 't Hart, L. M. 363

289 fp4_2013__ 15.08.13 10:45 Seite 290

Tahrani, A. 1225 Toplak, H. 638 Takahashi, H. 496 Toppe, C. 1182

Presenting authors of posterPresenting and presentationsauthors oral Takahashi, H. 517 Torekov, S. S. 338 Takahashi, H. K. 483 Toulis, K. A. 562 Takahashi, I. 476 Trachta, P. 720 Takahashi, K. 1173 Trento, M. 1155 Takamura, T. 810 Trevisan, M. 299 Takiyama, Y. 144 Trico', D. 229 Takizawa, M. 353 Trifiro', S. 380 Talbot, N. A. 857 Tripathy, D. 241 Talchai, C. 215 Trombetta, M. 1101 Tamura, K. 666 Tronko, M. D. 304 Tan, Y. 646 Tsuboi, K. 1242 Tanabe, N. 278 Tsujinaka, H. 1214 Tanaka, K. 284 Tubbs, E. L. P. 702 Tanaka, S. 450 Tudurí, E. 492 Tänczer, T. 1287 Tugay, K. 343 Taneera, J. 20 Tunceli, K. 270 Tanizawa, Y. 185 Tundidor, D. 1264 Tavakoli, M. 1359 Tura, A. 659 Teare, J. 83 Turner, D. 687 Templeman, N. M. 669 Tziomalos, K. 1325 Tengholm, A. 499 Umezawa, K. 530 Terasaki, M. 153 Usiskin, K. 949 Terruzzi, I. 966 Vaag, A. 187 Tesic, D. S. 1236 Vaittinen, M. 824 Tessari, P. 832 Valderhaug, T. G. 711 Theilade, S. 1209 Valsamakis, G. 1291 Therapontos, C. 1049 Valtat, B. 490 Theurey, P. 820 van Bloemendaal, L. 885 Thilmany, S. 285 Van Brunt, K. 985 Thomas, S. 316 van der Valk, F. M. 1017 Tian, G. 466 van der Weg, W. 508 Tikkanen, I. 942 van Dijk, P. R. 41 Tillin, T. 400 van Duinkerken, E. 1312 Tillner, J. A. 1033 van Eupen, M. G. A. 1348 Tinahones, F. J. 1025 van Hateren, K. J. J. 221 Tinetti, M. 1347 van Leeuwen, N. 205 Tofé Povedano, S. 4 van Nierop, S. 677 Tomic, M. 1221 van Poppel, P. C. M. 739 Tomoyasu, M. 156 van Schinkel, L. D. 1333

290 fp4_2013__ 15.08.13 10:45 Seite 291

van Vliet-Ostaptchouk, J. V. 373 Welsh, P. 206 van Zuydam, N. R. 171 Wender-Ozegowska, E. 159 Vangoitsenhoven, R. 322 Wens, J. 1142 Vantyghem, M.-C. 571 White, A. T. 614 Varadhan, L. 1227 White, S. A. 253 Vasileiou, V. 157 Whitehurst, T. 1084 Vater, A. 150 Wiebe, J. C. 1289 Ved, N. 1216 Wiedemann, M. S. F. 815 Vejrazkova, D. 1279 Wiederkehr, A. 487 Vercruysse, F. 934 Wierup, N. 728 Vial, G. 704 Wild, S. 273 Viana-Huete, V. 250 Wilding, J. 946 Vidakovic, M. 456 Wilhelm, K. 307 Vidal, J. 6 Willaing, I. 1136 Vieira, E. 500 Willenborg, M. 473 Vikman, P. 707 Williams, A. J. K. 25 Vilà, L. 237 Winckler, K. 1332 Villarroya, F. 71 Winhofer, Y. 1276 Villarroya, J. 757 Winnick, J. J. 107 Villena, J. A. 194 Witte, D. R. 210 Vinagre, I. 1166 Woerle, H. J. 930

Virdis, A. 742 Wohlfart, P. 984 authorsoralpresentations and Presenting poster of Viswanathan, P. 887 Wojciechowski, P. 1042 Vlad, A. 287 Wolffenbuttel, B. H. R. 1 Vogel, C. 1073 Wong, F. S. 134 von Eynatten, M. 913 Woo, V. 953 von Scholten, B. Johan. 1343 Wouters, K. 855 Vonbank, A. 1175 Wreglesworth, N. I. 359 Voulgari, C. 1308 Wright, A. D. 1220 Walraven, I. 51 Wright, J. 676 Walsh, B. 865 Wright, L. A. 1293 Wang, J. 1217 Wronkowitz, N. 745 Wang, J.-S. 970 Wu, X. 516 Wang, P. 1116 Wueest, S. 119 Wang, Y. 472 Wysham, C. 919 Ward, T. 16 Xia, M. 405 Ways, K. 950 Xia, W. 86 Wei, Q. 162 Xiao-yun, W. 534 Weir, D. L. 979 Xu, F. 239 Weir, M. 945 Xu, Y. 1162 Weiss, H. 197 Yagi, K. 835

291 fp4_2013__ 15.08.13 10:45 Seite 292

Yamada, T. 387 Zinman, B. 1051 Yamada, T. 1205 Zisser, H. C. 1091

Presenting authors of posterPresenting and presentationsauthors oral Yamauchi, T. 772 Zitzmann, M. 713 Yang, D. 272 Zoffmann, V. 1124 Yang, H. 404 Zografou, I. 1019 Yang, J. 441 Zoso, A. 615 Yang, L. 109 Ye, G.-L. 186 Yetukuri, L. 129 Yeung, C. Yip. 423 Yin, J. 958 Yin, J. M. 315 Yokoi, N. 623 Yokomizo, H. 668 Yoo, H. 716 Yoshida, M. 733 Yoshizawa, S. 318 Young, A. A. 994 Yu, S. 1317 Yuki, T. 276 Yun, M.-R. 662 Zabarovskaya, Z. 1282 Zambrowicz, B. 996 Zamora-Ros, R. 377 Zangen, S. W. 700 Zawiejska, A. 160 Zdunczyk, B. M. 1138 Zethelius, B. 422 Zha, M. 523 Zhang, D. Dan. 965 Zhang, E. 718 Zhang, L. 806 Zhang, L. 1337 Zhang, Y. 292 Zhao, X. 528 Zhao, Y. 601 Zhou, B. 1252 Zhou, M. 583 Zhou, Y. 503 Zhu, H. 96 Ziegler, D. 1229

292 fp5-2013__ 29.08.13 16:16 Seite 293

Last name First name Page

Ahrén Bo 78 Holman Rury R 60 Barrès Romain 79 Home Philip D 104 Beck-Nielsen Henning 83 Jones Peter M 62 Bethel Mary A 60 Kahn Barbara B 80 Bewick Gavin A 62 Kaul Sanjay 100 Bhatt Deepak L 82 Kielgast Urd 78

Boström Pontus 105 Kilpeläinen Tuomas O 84 s Boulton Andrew JM 37 Kim Hail 62 r k e

Butte Atul J 102 Kim Seung K 102 a

Calderon Boris 80 Kunos George 62 e s p

Cartee Gregory D 84 Laakso Markku 119

Chapman MJ 101 Lauritzen Torsten 55 d e Christie Michael R 80 Lorenzi Gayle M 100 t v i

Cnop Miriam 37 Malik Rayaz A 61 n I Cohen Deborah 60 Mann Jim 105 de Zeeuw Dick 104 Matthews David R 60 Del Prato Stefano 83 McGuire Darren K 82 Di Marzo Vincenzo 62 McMurray John J 82 Dixit Vishwa D 78 Meier Juris J 100 Eriksson Ulf 84 Meneghini Luigi F 104 Ferrannini Ele 101 Nardi Nance B 83 Fisher Barrie Miles 82 Natarajan Rama 79 Fleming Thomas 61 Newgard Christopher B 102 Florez Jose C 102 Nóbrega Marcelo A 105 Forouhi Nita G 105 Nuutila Pirjo 104 Forsblom Carol M 61 Orchard Trevor J 100 García-Mayor Ricardo V 79 Pacher Pal J 62 Ginsberg Henry N 101 Paré Guillaume 84 Gluckman Peter 79 Pedersen Bente K 105 Gomis Ramon 37 Peyrot Mark 79 Gorelick Fred 100 Pickup John C 60 Gotthardt Martin 104 Pospisilik John A 58 Gough Stephen CL 78 Postic Catherine 80 Groop Leif 83 Pournaras Dimitri J 101 Hattersley Andrew 102 Pouwer François 79 Heinemann Lutz 60 Preiss David J 58, 101 Heller Simon R 82 Raz Itamar 82 Hivert Marie-France 84 Rorsman Patrik 57

293 fp5-2013__ 29.08.13 16:16 Seite 294

Last name First name Page

Rosengren Anders 58, 78 Rossing Peter 61 Sacks David B 60 Sattar Naveed 82 Semb Henrik 83 Semenkovich Clay F 84 I n Sharma Kumar 61 v i

t Sjöström Lars 101 e

d Smith Ulf 78

s p Sordi Valeria 83

e Sumara Grzegorz 58

a Tamborlane William V 100 k e Todd John A 105 r s Uyeda Kosaku 82 Viberti Giancarlo 104 White William B 82 Wong F Susan 80 Wright Christopher VE 102 Ziegler Dan 61 Zinman Bernard 100

294 fp5-2013__ 29.08.13 16:16 Seite 295 welcome2014__ 15.08.13 10:48 Seite 296

Welcome Address

on behalf of the local organising committee I would like to invite you to participate in the 50th Annual meeting of the eAsd and welcome you to Vienna. Vienna, the capital of Austria, is well known for its imperial history with a variety of palaces, theatres, museums, parks and avenues dating back centuries. In addition, the heritage of a cultural background of famous composers, musicians, painters, sculptors, and architects inspired the development of a modern european city which attracts tourists as well as students and employees from all over the world. contemporary applied as well as performing arts are lively in the various districts of Vienna.

The background of our flyers and posters symbolises the association of medicine and music by the genetic code and the notes, representing an example for scientific progress within a cultural environment. Billroth, Wertheim, landsteiner, Wenckebach and mozart, Beethoven, strauß, schönberg are just some names to illustrate the various medical and musical sources which spread their seeds worldwide.

The messe Wien exhibition & congress center, one of the most modern facilities in europe and easily accessible by public transportation, will serve as the meeting venue. We are looking forward to seeing you in Vienna, in a city, and a country, well known for its hospitable atmosphere.

raimund Weitgasser chairman, local organising committee

296 welcome2014__ 15.08.13 10:48 Seite 297 Title_Final_prog2013__ 15.08.1310:51Seite1

EASD 2013 BARCELONA FINAL PROGRAMME Programme Final